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Abstract 
The objective of the project was to identify common assessment groups (CAGs) for the 
pesticide active substances included in Annex I of Council Directive 91/414/EEC (up to 31st 
of May 2009). Initially, 120 substances were excluded for further consideration using 
objective criteria. For the remaining 224 substances information regarding e.g. name, 
chemical identity, pesticidal mode of action, and toxicological effects was collected. The 
establishment of CAGs was based on a tiered approach comprising up to four CAG levels 
spanning from grouping of all compounds having effects on a given target organ or tissue at 
CAG Level 1 to grouping at CAG Level 4 only those compounds for which a common 
mechanism of action could been established. Draft Assessment Reports (DARs) prepared for 
the “European Commission Programme for inclusion of Active Substances in Annex I of 
Council Directive 91/414/EEC (Articles 5 and 6 of Council Directive 91/414/EEC)” were 
used to identify the relevant target organs and tissues (end-points) for the toxicological effects 
of the active substances. For each relevant target all compounds exerting a toxicological effect 
were allocated to CAG Level 1. In the next step detailed toxicological information was 
scrutinized and compounds showing a common toxic effect on a phenomenological/specific 
effect basis in each target organ and tissue were grouped into CAGs at Level 2. Refined CAGs 
were established when it could be demonstrated that the compounds actually possess the same 
mode of action (CAG Level 3) or mechanism of action (CAG Level 4). All chemical and 
toxicological information that formed the basis for the establishment of CAGs was included in 
a searchable database. 
Summary 
EFSA has initiated a project to provide a report that identifies the toxicological effects and 
endpoints that can form the basis for allocating the active pesticide substances included in 
Annex I. of Council Directive 91/414/EEC (up to 31st of May 2009) into common assessment 
groups (CAG) and to propose specific CAGs of the pesticides for consideration in MRL 
setting. In addition, a searchable database should be prepared for the effects identified as 
important for cumulative risk assessment listing the pesticide active substances having these 
effects with the related endpoints together with their no observed adverse effect levels 
(NOAEL). 
Regulation of the European Council and the European Parliament (EC) No. 396/2005 on 
Maximum Residue Levels (MRLs) for pesticides in food emphasises the importance “to carry 
out further work to develop a methodology to take into account cumulative and synergistic 
effects of pesticides”. As there were no internationally agreed methodology to assess risks 
from simultaneous exposure to more than one pesticide, EFSA in November 2006, started to 
work on cumulative risk assessment of pesticides. In opinions of EFSA’s Scientific Panel on 
Plant Protection Products and their Residues (PPR Panel) on how to assess cumulative risk 
from pesticides to human health the PPR Panel proposed to follow a step-wise approach to 
identify a common assessment group (CAG) consisting of pesticides having a common mode 
of action.  
Experimental studies have produced strong evidence that mixtures of chemicals with common 
specific modes of action work together to produce combined effects that are larger than the 
effects of each mixture component applied singly. The principle of dose additivity apply for 
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such chemicals and mean that mixture effects are to be expected even when each chemical is 
present below zero-effect levels, because it is assumed that all toxicants in the mixture behave 
as if they were a dilution of one another. Hence, any concentration of any compound needs to 
be considered because it may add to the mixture concentration. 
Initially, 120 substances were excluded for further consideration using objective criteria. For 
the remaining 224 substances information regarding e.g. name, chemical identity, pesticidal 
mode of action, and toxicological effects was collected. Information on toxicological effects 
and potential modes and/or mechanisms of action for mammalian toxicity were obtain from 
Draft Assessment Reports (DARs), DAR addenda, and EFSA/ECCO/EPCO peer review 
reports, reports from the Joint FAO/WHO Meting on Pesticide Residues (JMPR), and the 
open literature.  
The establishment of CAGs was based on a tiered approach comprising up to four CAG levels 
spanning from grouping of all compounds having effects on a given target organ or tissue at 
CAG Level 1 to grouping of only those compounds at CAG Level 4 for which a common 
mechanism of action could been established. Draft Assessment Reports (DARs) prepared for 
the “European Commission Programme for inclusion of Active Substances in Annex I of 
Council Directive 91/414/EEC (Articles 5 and 6 of Council Directive 91/414/EEC)” were 
used to identify the relevant target organs and tissues (end-points) for the toxicological effects 
of the active substances. For each relevant organ/tissue all compounds excerting a 
toxicological effect were allocated to CAG Level 1. In the next step detailed toxicological 
information was scrutinized and compounds showing a common toxic effect on a 
phenomenological/specific effect basis in each target organ and tissue were grouped into 
CAGs at Level 2. Refined CAGs were established when it could be demonstrated that the 
compounds actually possess the same mode of action (CAG Level 3) or mechanism of action 
(CAG Level 4).  
All chemical and toxicological information that formed the basis for the CAGs was included 
in an Excel spreadsheet containing the following entries: Name of active substance, 
pesticiddal category, chemical class, IUPAC name, CAS number, pesticidal mode/mechanism 
of action, ADI, ArfD, AOEL, target organ/tissue (CAG level 1), phenomenological / specific 
effect (CAG level 2), species, strain, sex, study duration, route of exposure, NOAEL, LOAEL, 
reference, source (DAR, EFSA peer-review, open literature, etc.), remarks, toxicological 
mode of action (CAG level 3), and toxicological mechanism of action (CAG level 4).  
A searchable database in Microsoft Access was established based on the Excel spreadsheet.  
For the following target organs/tissues, recommendations are given on potential CAGs that 
should be considered for use in cumulative risk assessment (CRA): 
• Adrenal gland (chapter 7) 
• Bone marrow (chapter 8) 
• Bones / skeleton (chapter 9) 
• Cardiovascular system (chapter 10) 
• Eye (chapter 11) 
• Gallbladder (chapter 12) 
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• Haematological system (chapter 14) 
• Kidney (chapter 16) 
• Liver (chapter 17) 
• Muscles (chapter 20) 
• Nervous system (chapter 21) 
• Parathyroid gland (chapter 23) 
• Reproductive system and developmental toxicity (chapter 25) 
• Spleen (chapter 28) 
• Thyroid gland (chapter 30) 
• Urinary bladder (chapter 31) 
 
No CAGs were recommended for CRA the following target organs/tissues: 
• Gastrointestinal tract (chapter 13) 
• Immune system (chapter 15) 
• Lung (chapter 18) 
• Lymph node (chapter 19) 
• Pancreas (chapter 22) 
• Pituitary gland (chapter 24) 
• Salivary gland (chapter 26) 
• Skin (chapter 27) 
• Thymus (chapter 29) 
 
In conclusion, CAGs at level 3 based on knowledge on the mode of action could only be 
recommended for the bone marrow, bones / skeleton, eye, haematological system, liver, 
muscles, nervous system, reproductive and developmental system, and thyroid gland, whereas 
CAGs at level 4 based on the mechanism of action could only be recommended for some 
toxicological effects on the eye, liver, nervous system and reproductive and developmental 
system. These CAGs should provide a reasonable basis for performing cumulative risk 
assessments (CRA). 
The CAGs at level 2 are established without any knowledge about mode/mechanism of action 
and do therefore not fulfil the criteria for a cumulative mechanism group that can be expected 
to exert dose additivity. However, risk managers may wish to use a CAG at level 2 in order to 
consider whether a realistic cumulative exposure to certain active substances would need to be 
further investigated. 
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Data on mode/mechanism of action are lacking for the majority of the different toxicological 
effects of the active pesticide substances included in the assessment. However, before using 
expensive resources to obtain such information a systematic review of pesticide occurrence 
and exposure data for food in Europe should be carried out with the aim of identifying 
combinations of active pesticide substances that are either realistic candidates or not for 
cumulative risk assessment. 
Although the CAGs at level 2 do not fulfil the criteria for a cumulative mechanism group that 
can be expected to exert dose additivity they can be useful for a preliminary assessment of 
realistic mixtures of active substances. This in particular, because it can be expected that such 
an assessment will be conservative in the absence of dose additivity between the compounds. 
For such an assessment, it is recommended to use the Reference point index (RfPI) (based on 
the NOAELs for the compounds in the CAG) as described by the PPR Panel in 2008. The 
RfPI is similar to the Point of departure index (PODI) that was advocated by EFSA in 2007 
and by WHO in 2009 to be used in cumulative risk assessment. 
 
Key words: 
Cumulative risk assessment, cumulative assessment group, mechanism of action, mode of 
action, phenomenological effects, pesticidal active substance.  
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Background 
Regulation of the European Council and the European Parliament (EC) No. 396/2005 on 
Maximum Residue Levels (MRLs) for pesticides in food emphasises the importance “to carry 
out further work to develop a methodology to take into account cumulative and synergistic 
effects of pesticides”. As there were no internationally agreed methodology to assess risks 
from simultaneous exposure to more than one pesticide, EFSA in November 2006, started to 
work on cumulative risk assessment of pesticides by organising a colloquium on “Cumulative 
risk assessment of pesticides to human health: the way forward”. The summary report of this 
colloquium includes the results from two discussion groups dealing with cumulative exposure 
(EFSA 2007).   
In 2008, EFSA’s Scientific Panel on Plant Protection Products and their Residues (PPR Panel) 
elaborated an opinion “to evaluate the suitability of existing methodologies and, if 
appropriate, the identification of new approaches to assess cumulative and synergistic risk 
from pesticides to human health with a view to set MRLs for those pesticides in the frame of 
Regulation (EC) No. 396/2005” (EFSA 2008). The PPR Panel proposed to follow a step-wise 
approach to identify a common assessment group (CAG) consisting of pesticides having a 
common mode of action.  The proposal was mainly based on US EPA documents (EPA, 
1999; 2002) and an ILSI report (ILSI, 1999). According to EPA (1999) a “Common 
Mechanism Group (CMG) consists of chemicals for which scientifically reliable data 
demonstrate that the same toxic effect occurs in or at the same organ or tissue by essentially 
the same sequence of major biochemical events. However, not all members of a CMG should 
necessarily be included in a more refined quantitative estimate of cumulative risk”.  
The PPR Panel agreed that full consideration of all of the criteria put forward for grouping 
compounds in CAGs would provide the most sound and robust grouping. However, for the 
purposes of risk assessment, compounds might be grouped even in the absence of such 
detailed data, on the basis of a less refined evaluation of the mode of action (i.e., based only 
on target organ toxicity). (EFSA, 2008).   
Following the general opinion of the PPR Panel, the proposed tiered approach to assess 
cumulative effects from exposure to pesticides was tested for a selected group of triazole 
pesticides (EFSA 2009). The PPR Panel concluded that the previously proposed tiered 
approach could be simplified by starting with a CAG as refined as the data allow and using 
the same CAG in all steps of the assessment, and restricting the exposure scenario to two tiers, 
one deterministic and one probabilistic tier. 
Overall, the PPR Panel concluded that although a tiered approach is an appropriate way to 
address cumulative dietary risk assessment it cannot yet be applied on a routine basis. First, 
the following issues should be resolved: 
• The basis for and establishment of relevant CAGs, on an European level 
• Confirmation that both the deterministic and probabilistic approaches for cumulative 
exposure assessment provide appropriate levels of protection 
• Completion of further guidance on appropriate methodologies for exposure 
assessment.  
 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
12 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
Therefore EFSA launched a call to obtain proposals for a project, which will search and 
explore the existing pesticide data bases, open literature and Draft Assessment Reports 
(DARs) to identify the toxicological effects and endpoints that can be the basis of a 
cumulative risk assessment. Furthermore proposal for common assessment groups of active 
substances having these identified effects and the related endpoints should be made. The aim 
of this project is to set the basis for carrying out of cumulative risk assessments on a routine 
basis in MRL setting. 
Terms of reference 
The specifications of the invitation to tender defined the following tasks and these are taken as 
the term of reference for this report.  
Scrutinize the available databases and DARs of pesticides included to Annex I. of Council 
Directive 91/414/EEC (up to 31st of May 2009) in order to identify every single specific 
effects and their respective endpoints that can be the basis of a Common Assessment Group 
on which a cumulative risk assessment should be performed. To the best possible extent, 
assumption of the existence of specific mode of action (MOA) will have to be substantiated 
by identifying appropriate information in open scientific literature. 
Collect NOAELs and mechanistic data for the identified effects, if available or sufficiently 
covered in the peer reviewed dossier prepared in line with Council Directive 91/414/EEC as 
well as resulting from the evaluation of scientific literature. 
Develop the definition of non specific effects and establishment of criteria allowing 
concluding that an effect meets the definition of non specific effect. List and discuss non-
specific effects that will be considered not relevant for cumulative risk assessment. 
Prepare a searchable database of the effects identified as important for cumulative risk 
assessment, and the list of pesticide active substances having these effects with the related 
endpoints. 
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 Introduction and Objectives 
INTRODUCTION 
During more than two decades several suggestions have been published on how to perform 
risk assessment on mixtures of pesticides (reviewed by Kortenkamp et al. 2009; Reffstrup et 
al. 2010). In 1986 the Environmental Protection Agency in USA (US EPA) published a 
guideline for health risk assessment of chemical mixtures (EPA, 1986). However, what really 
put focus on this topic was the Food Quality Protection Act of 1996 which concerning 
pesticide residues requires US EPA to consider ”available information concerning the 
cumulative effects of such residues and other substances that have a common mechanism of 
toxicity” (United States of America in Congress, 1996). Since then US EPA has published 
several reports and guidelines on health risk assessment of chemical mixtures (EPA, 1999a, 
2000, 2002, 2003). 
The Agency for Toxic Substances and Disease Registry in USA (ATSDR) has published two 
guidelines with instructions to users on how to apply current methodologies for risk 
assessment of combined actions of chemicals (ATSDR, 2001, 2004). 
In 2002 the Health Council of The Netherlands as well as the Committee on Toxicity of 
Chemicals in Food, Consumer Products and the Environment in United Kingdom published 
advisory reports on risk assessment of mixtures (COT, 2002; Feron et al., 2004; Health 
Council of the Netherlands, 2002). 
The Danish Veterinary and Food Administration has published the reports “Combined 
Actions of Pesticides in Food” (Reffstrup, 2002) and “Combined Actions and Interactions of 
Chemicals in Mixtures” (Binderup et al., 2003) which summarised and evaluated the present 
knowledge about combined toxic effects of mixtures of chemicals. 
Since then, international initiatives have been taken in order to more closely explore what 
approaches can be used to evaluate chemical mixtures. Most notably, the European Food 
Safety Authority (EFSA) organised a workshop on cumulative risk assessment of pesticides 
(EFSA, 2007) and the Norwegian Scientific Committee for Food Safety and EFSA have 
published opinions on risk assessment of combined actions on chemicals (EFSA, 2008; 
Norwegian Scientific Committee for Food Safety (VKM 2008). In addition, WHO/IPCS 
hosted an International Workshop on Aggregate/Cumulative Risk Assessment in Washington 
in March 2007 (IPCS 2009a). 
Based on all these reports, there is strong evidence that chemicals with common specific 
modes of action work together to produce combined effects that are larger than the effects of 
each mixture component applied singly. The literature shows that this applies to a number of 
different endpoints of relevance to mammalian toxicology and there is a consensus in the field 
of mixture toxicology that the customary chemical-by chemical approach to risk assessment 
might be too simplistic (Kortenkamp et al. 2009).  
The basic types of combined action of compounds are either combined effect without 
interaction in the form of simple similar action (dose addition) and simple dissimilar action 
(response addition) or combined effect with interaction (antagonism, synergism). Many terms 
have been used for additivity, but it seems as the terminology that has become fairly common 
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includes the terms simple similar action and simple dissimilar action to describe additivity 
(Teuschler, 2007). 
The model for simple similar action (synonyms: dose additivity, Loewe additivity) assumes 
that the compounds in the mixture behave as if they are dilutions of each other. This means 
that the compounds act on the same biological site by the same mechanism/mode of action 
and differ only in their potencies. The theoretical basis for the simple dissimilar action 
(synonyms: response additivity, Bliss independence) is probabilistic independence. This 
means that the compounds in the mixture do not interfere with each other but they all 
contribute to a common result. The model assumes that the compounds in the mixture do not 
act by the same mode of action and the nature and site of action may also differ among the 
compounds (Reffstrup et al. 2010). 
Interactions are defined as combined actions resulting in a stronger (synergism) or weaker 
(antagonism) effect than would be expected based on the assumption of additivity. 
Interactions can be divided into direct chemical-chemical, toxicokinetic and toxicodynamic 
actions. It is difficult to predict toxic interactions. If the actual exposure is very low it is often 
unclear whether knowledge about the combined action at higher concentrations is relevant for 
the low exposure level. Overall, it is generally anticipated that interactions will not appear at 
relatively low exposure levels since they are primarily caused by various thresholds and 
saturation phenomenon (saturation of activating, detoxification or reparative processes) 
(Reffstrup et al. 2010). 
Risk assessments of pesticides normally result in the establishment of acceptable daily intakes 
(ADI) for individual pesticides which are based on so-called points of departure (No Observed 
Adverse Effect Levels (NOAELs) or benchmark doses) by using a large uncertainty factor. 
Exposures below these levels are usually considered safe. However, the experimental 
evidence on mixture effects provokes the question as to whether there is sufficient protection 
also against combined exposures when each component is present below their individual 
threshold doses. Experimental studies have produced strong evidence that mixture effects may 
arise when several chemicals are combined at doses around, or below their points of 
departure. The majority of these studies have analyzed the effect of combinations composed 
of chemicals that interact with the same sub-system of an organism. In such cases, the concept 
of dose addition is applicable. The principles of dose additivity mean that mixture effects are 
to be expected even when each chemical is present below zero-effect levels, because it is 
assumed that all toxicants in the mixture behave as if they were a dilution of one another. 
Hence, any concentration of any compound needs to be considered because it adds to the 
mixture concentration. This implies that all compounds contribute to the mixture toxicity in 
direct proportion to their concentration in the mixture and their individual potency. Whether 
the individual concentrations in the mixture are above or below the corresponding effect 
thresholds does not matter. This has been demonstrated repeatedly for a broad range of 
mixtures in toxicological studies (Kortenkamp et al. 2009). 
The toxicity of the simultaneous administration of two or more chemical has been investigated 
in several experiments. In 2008 the PPR Panel carried out a search of the PUB-MED database 
from 1980 onwards using the search terms “toxicity and mixture”. While there are many 
papers in the scientific literature concerning the toxic effects of mixtures, both in vivo and in 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
15 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
vitro, only a few were found that addressed combined effects from dose levels at or below the 
NOAELs for the compounds when tested individually (EFSA,2008).  
The evidence reviewed by EFSA does not exclude the possibility that interactions could in 
some circumstances lead to toxic effects from combinations of pesticide residues at doses 
below their individual NOAELs. Only a limited number of compounds have been tested in 
combination at low doses; and for those combinations that have been tested, interactions 
might in some cases have been missed because of the spacing of the dose levels that were 
employed. However, the available evidence support the view that significant toxic interactions 
between chemicals are much less likely to occur at doses below the effect levels for individual 
component compounds than at higher doses. To this extent, interaction is less relevant to risk 
assessment for pesticide residues in food (EFSA, 2008). However, it was recommended that a 
case-by-case approach should be adopted to consider whether it is biological plausible that 
interaction might occur between specific pesticides at low, non-effective doses. In some cases, 
ad hoc tests might then be required (EFSA, 2008). 
Concerning dose addition EFSA found that this might occur when certain mixtures of 
chemicals are administered at relatively low doses. With regard to pesticide residues in food, 
this form of combined toxicity therefore requires further systematic consideration.  
In their 2008 opinion (EFSA, 2008) the PPR Panel proposed to follow a step-wise approach to 
identify a common assessment group (CAG) consisting of pesticides having a common mode 
of action. The proposal was mainly based on US EPA documents (EPA, 1999; 2002) and an 
ILSI report (ILSI, 1999). 
The proposed approach included the following steps: 
• Preliminary identification of a candidate set of substances that might cause a common 
toxic effect by a common mode of action. This preliminary grouping is based on one 
or more of the following criteria:  
Chemical structure. This can be explored by substructure searches in databases for 
toxophore (a structural feature or moiety contained in substances causing the same 
toxic effect. The toxic effect is attributed to the interaction of such a feature or 
moiety with the molecular target) (or a metabolic precursor of a toxophore), core 
molecular structure, and functional groups;   
Mechanism of pesticidal action. This is considered informative because it is not 
uncommon that pesticides are toxic to humans through a mechanism that is 
similar to that of their activity against their target pests;  
General mode/mechanism of mammalian toxicity;  
A particular toxic effect. It is conceivable that similar toxic effects by different 
compounds might be caused via a common mode/mechanism. This criterion might 
allow the identification of structurally unrelated substances that act by the same 
mode of action. It is emphasized that non-specific effects such as body weight 
changes or death can result from many unrelated factors and consequently are of 
limited value in identifying potential candidate substances for a common 
mode/mechanism group (CMG).  
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• Definitively identify those substances that cause a common toxic effect(s). This step 
allows a first refinement of the preliminary grouping described above. This is 
performed by detailed evaluation of available toxicology data for each substance and 
those not causing a common (i.e. concordant in both site and nature) toxic effect are 
excluded.  
• Determine the toxic mode/mechanism of action by which each substance causes a 
common toxic effect. While desirable, not all of the specific biochemical events 
leading to toxicity need to be known or completely characterized. A minimum set of 
data is required to identify those events that are most crucial in causing the toxicity 
(mode of action). All available reliable sources of information should be used, 
including published literature, and textbooks.  
• Compare the mechanisms of toxicity/modes of action of the different substances.  
• Refine groupings by excluding substances that cause a common toxic effect by a 
different mechanism/mode of action.  
 
The PPR panel was aware that such a detailed evaluation up to the last step might not be 
necessary or even possible in all cases. The identification of a CAG is complicated and it is 
anticipated that it often has to be based on a relative broad set of criteria due to absence of 
information/data on mechanism/ mode of action. The assessment of the available data 
therefore requires expert judgement involving knowledge on toxicological effects and their 
underlying mechanisms. This involves several scientific disciplines, such as biology, 
biochemistry, molecular biology, and pathology. 
An additional consideration arises from evidence in the literature that certain endocrine active 
compounds in mixture show a dose-additive common effect even if they do not share the same 
primary molecular target and when exposures are at or below their individual NOAELs 
(Kortenkamp, 2007, EC 2009, Christiansen et al. 2008, Moretto, 2008, Kortenkamp and Hass 
2009, Jacobsen et al, 2010, Reffstrup et al, 2010). Therefore, the issue is the definition of the 
concept of common mode of action (MOA), and what this would mean for endocrine active 
compounds. For instance, compounds affecting male sexual development via interference 
with steroid synthesis and not by antagonism of the androgen receptor would not be grouped 
according to a narrow definition of MOA whereas it has been shown that a mixture of such 
compounds results in a dose additive effect (Gray et al., 2001; Hotchkiss et al., 2004). Similar 
considerations can be applied to estrogenic or estrogen-like chemicals (Picard, 2003). 
Therefore, it appears that in these cases the criterion for grouping should rather be that of a 
common phenomenological effect (e.g.: altered ano-genital distance for anti-androgens) 
(Kortenkamp, 2007). To embrace all scientific issues regarding the appropriate grouping of 
compounds for cumulative risk assessment, a group of compounds for which a cumulative 
assessment is thought to be required will be defined as a common assessment group (CAG). 
Hence, CAGs are not always identical to common mechanism groups (CMG).  
Following the general opinion of the PPR Panel (EFSA 2008), the proposed tiered approach to 
assess cumulative effects from exposure to pesticides was tested in practice for a selected 
group of triazole pesticides (EFSA 2009). Cranio-facial malformation was selected as the 
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common endpoint for acute effect of seven compounds and hepatotoxicity was selected as the 
common endpoint for the chronic assessments of 11 compounds. 
The PPR Panel used the following tiers for the hazard characterisation 1) ADI, ARfD; 2) 
“ADI”, “ARfD”, adjusted for the common endpoint; 3a) NOAEL for the common endpoint; 
3b) BMD for the common endpoint. Several exposure scenarios were considered, including 
exposure relevant for MRL-setting. The risk assessment was performed for each scenario by 
calculating the Hazard Index (HI), an adjusted HI, and using the Relative Potency Factor 
(RPF) method, where the RPF method was applied using either NOAELs or BMDs as 
Reference Point (RfP). 
This example proved to be very valuable in testing the methodology and identifying the 
necessary next steps before its routine application by EFSA could be recommended. 
The PPR Panel concluded that the previously proposed tiered approach could be simplified by 
starting with a CAG as refined as the data allow and using the same CAG in all steps of the 
assessment, and restricting each exposure scenario to two tiers, one deterministic and one 
probabilistic tier. 
The Panel concluded that the establishment of relevant CAGs is the starting point for all 
cumulative risk assessments. Consensus should be reached at an international level on the 
criteria and compounds that should be used to create a CAG, to avoid differences between 
national cumulative risk assessments. An important issue is that a first tier should be more 
conservative compared to the next tiers. In itself, the hazard assessment tiers are clear and 
could be performed for any CAG.  
The present project explores the existing data on pesticide active substances to identify the 
toxicological effects and endpoints that can be the basis of a cumulative risk assessment. 
Furthermore proposal for common assessment groups of active pesticide substances having 
these identified effects and the related endpoints is given with the aim to set the basis for 
carrying out cumulative risk assessments on a routine basis. 
The project thus aims to identify specific adverse, toxic effects considered for cumulative risk 
assessment (CRA) and as a consequence as far as possible identify effects not relevant in this 
context. In a searchable database, the outcome of the project will contribute to an overview of 
toxicological data on pesticide active substances in a manner which facilitate the identification 
of adverse, toxicological specific effects of the single substance including the dose or NOAEL 
for these specific effect and where possible data on mechanism or mode of action.  
OBJECTIVES 
The objectives of the project are: 
• To provide EFSA with a clear and concise report that identifies the toxicological 
effects and endpoints that can form the basis for allocating the active pesticide 
substances included in Annex I. of Council Directive 91/414/EEC (up to 31st of May 
2009) into common assessment groups (CAG) thereby setting the basis for carrying 
out cumulative risk assessment (CRA) of pesticides on a routine basis in MRL setting. 
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• To prepare a searchable database of the effects identified as important for cumulative 
risk assessment listing the pesticide active substances having these effects with the 
related endpoints together with their no observed adverse effect levels. 
• To propose specific common assessment groups of the pesticides for consideration in 
MRL setting. 
Working strategy 
1. Working plan 
The original working plan suggested by the tenderer was discussed at an interim meeting with 
the Project Steering Group. Based on the experiences obtained so far in the project it was 
agreed to change the strategy to make the work more efficient. The new strategy involved the 
following six steps:  
• Step one. Identify the pesticide active substances, which are considered relevant for 
inclusion in CAGs, i.e. exclude the pesticides which are not considered relevant for 
inclusion in a CAG. This is addressed in Chapter 2. 
• Step two. Collect information from Annex 1 of Council Directive 91/414/EEC on 
chemical identity and pesticidal mode of action of each of the included pesticide active 
substances. The information is included in a working spreadsheet. 
• Step three. Identify the toxicological targets (effect points) for each pesticide active 
substance based on the DAR or similar information and add to the working 
spreadsheet. 
• Step four. Collect detailed toxicological information for each active substance and add 
to the working spreadsheet. The data collection should be sufficient to identify 
possible CAGs. At this stage, the available information on mode or mechanism of 
action is also recorded. Word documents are prepared for each target organ or tissue 
with short descriptions of each specific effects and mode/mechanism of action. 
• Step five. Based on the information and the Word documents obtained at step four, 
chapters are included in the final report outlining the potential CAGs that can be 
established for each of the specific toxicological endpoints.   
• Step six. The information added to the working spreadsheet is imported into a 
searchable Microsoft Access database. 
 
At the interim meeting it was also agreed to include toxicological active metabolites in the 
database, where relevant information is reported in the DAR. This is done during the 
collection of data from the DARs for all target organs and tissues and a complete file 
containing all these substances will be finalised when all working spreadsheets are finalised. 
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2. Identification of active substances considered relevant for cumulative risk 
assessments (CRA) 
All the 344 active substances included in Annex I of Council Directive 91/414/EEC (up to 
31st of May 2009) are listed in Appendix A of this report. However, not all of these 
substances are suited for inclusion in CRA and therefore, should not be part of a CAG.  
The main criteria for further considerations of an active substance for inclusion in a CAG are 
that the substance is chemically well-defined and that adequate toxicological data are 
available. The rationales for the exclusion of in total 120 of the 344 active substances included 
in Annex I of Council Directive 91/414/EEC for further considerations for inclusion in CAGs 
are presented below: 
Twenty-five of the active substances included in Annex I of Council Directive 91/414/EEC 
are micro-organisms (virus, bacteria, fungi etc.) (42, 45-50, 89, 96, 173, 195, 214, 235, 236, 
247, 269, 278, 300, 302, 326-330, and 339). As these active substances are not chemicals, 
they are irrelevant for inclusion in CAGs. These substances appear on an orange background 
in Appendix A of this report. 
Straight Chain Lepidoptera Pheromones (SCLPs) is a group of pheromones naturally 
produced by insects in the order Lepidoptera, which includes butterflies and moths. The 
SCLPs are characterised by an unbranched aliphatic chain (between 9 and 18 carbons) ending 
in an alcohol, aldehyde or acetate functional group and containing up to 3 double bonds in the 
aliphatic backbone and thus, not chemically well-defined. Twenty-seven active substances 
belonging to the SCLPs group are included in Annex I of Council Directive 91/414/EEC (1-
24, 124, 301, and 311). Furthermore, it is concluded in the SANCO Review Report 
(SANCO/2633/08) “... there are clear indications that it may be expected that Straight Chain 
Lepidopteran Pheromones, when they are applied via retrievable sized dispensers, do not have 
any harmful effects on human or animal health ...”. In addition, no ADIs have been 
established for the SCLPs (stated as ‘not applicable’ in Annex I of Council Directive 
91/414/EEC). For these reasons, the SCLPs are considered as irrelevant for inclusion in 
CAGs. These substances appear on a dark green background in Appendix A of this report. 
For fifteen of the active substances included in Annex I of Council Directive 91/414/EEC, 
there is a cross reference to another active substance in the remark column. As these 
substances were grouped due to similar chemical and toxicological properties, only one 
substance in the group has to be considered for inclusion in CAGs. For Bordeaux mixture 
(62), copper hydroxide (91), copper oxychloride (92), cuprous oxide (93) and tribasic copper 
sulphate (324), there is a reference to “copper compounds” (90) and all the substances are 
covered by the toxicological data for copper compounds and will be placed in the same CAGs 
as copper compounds. For capric acid (68), caprylic acid (69), fatty acids C7-C18 and C18 
unsaturated potassium salts (139), fatty acids C8-C10 methyl esters (140), lauric acid (194), 
methyl decanoate (220), methyl octanoate (222), and pelargonic acid (241), there is a 
reference to “fatty acids C7 to C20” (138) and all the substances are covered by the 
toxicological data for fatty acids C7-C20 and will be placed in the same CAGs as fatty acids 
C7-C20. For quizalofop-P-ethyl (283) and quizalofop-P-tefuryl (284), there is a reference to 
“quizalofop-P” (282) and these substances are covered by the toxicological data for 
quizalofop-P and will be placed in the same CAGs as quizalofop-P. It should be noted, 
however, that the toxicological information for quizalofop-P in fact is for quizalofop-P-ethyl 
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and quizalofop-P-tefuryl.  The fifteen cross referenced substances appear on a blue 
background in Appendix A of this report. 
Twenty-four of the remaining 277 active substances included in Annex I of Council Directive 
91/414/EEC are either complex mixtures or in other ways not a chemically well-defined 
substance (61, 135, 137, 138, 170, 177, 191, 193, 197, 237-240, 244, 254-257, 285-288, , and 
294). These substances, which appear on a red background in Appendix A of this report, are 
irrelevant for inclusion in CAGs. 
For 22 of the remaining 253 active substances included in Annex I of Council Directive 
91/414/EEC (25, 32, 38, 41, 66, 72, 106, 109, 111, 112, 132, 171, 176, 221, 230, 258, 270, 
279, 305, 334, 338, and 340), an ADI has not been established (stated as ‘not applicable’ in 
Annex I of Council Directive 91/414/EEC). For the major part of these substances (25, 32, 38, 
41, 66, 72, 106, 132, 171, 221, 230, 258, 270, 279, 334, and 338), it is concluded in the 
respective SANCO Review Reports “... there are clear indications that it may be expected that 
XXX does not have any harmful effects on human or animal health ...”. For three of these 
substances (109, 111, 112), it is concluded in the respective SANCO Review Reports “With 
particular regard to residues, the review has established that the residues arising from the 
proposed use will not be significant and … they will have no harmful effects on human or 
animal health.”. For one substance (176), it is concluded in the SANCO Review Report 
“Based on the proven low toxicity of the active substance from the available toxicity studies, 
it was not necessary to set any of the following reference values: ADI, ARfD or AOEL.”. For 
one substance (305), it is concluded in the SANCO Review Report “... for an essential 
element as sulphur, exposure is evaluated against background levels and sulphur is considered 
to be low risk.”. For one substance (340), it is concluded in the SANCO Review Report 
“Since the plant protection products containing warfarin are not used on plants or plant 
products, use, consequent on application consistent with good plant protection practice, has no 
harmful effects on human or animal health.”. For two of the remaining 231 active substances 
included in Annex I of Council Directive 91/414/EEC (36, 65), data are insufficient to 
consider the inclusion of the substances in any CAG (only acute toxicity data have been  
submitted). For these two substances (36, 65), it is concluded in the respective SANCO 
Review Reports “... there are clear indications that it may be expected that XXX does not have 
any harmful effects on human or animal health ...”. Two of the remaining 229 active 
substances included in Annex I of Council Directive 91/414/EEC are inorganic substances 
(148, 188). For one of these substances (148), it is concluded in the SANCO Review Report 
“... no harmful effects on human or animal health will be arising from the proposed uses ...”. 
For the other substance (188), it is concluded in the SANCO Review Report “... there are clear 
indications that it may be expected that iron sulphate does not have any harmful effects on 
human or animal health ...”. As all these 26 active substances are considered as having no 
harmful effects on human health (SANCO Review Reports), these substances are considered 
irrelevant for inclusion in CAGs. These substances appear on a yellow background in 
Appendix A of this report. 
For 3 of the remaining 227 active substances included in Annex I of Council Directive 
91/414/EEC (160, 231, 275), the DAR was not available neither from the CIRCA database 
nor from the Danish Environmental Protection Agency. The Rapporteur Member States 
(RMS) have been contacted by email twice, but the DARs are still missing. Therefore, these 
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substances, which appear on a pink background in Appendix A of this report, have also been 
excluded for further considerations for inclusion in CAGs. 
In total, 120 of the 344 active substances included in Annex I of Council Directive 
91/414/EEC have been excluded for further considerations for inclusion in CAGs. The 
remaining 224 active substances to be evaluated for inclusion in CAGs appear on a light green 
background in Appendix A of this report and are also listed in Appendix B of this report.  
3. Collection of information 
3.1. Chemical structure and pesticidal mode of action 
The specific numbers for the pesticide active substances used in the present project refers to 
the numbers according to an alphabetic ordering of the compounds (Appendix A and 
Appendix B of this report). 
Information on the chemical identity and pesticidal mode of action of the active substances 
was obtained from the Pesticide Properties Database (PPDB 2009) and the Pesticide Manual 
(2010). The following information on the chemical identity as well as the mode of action of 
each substance was included in a working spreadsheet: Substance name according to the 
CIRCA database (with possible alternative names also included), pesticide category, chemical 
group, IUPAC name, CAS Register No, and EC No if available. The chemical structure of 
each substance was drawn based on the SMILES code (available in the PPDB) by using the 
ChemDraw program. The structures were saved as the ChemDraw filetype ‘.emf’ (this can be 
imported to Access databases) and included in a separate document, as agreed with the 
database developer.  
The information that substances contain similar chemical structures or have the same 
pesticidal mode of action may indicate a possible similar toxicity to experimental animals and 
humans. In this project this information is a part of the quality control. When a CAG is 
identified it will be checked if there are pesticide active substances with similar chemical 
structure or the same pesticidal mode of action that were not included. If that is the case, it 
will be checked if it was a mistake not to include this/these substances in the CAG. 
3.2. Toxicological effects and mode/mechanism of action 
Information on toxicological effects and potential modes and/or mechanisms of action for 
mammalian toxicity were obtain from Draft Assessment Reports (DARs), DAR addenda, and 
EFSA/ECCO/EPCO peer review reports. Reports from the Joint FAO/WHO Meting on 
Pesticide Residues (JMPR) were consulted in order to examine whether additional relevant 
toxicological information was available. In addition, a search in the open literature, such as 
PubMed, was performed on additional toxicological studies and potential modes/mechanisms 
of action of the active substances.  
Initially, DARs for the included active substances were examined for toxic effects on specific 
organs or tissues. On the basis of this examination, Excel spread sheets were established for 
each individual organ/tissue system containing the following information: Substance number, 
substance name, phenomenological/specific toxicological effect(s), study type (species, strain, 
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duration, mode of administration), mode of action, mechanism of action, NOAEL, LOAEL, 
reference/source, and remarks.  
Due to the organisation of the work load where all the studies were to be scrutinised further by 
experts in the specific toxicological areas it was decided to group some traditional endpoints 
into a larger common group. An example was that effects on fertility and fetal development 
were grouped under the heading reproductive and developmental toxicity. The term effect 
point was therefore used for either a traditional endpoint (toxicological target) or a group of 
traditional endpoints.   
For all the effects identified in the DARs the relevant studies were evaluated by the experts 
allocated to the various effect areas. As the purpose of this project was not to review the 
DARs the information therein was considered valid. Consequently, the evaluations regarding 
a particular effect of an active substance to be treatment-related or not, as well as the NOAELs 
and LOAELs for the effects observed in the individual toxicological studies were taken from 
the DARs whenever available.  
For many active substances, the effect observed for a particular target organ/tissue the changes 
were small in comparison to the control group, did not reach statistically significance, were 
not dose-related, reported in only one or a few studies, and/or findings were not consistent 
across studies, sex and/or species. Therefore, the findings were often considered in the DARs 
not to be treatment-related. For findings in long-term studies, the findings were often 
considered in the DARs to be age-related – not treatment-related. Thus, a particular target 
organ/tissue in such cases seems not to be a primary target organ/tissue for the active 
substances included in this project and the substances identified to affect a target organ/tissue 
in such cases were not considered further for CAGs in this report. Moreover, the description 
of the findings in the various DARs are very different regarding details and exactness, which 
contributes to uncertainties in the interpretation of the findings described in the DARs.  
In many cases, the NOAELs and LOAELs for the specific effects were not identical with the 
study NOAELs and LOAELs. In these cases, the NOAELs and LOAELs were carefully 
evaluated by the experts based on the information in the DARs and relevant comments are 
presented in the remark column of the spreadsheets. The NOAELs and LOAELs in the 
spreadsheets are generally expressed as a systemic dose in the unit ‘mg/kg bodyweight/day’ 
regardless of the exposure route / mode of administration. For dietary studies (and inhalation 
studies) where the amount of the test substance is expressed as a concentration in the feed (or 
in the test atmosphere), the systemic dose was cited from the DAR whenever available. In 
other cases the systemic dose was calculated from the dietary concentration by using the 
general conversion factors provided in the OECD ‘Guidance notes for analysis and evaluation 
of chronic toxicity and carcinogenicity studies’ (OECD 2002) and presented in Appendix C of 
this report. 
However, more recent information from DAR addenda, and EFSA/ECCO/EPCO peer review 
reports was obtained, when available, and JMPR reports were also consulted for additional 
information. The open literature was searched via PubMed. Pubmed was mainly used for the 
literature searches as this database is the most comprehensive one covering toxicological 
topics of relevance for human health, including information of modes/mechanisms of action. 
For all active substances identified to affect a target organ/ tissue, the search was performed 
for all the substances by name and by CAS number. If the number of hits were below 100, all 
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abstracts were checked. If more than 100 hits, the search was refined to include the name of 
the specific target organ/tissue. The literature search for active substances on reproductive and 
developmental toxicity was slightly different from the general search strategy and is described 
in section 25.2.2. Unless otherwise stated, the introductory text for a specific target 
organ/tissue is based on relevant text books (without a reference to these text books) and the 
information on specific substances is taken from the respective DAR (without a reference to 
the DARs either located from the Circa database or from the rapporteur on request if not 
available from the Circa database). 
The quality control was performed in two steps: 
• The first step consisted of a multilateral quality check in form of an in-house meeting 
with participation of all the experts involved in this project. The individual effect point 
sections included in the preliminary draft report for discussion at the fourth Steering 
Group meeting held on 15-16 March 2011 in Parma were presented and discussed at 
the meeting. The in-house meeting was considered as being more feasible and valuable 
for the project instead of a consultation with external toxicologists as the expertise on 
the various toxicological targets and effect points is represented by the in-house 
experts. This decision was agreed at the third Steering Group meeting held on 13 
October 2010 (teleconference). 
• The second step consisted of a quality check of both the individual effect point 
spreadsheets and sections for the report. This step was predominantly performed by the 
senior experts involved in the project. 
 
Based on the evaluations of the relevant studies and the quality control final versions of the 
individual effect point spreadsheets and sections for this report were prepared. 
The report sections for the various target organs/tissues are kept as consistent as possible, i.e. 
following a predefined template. However, as target organs/tissues are different, the report 
sections will consequently be somewhat inconsistent reflecting the differences between the 
target organs/tissues. 
4. Criteria for dismissing effects for CAG 
Clearly, effects reported in toxicological studies that are considered to be either not adverse or 
of no relevance for human risk assessment should not be used for establishing CAGs. It is 
outside the scope of this report to prepare a comprehensive list of non-adverse effects and 
effects without relevance for humans. However, at number of examples relevant for the 
pesticide active substances can be found in the chapters dealing with CAGs for the different 
toxicological target organs and tissues. Examples are non-adverse discoloration of an 
organ/tissue, for instance the bone marrow, and development of thyroid tumours in rats and 
mice because of changes in the thyroid and pituitary hormone levels, considered to be of no 
relevance for humans.   
However, there are a number of effects that can be considered adverse and also of relevance 
for humans but nevertheless are not considered relevant for inclusion in a CAG. These non-
specific or indirect effects can occur either as a result of an advanced state of a toxic 
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impact/insult i.e. a secondary effect to a specific (direct) effect or as a consequence of high, 
massive (unrealistic) exposure to a pesticide active substance.   
Acute effects like mortality and clinical signs of toxicity will not be taken into consideration as 
CRA is generally only relevant following cumulative exposure to the active substances over 
time. 
Clinical observations will constitute a major part of the group of non-specific effects as they 
often occur as a consequence of a substantial toxicological impact or an advanced state of 
toxicological injury leading to a terminal effect including “near death” . These effects 
represent the state beyond which the resources of the organism are exhausted in compensating 
for an effect of a toxicological insult. Clinical observations/effects reported from acute 
toxicity tests including the LD50 tests are often of such nature e.g. decreased activity/not alert, 
subdued appearance, persistent recumbency, catalepsia, lethargy, comatose, sedation, 
lacrimation, chromodacryorrhea, salivation, nasal discharge, diarrhoea, pinched abdomen, 
hunched posture, distended abdomen, piloerection, laboured respiration, pinched abdomen, 
ataxia, paresis, tremor, convulsion etc. Many of these clinical observations especially the latter 
four mentioned could very well be referred to a neurotoxicological MOA. However, this is not 
done unless data are available that allow for categorizing these effects as a result of a specific 
MOA contrary to a terminal state of an un-specific toxicological effect. 
Effects on body weight and related parameters such as decreased body weight (BW), 
decreased body weight gain (BWG), decreased food consumption (FC), decreased water 
consumption, dehydration, soft stool, etc. seen after repeated exposure are also examples of 
unspecific effects as a consequence of exposure to a toxicant or simply as a secondary effect 
of a specific toxicological effect where the organisms resources to adapt are depleted or 
exhausted. Where effects like decrease in BWG or FC are the only effects observed even at 
low doses they will also be referred to the category of non-specific effects due to lack of data 
to establish a specific MOA. 
Changes in organ weights are generally only considered relevant if the change is relative, i.e. 
relative to the bodyweight or brain weight: 
• When the changes in the absolute weight of an organ is recorded together with similar 
changes in absolute weights of other organs and these changes relate usually to 
changes in body weight and are not accompanied with any pathological changes the 
change is considered as an unspecific effect, which is not related to toxicity to the 
organ. 
• When the changes in the relative weight of an organ (alone or accompanied by a 
change in absolute organ weight) alone or accompanied by changes in relative (and 
absolute) weights of other organs without pathological changes and which can be 
related to changes in body weight (i.e. secondary to body weight changes) this is 
considered an indirect effect, which is not related to toxicity per se although it is a 
treatment related effect. 
• When the changes in the relative weight of an organ (alone or accompanied by a 
change in absolute organ weight) not necessarily accompanied by changes in relative 
(and absolute) weights of other organs, but accompanied by dose related 
morphological changes in the organ this is considered to be a direct effect. 
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Many active substances were reported to increase or decrease the relative weight of a target 
organ or tissue. In general, the changes were small in comparison to the control group, did not 
reach statistically significance, were not dose-related, increased weights were related to an 
increased incidence of masses (noted in the macroscopic examination) and/or neoplasms 
(noted in the microscopic examination), observed in only one or a few studies, and/or findings 
were not consistent across studies, sex and/or species. Therefore, the changes in relative organ 
weight were often considered in the DARs not to be treatment-related. Moreover, the 
description of the findings in the various DARs are very different regarding details and 
exactness, which contributes to uncertainties in the interpretation of the findings described in 
the DARs. In conclusion, increased and decreased relative organ weight are considered as not 
being applicable for a CAG at level 2 and consequently, not relevant in terms of CRA for 
effects on a specific target organ or system. 
Changes in white blood cell parameters are not recommended for CRA, see section 14.2.2.4. 
Changes in blood and urine clinical biochemistry parameters, such as hepatic leakage 
enzymes (i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate 
dehydrogenase (LDH), ornithine carbamyltransferase (OCT), and sorbitol dehydrogenase 
(SDH)) and creatinine are indirect indicators for damage to various organs, in particular the 
liver and kidneys. However, the CAGs for different morphological/histopathological effects 
on the tissues will cover more adequately the potential injury indicated by these blood and 
urine parameters.  
Some effects like increased plasma cholesterol are usually considered non adverse if the 
increase is under a certain limit. However, in cumulative risk assessment it is not relevant to 
distinguish between adverse/not adverse effects based on such limits because the accumulated 
increase caused by several substances each contributing with an increase under the specified 
limit may exceed the limits. Effects which are considered non adverse under a certain limit in 
traditional risk assessments may therefore be considered adverse in cumulative risk 
assessment.  As a consequence, no effects will be considered non adverse based on a limit of 
the effect.  
Experimental animals or humans may adapt to chemicals. In toxicological experiments an 
effect is considered adaptive if the effect is observed after relative short time of exposure but 
vanish after prolonged exposure. There are some discussions whether this should be 
considered adverse. Although there are no toxic effects after long-time exposure to such 
substances some scientist consider adaptive effects adverse because the organism clearly uses 
some of its “spare capacity” to deal with this single substance. As it cannot be excluded that 
an organism will not be able to adapt to several substances simultaneously an effect is 
considered adverse even though the effect vanish after prolonged exposure.  
The above text represents general considerations of effects which are referred to as non-
specific (indirect) in the present report. However, many more examples are given under the 
specific target organs/tissue and moreover those effects not considered/listed as the basis for 
establishing the CAG can be taken as non-specific effects according to the consideration 
above. 
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5. Considerations on mode / mechanism of action 
The initial step in the cumulative risk assessment of a mixture of chemicals is to identify one 
or more groups of compounds that induce a common toxic effect by a common mechanism of 
toxicity. Such compounds belong to a “common mechanism group” (CMG) for which dose-
addition (simple similar action) apply. When chemicals in a mixture act in the same way, by 
the same mechanism or mode of action, and differ only in their potencies dose-addition 
implies that the effect of exposure to the mixture is equivalent to the effect of the sum of the 
potency-corrected doses of each component.  
The International Life Sciences Institute (ILSI) has considered the definition of the term 
common mechanism of toxicity. It was concluded that chemicals act via a common 
mechanism of toxicity if they cause the same critical effect, act on the same molecular target 
tissue, act by the same biochemical mechanism of action, or share a common toxic 
intermediate (ILSA 1999). 
The toxicological literature on mixtures and regulatory guidance documents for mixture 
assessment often fail to make clear distinctions between the terms mode of action and 
mechanism of action. 
In 1999, the US EPA provided “Guidance for identifying pesticide chemicals and other 
substances that have a common mechanism of toxicity” (EPA 1999a). In this guidance US 
EPA defined a common mechanism of toxicity to be caused “by the same, or essentially the 
same, sequence of major biochemical events.” This definition is equivalent to the definition of 
the term mode of action used by US EPA in 2002 (EPA 2002). In other reports US EPA 
distinguished between mechanism of action and mode of action: The term mode of action 
describes “the key events and processes starting with interaction of a compound with a cell via 
operational and anatomical changes, resulting in the toxic effect. Mechanism of action implies 
a more detailed understanding and description of the steps at the molecular level” (EPA 2000, 
2005). 
EFSAs PPR Panel also noted that in some US EPA documents on cumulative risk assessment, 
when the term mechanism of action is used it implies mode of action as defined above. Thus, 
a common mechanism of toxicity was defined as occurring when “two or more pesticide 
chemicals cause a common toxic effect by the same, or essentially the same, sequence of 
major (or key) biochemical events” (EFSA 2008). 
According to Borgert et al. (2004) mechanism of action denotes the molecular sequence of 
events leading from the absorption of an effective dose of a chemical to the production of a 
specific biological response in the target organ. Mode of action is a more general description 
of the chemical action. It refers to the type of response produced in an exposed organism or to 
only critical steps or features of the mechanism required for the production of the particular 
biological response. Therefore, when determining similarity between chemicals in a mixture, 
chemicals may not appear adequately similar to support use of an addition model when 
looking for a similar mechanism of action, but may appear adequately similar when looking 
for a similar mode of action. Thus, the mode of action is known if the full mechanism is 
known, but the reverse is not true. (Borgert et al. 2004). 
Lambert and Lipscomb (2007) considered that “mode and mechanism of toxic action are 
mutually supportive concepts that differ only in the level of detail regarding the processes 
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involved in toxicity”. They cited the definitions originally given by the US EPA (EPA 2000) 
and stated that mechanism of action typically has been relegated to molecularly discrete 
reactions (e.g. DNA/RNA modifications, enzyme-substrate interactions, oxidative stress), 
while mode of action has commonly been described at a more macrospopic level of biological 
organisation. For example a toxic mode of action has been decribed as a set of physiological 
and behavioural sign characteristic of an adverse biological response. 
Teuschler (2007) discussed the importance of having a clear set of definitions and ideas of the 
concept of similarity of toxic action in order to develop a common understanding among risk 
assessors. She pointed out that “similarity of toxicological action represents a continuum of 
information ranging from a high level of detail regarding the molecular basis of the toxic 
effect (mechanism of action) to knowledge of key cellular and biochemical events (mode of 
action), to a low level of knowledge regarding a general toxicological effect at the target 
organ level” (toxicological similarity) (Table 5.1). 
 
Table 5.1. The continuum of information behind similar toxic action (after Teuschler 
2007). 
Terminology 
describing 
toxicological action 
Mechanism of 
action 
Mode of action Toxicological 
similarity 
Level of knowledge 
needed 
High Medium-High Low 
Likelihood of having 
knowledge 
Low Low-Medium High 
Interpretation of 
terminology 
Knowledge of the 
details of the 
molecular basis of 
the toxic effect  
Knowledge of the 
sequence of key 
cellular and 
biochemical events 
(measurable 
parameters) that 
result in a toxic 
effect 
General knowledge 
of toxicological 
effect at the target 
organ level 
 
 
According to the International Programme on Chemical Safety (IPCS 2009b) mode of action 
(MOA) is “a biologically plausible sequence of key events leading to an observed effect 
supported by robust experimental observations and mechanistic data. A mode of action 
describes key cytological and biochemical events - that is, those that are both measurable and 
necessary to the observed effect- in a logical framework” (IPCS 2009b).  The mode of action 
contrasts with mechanism of action, which generally involves a sufficient understanding of 
the molecular basis for an effect and its detailed description, so causation can be described in 
molecular terms (Boobis et al. 2006). IPCS (2009b) has defined mechanism of action as “the 
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specific biochemical interaction through which a substance produces an effect on a living 
organism or in a biochemical system”.  
The IPCS originally developed a framework for establishing the mode of action of chemical 
carcinogens in animals.  The first step is to determine whether the weight of evidence based 
on experimental observations is sufficient to establish a hypothesized mode of action. This 
comprises a series of key events causally related to the toxic effect, identified using an 
approach based on the Bradford Hill criteria for causality (Sonnich-Mullin et al. 2001). This 
mode of action framework was later updated and incorporated into the IPCS framework for 
analysing the relevance of a cancer mode of action for humans (Boobis et al. 2006).  In 2008 
the IPCS mode of action framework was extended to embrace also non-cancer endpoints and 
was incorporated in the IPCS framework for analysing the relevance of a non-cancer mode of 
action for humans (Boobis et al. 2008). 
The present report agrees with Teuschler (2007) in that mode of action and mechanism of 
action represents a continuum of information that includes different sets of mechanistic 
information. For the purpose of this report mechanism of action (common assessment group 
(CAG) level 4) denotes detailed, stepwise information at various levels of biological 
organization whereas mode of action (common assessment group (CAG) level 3) includes 
only the critical mechanistic steps that produce a characteristic biological effect. 
As already mentioned in the introduction, evidence in the literature suggest that certain 
endocrine active compounds having a common phenomenological effect in mixture show a 
dose-additive common effect (such as for instance altered ano-genital distance for anti-
androgenic compounds) when exposures are at or below their individual NOAELs even if they 
do not share the same primary molecular target. Therefore, it appears that the first criterion for 
grouping compounds in a CAG should be that of a common phenomenological effect 
(toxicological similarity) (common assessment group (CAG) level 2). Hence, CAGs are not 
always identical to common mechanism groups (CMG).  
6. Development of CAGs 
The toxicological targets identified in step three for each of the 224 active substances to be 
evaluated for inclusion in CAGs were (in alphabetical order): Adrenal gland, bone marrow, 
bones / skeleton, brain, cardiovascular system (including the heart), eye, gall bladder, 
gastrointestinal tract, haematological system, immune system, kidney, liver, lung, lymph node, 
mamma, muscle, nervous system, pancreas, parathyroid, pituitary gland, reproductive and 
developmental toxicity (including reproductive organs), salivary gland, skin, spleen, stomach, 
thymus, thyroid, and urinary bladder. 
For several of the active substances listed in Appendix B of this report, neoplasms observed in 
the toxicological target organs/tissues were also initially registered in step three. Based on 
information in the DARs, neoplasms in the target organs/tissue were evaluated for the 
carcinogenic effect(s) concurrently with the assessments of non-carcinogenic effects for the 
respective target organs/tissues. Generally, the incidences of tumours at the highest dose 
levels tested did not reach statistically significance, were within the historical control range 
and/or were not dose-related. Therefore, the neoplasms were often considered in the DARs 
not to be treatment-related and consequently, the substances were concluded not to be 
carcinogenic. It is presumed that a substance is not approved as a pesticide active substance 
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and included in Annex I of Council Directive 91/414/EEC if the substance is carcinogenic and 
a genotoxic mode of action has been proposed for the carcinogenic effect(s). Therefore, for 
the purpose of the CAG project, a non-genotoxic mode of action has been assumed for the 
substances for which tumours were noted as an endpoint. Consequently, the NOAEL set for 
the effect(s) leading to the formation of such neoplasms are generally much lower than the 
NOAEL for the induction of neoplasms and thus, CRA based on a NOAEL set for the 
effect(s) leading to the formation of such neoplasms will also protect against induction of 
neoplasms. In addition, certain neoplasms are not relevant for humans, i.e. the induction of 
neoplasms are generally via a mode / mechanisms of action that is specific for a particular 
experimental animal. Examples of that include liver tumours in rodents via peroxisome 
proliferation, renal tumours in male rats via induction of alpha-2-microglobulin, thyroid 
tumours in rodents via increased serum TSH leading to stimulation of thyroid follicular cell 
growth and toxicity. In conclusion, the CAG level 2 for neoplasms is generally not 
recommended for CRA. However, information regarding neoplasms has been included and 
addressed in several of the endpoint sections when considered of relevance. 
At the interim meeting with the EFSA Project Steering Group it was decided that there should 
be several possible levels for CAGs for a given toxicological target. In the EFSA opinion on 
triazoles (EFSA 2009) two approaches were considered. An approach consisting in only 
including substances in a CAG when it has been demonstrated that they actually possess the 
same mode/mechanism of action; and an approach consisting in including all compounds that 
show a common phenomenological effect on the target in question.  
This led to the suggestion of a tiered approach in which four levels of CAGs would be 
possible reflecting increased knowledge on the mode/mechanism of action behind the 
toxicological effect observed. The four levels are 1) toxicological target, 2) common 
phenomenological effect, 3) common mode of action, and 4) common mechanism of action 
(see Figure  6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 1. Organ system affected 
 
Level 2.  Specific Effect 
Level 3. Mode of action 
Level 4.  Mechanism  x Level 4. Mechanism y 
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Figure 6.1. Tiered approach for allocating CAGs at different levels 
 
 
CAG level 1: 
All the active substances mentioned in the DARs to have toxicological effects on the target 
organ/tissue in question were generally allocated to the CAG level 1. This CAG merely 
collects all the substances that were to be further examined for specific phenomenological 
effects on the organ/tissue and, if possible the underlying mode/mechanism of action. The 
CAGs at level 1 should not be used for cumulative risk assessment. 
 
CAG level 2: 
A CAG at level 2 includes the active substances that exert a specific phenomenological effect 
on the target in question. Several CAGs at level 2 may be relevant for each target when 
different distinct specific effects are induced by different substances. As an example, the 
active substances that show effect on the thyroid gland were allocated into six distinct CAGs 
at level 2: Changes in serum T3 (and T4), increased TSH, follicular cell hyperplasia, follicular 
cell tumours, parafollicular cell hyperplasia, and parafollicular cell neoplasms. As a special 
case, due to the complexity, the active substances showing reproductive and developmental 
toxicity were initially allocated to eight distinct CAGs at level 2, which were further 
subdivided based on a number of specific phenomenological effects. 
The CAGs at level 2 are established on the basis of specific phenomenological effects without 
any prior knowledge about mode/mechanism of action and do therefore not fulfil the criteria 
for a cumulative mechanism group that can be expected to exert dose additivity. However, 
risk managers may wish to use a CAG at level 2 in order to consider whether a more realistic 
cumulative exposure assessment (for instance response addition) to certain active substances 
would need to be further investigated. 
For such an assessment, it can be recommended to use the Reference point index (RfPI) 
(based on the NOAELs for the compounds in the CAG) as described by the PPR Panel (EFSA 
2008). The RfPI is similar to the Point of departure index (PODI) advocated by EFSA (2007) 
and by WHO (2009) to be used in cumulative risk assessment. 
The Reference Point Index (RfPI) represents the sum of the exposures to each pesticide 
expressed as a fraction of their respective RfPs for the relevant effect (e.g., the dose that 
causes a 10% effect, BMD10; or the NOAEL). When the RfPI multiplied by a chosen group 
uncertainty factor (UF) is lower than 1, the combined risk is considered acceptable. An UF of 
100 is recommended. 
 
CAG level 3: 
For a number of pesticide active substances, information is available that show or permit a 
hypothesis on the mode of action for several specific effects (reported at CAG level 2), mostly 
for substances that affect the liver and the endocrine systems (reproductive organs, thyroid) as 
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well as the nervous system. An example is that a number of active substances which affect the 
performance of the male reproductive organ system may do so via an anti-androgenic mode of 
action. The CAGs at level 3 established based on these criteria are considered valid for 
cumulative risk assessment. 
 
CAG level 4: 
For some of the pesticide active substances, studies are available (mainly in the open 
literature) that point upon a specific mechanism of action for the toxicological effects seen, 
most notably for endocrine active substances. Most of these studies are in vitro studies and 
care should therefore be taken in the interpretation of the results. However, for many of the 
active substances the mechanistic effects observed in vitro are substantiated by the effects 
seen in the animal studies and can therefore form the bases for allocation of a CAG at level 4. 
An example would be that an anti-androgenic mode of action for effect of an active substance 
on male reproductive performance (reported at CAG level 3) was likely due to an antagonistic 
effect on the androgen receptor as shown in vitro. The CAGs at level 4 are considered valid 
for cumulative risk assessment. 
 
CAG nomenclature: 
The ideal is that an active substance allocated to a specific CAG level 4 could be tracked back 
to the associated CAG at level 3 and again tracked back to the associated CAG at level 2. 
Therefore, the following nomenclature has been applied for the CAGs at level 2, level 3 and 
level 4 for the target organs (excluding reproductive and developmental toxicity) as far as 
possible.  
A CAG at level 2 includes the active substances that exert a specific phenomenological effect 
on the target in question. Several CAGs at level 2 may be relevant for each target when 
different distinct specific effects are induced by different substances. A CAG at level 2 is 
therefore described by a number followed by a letter: CAG level 2a, CAG level 2b etc. 
A CAG at level 3 includes the active substances that exert a specific phenomenological effect 
on the target in question via a specific mode of action. Several CAGs at level 3 may be 
relevant for each target when different distinct specific effects (CAG level 2) are induced by 
different mode of actions for the respective substances (CAG level 3). A CAG at level 3 is 
therefore described by a number followed by a letter and a number: CAG level 3a1, CAG 
level 3a2, CAG level 3b1 etc.  
If a CAG at level 3 is associated with a specific CAG level 2 then: 
• A substance allocated to CAG level 3a1 is also allocated to CAG level 2a 
• A substance allocated to CAG level 3a2 is also allocated to CAG level 2a 
• A substance allocated to CAG level 3b1 is also allocated to CAG level 2b etc.  
 
A CAG at level 4 includes the active substances that exert a specific phenomenological effect 
on the target in question via a specific mode of action and a specific mechanism of action. 
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Several CAGs at level 4 may be relevant for each target when different distinct specific effects 
(CAG level 2) are induced by different mode of actions for the respective substances (CAG 
level 3) and by different mechanisms of action (CAG level 4). A CAG at level 4 is therefore 
described by a number followed by a letter, a number and a letter: CAG level 3a1a, CAG level 
3a1b, CAG level 3a2a, CAG level 3a2b, CAG level 3b1a, CAG level 3b1b etc.  
If a CAG level 4 is associated with a specific CAG level 3 which again is associated with a 
specific CAG level 2 then: 
• A substance allocated to CAG level 3a1a is also allocated to CAG level 3a1 and CAG 
level 2a 
• A substance allocated to CAG level 3a1b is also allocated to CAG level 3a1 and CAG 
level 2a  
• A substance allocated to CAG level 3a2a is also allocated to CAG level 3a2 and CAG 
level 2a  
• A substance allocated to CAG level 3a2b is also allocated to CAG level 3a2 and CAG 
level 2a  
• A substance allocated to CAG level 3b1a is also allocated to CAG level 3b1 and CAG 
level 2b  
• A substance allocated to CAG level 3b1b is also allocated to CAG level 3b1 and CAG 
level 2b etc.  
 
It should be noted, however, that for some substances for which a mode and/or mechanism of 
action has been identified, there is no association to a particular CAG at level 2 or 3, 
respectively. In such cases, the first letter assigned to a particular CAG at level 3 is described 
by the next letter in the alphabet which is not associated with a CAG level 2 or 3 for a 
particular target organ. As an example, specific phenomenological effects on the target in 
question have been allocated to CAG level 2a, 2b, 2c and 2d. If a mode of action (CAG level 
3) could not be associated with one of the CAGs at level two, then this mode of action would 
be assigned to CAG level 3e1. If a mechanism of action (CAG level 4) could not be associated 
with neither any of the CAGs at level 2 nor the CAG at level 3, then this mechanism of action 
would be assigned to CAG level 4f1a.  
It should also be noted that the general CAG nomenclature has not been applied for the liver 
as this approach turned out to be too complicated due to the fact that the mode of actions 
(CAG level 3) in general could be tracked back to a single specific phenomenological effect 
(CAG level 2). Therefore, a CAG at level 3 is described by a number followed by a letter, e.g. 
3a and the associated CAG at level 4 is described by a number followed by a letter and a 
number, e.g. 4a1, 4a2 etc. 
For the thyroid, a slightly different approach has been used as a combined mod of action 
model has been proposed for CAG level 3. The CAGs at level 4 are therefore, described by a 
number followed by a letter, e.g. 4a, 4b etc. 
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General remark: 
For some CAGs, there is only one active substance included. However, such potential CAGs 
are included in the report because novel research may identify such effects for other active 
substances. In addition, regulatory bodies may in the future consider active substances not 
included in the present project, i.e. substances adopted for inclusion in Annex 1 of Council 
Directive 91/414/EEC after the 31st of May 2009. 
 
Consideration of pesticide active substances having similar structures or belonging to the 
same chemical class: 
The PPR Panel (EFSA 2008) suggested that pesticide active substances could also potentially 
be grouped in a CAG based on similar chemical structure. This could be explored by 
substructure searches in databases for toxophores (a structural feature or moiety contained in 
substances causing the same toxic effect. The toxic effect is attributed to the interaction of 
such a feature or moiety with the molecular target) (or a metabolic precursor of a toxophore), 
core molecular structures, and functional groups. A detailed substructure search was judged to 
be outside the scope of this report. However, the CAGs at level 2, 3, and 4 that were 
established based on the toxicological effects were examined for completeness or not of active 
substances having similar structures based on the chemical grouping outlined in Appendix A. 
Active substances belonging to the same chemical class may have similar toxicological 
effects. For selected target organs, information in the DARs on effects on the respective target 
organ has been summarised for evaluation of similarity of toxicological effects within the 
relevant chemical classes, i.e. the chemical classes containing more than one active substance. 
The selected target organs include the liver (see section 17.4), the nervous system (see section 
21.4) and the eye (see section 11.4). 
 
 
Results 
The available toxicological studies on the active substances listed in Appendix B were 
carefully scrutinized for toxicological effects and CAGs are proposed for a number of specific 
target organs and tissues. For each target recommendations are given on potential CAGs that 
should be considered for use in cumulative risk assessment (CRA). The results are describe 
below for each target organ/tissue (see chapter 7-31). 
A searchable database in Microsoft Access has been provided to EFSA. Together with key 
information on the chemical and pesticidal properties and the acceptable daily intake (ADI) 
established by the EU for the active substances, the database contains the results of the present 
evaluations of all the available toxicological studies used to allocate the active substances into 
different CAGs, including the NOAELs and LOAELs (see chapter 32). 
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7. Adrenal gland 
7.1. Introduction 
There are two adrenal glands, one on top of each kidney, see Figure 7.1. Each adrenal gland 
constitutes two distinct endocrine glands.  
 
 
From http://www.britannica.com/EBchecked/topic-art/6405/121578/Human-adrenal-gland 
Figure 7.1. Anatomy of the adrenal gland 
 
 
The inner adrenal medulla mainly secretes the hormones adrenaline and noradrenaline. The 
surrounding adrenal cortex secretes different steroid hormones. 
7.1.1. Adrenal medulla 
The adrenal medulla, together with the sympathetic nervous system, is embryonically derived 
from neural crest cells. Adrenaline (about 75%) and noradrenaline (about 25%) are the main 
hormones secreted from the adrenal medulla. The main neurotransmitter between the 
sympathetic nervous system and the effector cells is noradrenaline.   
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The adrenal medulla synthesizes adrenaline (also 
called epinephrine) and noradrenaline (also called 
norepinephrine) from the amino acid phenylalanine 
through a series of enzymatic reactions – see Figure 
7.2. 
The regulation of adrenal release of adrenaline and 
noradrenaline is complex. Secretion is increased by 
adrenocorticotropic hormone (ACTH) from the 
anterior pituitary, by the adrenocortical hormone, 
cortisol, and by the sympathetic nervous system. The 
hormones inhibit their own secretion by decreasing 
the formation of the rate limiting enzyme tyrosine 
hydroxylase. There are other stimuli to adrenal 
medullary secretion. 
The sympathetic nervous system and the adrenal 
medulla are usually activated during stress. The 
release of adrenaline and noradrenaline and the 
response of the body are often termed the “fight or 
flight” response. In general, the main effect of 
adrenaline and noradrenaline is to prepare the body 
for “fight of flight” by getting energy to the skeletal 
muscles. Blood will be shunted from viscera to 
skeletal muscles to provide glucose and oxygen to the 
muscles. The glucose concentration will increase 
through a variety of mechanisms. Heart rate and 
ventilation will increase to increase the oxygen 
supply.  
 
 
From http://en.wikipedia.org/wiki/Epinephrine 
Figure 7.2. Biosynthesis of adrenaline 
 
7.1.2. Adrenal cortex 
The adrenal cortex secretes different steroid hormones. They are all synthesized from 
cholesterol – see Figure 7.3. Cortisol and corticosterone are glucocorticoids, which regulate 
carbohydrate metabolism. Aldosterone is a mineralocorticoid, which regulate the body levels 
of sodium and potassium. Androstenidione is an androgen, whose action is similar to that of 
testosterone although much weaker.  
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The adrenal cortex has insignificant stores of steroid hormones. Instead lipid droplets in the 
adrenal cells store cholesterol precursors, which can rapidly be metabolised to the steroid 
hormones. The level of the steroid hormones naturally varies during the day and night. 
The adrenal cortex contains three different zones termed zona glomerulosa, zona fasciculate 
and zona reticularis – see Figure 7.1. The hormones are synthesized and secreted in different 
zones as can be seen on Figure 7.3 because the gland contains different enzymes (written in 
green in the figure) necessary for the synthesis in the different zones. 
 
3b-DH is 3b-dehydrogenase, P450c11 is 11b-hydroxylase, P450c17 is 17a-hydroxylase, P450c21 is 21b-hydroxylase.  
From http://eglobalmed.com/core/Biochemistry_Kings/web.indstate.edu/thcme/mwking/steroid-hormones.html 
Figure 7.3. Synthesis of adrenal steroid hormones from cholesterol in humans 
 
 
7.1.2.1. Species differences 
The zona reticularis in all animals is not always easily distinguishable and dedicated to 
androgen synthesis. In rodents, for instance, the zona reticularis also generates corticosterone, 
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which is the dominant glucocorticoid in rodents because of a negligible expression of 
P450c17. Female rodents also exhibit another cortical layer called the "X zone" whose 
function is not yet clear. 
7.1.2.2. Zona glomerulosa (aldosterone secretion) 
The primary role of aldosterone is to conserve sodium. This is accomplished by increasing the 
activity of the sodium pump of the epithelial cells especially in the kidney. 
Aldosterone synthesis and secretion are regulated mainly by the renin-angiotensin system – 
see Figure 7.4. The renin-angiotensin system regulates blood pressure and water balance. 
 
When blood volume is low, the 
kidneys secrete renin .  
Renin stimulates the production of 
angiotensin I , which is then 
converted to angiotensin II . 
Angiotensin II causes blood vessels to 
constrict, resulting in increased blood 
pressure. Angiotensin II also 
stimulates the secretion of aldosterone 
. Aldosterone causes the kidneys to 
increase the reabsorption of sodium 
and water into the blood . This 
increases the volume of fluid in the 
body, which also increases blood 
pressure. 
 
From http://www.merckmanuals.com/home/sec03/ch022/ch022a.html  
Figure 7.4. The renin-angiotensin system 
 
 
7.1.2.3. Zona fasciculate (cortisol and corticosterone secretion) 
In humans cortisol is by far more important than corticosterone. Like adrenaline, cortisol is 
elevated during stress and increases the glucose concentration by various mechanisms.  
Cortisol also has anti-inflammatory and growth-suppressing effects.  
The secretion of cortisol is regulated primarily by ACTH from the anterior pituitary via a 
negative feedback mechanism.  
Secreted cortisol is transported in plasma bound to CBG (corticosteroid binding globulin). 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
38 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
7.1.2.4. Zona reticularis (androstenedione secretion) 
Because androstenedione and other androgens secreted from the adrenal gland are much less 
potent than testosterone, they are of little physiological significance in men. Some of the 
weakly androgenic substances secreted by the adrenal gland may be converted to testosterone 
in peripheral tissue thus accounting for some androgenic effect initiated by the adrenal cortex. 
In women, sexual desire is probably more dependent upon androgens secreted by the adrenal 
glands than upon oestrogen.   
ACTH from the anterior pituitary appears to be the major regulator of androgen secretion 
from the adrenal gland. 
7.2. Establisment of CAGs for toxicity to the adrenal glands 
7.2.1. CAG level 1: Toxicity to the adrenal glands 
The active substances identified as having an effect on the adrenal glands in the toxicological 
studies included in the DARs are allocated to CAG level 1 and are listed in Table 7.1.  
 
Table 7.1. CAG level 1: Toxicity to the adrenal glands 
2,4-D Fosthiazate Quizalofop-P (test substance: tefuryl) 
Chlorothalonil Iprodione Tebuconazole 
Chlorpyrifos-methyl Lufenuron Thiamethoxam 
Epoxiconazole Metconazole Tralkoxydim 
Fluoxastrobin Oxadiazon Triticonazole 
 
 
7.2.2. CAG level 2: Phenomenological / specific effects on the adrenal glands 
Various types of effects on the adrenal glands identified as a basis for establishing CAGs at 
level 2 include effects on the adrenal cortex such as enlargement, hypertrophy, hyperplasia, 
cytomegaly, vacuolation, lipid accumulation in adrenal cells, atrophy, degeneration, necrosis, 
and tumours. 
Based on these effects, four distinct CAGs at level 2 are proposed. More information is given 
in Appendix D. 
7.2.2.1. CAG level 2a: Hypertrophy / hyperplasia of the adrenal cortex 
Hypertrophy is an increased size of cells, cytomegaly is an abnormal enlargement of cells, and 
hyperplasia is an increased number of cells. It is not always clear in the DARs, whether the 
terms ‘hypertrophy’ and ‘hyperplasia’ have been used to distinguish between the two different 
types of histopathological effects and the terms have in many cases been used synonymously.  
For the purpose of the CAG project, gross pathology findings in form of enlarged zona(s) in 
the adrenal cortex and histopathological findings in form of hypertrophy, hyperplasia and 
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cytomegaly of cells in the adrenal cortex are allocated to a single CAG level 2, termed ‘CAG 
level 2a: Hypertrophy / hyperplasia of the adrenal cortex’.  
The active substances identified as inducing one or more of the above-mentioned effects in 
the adrenal cortex are allocated to CAG level 2a and are listed in Table 7.2. 
 
Table 7.2. CAG level 2a: Hypertrophy / hyperplasia of the adrenal cortex 
2,4-D Fosthiazate Quizalofop-P (test substance: tefuryl) 
Chlorothalonil Iprodione Tebuconazole 
Chlorpyrifos-methyl Lufenuron   
 
 
7.2.2.2. CAG level 2b: Fatty changes in the adrenal cortex 
For some active substances, vacuolation and lipid accumulation is a description of the same 
effect in the DARs as the lipid is accumulated in the vacuoles. Although it is not clear from 
the DARs if this is always the case, these findings are, for the purpose of the CAG project,  
interpreted as representing the same type of effect in the adrenal cortex. 
For the purpose of the CAG project, histopathological findings described as vacuolation, lipid 
droplets, lipid storage, fat/lipid vacuoles, fatty changes, fatty degeneration, and fatty 
metamorphosis are allocated to a single CAG level 2, termed ‘CAG level 2b: Fatty changes in 
the adrenal cortex’. 
The active substances identified as inducing one or more of the above-mentioned effects in 
the adrenal cortex are allocated to CAG level 2b and are listed in Table 7.3. 
 
Table 7.3. CAG level 2b: Fatty changes in the adrenal cortex 
Chlorpyrifos-methyl Iprodione Tebuconazole 
Epoxiconazole Metconazole  Thiamethoxam 
Fluoxastrobin Oxadiazon Tralkoxydim 
Fosthiazate Quizalofop-P (test substance: tefuryl) Triticonazole 
 
 
7.2.2.3. CAG level 2c: Cell degeneration / cell death in the adrenal cortex 
Atrophy is loss of tissue, totally or partially and necrosis is death of cells and tissues.  
For the purpose of the CAG project, histopathological findings described as atrophy, 
degeneration, and necrosis are allocated to a single CAG level 2, termed ‘CAG level 2c: ‘Cell 
degeneration / cell death in the adrenal cortex’.  
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The active substances identified as inducing one or more of the above-mentioned effects in 
the adrenal cortex are allocated to CAG level 2c and are listed in Table 7.4. 
 
Table 7.4. CAG level 2c: Cell degeneration / cell death in the adrenal cortex 
Epoxiconazole Thiamethoxam  
 
 
7.2.2.4. CAG level 2d: Neoplasms in the adrenal cortex 
One active substance was reported to induce adenomas in the adrenal cortex. This substance is 
allocated to the CAG level 2d and is listed in Table 7.5. 
 
Table 7.5. CAG level 2d: Neoplasms in the adrenal cortex 
Epoxiconazole   
 
 
7.2.2.5. Effects not considered relevant for CAGs at level 2 
Effects such as sinus dilation, angiectasis (dilation of the blood vessels), pigmentation, 
multinucleated cells, amyloidosis (the tissue is filled with amyloid, a wax-like protein), 
mineralisation, and eosinophilic foci have been noted for a few active substances.  
These effects are considered either as indirect effects on the adrenal gland or as being non-
adverse effects and therefore, not relevant for CAGs at level 2 and consequently, not relevant 
in terms of CRA for effects on the adrenal glands. 
7.2.3. CAG level 3: Mode of action  
The most common effect noted in the adrenals is an increased relative adrenal weight for 
which a CAG is not considered to be relevant. An increased relative adrenal weight can be an 
indication of a toxic effect directly on the adrenal glands. If the secretion of e.g. cortisol is 
decreased because of a direct effect on the adrenal gland, the adrenal gland will try to increase 
the production and secretion of cortisol. The level of ACTH will increase and will stimulate 
the adrenal gland to grow in an attempt to maintain circulating basal levels of cortisol. In this 
situation, the level of ACTH will be increased and the level of cortisol will be low or normal.  
However, an increased adrenal weight might also reflect an increased activity of the adrenal 
gland due to stress because of effects on other organ systems. In this situation the level of 
ACTH will also be increased, but the level of cortisol will at least initially also be increased.  
Stress (and increased levels of cortisol) is known to induce thymus atrophy and decreased 
thymus weight. So for the active substances where thymus atrophy and/or decreased thymus 
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weight has been noted in addition to increased adrenal weight, the effect on the adrenal gland 
is most likely a consequence of stress due to effects on other organ systems and thus, the 
increased adrenal weight might be an indirect effect on the adrenal gland.  
Standard toxicological studies are not designed to differentiate the effects of active substances 
on other organ systems from direct effects on the adrenal gland as the hormone levels in 
general are not measured.  
Four types of phenomenological effects in the cortex of the adrenal gland have been noted: 
Hypertrophy / hyperplasia (CAG level 2a), fatty changes (CAG level 2b), cell degeneration / 
cell death (CAG level 2c), and neoplasms (CAG level 2d). 
As for increased relative adrenal weight, the increased growth (hypertrophy) of the cortex can 
be stress-related or a direct toxic effect on the adrenal cortex. 
If the production of steroid hormones is inhibited, the excess steroid precursors will 
accumulate in the cytoplasma and the number and size of cytoplasmic vacuoles may increase. 
However, hyperactivity in the adrenal gland because of stress may also result in vacuolation. 
For some of the active substances, vacuolation and lipid accumulation is a description of the 
same effect as the lipid is accumulated in the vacuoles. 
Loss of adrenocortical cells (atrophy) due to necrosis, cell lysis, or apoptosis can be a 
consequence of severe or prolonged toxicity to the adrenal gland.  
No information to clarify whether the phenomenological effects in the adrenal cortex are 
direct or indirect effects on the adrenal gland has been found, except for epoxiconazole, see 
below. No other information regarding the mode of action for these effects has been found. 
Consequently, none of the substances identified as having these phenomenological effects in 
the adrenal cortex can be allocated to a CAG level 3. 
7.2.3.1. CAG level 3d1: Hormonal alterations 
One substance, epoxiconazole, induced adenomas in the adrenal cortex and is allocated to 
CAG level 2d ‘Neoplasms in the adrenal cortex’. There is some information on the mode of 
action for the tumourigenic effect of epoxiconazole as adrenal hormone levels have been 
measured. The levels of androgen steroids and ACTH were increased while the levels of 
corticosterone and aldosterone were decreased. These changes can be explained by a test 
substance-related decrease of the adrenal enzyme activity of either 11- or 21-hydroxylase. The 
decreased adrenal steroid levels trigger a feedback response in the hypothalamic-pituitary axis 
resulting in increased ACTH levels. The continuous stimulation of adrenocortical cells by 
ACTH is considered to be responsible for the induction of the adrenal tumours by 
epoxiconazole. Based on this information, epoxiconazole is allocated to CAG level 3d1 
‘Hormonal alterations’ and is listed in Table 7.6. 
Table 7.6. CAG level 3d1: Adenomas in the adrenal cortex related to hormonal 
alterations 
Epoxiconazole   
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7.2.4. CAG level 4: Mechanism of action  
Effects on the adrenal glands can be elicited by a number of mechanisms: 
• Inhibition of one or more of the enzymes of steroidogenesis (appears to be the most 
common mechanism) => excess steroid precursors => accumulation of increased 
cytoplasmic lipid  
• Increased enzyme expression 
• Enzymes in adrenal gland may metabolise and potentially activate chemicals 
• Altered expression of receptors on the adrenocortical cells 
• Inhibition of the StAR protein (Steroidogenic Acute Regulatory protein is a protein 
necessary for moving cholesterol from the cell cytosol to the inner mitochondrial 
membrane) 
• Decreased binding affinity of CBG leading to increased plasma level of cortisol 
• Increased metabolism of steroid hormones e.g. in the liver leading to decreased plasma 
levels 
• Affected binding to target receptors 
• Inhibition of hormones in the hypothalamus (CRH) or pituitary (ACTH) 
• Generation of free radicals during steroid hydroxylation reactions 
• Potential lipid peroxidation as a result of high membrane content of unsaturated fatty 
acids.  
 
Mechanisms of action have not been studied for any of the active substances identified as 
having effects on the adrenal glands. Consequently, none of the substances identified as 
having effects on the adrenal gland can be allocated to a CAG level 4.  
7.3. Discussion of CAGs for the adrenal glands 
Fifteen active substances were identified to have effects on the adrenal glands and were 
allocated to CAG level 1. Four distinct CAGs at level 2 have been proposed. Information on 
mode of action is only available for one of the active substances, epoxiconazole. No 
information on the mechanism(s) of action is available for any of them. The information is 
summarised in Appendix F. 
Epoxiconazole is the only active substance, which induces neoplasms and is the only active 
substance for which a mode of action has been proposed. It should be noted however, that the 
CAG level 2 for neoplasms is not recommended for CRA, see Chapter 4.  
As no information regarding the mode / mechanism(s) of action for the phenomenological 
effects in the adrenal gland of the active substances in general has been found, the three CAGs 
at level 2 (2a-2c) could be considered for CRA for effects on the adrenal gland. It should be 
noted that the effects allocated to these CAGs may be interrelated. 
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7.4. Recommended CAGs for the adrenal glands  
The following CAGs at level 2 are recommended for CRA for effects on the adrenal gland: 
• CAG level 2a: Hypertrophy / hyperplasia of the adrenal cortex, see Table 7.2. 
• CAG level 2b: Fatty changes in the adrenal cortex, see Table 7.3. 
• CAG level 2c: Cell degeneration / cell death in the adrenal cortex, see Table 7.4. 
 
 
8. Bone marrow 
8.1. Introduction 
The bone marrow, also called myeloid tissue, is confined to the cavities of bones. Bone 
marrow consists of blood vessels, nerves, mononuclear phagocytes, stem cells, blood cells in 
various stages of differentiation, and fatty tissue.  
• Adults have two kinds of bone marrow:  
• Red marrow (active marrow, consisting mainly of haematopoietic tissue)  
• Yellow marrow (inactive marrow, consisting mainly of fat cells – it is the large 
quantities of fat that makes it yellow).  
 
Not all bones contain active marrow. In adults, active marrow exists in the pelvic bones (ring 
formed of the two hip bones), vertebrae, cranium and mandible (lower bone in the jar), 
sternum (the breastbone) and ribs, and extreme proximal portions of the humerus (top bone in 
the arm) and femur (top bone in the leg). Inactive marrow predominates in cavities of other 
bones. 
The bone marrow contains three types of stem cells:  
• Haematopoietic stem cells that give rise to the three classes of blood cells that are 
found in the circulation: White blood cells (leukocytes), red blood cells (erythrocytes), 
and platelets (thrombocytes).  
• Mesenchymal stem cells that have the capability to differentiate into osteoblasts, 
chondrocytes, myocytes, and many other types of cells.  
• Endothelial stem cells. 
 
Blood cell production, termed haematopoiesis, occurs under normal conditions only in the 
bone marrow and is known as medullary haematopoiesis. Medullary haematopoiesis increases 
in response to various disorders that deplete blood cells. Increased medullary haematopoiesis 
is thus, an indirect effect on the bone marrow, i.e., is secondary to a decreased number / 
depletion of circulating blood cells, see Chapter 14 ‘Haematological system’.  
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The blood vessels in the bone marrow constitute a barrier, the bone marrow barrier, which 
inhibits immature blood cells from leaving the bone marrow. Only mature blood cells contain 
the membrane proteins required to attach to and pass the bone marrow barrier. 
The normal bone marrow architecture can be displaced by malignancies, aplastic anaemia, or 
infections such as tuberculosis, leading to a decrease in the production of blood cells and 
platelets. In addition, cancers of the haematological progenitor cells in the bone marrow can 
arise; these are the leukemias. 
8.2. Establishment of CAGs for toxicity to the bone marrow  
8.2.1. CAG level 1: Toxicity to the bone marrow 
Various types of effects on the bone marrow were identified including: 
• Hyperplasia 
• Hypercellularity 
• Increased medullary haematopoiesis 
• Increased number of megakaryocytes 
• Haemosiderosis (increased amounts of a yellow-brown iron containing pigment) 
• Hypoplasia 
• Hypocellularity 
• Atrophy 
• Necrosis 
• Haemorrhage 
• Congestion 
 
Most of the active substances identified to affect the bone marrow induced hyperplasia, 
hypercellularity, increased medullary haematopoiesis, increased number of megakaryocytes, 
haemosiderosis, effects that are secondary to a direct effect on the cellular elements in the 
blood stream and are therefore covered by the CAGs for the cellular elements in the blood 
stream, see Chapter 14. Overall, these effects are not considered relevant in terms of CRA for 
direct effects on the bone marrow and the active substances causing these effects are therefore 
not considered further for CAGs in relation to the bone marrow.  
Some of the active substances identified to affect the bone marrow induced hypocellurarity, 
hypoplasia, atrophy and/or necrosis, effects that are considered as a direct effect on the bone 
marrow. The active substances identified as causing these effects in the bone marrow in the 
toxicological studies included in the DARs are allocated to CAG level 1 and are listed in 
Table 8.1. 
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Table 8.1. CAG level 1: Toxicity to the bone marrow 
2,4-D Clodinafop Metiram 
2,4-D metabolite: 2,4-
dichlorophenol 
Clothianidin Pethoxamid 
Acibenzolar-S-methyl metabolite: 
CGA 210007 
Fluopicolide Pyraflufen-ethyl 
Bifenazate Flutolanil Spinosad 
Bromoxynil Ioxynil Trifloxystrobin 
Chlorotoluron Isoproturon Tritosulfuron-methyl 
Chlorsulfuron metabolite: IN-A4097 MCPA og MCPB  
 
 
8.2.2. CAG level 2: Phenomenological / specific effects on the bone marrow 
Based on the effects on the bone marrow considered as being direct effects, two distinct CAGs 
level 2 are proposed. More information is given in Appendix F. 
8.2.2.1. CAG level 2a: Hypoplasia 
Hypoplasia is a decrease in the number of cells and hypocellularity is an abnormal decrease in 
the number of cells. 
For the purpose of the CAG project, hypoplasia and hypocellularity in the bone marrow are 
allocated to a single CAG level 2, termed ‘CAG level 2a: Hypoplasia’.  
The active substances identified as inducing hypoplasia or hypocellularity in the bone marrow 
are allocated to CAG level 2a and listed in Table 8.2. 
 
Table 8.2. CAG level 2a: Hypoplasia 
2,4-D Clodinafop Metiram 
Acibenzolar-S-methyl metabolite: 
CGA 210007 
Clothianidin Pyraflufen-ethyl 
Bifenazate Fluopicolide Spinosad 
Bromoxynil Flutolanil Trifloxystrobin 
Chlorotoluron Ioxynil Tritosulfuron-methyl 
Chlorsulfuron metabolite: IN-A4097 Isoproturon  
 
8.2.2.2. CAG level 2b: Cell degeneration / cell death 
Atrophy is loss of tissues, totally or partially and necrosis is death of cells and tissues.  
For the purpose of the CAG project, histopathological findings described as atrophy and 
necrosis are allocated to a single CAG level 2, termed ‘CAG level 2b: ‘Cell degeneration / cell 
death’.  
The active substances identified as inducing one or more of the above-mentioned effects in 
the bone marrow are allocated to CAG level 2b and are listed in Table 8.3. 
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Table 8.3. CAG level 2b: Cell degeneration / cell death 
2,4-D metabolite: 2,4-
dichlorophenol 
Pethoxamid Trifloxystrobin 
MCPA and MCPB Spinosad  
 
 
8.2.2.3. Effects not considered relevant for CAGs at level 2 
Effects such as discolouration, haemorrhage and congestion of the bone marrow have been 
observed. These effects are considered as being non-adverse or non-specific effects and 
therefore, not relevant for CAGs at level 2 and consequently, not relevant in terms of CRA for 
effects on the bone marrow.  
8.2.3. CAG level 3: Mode of action  
For some of the effects considered as being direct effects on the bone marrow described under 
CAG level 2, a mode of action has been proposed. For the remaining substances, no 
information regarding mode of action has been found and consequently, these substances 
cannot be allocated to a CAG level 3. 
8.2.3.1. CAG level 3a1: Hypoplasia related to a direct effect on the bone marrow 
For a metabolite of the active substance acibenzolar-S-methyl (metabolite CGA 210007) 
identified as inducing hypoplasia in the bone marrow and allocated to CAG level 2a, there is 
information in the DAR that the effect is probably due to a direct cytotoxic effect of the 
metabolite to bone marrow cells. This substance is allocated to CAG level 3a1 and is listed in 
Table 8.4. 
 
Table 8.4. CAG level 3a1: Hypoplasia related to a direct effect on the bone marrow 
Acibenzolar-S-methyl (metabolite CGA 210007)   
 
 
8.2.3.2. CAG level 3b1: Atrophy related to a direct effect on the bone marrow 
For two (MCPA and MCPB – MCPA a metabolite of MCPB) of the three active substances 
identified as inducing atrophy in the bone marrow and allocated to CAG level 2b, there is 
information in the respective DARs that the effect is probably due to a direct effect on the 
bone marrow. These substances are allocated to CAG level 3b1 and are listed in Table 8.5. 
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Table 8.5. CAG level 3b1: Atrophy related to a direct effect on the bone marrow 
MCPA and MCPB   
 
 
8.2.4. CAG level 4: Mechanism of action  
For three active substances, a mode of action for direct effects observed in the bone marrow 
has been proposed. However, no information regarding the mechanism(s) of action has been 
found for these four substances. Consequently, these four substances cannot be allocated to a 
CAG level 4. 
No information on mechanism(s) of action has been found for any of the other active 
substances identified as having an effect on the bone marrow. 
8.3. Discussion of CAGs for the bone marrow 
Twenty active substances or metabolites were identified to have potential direct effects on the 
bone marrow and were allocated to CAG level 1. Two distinct CAGs at level 2 have been 
proposed. Information on mode of action is available for three of the active substances and 
information on the mechanism(s) of action is available for a few of them. The information is 
summarised in Appendix G. 
A mode of action for direct effects on the bone marrow has been identified for one of the 
substances allocated to CAG level 2a, and for two of the substances allocated to CAG level 
2b. There is, however, no information on the mechanism(s) of action for any of them. 
Therefore, the two CAGs at level 3 could be considered for CRA. However, as only one 
active substance is allocated to each of these CAGs at level 3 (MCPB allocated to CAG level 
3b1 is extensively metabolised to MCPA in mammalian species and MCPA is the toxic 
metabolite of MCPB), these two CAGs at level 3 are not recommended for CRA for the time 
being. However, these CAGs may become relevant in the future provided that new 
information on other active substances justifies the mode of action forming the basis for the 
respective CAGs. 
No information regarding the mode of action for the remaining active substances allocated to 
CAG level 2a and 2b, respectively, has been found. Therefore, these CAGs at level 2 could be 
considered for CRA. 
8.4. Recommended CAGs for the bone marrow 
The following CAGs at level 2 are recommended for CRA for effects on the bone marrow: 
• CAG level 2a: Hypoplasia, see Table 8.2. 
• CAG level 2b: Cell degeneration / cell death, see Table 8.3. 
 
The following CAGs are not recommended for CRA for the time being. However, these 
CAGs may become relevant in the future provided that new information on other active 
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substances justifies the mode of action / reveals the phenomenological effects forming the 
basis for the respective CAGs: 
• CAG level 3a1: Hypoplasia related to a direct effect on the bone marrow, see Table 
8.4. 
• CAG level 3b1: Atrophy related to a direct effect on the bone marrow, see Table 8.5. 
 
 
9. Bones / skeleton 
9.1. Introduction 
Bones are the calcified pieces of connective tissue which make the skeleton. The human 
skeleton consists of 206 bones. The major functions of the bones are: 
• to give form to the body, permit movement and to provide protection of vital organs  
• to house the bone marrow which produces blood cells  
• to store minerals such as calcium, phosphate, magnesium 
 
Bones are composed of: 
• bone cells (osteoblasts, osteocytes, and osteoclasts)  
• bone matrix (mainly collagen, proteoglycans, and glycoproteins)  
• bone minerals (mainly calcium and phosphate) 
• blood vessels and nerves 
 
Osteoblasts are the bone-forming cells. They are responsible for bone matrix synthesis and its 
subsequent mineralization.  
Osteocytes are osteoblasts that become incorporated within the newly formed bone matrix. 
They have a role in maintaining the bone matrix.  
Osteoclasts function primarily to resorb (remove) bone during processes of growth and repair.   
The hardness and rigidity of bone is due to the presence of minerals in the bone matrix. As 
can be seen from figure 9.1 the metabolism of calcium and phosphate is regulated by a 
complex interplay mainly between the parathyroid hormone, vitamin D and calcitonine. 
Acting together, these substances determine the amount of dietary calcium and phosphate 
absorbed from the intestine, the reabsorption and excretion of calcium and phosphate by the 
kidney, and the deposition and release of calcium and phosphate from the bone. Both 
parathyroid hormone and active vitamin D stimulate osteoclasts to resorb bone (and release 
calcium and phosphate from bone) whereas calcitonin suppresses calcium release from bone 
by suppression of osteoclasts. 
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The production of parathyroid hormone, active vitamin D and calcitonin is mainly regulated 
by the serum level of calcium but also by other minerals and other substances. 
 
 
From http://www.orthoteers.com/(S(j0xys0d0pf4cams5k0qeo11b))/mainpage.aspx?section=10&article=48 
Figure 9.1. Calcium and phosphate metabolism 
 
9.2. Establishment of CAGs for toxicity to the bones / skeleton 
9.2.1. CAG level 1: Toxicity to the bones / skeleton 
The active substances identified as having an effect on the bones / skeleton in the 
toxicological studies included in the DARs are allocated to CAG level 1 and are listed in 
Table 9.1. 
Table 9.1. CAG level 1: Toxicity to the bones / skeleton 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Flazasulfuron Thiophanate-methyl 
Cinidon ethyl Sulfosulfuron Tolylfluanid 
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Etoxazole Tetraconazole  
 
 
It should be noted that developmental effects on bones / skeleton, such as delayed ossification 
and skeletal malformations in foetuses, which are generally observed in reproductive toxicity 
and teratogenicity studies are not included here, but considered in the section on effects on the 
reproductive system and developmental toxicity (chapter 25). 
9.2.2. CAG level 2: Phenomenological / specific effects on bones / skeleton 
Various types of effects on bones / skeleton were identified as a basis for establishing CAGs 
at level 2. Based on these effects, three distinct CAGs at level 2 are proposed. More 
information is given in Appendix H. 
9.2.2.1. CAG level 2a: Fibrous osteodystrophy 
Fibrous osteodystrophy is a lesion of the bone in which fibrous tissue replaces resorbed bone.  
The active substances identified as inducing fibrous osteodystrophy are allocated to CAG 
level 2a and are listed in Table 9.2. 
For thiophanate-methyl, the effect on bone was described in the DAR as demineralisation of 
bone. However, as fibrous osteodystrophy is a consequence of demineralisation of bone, 
thiophanate-methyl was also allocated to the CAG level 2a. 
 
Table 9.2. CAG level 2a: Fibrous osteodystrophy 
2-Phenylphenol  Flazasulfuron Thiophanate-methyl 
Cinidon ethyl Sulfosulfuron  
 
 
9.2.2.2. CAG level 2b: Hypertrophy / hyperplasia 
Active substances that induce effects described as hyperostosis (excessive growth of bone), 
hyperplasia of bone tissue (increased number of cells in bone), osseous hypertrophy (increased 
size of cells in bone), and thickening of bone are allocated to CAG level 2b and are listed in 
Table 9.3. 
 
Table 9.3. CAG level 2b: Hypertrophy / hyperplasia 
Etoxazole Tetraconazole Tolylfluanid 
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9.2.2.3. CAG level 2c: Osteopetrosis. 
One active substance was identified as inducing osteopetrosis (hardening of bone). This 
substance is allocated to CAG level 2c and is listed in Table 9.4. 
 
Table 9.4. CAG level 2c: Osteopetrosis 
Tolylfluanid   
 
 
9.2.3. CAG level 3: Mode of action  
For some of the phenomenological / specific effects on the bones / skeleton described under 
CAG level 2, a mode of action has been proposed. For the remaining substances, no 
information regarding mode of action has been found and consequently, these substances 
cannot be allocated to a CAG level 3. 
9.2.3.1. CAG level 3a1: Chronic nephropathy and hyperparathyroidism 
In early chronic renal failure, excreted phosphate levels decrease and the plasma phosphate 
concentration increases. Plasma phosphate binds calcium which results in hypocalcaemia. As 
a consequence, the parathyroids start to secrete parathyroid hormone in order to return calcium 
and phosphate levels to normal. The consequence is activation of osteoclasts and resorption of 
bone.  At later stages of chronic renal failure the effects on bone are accelerated as the 
synthesis of active vitamin D may be impaired.  
For four of the five active substances identified as inducing fibrous osteodystrophy and 
allocated to CAG level 2a, the mode of action was suggested to be secondary to chronic 
nephropathy and hyperparathyroidism. These substances are allocated to CAG level 3a1 and 
are listed in Table 9.5. 
 
Table 9.5. CAG level 3a1: Fibrous osteodystrophy related to chronic nephropathy and 
hyperparathyroidism 
Cinidon ethyl Sulfosulfuron Thiophanate-methyl 
Flazasulfuron   
 
 
9.2.3.2. CAG level 3b1: Accumulation of fluoride 
For two of the three active substances (tetraconazole and tolylfluanid) identified as inducing 
hypertrophy / hyperplasia and allocated to CAG level 2b, the mode of action has been ascribed 
to accumulation of fluoride in bone. Fluoride is released when the substances are metabolised 
in the liver. For the remaining substance (etoxazole) allocated to CAG level 2b, the mode of 
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action is likely the same, as etoxazole like tetraconazole and tolylfluanid contains fluoride. 
These substances are allocated to CAG level 3b1 and are listed in Table 9.6. 
 
Table 9.6. CAG level 3b1: Hypertrophy / hyperplasia of bone related to accumulation of 
fluoride in bone 
Etoxazole Tetraconazole Tolylfluanid 
 
 
Whitening of bone is caused by an increased concentration of fluoride in the bone,  an effect 
covered by the CAG level 3b1 for accumulation of fluoride in bone. 
9.2.4. CAG level 4: Mechanism of action 
No information on mechanism(s) of action have been found for any of the active substances 
identified as having an effect on the bones / skeleton. 
9.3. Discussion of CAGs for the bones / skeleton 
Eight active substances were identified to have effects on the bones / skeleton and were 
allocated to CAG level 1. Three distinct CAGs at level 2 have been proposed. Information on 
mode of action is available for some of the active substances. No information on the 
mechanism(s) of action is available for any of them. The information is summarised in 
Appendix I. 
For four of the five active substances allocated to CAG level 2a, the available information on 
mode of action indicates that the effects are indirect effects in the bone, i.e., are secondary to 
chronic nephropathy and hyperparathyroidism (CAG level 3a1). The CAG level 3a1 as well as 
the CAG level 2a for these substances are therefore, not considered relevant in terms of CRA 
for a direct effect on the bones / skeleton. 
For the three active substances allocated to CAG level 2b, the available information on mode 
of action indicates that the effects are due to accumulation of fluoride in bone (CAG level 
3b1), which is released when the substances are metabolised in the liver. This is considered as 
being a direct effect of these substances on bone and therefore, relevant for CRA. 
No information regarding the mode of action for the remaining active substance allocated to 
CAG level 2a as well as for the active substance allocated to CAG level 2c has been found. 
Therefore, these two CAGs at level 2 could be considered for CRA. However, as only one 
active substance remains allocated to CAG level 2a and only one substance is allocated to 
CAG level 2c, these two CAGs at level 2 are not recommended for CRA for the time being. 
However, these CAGs may become relevant in the future provided that new information on 
other active substances reveals the phenomenological effects forming the basis for the 
respective CAGs and for CAG level 2a, provided that no information on the mode of action is 
available. 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
53 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
9.4. Recommended CAGs for bones / skeleton 
The following CAG at level 3 is recommended for CRA for effects on the bones / skeleton: 
• CAG level 3b1: Accumulation of fluoride, see Table 9.6. 
 
The following CAGs are not recommended for CRA for the time being. However, these 
CAGs may become relevant in the future provided that new information on other active 
substances reveals the phenomenological effects forming the basis for the respective CAGs: 
• CAG level 2a: Fibrous osteodystrophy, see Table 9.2 (only if no information on the 
mode of action is available). 
• CAG level 2c: Osteopetrosis, see Table 9.4. 
 
 
10. Cardiovascular system 
10.1. Introduction 
The cardiovascular (CV) system has two units: the heart (myocardium) and the vascular 
system (vasculature comprising arteries, capillaries and veins, lymphatic system; vascular 
bed). The function of both units is to supply cells of all tissues with nutrients, oxygen, 
hormones and metabolites and removing “waste products” from tissue. Thus the CV system 
plays an important role in maintaining homeostasis in the body, including maintaining body 
temperature. Damage to the CV system by a toxicant may impact on other organs, especially 
highly vascularised organs that are dependent on nutrients and oxygen carried by the blood. 
The assessment of the potential toxic effects of a pesticide active substances on the CV system 
may involve both a review of the results from routine regulatory toxicity studies and of special 
studies designed to detect changes in function and structure of the heart and vascular bed.  
The majority of animal studies on pestide active substances have been conducted in rodents 
and were not designed to detect clinically manifested disturbances in the function of the heart 
and/or blood vessels, although they can show a range of clinical, biochemical and pathological 
effects. Furthermore the routine regulatory toxicity studies will not provide information on 
potential atherogenicity or acceleration of atherosclerosis by test compounds because 
laboratory rodents and dogs do not develop atherosclerosis.  
10.1.1. Manifestation of CV toxicity 
CV toxicity is manifested directly on the CV system or indirectly on other organs, which are 
dependent on nutrient and oxygen carried by the blood. Both categories are manifested by 
functional changes (alterations) often clinically manifested or by morphological changes 
which are recorded by macroscopy and/or microscopy (morphological changes are also termed 
structural alterations, (histo)pathological changes), and changes in absolute and/or relative 
organ weights. 
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Functional changes (alterations) to the heart induced by direct action of a toxicant are 
manifested as disturbed rhythmicity and contractility of the heart (arrhythmias). 
Morphological changes (structural alterations) may lead to functional changes, which persists 
after cessation of the exposure to the toxicant. 
The range of reactions to a toxicant in blood vessels is limited. The pathogenesis of any 
change may be difficult to determine by morphological examination. Functional changes such 
as prolonged vasoconstriction may result in ischemia and necrosis of the surrounding tissues 
with no obvious morphological change in the vessel. 
Vascular injuries may be due to a direct (specific) interaction with the compound or it may be 
a secondary (indirect; unspecific) effect.. Secondary lesions develop as an extension of a 
disease process in surrounding tissues. However, direct vascular diseases (toxicoses) are the 
most frequent type seen and the lesions may be generalized or regional in distribution. 
Blood vessels vary in their functional responses to chemicals. The heterogeneity in response 
occurs not only between the vein and arteries, but between anatomically similar vessels in 
different regions of the circulation. 
10.2. Establishment of CAGs for toxicity to the cardiovascular system 
The CAG level system constructed in order to establish CAGs for CV toxicity is based on the 
anatomical components of the CV system: Heart,  vascular bed (major vessels and peripheral 
capillaries, and vasculature of organs other than the heart. The CAGs takes into account the 
clinical/functional and morphological changes noted after exposure to the active substances. 
In the evaluation, special attention was paid to determine whether the toxic effects on the CV 
system were due to a direct (specific) interaction of the compound with the CV system. If the 
changes seen were considered to be secondary to some other effects, i.e. indirect (unspecific), 
the compound was not included in a CAG.  
10.2.1. CAG level 1: Toxicity to the cardiovascular system 
The active substances identified as having an effect on the cardiovascular system in the 
toxicological studies included in the DARs are allocated to CAG level 1 and are listed in 
Table 10.1. 
 
Table 10.1. CAG level 1: Toxicity to the cardiovascular system 
Chlorsulfuron Difenoconazole Prosulfuron 
Chlorsulfuron, metabolite IN-
A4098 
Formetanate Quizalofop-P-tefuryl 
Clothianidin Fuberidazole Spinosad 
Cyflufenamid Glufosinate Tepraloxydim 
Cyromazine Propaquizafop Ziram 
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10.2.2. CAG level 2: Phenomenological / specific effects on the CV system 
Various types of effects on the CV system were identified as a basis for establishing CAGs at 
level 2:  
• Functional changes in the heart 
• Morphological changes in the hearth 
• Functional changes in the vascular bed 
• Morphological changes in the vascular bed 
• Toxicity to the vasculature of different organs 
 
Based on these effects, five distinct CAGs at level 2 are proposed. 
10.2.2.1. CAG level 2a: Functional changes in the heart 
The functional changes (clinically manifested disturbances) reported were abnormal heart rate 
(bradycardia, tachycardia) and arrhythmia, either supraventricular (supraventricular 
tachycardis, arterial fibrillation) or ventricular (ventricular fibrillation, ectopic heart beat, heart 
block).  
These functional effects are difficult to detect by a clinical examination in routine regulatory 
studies in rodents. They can be detected in special studies, for instance when 
electrocardiography is performed. 
Functional symptoms from the hearth caused by acetylcholine esterase inhibitors will occur 
together with several other effects characteristic for overstimulation of muscarinic receptors. 
More detailed information is given in Appendix J. 
The active substances identified as inducing functional changes in the heart are allocated to 
CAG level 2a and are listed in Table 10.2. 
 
Table 10.2. CAG level 2a: Functional changes in the heart 
Clothianidin Fuberidazole Glufosinate 
Cyflufenamid   
 
 
10.2.2.2. CAG level 2b: Morphological changes in the heart 
The morphological changes observed were cardiac hypertrophy, cardiac atrophy, dilated 
cardiomyopathies, degenerations (hydropic, myofibrillar, fatty (lipofuscinosis), necrosis, 
inflammation (myocarditis, infarction), and mineralisation (predominantly calcification). The 
morphological changes can be detected in toxicological studies, in which histological 
examinations are performed. More detailed information is given in Appendix K. 
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The active substances identified as inducing morphological changes in the heart are allocated 
to CAG level 2b and are listed in Table 10.3. 
 
Table 10.3. CAG level 2b: Morphological changes in the heart 
Chlorsulfuron, and metabolite IN A4098 Formetanate Prosulfuron 
Clothianidin Fuberidazole Quizalofop-P-tefuryl 
Cyflufenamid Glufosinate Spinosad 
Difenoconazole Propaquizafop Tepraloxydim 
 
 
10.2.2.3. CAG level 2c: Functional changes in the vascular bed 
The functional changes are clinically manifested disturbances in the function of blood vessels. 
The functional changes in blood vessels (arteries and veins) like hypo- or hypertension (as a 
consequence of vasodilatation or vasoconstriction) cannot be detected in the clinical phase of 
the routine regulatory studies in rodents. They can be detected in special in vivo studies, in 
which measurement of blood pressure, blood flow measurement, or a direct observation of 
blood vessels is performed. More detailed information is given in Appendix L. 
The active substances identified as inducing functional changes in the vascular bed are 
allocated to CAG level 2c and are listed in Table 10.4. 
 
Table 10.4. CAG level 2c: Functional changes in the vascular bed 
Fuberidazole Spinosad Tepraloxydim 
 
 
10.2.2.4. CAG level 2d: Morphological changes in the vascular bed 
The morphological changes in the wall of major blood vessels (arteries and veins) or 
peripheral capillaries can be detected in routine regulatory toxicity studies which include gross 
examination of the large vessels and histopathological examination of blood vessels. 
Only one active substance was identified to cause morphological chandes in the blood vessels 
(endothelial cells). It produced haemorrhage possibly due to damage of the wall of the blood 
vessels. This substance is allocated to CAG level 2d and is listed in Table 10.5. 
 
Table 10.5. CAG level 2d: Morphological changes in the vascular bed 
Quizalofop-P-tefuryl   
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10.2.2.5. CAG level 2e: Toxicity to the vasculature of different organs 
The most frequent morphological change in the vasculature of different organs after exposure 
to the active substances was congestion. The aetiology of congestion can be connected to 
cardiac toxicity (diminished “vital power” of the heart) i.e. pulmonary congestion or to 
obstruction of escape of blood from the organ in question due to functional or morphological 
changes. Other vascular changes in different organs, which may be recorded, are for instance 
an infarct, haemorrhage, thrombus, vascular ectasia or the expansion of sinusoids in endocrine 
tissue. The two last changes however, may be a part of the physiology of aging laboratory 
animal, thus not associated with toxicity toward vasculature of the organ in question. 
The changes in vasculature of certain organs can be detected in routine regulatory toxicity 
studies which include gross and histopathological examination of organs. Their specificity 
towards the CV system can be unclear as these changes can be secondary lesions as an 
extension of a direct toxicity toward a specific organ.  
More detailed information is given in Appendix M. 
The active substances considered to exert direct toxicity of the vasculature in different organs 
(congestion / haemorrhage) are allocated to CAG level 2e and are listed in Table 10.6. 
 
Table 10.6. CAG level 2e: Toxicity to the vasculature of different organs 
Clothianidin Formetanate Spinosad 
Cyflufenamid Glufosinate Ziram 
Cyromazine Quizalofop-P-tefuryl  
 
 
10.2.2.6. Effects not considered relevant for CAGs at level 2 
Changes in the relative weight of the heart are considered to be indirect and unspecific to the 
heart and therefore, not considered relevant for a CAG at level 2 (see also Chapter 4). 
10.2.3. CAG level 3 and level 4: Mode / mechanism of action  
No consistent modes/mechanisms of actions could be identified that would form the basis for 
CAGs at level 3 or 4 for toxicity on the CV system. 
The modes/mechanisms of action behind the functional changes in the heart could be related 
to either disturbances in ion transport or disturbances in the contractile or energy producing 
systems causing the following effects: Chronotropic (on heart rate), inotropic (on 
contractility), dromotropic (on conductivity), bathmotropic (on excitability). Disturbances due 
to inhibition of acetylcholinesterase (signs of stimulation of muscarinic receptor) were also 
reported. 
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Biochemical mechanisms behind the morphological changes could be: Hypoxia, oxidative 
stress, mitochondrial dysfunction, and inhibition of mitochondrial enzymes. 
10.3. Discussion of CAGs for the cardiovascular system 
Twenty-two active substances were identified to have effects on the cardiovascular system and 
were allocated to CAG level 1. Five distinct CAGs at level 2 have been proposed. No 
information on the modes/mechanisms of action is available for any of them. The information 
is summarised in Appendix N. 
Most of the substances that showed effects related to the CV system produced functional 
(CAG level 2a) or morphological (CAG level 2b) changes in the heart. These are the only two 
CAGs suggested to be considered for CRA for effects on the heart. 
The functional changes (CAG level 2c) in the vascular bed (major vessels) were general or 
visceral congestion or congestion in capillaries, decreased blood pressure and circulatory 
failure. No specific modes of action have been demonstrated, but these effects could have 
occurred due to vasodilatation, which can be caused by relaxation of smooth muscles of the 
blood vessel wall.  
Congestion (CAG level 2e) was also the most often recorded sign of toxicity towards the 
vasculature of specific organs. Haemorrhage was another often recorded change in this CAG. 
Haemorrhage is a consequence of the compromised wall of a blood vessel. In most cases, the 
haemorrhage is caused by a direct effect of the toxicant on the wall (endothelial cells) of the 
blood vessel (due to its presence in the blood).  
10.4. Recommended CAGs for the cardiovascular system 
The following CAGs at level 2 are recommended for CRA for effects on the cardiovascular 
system: 
• CAG level 2a: Functional changes in the heart, see Table 10.2. 
• CAG level 2b: Morphological changes in the heart, see Table 10.3. 
• CAG level 2c: Functional changes in the vascular bed, see Table 10.4. 
• CAG level 2e: Toxicity to the vasculature of different organs, see Table 10.6. 
 
The following CAG is not recommended for CRA for the time being. However, the CAG may 
become relevant in the future provided that new information on other active substances 
reveals the phenomenological effect forming the basis for the CAG: 
• CAG level 2d: Morphological changes in the vascular bed, see Table 10.5. 
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11. Eye 
11.1. Introduction 
The eyes are complex sense organs responsible for vision. Each eye has receptors, a lens 
system for focusing light on the receptors, and a system of nerves for conducting impulses 
from the receptors to the brain. 
The eye is protected by external structures consisting of the eyelids, conjunctivae, and 
lacrimal apparatus. The eyeball is the receptor part of the eye, a round ball of tissue through 
which light passes and which is controlled by various muscles. The eyeball is formed of three 
layers (sclera, choroid and retina), which encloses the aqueous humour, lens and vitreous body 
(Figure 11.1): 
• The sclera is the thick, white, outermost layer which becomes transparent at the 
cornea, the part of the sclera in the central anterior region that allows light to enter the 
eye.  
• The uvea is formed of the iris, the ciliary body and choroid. The choroid is the deeply 
pigmented middle layer that prevents light from scattering inside the eye. The iris, 
which is connected to the choroid by the ciliary body, has a round opening, the pupil, 
through which light passes. The ciliary muscle changes the shape of the lens in order 
to focus on objects at different distances.  
• The retina is the innermost layer and contains millions of rods and cones, which are 
special photoreceptors that convert the ocular light image into nerve impulses before 
sending them toward the brain. The photoreceptive rods and cones are distributed over 
the entire retina, except where the optic nerve leaves the eyeball.  
• The aqueous humour is the clear fluid filling the cavity between the cornea and the 
lens. 
• The lens is the part of the eye behind the iris and pupil which focuses light coming 
from the cornea onto the retina. The lens is an avascular, transparent tissue surrounded 
by an elastic, acellular, collagenous capsule, and is composed of only a single cell 
type. It can be arbitrarily divided into its anterior (corneal side) and posterior parts. 
• The vitreous body is the transparent jelly filling the main behind the lens. 
 
The anterior / posterior chambers of the eye are parts of the aqueous chamber. The anterior 
chamber is the space between the cornea and the iris, while the posterior chamber is the much 
smaller space behind the iris. 
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From http://www.britannica.com/EBchecked/topic/1688997/human-eye 
Figure 11.1. Anatomy of the eye 
 
 
11.2. Establishment of CAGs for toxicity to the eye 
11.2.1. CAG level 1: Toxicity to the eye 
The active substances identified as affecting the eye in the toxicological studies included in 
the DARs are allocated to CAG level 1 and are listed in Table 11.1. 
Table 11.1. CAG level 1: Toxicity to the eyes 
2,4-D Famoxadone Metribuzin 
2,4-DB Fenhexamid Oxamyl 
2-Phenylphenol Fenpropidin Oxasulfuron 
Acetamiprid Flazasulfuron Penconazole 
Benfluralin Fluazinam Propamocarb 
Chlorothalonil (metabolite: SDS-3701) Flufenacet (formerly fluthiamide) Propineb (metabolite: PU) 
Chlorpropham Fosthiazate Prosulfocarb 
Chlorpyrifos Glufosinate Prothioconazole 
Cymoxanil Glyphosate Rimsulfuron 
Daminozide Imazosulfuron Spiroxamine 
Dichlorprop-P Imidacloprid Sulcotrione 
Difenoconazole Iodosulfuron-methyl-sodium Tebuconazole 
Dimethachlor Isoxaflutole Thiacloprid 
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Dimethenamid-P Lenacil Thiamethoxam 
Dimethoate (metabolite: omethoate) Mancozeb Thiram 
Dinocap Mesosulfuron Tralkoxydim 
Diquat (dibromide) Mesotrione Tri-allate 
Ethofumesate Metamitron Tribenuron 
Ethoprophos Metconazole Triticonazole 
 
 
11.2.2. CAG level 2: Phenomenological / specific effects on the eye 
Various types of effects on the eyes were identified as a basis for establishing CAGs at level 
2. The cornea, the uvea/iris, the lens and the retina are primarily affected. 
Based on these effects, four distinct CAGs at level 2 are proposed. More information is given 
in Appendix O.  
11.2.2.1. CAG level 2a: Corneal opacity 
The main effects reported in the cornea are opacity and keratitis (inflammation). These effects 
might be related, e.g. keratitis may lead to opacity. However, corneal opacity is not necessarily 
related to inflammation. The active substances identified as inducing corneal opacity are 
allocated to ‘CAG level 2a: Corneal effects’, whereas the substances inducing keratitis are 
allocated to CAG level 2d, see below. 
For one substance, sulcotrione, keratopathy (a non-inflammatory disease of the cornea) was 
reported in the dog study, but not in the rat studies. This effect is also allocated to CAG level 
2a. 
The active substances allocated to CAG level 2a are listed in Table 11.2. 
 
Table 11.2. CAG level 2a: Corneal opacity  
Benfluralin Isoxaflutole Rimsulfuron 
Chlorpropham Mesotrione Spiroxamine 
Daminozide (metabolite: UDMH) Metribuzin Sulcotrione 
Ethoprophos Propineb (metabolite: PU) Tri-allate 
 
 
11.2.2.2. CAG level 2b: Cataract 
The main effect reported in the lens is cataract. Any opacity of the lens and its capsule is 
clinically termed a cataract, a condition where the lens gradually changes from perfect 
transparency to translucency. A number of different terms have been used in the DARs to 
describe cataract, see Appendix Q for a list of these terms. 
The active substances identified as inducing cataract are allocated to ‘CAG level 2b: Cataract’ 
and are listed in Table 11.3. 
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Table 11.3. CAG level 2b: Cataract  
2,4-D Dimethoate (metabolite: omethoate) Mesotrione  
2,4-DB Dinocap  Metconazole 
2-Phenylphenol Diquat (dibromide) Prosulfocarb 
Acetamiprid Famoxadone Prothioconazole 
Benfluralin Fenhexamid Rimsulfuron 
Chlorothalonil (metabolite: SDS-3701)  Fenpropidin Spiroxamine 
Chlorpropham Flazasulfuron Sulcotrione 
Chlorpyrifos Flufenacet (formerly fluthiamide) Tebuconazole  
Cymoxanil  Glyphosate Thiacloprid  
Difenoconazole  Imazosulfuron Thiamethoxam 
Dimethachlor Lenacil Triticonazole 
Dimethenamid-P  Mesosulfuron  
 
 
11.2.2.3. CAG level 2c: Retinal effects 
A number of different effects have been reported for the retina including degeneration, 
atrophy, grey pigmentation / grey mottling / brown granularity of the tapetal fundus 
(membranous layer or region of the choroid / retina), degeneration of the optic fundus, 
hyperreflection, hyporeflection, tapetal lesions, dystrophy of the pigment epithelium, 
electroretinographic (ERG) abnormalities, cystic vacuolisation of the peripheral optic retina, 
and desquamation, see Appendix Q for a description of these effects. These effects might to 
some extent be interrelated. For the purpose of the CAG project, the abovementioned effects 
in the retina are allocated to a single CAG level 2, termed ‘CAG level 2c: Retinal effects’. 
The active substances identified as inducing retinal effects and allocated to CAG level 2c are 
listed in Table 11.4. 
 
Table 11.4. CAG level 2c: Retinal effects  
2,4-D Fluazinam  Oxasulfuron 
2,4-DB Flufenacet (formerly fluthiamide) Penconazole 
Acetamiprid Fosthiazate Propamocarb  
Chlorothalonil, metabolite  Glufosinate Spiroxamine 
Chlorpyrifos Imazosulfuron Sulcotrione 
Cymoxanil Imidacloprid Thiacloprid 
Dichlorprop-P Lenacil Thiram 
Dimethoate (metabolite: omethoate) Mancozeb Tralkoxydim 
Dinocap  Metamitron Tribenuron 
Ethofumesate Oxamyl  
 
 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
63 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
11.2.2.4. CAG level 2d: Inflammation 
A number of substances have been reported to induce inflammation around or in the eye, e.g. 
conjunctivitis (inflammation of the conjunctiva), keratitis (inflammation of the cornea), 
uveitis (inflammation of the uvea, which is formed of the iris, the ciliary body and the 
choroid), iritis (inflammation of the iris), and panophthalmitis (inflammation of the whole of 
the eye).  
Other effects have also been reported, which are interpreted as being signs of inflammation, 
see Appendix Q for a list of these terms.  
The active substances identified as inducing inflammation / signs of inflammation are 
allocated to ‘CAG level 2d: Inflammation’ and are listed in Table 11.5. 
 
Table 11.5. CAG level 2d: Inflammation  
2,4-D Fenpropidin  Metconazole  
2-Phenylphenol Flazasulfuron Sulcotrione  
Acetamiprid Imazosulfuron Thiram  
Chlorpyrifos Iodisulfuron-methyl-sodium Triticonazole 
Difenoconazole Isoxaflutole  
Dimethoate (metabolite: omethoate) Mesotrione   
 
 
11.2.2.5. Effects not considered relevant for CAGs at level 2 
Discolouration of an organ or tissue is generally not considered as being an adverse effect; 
however, for the eye, discolouration is accepted as an adverse effect. Discolouration of the eye 
or part of the eye has been reported for a number of the active substances identified as having 
an effect of the eyes. For some substances, the discolouration is observed in a particular part 
of the eye and thus, covered by the respective CAGs at level 2. For other substances, the 
discolouration is due to various effects not already included in a CAG at level 2, e.g. dark red 
discolouration due to haemorrhage. Although discolouration of the eye is regarded as an 
adverse effect, this effect is not considered as being applicable for a CAG at level 2 and 
consequently, not relevant in terms of CRA for effects on the eye. 
Chromodacryorrhea, i.e. rats shedding red tears, is not caused by haemorrhage, but by the 
secretion of a red pigment, porphyrin, from a gland behind the eye (the Harderian gland). This 
effect is not considered as being applicable for a CAG at level 2 and consequently, not 
relevant in terms of CRA for effects on the eye. 
Other effects on the eye have been noted for single substances, e.g. vacuolisation of the ciliary 
body epithelium, vacuolation and superficial exfoliation of epithelial cell (loosing layers of 
tissue), epithelial thickening, necrosis, subepithelial fibroblastic reaction and vascularisation 
of stroma (supporting tissue), fundal haemorrhage, miosis (contraction of the pupil), 
blepharospasms (sudden contraction of the eyelid), photophobia (the eyes become sensitive to 
light), and sclerosis (hardening of tissue). These effects are considered either as being non-
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adverse effects and therefore, not relevant for CAGs at level 2, or as not being applicable for a 
CAG at level 2 and consequently, not relevant in terms of CRA for effects on the eye.  
11.2.3. CAG level 3: Mode of action  
For one type of the phenomenological / specific effects on the eye described under CAG level 
2, a mode of action has been proposed. For the remaining substances, inadequate or no 
information regarding mode of action has been found and consequently, these substances 
cannot be allocated to a CAG level 3. 
11.2.3.1. CAG level 3a1: Increased systemic tyrosine concentration 
Increased systemic tyrosine concentration has been shown in a study of sulcotrione in rats to 
be accompanied by corneal lesions and keratitis (data summarised in the sulcotrione DAR 
July 2006). Isoxaflutole and mesotrione also increase the systemic tyrosine concentration in 
rats and, as for sulcotrione, this is accompanied by corneal lesions and keratitis (data 
summarised in the isoxaflutole March 1998 and mesotrione DAR December 1999, 
respectively). 
The active substances inducing corneal opacity and keratitis (CAG level 2a) due to an 
increased systemic tyrosine concentration are allocated to CAG level 3a1 and are listed in 
Table 11.6. 
 
Table 11.6. CAG level 3a1: Increased systemic tyrosine concentration 
Isoxaflutole Mesotrione Sulcotrione 
 
 
11.2.4. CAG level 4: Mechanism of action 
For the active substances allocated to CAG level 3a1, a mechanism of action has been 
proposed. For the remaining substances, inadequate or no information regarding mechanisms 
of action has been found and consequently, these substances cannot be allocated to a CAG 
level 4. 
11.2.4.1. CAG level 4a1a: HPPD inhibition 
The mode of action for the two active substances of the triketone family included in Annex I 
of Council Directive 91/414/EEC (up to 31st of May 2009), mesotrione and sulcotrione, in 
both plants and animals is inhibition of the 4-hydroxyphenyl pyruvic acid dioxygenase 
(HPPD) enzyme, a key enzyme in the tyrosine catabolic pathway. Administration of an HPPD 
inhibitor results in increased systemic tyrosine concentrations, likely due to a competition of 
tyrosine and the accumulating substrate of HPPD (4-hydroxyphenyl pyruvate, 4-HPP) for the 
tyrosine transaminase enzyme (TAT) which can convert 4-HPP to 4-hydroxybenzaldehyde or 
re-convert it to tyrosine (Sulcotrione DAR July 2006, SCP 2002). 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
65 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
Data are available indicating that the main metabolite (2-cyano-3-cyclopropyl-1-(2-
methylsulfonyl-4-trifluoromethylphenyl)propan-1,3-dione) of the active substance, 
isoxaflutole (the only isoxasole included in Annex I of Council Directive 91/414/EEC (up to 
31st of May 2009)) is an HPPD inhibitor; isoxaflutole did not inhibit the enzyme (data 
summarised in the isoxaflutole DAR March 1998).   
The active substances where corneal opacity and keratitis (CAG level 2a) are a result of 
increased systemic tyrosine concentration (CAG level 3a1) due to inhibition of HPPD are 
allocated to CAG level 4a1a and are listed in Table 11.7. 
 
Table 11.7. CAG level 4a1a: HPPD inhibition 
Isoxaflutole, main metabolite Mesotrione Sulcotrione 
 
 
11.3. Discussion of CAGs for the eyes 
Fifty-seven active substances were identified to have effects on the eye and were allocated to 
CAG level 1. Four distinct CAGs at level 2 have been proposed. Information on mode / 
mechanism of action is available for only three the active substances. The information is 
summarised in Appendix P. 
11.3.1. Ad CAG level 4a1a: HPPD inhibition 
As mentioned in section 1.2.4.1, administration of an HPPD inhibitor results in increased 
systemic tyrosine concentrations, likely due to a competition of tyrosine and the accumulating 
substrate of HPPD (4-hydroxyphenyl pyruvate, 4-HPP) for the tyrosine transaminase enzyme 
(TAT), which can convert 4-HPP to 4-hydroxybenzaldehyde or re-convert it to tyrosine. 
Alternative but normally inactive tyrosine catabolic pathways involve transformation of 4-
HPP to 4-hydroxyphenyl lactic acid (4-HPLA), or of tyrosine itself to either N-acetyl tyrosine 
or 4-hydroxyphenyl acetic acid (4-HPAA). It is known that different species vary in their 
ability to metabolise tyrosine via other pathways and therefore show differing responses to 
administration of HPPD inhibitors. From the data available so far it has been concluded that 
rats (particularly male rats) are much more sensitive to the consequences of the enzyme 
inhibition on tyrosine so that the threshold tyrosine concentration for ocular effects can be 
reached in the rat after administration of far less HPPD inhibitor than would be needed in the 
mouse, monkey, or human. (Sulcotrione DAR, SCP 2002). 
The Scientific Committee on Plants (SCP 2002) has summarised a number of volunteer 
studies of mesotrione and concluded that a tyrosine concentration threshold exists for the 
development of ocular lesions after HPPD inhibition, and further that in humans even 
complete inhibition of HPPD activity does not produce tyrosine concentrations greater than 
this threshold.  
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The corneal lesions seen with administration of HPPD inhibitors in rats have been accepted as 
a result of increased blood tyrosine or tyrosine metabolite concentrations and not relevant to 
humans (Sulcotrione DAR).  
Thus, corneal opacities and keratitis resulting from administration of the two active 
substances of the triketone family included in Annex I of Council Directive 91/414/EEC (up 
to 31st of May 2009), mesotrione and sulcotrione, as well as isoxaflutole (the only isoxasole 
included in Annex I of Council Directive 91/414/EEC (up to 31st of May 2009)), to rats are 
not relevant for human risk assessment. Consequently, CAG level 4a1a and 3a1, as well as 2a 
and 2d for these three substances are not recommended for CRA for effects on the eye 
observed in rats. However, these CAGs are recommended for CRA for effects on the eye 
observed in mouse (mesotrione) and dog (mesotrione and sulcotrione). 
11.3.2. Ad CAG level 2b: Cataract 
The lens epithelium and the differentiating fibre cells in the lens bow are crucial for 
maintaining the state of hydration of the lens which is strongly dependent on the energy (ATP) 
content of the cells and on the activities of ion and water channels. The normal lens is in a 
“dehydrated” state. This strongly depends on the proper functioning of the ion and water 
pumps which derive their energy from the ATP delivered by lens epithelium and superficial 
lens fibres. The lens osmolarity is maintained by cations (Na+ and K+) and anions (Cl-, 
bicarbonate, sulphate, ascorbate, glutathione, acidic groups of lens proteins and 
glycoproteins). Some of the markers used in various studies on cataractous ion changes in the 
lens include ATP-content, glutathione peroxidase and reductase activities, and ascorbate 
content. (SCP 2001). 
Lenticular opacities can be caused by different mechanisms such as (SCP 2001, JMPR 2003): 
• Changes in osmotic pressure caused by accumulation of active osmolytes, leading to 
an increased water content and lens weight which change the refractive properties and 
clarity of the lens (e.g. diabetic cataract). 
• Post-translational denaturation of lens proteins, especially the crystallins, which are 
critical for maintaining lens clarity and refractive index (e.g. nuclear and cortical 
agerelated cataracts). 
• Impairment of the normal differentiation process, including synthesis of crystallins, 
which is strongly dependent on unrestricted energy and nutrient supply. Dose-
dependent reductions in lenticular ATP content correlate with a dose-dependent 
decrease in lenticular crystallin content. This effect seems not to be species specific 
(e.g. X-ray and steroid cataracts). 
 
Nevertheless, the vast majority of chemicals induce cataracts with unknown mechanisms 
(SCP 2001).  
It has been noted in some DARs that cataracts are frequent, age-induced manifestations with a 
variable incidence and occurring in the treated groups as well as in the control group and 
therefore, considered not likely to be a substance-induced effect. However, cataracts in long-
term studies were considered in other DARs to be treatment-related. As no general conclusion 
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could be taken regarding the toxicological significance of cataracts in long-term studies based 
on the available data, active substances inducing cataracts in such studies have been allocated 
to CAG level 2b unless it was clear from the DAR that the incidences in treated groups were 
similar to that in the control group. Consequently, CAG level 2b is recommended for CRA for 
effects on the eye. 
The active substances for which some information on mode / mechanism of action is available 
are addressed below. 
11.3.2.1. Famoxadone 
According to the famoxadone DAR, the precise mechanism of action of famoxadone (the only 
oxazole included in Annex I of Council Directive 91/414/EEC (up to 31st of May 2009)), in 
inducing cataracts in the dog is not known. However, mechanistic information indicates that it 
may involve some combination of effects on the metabolic state of the lens and/or the ion 
channels in the lens epithelium.  
According to the famoxadone DAR, the known biochemical mechanism of action of 
famoxadone is inhibition of the mitochondrial respiratory chain at Complex III 
(ubiquinol:cytochrome c oxidoreductase) (HLO-1997-00761), resulting in decreased 
production of ATP by the cell. ATP is essential for maintenance of cellular metabolism and 
the function of ATP-dependent cellular enzymes, in particular the Na-K-ATPase which is 
critical to maintaining cellular hydration. Therefore, reduction in cellular ATP could result in 
an increase in lens hydration and subsequent cataract formation. Furthermore, ATP is required 
to maintain the reducing power of the cell, thus a decrease in ATP would increase 
susceptibility to oxidative stress, also implicated in cataract formation. A second, less well-
characterised effect of famoxadone may be alterations in ion channel activity. Imbalances in 
cellular ion homeostasis, leading to increased cellular hydration, and alterations in calcium 
homeostasis, leading to protease activation, are both proposed mechanisms of cataract 
formation. These ion balances may be altered by famoxadone indirectly, through decreases in 
cellular energy (ATP) content. There is also limited evidence for a direct action of 
famoxadone on ion channels.  In vitro exposure of cultured embryonic cockroach neurones to 
famoxadone produced inhibition of voltage-dependent sodium and calcium currents. Although 
direct ion channel effects have not been demonstrated in vivo, the in vitro data suggest ion 
channel imbalances may be another possible explanation for the toxicity of famoxadone in the 
lens.  
According to the famoxadone DAR, the dog has been demonstrated to be relatively deficient 
(compared to primates) in numerous oxidative stress protective mechanisms. These 
deficiencies may underlie the observed increased sensitivity of the dog to lens toxicity, 
following exposure to famoxadone. There is strong support in the literature that the dog is not 
a good predictive model for assessing human risk of lens toxicity. Toxicity studies with 
famoxadone have demonstrated the lens toxicity to be specific to the dog and that a non-
human primate species (cynomolgus monkey) is not susceptible to this toxicity when exposed 
to very high doses (1g/kg bw/day) for up to a year. Thus, the lens toxicity observed in dogs 
exposed to famoxadone should not be considered a relevant endpoint in assessing human risk 
from exposure to famoxadone. The ADI (0.088 mg/kg bw) was therefore based on the more 
sensitive endpoints excluding eye effects (haemolytic anaemia) in the 1-year dog study.  
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The Scientific Committee on Plants (SCP 2001) has summarised the experimental data for the 
active substance, famoxadone as follows: ”Famoxadone has no ocular irritancy potential. 
Ocular effects are observed in short and long term dog studies and in a two year rat study. 
The known biochemical mechanism of famoxadone is inhibition of the mitochondria 
respiratory chain at complex III resulting in decreased production of ATP by the cell 
(SCP/FAMOX/011). In the dog study in which high dosages of famoxadone were given an 
increase in serum K+ was found, indicating an effect on ion homeostasis at toxic doses. 
Metabolic studies conducted with famoxadone in rats and dogs demonstrated a longer half-
life for radioactivity (parent and/or metabolite) in the dog, but no major qualitative 
differences in metabolic profile were found and the quantitative differences were only small 
(monograph, volume 3, annex B).” Regarding the species specificity of the cataractogenic 
effect and the relevance to humans, the SCP came to another conclusion than that expressed in 
the famoxadone DAR: ”Experimental data show that famoxadone has a clear cataractogenic 
effect in Beagle dog. The precise mechanism of action of famoxadone is unknown. Results 
from studies carried out with other species (rats, mice and monkeys) do not allow a definite 
conclusion on the absence of cataractogenic effect in these species. Many compounds have 
been shown to be cataractogenic in either rats or Beagle dogs but very few compounds are 
cataractogenic in both species. The extrapolation of animal data to human is therefore 
difficult. The Committee is of the opinion that the eye effect of famoxadone in dogs is to be 
considered relevant for humans. This opinion could be revised with a more complete 
understanding of the mechanism of action of famoxadone on the eyes in the various species.” 
JMPR (JMPR 2003) has summarised the experimental data for the active substance, 
famoxadone as follows: ”Exposure to famoxadone resulted in lens opacities and cataracts in 
outbred beagle dogs. These lesions (generally bilateral in occurrence) were observed after 
exposure to low doses of famoxadone in 90-day and 1-year studies. Exposures of similar and 
longer durations did not produce cataracts in mice or cynomolgus monkeys, despite exposure 
at much higher doses. Microscopically, however, cataracts were identified in the 18-month 
study in mice treated orally and in the 24-month study in rats treated orally. In mice there 
was clearly no dose-response relationship and in rats the excess incidence among males 
occurred at 40 and 400 mg/kg, but not at 200 mg/kg.” The available mechanistic data on 
famoxadone are summarised and discussed in detail in the monograph (JMPR 2003). JMPR 
recognised that the mechanism by which the lenticular effects in the dog are induced is not 
understood. JMPR concluded that the critical effect of famoxadone for the ADI was the 
occurrence of cataracts in dogs and the ADI (0-0.006 mg/kg bw) was established based on the 
NOAEL in the 1-year study in dogs. JMPR noted that some of these cataracts developed late 
in the study, indicating that progression might have been possible, had a long-term study been 
conducted.  
According to the US-EPA, the biochemical mechanism of action of famoxadone is inhibition 
of the fungal mitochondrial respiratory chain at Complex III, resulting in a decreased 
production of ATP by the fungal cell (US-EPA 2003). The dose and endpoint for establishing 
the chronic reference dose (cRfD, 0.0014 mg/kg bw/day) was based on a LOAEL for 
treatment-related microscopic lens lesions (cataracts) in eyes of female dogs in the 13-week 
study as a NOAEL could not be determined. This view is also expressed in a recent rule (US-
EPA 2009). 
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No further data have been found and therefore, allocation of famoxadone to a CAG level 3 or 
4 may await further mechanistic data. 
11.3.2.2. Fenpropidin, metconazole and triticonazole 
According to the fenprodidin DAR, it has been shown that the cholesterol content and 
synthesis are important for the structural and functional integrity of the fiber cell plasma 
membrane in the lens and that a disturbance in cholesterol synthesis and/or the accumulation 
of cholesterol-oxides or -precursors can lead to cataract. Lower cholesterol levels in blood 
were reported in almost all subchronic studies with rats and dogs at higher dose levels of 
fenpropidin (chemical class: Unclassified). This may indicate an impairment of cholesterol 
synthesis by fenpropidin in analogy to its mode of action in fungi, where it impairs ergosterol 
synthesis by inhibiting ∆14-reductase and ∆8-∆7-isomerase. Both enzymes play a role for late 
steps of cholesterol synthesis in mammals. Therefore the observed cataracts in several animals 
after prolonged treatment with fenpropidin at high dose levels might have been mediated by 
an impairment of cholesterol synthesis in the eye.  
For metconazole (a triazole), it is stated in the DAR that the cataractogenic potential of 
metconazole was related to the interference with steroid biosynthesis of the substance; 
however, no further details are presented in the DAR. It is noted that decreased plasma 
cholesterol concentrations have been reported in numerous studies. 
For triticonazole (a triazole), it was stated by the study author (quoted in the DAT) that the 
cause of the lenticular degeneration in the dog is not clearly known, but such effects were 
observed with some hypocholesterolaemic agents, and the administration of triticonazole was 
clearly associated with lowered plasma cholesterol concentrations. 
Other triazoles identified as inducing cataract in the dog are difenoconazole and tebuconazole, 
but exposure to these two triazoles did apparently not result in decreased plasma cholesterol 
concentrations. For penconazole, retinal effects but not cataract were reported. For the 
remaining triazoles (amitrole, epoxiconazole, flusilazole, propiconazole, tetraconazole and 
triadimenol) included in Annex I of Council Directive 91/414/EEC (up to 31st of May 2009), 
no effects on the eye were reported in the DARs. 
No further data regarding a relation between lowered plasma cholesterol concentrations and 
cataract have been found and therefore, allocation of fenpropidin, metconazole and 
triticonazole to a CAG level 3 or 4 may await further mechanistic data. 
11.3.3. Ad CAG level 2c: Retinal effects 
The most common retinal effect reported is retinal degeneration / atrophy and most often in 
long-term studies. It has been discussed in some DARs whether this effect is an age-related 
phenomenon; however, no clear conclusion has been presented. Consequently, CAG level 2c 
is recommended for CRA for effects on the eye. 
The active substances (flufenacet, dinocap, fluazinam, propamocarb) for which some 
information on mode / mechanism of action is available are addressed below. 
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11.3.3.1. Flufenacet 
According to the flufenacet DAR, the toxicological profile suggests a sensitivity in the dog 
relative to thiadione excretion. The preponderance of scientific mode of action data support 
the contention that limitations in glutathione interdependent pathways and antioxidant stress, 
resulted in metabolic lesions or abiotrophism in the eye, brain and kidney of these dogs. No 
further data have been found and therefore, allocation of flufenacet to a CAG level 3 or 4 may 
await further mechanistic data. 
11.3.3.2. Dinocap, fluazinam and propamocarb 
For three active substances (dinocap, fluazinam and propamocarb), some of the retinal effects 
observed in dogs are related to the tapetal fundus / tapetal lucidum. It has been discussed in 
the propamocarb DAR) whether these effects are relevant to humans as no tapetum is present 
in humans, see below.  
For propamocarb, degeneration of the optic fundus (retina) and hyporeflectivity were reported 
in the 90-day and 1-year dog studies. Loss of colour and reflectability of the tapetum lucidum 
of the ocular fundus was reported in the 2-year dog study. According to the DAR, 
hyporeflectibility of the fundus is ascribed to changes in the tapetum lucidum. 
Histopathological investigations (including electron microscopy) of these lesions indicated 
that the effects were due to degeneration of the cell-specific paraplasmatic inclusions (rodlets) 
and degenerative cytoplasmic changes in the tapetal cells. The cell organelles, however, were 
largely intact. No necrotic cells, macrophages or other cell infiltrates were demonstrated.  The 
ocular tissues adjacent to the tapetum (retina and choroid) were ultrastructurally normal. 
According to the DAR, these lesions could be due to a deficiency of zinc produced by 
chelating properties of propamocarb and the effects were considered to be species specific as 
such lesions were not seen in animals lacking a tapetum lucidum. It is highly likely therefore, 
according to the DAR, that the absence of a tapetum in humans excludes the possibility of this 
ocular lesion occurring in man due to exposure to propamocarb.  
For dinocap and fluazinam, effects on the tapetum lucidum were reported in the dog studies.  
No further data have been found and therefore, allocation of dinocap, fluazinam and 
propamocarb to a CAG level 3 or 4, as well as a conclusion regarding the relevance of the 
findings in dogs for humans, may await further mechanistic data. Consequently, CAG level 2c 
is recommended for CRA for effects on the eye for these three active substances. 
11.3.4. Chemical classes as basis for CAGs for the eye 
Active substances belonging to the same chemical class may have similar toxicological 
effects. Information in the DARs on effects on the eye is summarised below for evaluation of 
similarity of toxicological effects within the relevant chemical classes, i.e. the chemical 
classes containing more than one active substance. 
11.3.4.1. Aryloxyalkanoic acids 
Three aryloxyalkanoic acids were identified to affect the eye: 2,4-D (cataract, retinal effects, 
inflammation), 2,4-DB (cataract, retinal effects) and dichlorprop-P (retinal effects). For the 
remaining aryloxyalkanoic acids (MCPA, MCPB, mecoprop, mecoprop-P), no effects on the 
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eye were reported in the DARs. Therefore, the information in the DARs does not allow the 
conclusion that aryloxyalkanoic acids in general have similar effects on the eye although it is 
acknowledged that similar effects have been reported for the three aryloxyalkanoic acids 
affecting the eye.  
11.3.4.2. Carbamates 
Three carbamates were identified to affect the eye: Chlorpropham (corneal opacity, cataract), 
oxamyl (retinal effects) and propamocarb (retinal effects). For the remaining carbamates 
(benthiavalicarb, iprovalicarb, methiocarb, methomyl, pirimicarb), no effects on the eye were 
reported in the DARs. Therefore, the information in the DARs does not allow the conclusion 
that carbamates in general have similar effects on the eye although it is acknowledged that 
similar effects have been reported for some of the carbamates. 
11.3.4.3. Chloroacetamides 
Two chloroacetamides were identified to affect the eye: Dimethachlor (cataract) and 
dimethenamid-P (cataract). For the remaining chloroacetamides (metazachlor, pethoxamid, S-
metolachlor), no effects on the eye were reported in the DARs. Therefore, the information in 
the DARs does not allow the conclusion that chloroacetamides in general have similar effects 
on the eye although it is acknowledged that cataract has been reported for the two 
chloroacetamides affecting the eye. 
11.3.4.4. Cyclohexadione oximes 
One cyclohexadione oxime was identified to affect the eye: Tralkoxydim: (retinal effects). For 
the other cyclohexadione oxime (tepraloxydim), no effects on the eye were reported in the 
DAR. Therefore, the information in the DARs does not allow the conclusion that 
cyclohexadione oximes have similar effects on the eye. 
11.3.4.5. Dithiocarbamates 
Two dithiocarbamates and one metabolite of a dithiocarbamate were identified to affect the 
eye: Mancozeb (retinal effects), thiram (retinal effects, inflammation) and the propineb 
metabolite propylenurea (PU) (corneal clouding). For the remaining dithiocarbamates (maneb, 
metiram, propineb), no effects on the eye were reported in the DARs. Therefore, the 
information in the DARs does not allow the conclusion that dithiocarbamates in general have 
similar effects on the eye although it is acknowledged that retinal effects have been reported 
for the two dithiocarbamates affecting the eye.  
11.3.4.6. Morpholines 
One morpholine was identified to affect the eye: Spiroxamine (corneal opacity, cataract, 
retinal effects). For the other morpholines (demethomorph, fenpropimorph, dodemorph), no 
effects on the eye were reported in the DAR. Therefore, the information in the DARs does not 
allow the conclusion that morpholines have similar effects on the eye. 
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11.3.4.7. Neonicotinoids 
Four neonicotinoids were identified to affect the eye: Acetamiprid (cataract, retinal effects, 
inflammation), imidacloprid (retinal effects), thiacloprid (cataract, retinal effects) and 
thiamethoxam (cataract). For the remaining neonicotinoid (clothianidin), no effects on the eye 
were reported in the DARs. Therefore, the information in the DARs does not allow the 
conclusion that neonicotinoids in general have similar effects on the eye although it is 
acknowledged that similar effects have been reported for some of the neonicotinoids. 
11.3.4.8. Organophospates 
Five organophospates were identified to affect the eye: Chlorpyrifos (cataract, retinal effects, 
inflammation), ethoprophos (corneal opacity), fosthiazate (retinal effects), glufosinate (retinal 
effects), phosmet (opacity – not further specified in the DAR, adhesion or coloboma). In 
addition, a metabolite (omethoate) of dimethoate was identified to affect the eye (corneal 
effects, cataract, retinal effects, inflammation). For the remaining organophosphates 
(chlorpyrifos-methyl, fenamiphos, fosetyl, pirimiphos-methyl), no effects on the eye were 
reported in the DARs. Therefore, the information in the DARs does not allow the conclusion 
that organophospates in general have similar effects on the eye although it is acknowledged 
that retinal atrophy has been reported for a few organophosphates. 
It is noted that in the dimethoate DAR (July 2004) it is stated (in relation to the findings for 
omethoate) “The finding most likely to be treatment-related is retinal degeneration, which has 
been reported previously for other organophosphate pesticides.” 
11.3.4.9. Sulfonylureas 
Six sulfonylureas were identified to affect the eye: Flazasulfuron (cataract, inflammation), 
imazosulfuron (cataract, retinal effects, inflammation), iodosulfuron-methyl-sodium 
(inflammation), oxasulfuron (retinal effects), rimsulfuron (corneal opacity, cataract) and 
tribenuron (retinal effects).  
For chlorsulfuron it is noted in the DAR (July 2007) “With regard to ophthalmological 
examinations, these were only conducted in the 1-year dog study, as other subchronic studies 
were conducted prior to the availability of test guidelines requiring such examinations. An 
additional assessment was submitted (MacKenzie, 2004) evaluating histological data 
available for chlorsulfuron and histological and ophthalmological data of other structurally 
related sulfonylurea herbicides, as well as presenting ophthalmological versus histological 
detection of chemically induced ocular lesions. It was concluded that there is sufficient 
evidence to exclude the eye as a target organ for chlorsulfuron.” 
For mesosulfuron, the effects on the eye observed in the 2-year rat study (lens opacities) and 
in the 18-month mouse study (corneal and lens opacity) were considered as incidental changes 
in the DAR.  
For the remaining sulfonylureas (amidosulfuron, azimsulfuron, bensulfuron, chlorsulfuron, 
ethoxysulfuron, flupyrsulfuron-methyl, metsulfuron-methyl, nicosulfuron, prosulfuron, 
sulfosulfuron, thifensulfuron-methyl, triasulfuron, triflusulfuron, tritosulfuron), no effects on 
the eye were reported in the DARs. Therefore, the information in the DARs does not allow the 
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conclusion that sulfonylureas in general have similar effects on the eye although it is 
acknowledged that similar effects have been reported for some of the sulfonylureas.  
11.3.4.10. Thiocarbamates 
Two thiocarbamates were identified to affect the eye: Prosulfocarb (cataract) and tri-allate 
(corneal opacity). For the remaining thiocarbamate (molinate), no effects on the eye were 
reported in the DARs. Therefore, the information in the DARs does not allow the conclusion 
that thiocarbamates have similar effects on the eye. 
11.3.4.11. Triazinones 
Two triazinones were identified to affect the eye: Metamitron (retinal effects) and metribuzin 
(corneal opacity) No other triazinones are included in Annex I of Council Directive 
91/414/EEC (up to 31st of May 2009). Therefore, the information in the DARs does not allow 
the conclusion that triazinones have similar effects on the eye. 
11.3.4.12. Triazoles 
Five triazoles were identified to affect the eye: Difenoconazole (cataract, inflammation), 
metconazole (cataract, inflammation), penconazole (retinal effects), tebuconazole (cataract) 
and triticonazole (cataract, inflammation). For propiconazole, effects on the eye (not further 
specified in the DAR) were observed in the 1-year dog study. For the remaining triazoles 
(amitrole, epoxiconazole, flusilazole, tetraconazole, triadimenol), no effects on the eye were 
reported in the DARs. Therefore, the information in the DARs does not allow the conclusion 
that that triazoles n general have similar effects on the eye although it is acknowledged that 
similar effects have been reported for four of the five triazoles affecting the eye. 
11.3.4.13. Triketones 
The two triketones (mesotrione and sulcotrione) have similar effects in the eye of rats with 
similar mode / mechanism of action, see section 11.3.1. 
11.3.4.14. Conclusion: Chemical classes 
Based on the analysis whether active substances belonging to the same chemical class may 
have similar effects on the eye it is concluded that active substances belonging to the same 
chemical class in general do not have similar effects on the eye. However, it is acknowledged 
that similar effects have been reported for some of the substances belonging to a particular 
chemical class. 
11.4. Recommended CAGs for the eye 
The following CAGs are recommended for CRA for effects on the eye: 
• CAG level 4a1a: HPPD inhibition, see Table 11.7, mesotrione and sulcotrione – only 
if based on information from studies in dog and mouse. 
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• CAG level 3a1: Increased systemic tyrosine concentration, see Table 11.6, mesotrione 
and sulcotrione – only if based on information from studies in dog and mouse. 
• CAG level 2a: Corneal opacity, see Table 11.2, mesotrione and sulcotrione – only if 
based on information from studies in dog and mouse. 
• CAG level 2b: Cataract, see Table 11.3. 
• CAG level 2c: Retinal effects, see Table 11.4. 
• CAG level 2d: Inflammation, see Table 11.5, mesotrione and sulcotrione – only if 
based on information from studies in dog and mouse. 
 
 
12. Gallbladder 
12.1. Introduction 
The gallbladder is a saclike organ. Its primary function is to store and concentrate bile 
between meals. Bile is necessary for the digestion of lipids in the intestine. Bile is produced in 
the hepatocytes and flows through a network of different bile ducts into the common hepatic 
duct and the cystic duct into the gallbladder. The mucosa of the gallbladder wall readily 
absorbs water and electrolytes, leaving a high concentration of bile salts, bile pigments, and 
cholesterol. The gallbladder holds about 90 ml of bile. The bile is released into the duodenum 
within 30 minutes after eating. The bile release is controlled both by the nervous system and 
by the hormones cholecystokinin and motilin secreted by the duodenal mucosa in the presence 
of fat. It is bilirubin, which gives bile a yellowish green colour. (McCance and Huether 1998). 
It should be noted that rats do not have a gallbladder. Consequently, no studies on gallbladder 
effects are available for rats. 
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From: http://www.cheboygansurgical.com/biliary-dyskinesia-80/ 
Figure 12.1. Anatomy of the gallbladder. 
 
12.2. Establishment of CAGs for toxicity to the gallbladder 
12.2.1. CAG level 1: Toxicity to the gallbladder 
The active substances identified as having an effect on the gallbladder in the toxicological 
studies included in the DARs are allocated to CAG level 1 and are listed in Table 12.1.  
 
Table 12.1. CAG level 1: Toxicity to the gallbladder 
Azimsulfuron Cyhalofop-butyl Nicosulfuron 
 
 
12.2.2. CAG level 2: Phenomenological / specific effects on the gallbladder 
One type of effects on the gallbladder was identified as a basis for establishing CAGs at level 
2. Based on these effect, one distinct CAG at level 2 is proposed. More information is given in 
Appendix Q. 
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12.2.2.1. CAG level 2a:  Hypertrophy / hyperplasia 
Hypertrophy is an increased size of cells. Hyperplasia is an increased number of cells. 
Hyperplasia of the gallbladder may be a reaction to irritation of the gallbladder mucosa after 
xenobiotic exposure (Thoolen et al. 2010). 
For the purpose of the CAG project, hypertrophy and hyperplasia are allocated to a single 
CAG level 2, termed ‘CAG level 2a: Hypertrophy / hyperplasia’.  
The active substances identified as inducing hypertrophy and/or hyperplasia of the gallbladder 
are allocated to CAG level 2a and are listed in Table 12.2. 
 
Table 12.2. CAG level 2a: Hypertrophy / hyperplasia of the gall bladder 
Azimsulfuron Cyhalofop-butyl Nicosulfuron 
 
 
12.2.2.2. Effects not considered relevant for CAGs at level 2 
For nicosulfuron dysplasia and calculi was noted. The calculi may be the cause of the 
epithelial hyperplasia and dysplasia. Dysplasia is delayed cell maturation and differentiation, 
and is often indicative of an early neoplastic process. Although hyperplasia and dysplasia is 
not the same, the dysplasia is considered covered by the CAG level 2a for 
hypertrophy/hyperplasia. 
For the two active substances, azimsulfuron and cyhalofop-butyl, increased mucous secretion 
was noted. As the increased mucous secretion probably is a consequence of the same irritation 
that may be the cause of the epithelial hyperplasia, it is not considered relevant to create a 
CAG level 2 for increased mucous secretion. 
Deposits of e.g. bile pigment is considered a non-adverse effect. Thus no CAG level 2 has 
been created for this effect. 
12.2.2.3. Effects covered in the chapter about the liver 
Lesions of the biliary epithelium such as hyperplasia and cysts, as well as cholestasis (a 
condition where bile cannot flow from the liver to the intestine) are addressed in the chapter 
on the liver (see chapter 17). 
12.2.3. CAG level 3 / 4: Mode/mechanism of action  
No information on modes/mechanisms of action have been found for any of the active 
substances identified as having an effect on the gallbladder. 
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12.3. Discussion of CAGs for the gallbladder 
Three active substances were identified to have effects on the gallbladder and were allocated 
to CAG level 1. One distinct CAGs at level 2 has been proposed. No information on the 
modes/mechanisms of action is available. The information is summarised in Appendix R. 
No information regarding the modes/mechanisms of action for the phenomenological effects 
in the gallbladder has been found. Therefore, the CAGs at level 2 could be considered for 
CRA.  
12.4. Recommended CAGs for the gallbladder 
The following CAG at level 2 is recommended for CRA for effects on the gallbladder: 
• CAG level 2a: Hypertrophy / hyperplasia, see Table 12.2. 
 
 
13. Gastrointestinal tract 
13.1. Introduction 
The gastrointestinal (GI) tract consists of the mouth, esophagus, stomach, small intestine, 
large intestine, rectum, and anus. It carries out the following digestive processes: 
• Ingestion of food  
• Propulsion of food and wastes from the mouth to the anus 
• Secretion of mucus, water, and enzymes 
• Mechanical and chemical digestion of food particles 
• Absorption of digested food 
• Elimination of waste products by defecation. 
 
Histologically, the GI tract consists of four layers. From the inside out they are the mucosa, 
submucosa, muscularis, and serosa.  
Disorders of the GI tract disrupt one or more of its functions. Structural and neural 
abnormalities can slow, obstruct, or accelerate the movement of chyme (partially digested 
food) at any level of the GI tract. Inflammatory and ulcerative conditions of the GI wall 
disrupt secretion, motility, and absorption.  
13.2. Establishment of CAGs for toxicity to the gastrointestinal tract 
Various types of effects on the gastrointestinal tract were identified including:  
• Nausea 
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• Vomiting 
• Diarrhoea 
• Discolouration (white patches / zones, dark spots, reddening, red or black foci)  
• Distension / dilatation (swelling / expansion) 
• Hyperaemia (excess blood, here in the GI tract) 
• Haemorrhage (bleeding) 
• Irritation 
• Ulcer 
• Erosion 
• Hyperplasia (increased number of cells) 
• Acanthosis (diffuse epidermal hyperplasia) 
• Hypertrophy (increased size of cells) 
• Thickening 
• Gastric stenosis (passage becomes narrow) 
• Vacuolation 
• Inflammation 
• Gastritis (inflammation of the lining of the stomach) 
• Atrophy (loss of tissue, totally or partially) 
• Necrosis (death of cells and tissues) 
• Tumours 
 
Many of these effects in the GI tract are non-specific. Other effects are considered as being 
non-adverse.  
Effects such as irritation, ulcer and erosion are often observed shortly following gastric 
intubation. Atrophy and/or necrosis may be a result of the irritating / corrosive property of a 
particular substance. Long-term oral exposure to irritating substances may lead to 
inflammation as well as hyperplasia / hypertrophy and even to tumours. Irritation and the 
consequente effects are generally related to the concentration of the substance rather than the 
dose. 
Overall, the abovementioned effects are not considered relevant in terms of CRA for effects 
on the GI tract. 
Therefore, the GI tract is not considered further for CAGs in this report. 
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13.3. Recommended CAGs for the gastrointestinal tract 
No CAGs for toxicity to the gastrointestinal tract are recommended. 
 
 
14. Haematological system 
14.1. Introduction 
The haematological system consists of the blood and bone marrow. Blood delivers oxygen 
and nutrients to all tissues, removes wastes, and transports gases, blood cells, immune cells, 
antibodies and hormones throughout the body. 
Blood consist of various formed elements (cells and proteins) that circulate in the 
cardiovascular system suspended in plasma, which is approximately 90% water and 10% 
dissolved substances. All of these elements constitute the blood volume. Approximately 45-
50% of the blood volume consists of the formed elements, and the remainder is the plasma.  
The continuous movement of blood keeps the formed elements dispersed throughout the 
plasma, where they are able to carry out their chief functions: 1) delivery of substances needed 
for cellular metabolism in the tissues, 2) defence against invading micro-organisms and injury, 
and 3) acid-base balance.  
The cellular elements of the blood are broadly classified as erythrocytes (red blood cells), 
leucocytes (white blood cells), and thrombocytes (platelets). Erythrocytes and thrombocytes 
function entirely within blood vessels; some leucocytes remain in the blood while others can 
enter tissues. 
The erythrocytes are the most abundant cells of the blood and are responsible primarily for 
tissue oxygenation. Their cytoplasm consists of a solution containing protein (mostly 
haemoglobin, which carries the oxygen) and electrolytes. In healthy humans the total volume 
of circulating erythrocytes remains relatively constant. The feedback mechanism that 
maintains an optimal population of erythrocytes is mediated by erythropoietin. Erythropoietin 
(secreted by the kidney in response to tissue hypoxia) induces the production of erythrocytes 
(erythropoiesis), which takes place in the bone marrow. Erythrocytes are derived from 
precursor cells called erythroblasts (normal erythroblasts are called normoblasts, whereas 
abnormal ones are called megaloblasts). The erythroblasts loose the nucleus and the cell that 
remains is called a reticulocyte. The reticulocyte matures to an erythrocyte within 24-48 hours. 
Reticulocytes remain in the bone marrow approximately one day and then are released into the 
circulation and continue to mature in the blood. As the mature erythrocyte lacks the 
cytoplasmic organelles and cannot divide or carry out metabolic functions, it is replaced by a 
new erythrocyte generated in the bone marrow when it dies (life span approximately 120 
days). The normal reticulocyte count is 1% of the total erythrocyte count and is therefore, a 
useful clinical parameter of erythropoietic activity and indicates whether new erythrocytes are 
being produced.  
Leucocytes defend the body against organisms that cause infection and remove debris, 
including dead on injured host cells of all kinds. They act primarily in the tissues but are 
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transported in the circulation. Leucocytes are classified according to structure as either 
granulocytes or agranulocytes, and according to function as either phagocytes or 
immunocytes.  
The granulocytes are so called because of the many lysosomal granules in their cytoplasm. 
They are all phagocytes and are classified as neutrophils (about 55% of the total leukocyte 
count), eosinophils (1-4% of the total leukocyte count), and basophils (<1% of total leukocyte 
count, also called mast cells). 
The agranulocytes do not contain lysosomal granules in their cytoplasm. They are classified as 
macrophages, monocytes (immature macrophages), and lymphocytes (about 36% of the total 
leukocyte count).  
All of the leucocytes arise from stem cells in the bone marrow. The granulocytes normally 
mature fully in the bone marrow and then are released into the bloodstream. The 
agranulocytes, however, are released into the bloodstream before they undergo their final 
phase of maturation.  
Thrombocytes are not cells, but cytoplasmic fragments. They are formed in the bone marrow 
by fragmentation of very large cells known as megakaryocytes. Thrombocytes are essential for 
blood coagulation and control of bleeding. About 2/3 of the thrombocytes are in the 
circulating blood and the remaining 1/3 of the thrombocytes are in a reserve pool in the 
spleen. 
In the short-term repeated dose toxicity studies (28- and 90-day), the haematological 
examinations should include the following parameters: Erythrocyte count (RBC count), 
haematocrit (Ht or packed cell volume (PCV)), haemoglobin concentration (Hgb), total and 
differential leucocyte count (WBC count), platelet count and a measure of blood clotting 
time/potential (generally the prothrombin time (PT) and activated partial thromboplastin time 
(APTT)). In the long-term repeated dose toxicity studies (chronic, chronic/carcinogenicity 
combined), the following red blood cell parameters should also be included: Mean 
corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular 
haemoglobin concentration (MCHC). Other haematological parameters, such as e.g. Heinz 
bodies or other atypical erythrocyte morphology (anisocytosis, poikilocytosis), or 
methaemoglobin concentration may be included depending on known and/or suspected effects 
from a given substance. For a substance having an effect on the haematopoietic system, 
reticulocyte count and bone marrow cytology may also be included. 
This section deals with the toxicity to the cellular elements of the blood, i.e. erythrocytes, 
leucocytes and thrombocytes. Toxicity to the bone marrow is addressed in section 8. 
14.2. Establishment of CAGs for toxicity to haematological system 
14.2.1. CAG level 1: Toxicity to the haematological system 
The active substances identified as having an effect on the cellular elements of the blood in 
the toxicological studies included in the DARs are allocated to CAG level 1 and are listed in 
Table 14.1. 
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Table 14.1. CAG level 1: Toxicity to the haematological system 
1-Methyl-cyclopropene Etoxazole Molinate 
2,4-D Famoxadone Oxadiazon 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Fenamidone Pethoxamid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Fenhexamid Phenmedipham 
Azimsulfuron Fenoxaprop-P Picloram 
Benfluralin Fenpropidin Picolinafen 
Bensulfuron Fenpropimorph Pirimicarb 
Bentazone Fipronil Pirimicarb, metabolite R34836: 
desmethylpirimicarb 
Benthiavalicarb Flazasulfuron Pirimicarb, metabolite R34885: 
desmethylformamidopirimicarb 
Bifenazate Florasulam Prohexadione-calcium 
Bifenox Fluazinam Propaquizafop 
Bromoxynil Fludioxonil Prosulfocarb 
Bromoxynil, metabolite 3,5-
dibromo-4-hydroxybenzoic acid 
(DBHA) 
Flufenacet (formerly fluthiamide) Prosulfuron 
Carfentrazone-ethyl Flumioxazin Pymetrozine 
Chloridazon (aka pyrazone) Fluopicolide Pyraclostrobin 
Chlorothalonil Fluoxastrobin Pyraflufen-ethyl 
Chlorothalonil, metabolite SDS-
3701: 4-hydroxy-2,5,6-
trichloroisophtalonitrile 
Forchlorfenuron Pyrethrins 
Chlorotoluron Glufosinate Pyriproxyfen 
Chlorpropham Imazosulfuron Quinoclamine 
Chlorsulfuron Indoxacarb Quinoxyfen 
Chlorsulfuron, metabolite IN-
A4097 
Iodosulfuron-methyl-sodium Quizalofop-P-ethyl 
Cinidon ethyl Ioxynil Quizalofop-P-tefuryl 
Clodinafop-prop Iprodione Spinosad 
Clofentezine Isoproturon Sulcotrione 
Clothianidin Isoxaflutole Tebuconazole 
Cymoxanil Linuron Tebufenpyrad 
Cyromazine MCPA Tepraloxydim 
Daminozide MCPB Thiametoxam 
Daminozide, metabolite UDMH 
(1,1-dimethylhydrazine) 
Mancozeb Thiophanate-methyl 
Desmedipham Mancozeb (metabolite ETU) Tolclofos-methyl 
Dicamba Maneb Tralkoxydim 
Dichlorprop-P Maneb (metabolite ETU) Tri-allate 
Difenoconazole Mepiquat Triasulfuron 
Diflubenzuron Metalaxyl-M Triclopyr 
Dimethachlor Metamitron Triclopyr, metabolite: 3,5,6-
trichloro-2-pyridinol (TCP) 
Dimoxystrobin Metazachlor Trifloxystrobin 
Dinocap Metconazole Triflusulfuron 
Diuron Methomyl Triticonazole 
Epoxiconazole Methoxyfenozide Tritosulfuron 
Ethoprophos Metiram Ziram 
Ethoxysulfuron Metribuzin  
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Etofenprox Milbemectin  
 
 
14.2.2. CAG level 2: Phenomenological / specific effects on the cellular elements of blood 
Various types of effects on the cellular elements of the blood were identified as a basis for 
establishing CAGs at level 2. Based on these effects, three distinct CAGs at level 2 are 
proposed. More information is given in Appendix S. 
14.2.2.1. CAG level 2a: Anaemia 
Strictly speaking, anaemia is not a disease, but a term indicating a condition where the number 
of erythrocytes or the concentration of haemoglobin is less than normal, resulting in an 
insufficient supply of oxygen to the cells.  
The following haematological parameters are all signs of anaemia and are, for the purpose of 
the CAG project, therefore allocated to a single CAG level 2, termed ‘CAG level 2a: 
Anaemia’ (see Appendix U for a list of the terms that are interpreted as anaemia / signs of 
anaemia):  
• Decreased red blood cell (RBC) count 
• Decreased haemoglobin concentration 
• Decreased haematocrit (relates to the percentage of a given volume of blood occupied 
by red blood cells) 
• Increased / decreased MCV (relates to the average size of the red blood cell) 
• Increased / decreased MCH (relates to the amount of haemoglobin in a single red 
blood cell by weight) 
• Increased / decreased MCHC (relates to the amount of haemoglobin in a single red 
blood cell by percentage) 
• Increased / decreased reticulocyte count (reticulocytosis / reticulocytopenia) 
• Increase in Heinz bodies 
• Anisocytosis (the erythrocytes have variable and abnormal size) 
• Poikilocytosis (the erythrocytes have various shapes) 
• Increased methaemoglobin concentration 
 
Anaemia is usually a result of 1) impaired erythrocyte production, 2) blood loss, 3) increased 
erythrocyte destruction, or 4) a combination of the three. 
Anaemias are classified according to their aetiology or morphological basis. The most 
common classification of anaemias is based on cellular morphological structure. Descriptions 
of anaemias based on erythrocyte morphology refer to the size of the cells (terms end with 
‘cytic’) and concentration of haemoglobin (terms end with ‘chromic’). The changes in MCV, 
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MCH and MCHC are used for classification of anaemias and therefore, could be useful in 
considerations of mode of action. As an example, the microcytic-hypochromic anaemias are 
characterised by erythrocytes that are abnormally small (MCV decreased) and contain 
abnormally decreased amounts of haemoglobin (MCH/MCHC decreased).  
The reticulocyte count is a useful clinical index of erythropoietic activity in the bone marrow 
and indicates whether new red blood cells are being produced in the bone marrow. 
Reticulocytosis indicates a normal function of the bone marrow whereas reticulocytopenia 
indicates that the bone marrow is damaged more or less.  
The active substances identified as inducing one or more of the above-mentioned effects are 
allocated to CAG level 2a and are listed in Table 14.2. 
 
Table 14.2. CAG level 2a: Anaemia  
1-Methyl-cyclopropene Etoxazole Molinate 
2,4-D Famoxadone Oxadiazon 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Fenamidone Pethoxamid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Fenhexamid Phenmedipham 
Azimsulfuron Fenoxaprop-P Picloram 
Benfluralin Fenpropidin Picolinafen 
Bensulfuron Fenpropimorph Pirimicarb 
Bentazone Fipronil Pirimicarb, metabolite R34836: 
desmethylpirimicarb 
Benthiavalicarb Flazasulfuron Pirimicarb, metabolite R34885: 
desmethylformamidopirimicarb 
Bifenazate Florasulam Prohexadione-calcium 
Bifenox Fluazinam Propaquizafop 
Bromoxynil Fludioxonil Prosulfocarb 
Bromoxynil, metabolite 3,5-
dibromo-4-hydroxybenzoic acid 
(DBHA) 
Flufenacet (formerly fluthiamide) Prosulfuron 
Carfentrazone-ethyl Flumioxazin Pymetrozine 
Chloridazon (aka pyrazone) Fluopicolide Pyraclostrobin 
Chlorothalonil Fluoxastrobin Pyraflufen-ethyl 
Chlorothalonil, metabolite SDS-
3701: 4-hydroxy-2,5,6-
trichloroisophtalonitrile 
Forchlorfenuron Pyrethrins 
Chlorotoluron Glufosinate Pyriproxyfen 
Chlorpropham Imazosulfuron Quinoclamine 
Chlorsulfuron Indoxacarb Quinoxyfen 
Chlorsulfuron, metabolite IN-
A4097 
Iodosulfuron-methyl-sodium Quizalofop-P-ethyl 
Cinidon ethyl Ioxynil Quizalofop-P-tefuryl 
Clodinafop-prop Iprodione Spinosad 
Clofentezine Isoproturon Sulcotrione 
Clothianidin Isoxaflutole Tebuconazole 
Cymoxanil Linuron Tebufenpyrad 
Cyromazine MCPA Tepraloxydim 
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Daminozide MCPB Thiametoxam 
Daminozide, metabolite UDMH 
(1,1-dimethylhydrazine) 
Mancozeb Thiophanate-methyl 
Desmedipham Mancozeb (metabolite ETU) Tolclofos-methyl 
Dicamba Maneb Tralkoxydim 
Dichlorprop-P Maneb (metabolite ETU) Tri-allate 
Difenoconazole Mepiquat Triasulfuron 
Diflubenzuron Metalaxyl-M Triclopyr 
Dimethachlor Metamitron Triclopyr, metabolite: 3,5,6-
trichloro-2-pyridinol (TCP) 
Dimoxystrobin Metazachlor Trifloxystrobin 
Dinocap Metconazole Triflusulfuron 
Diuron Methomyl Triticonazole 
Epoxiconazole Methoxyfenozide Tritosulfuron 
Ethoprophos Metiram Ziram 
Ethoxysulfuron Metribuzin  
Etofenprox Milbemectin  
 
 
14.2.2.2. CAG level 2b: Thrombocytosis  
Thrombocytosis is a condition where the level of thrombocytes (platelets) is higher than 
normal. 
The active substances identified as increasing the number of thrombocytes are allocated to 
CAG level 2b and are listed in Table 14.3. 
 
Table 14.3. CAG level 2b: Thrombocytosis  
Azimsulfuron Indoxacarb Prosulfocarb 
Benfluralin Isoxaflutole Pyriproxyfen 
Benthiavalicarb Linuron Quinoclamine 
Bifenazate Metalaxyl-M Sulcotrione 
Chlorpropham Metazachlor Tebuconazole 
Clodinafop-prop Methomyl Tebufenpyrad 
Clofentezine Methoxyfenozide Tepraloxydim 
Desmedipham Milbemectin Thiophanate-methyl 
Etoxazole Molinate Tralkoxydim 
Fludioxonil Pethoxamid Tri-allate 
Flufenacet (formerly fluthiamide) Phenmedipham Triasulfuron 
Forchlorfenuron Pirimicarb Trifloxystrobin 
 
 
14.2.2.3. CAG level 2c: Thrombocytopenia  
Thrombocytopenia is a condition where the level of thrombocytes (platelets) is less than 
normal. 
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The active substances identified as decreasing the number of platelets are allocated to CAG 
level 2c and are listed in Table 14.4. 
 
Table 14.4. CAG level 2c: Thrombocytopenia  
2,4-D Indoxacarb Prosulfuron 
Azimsulfuron MCPA Pymetrozine 
Chlorpropham MCPB Pyriproxyfen 
Clodinafop-prop Metconazole Tebufenpyrad 
Clothianidin Metribuzin Triclopyr 
Difenoconazole Pethoxamid Triticonazole 
 
 
14.2.2.4. Effects not considered relevant for CAGs at level 2 
Anaemia is usually a result of 1) impaired erythrocyte production, 2) blood loss, 3) increased 
erythrocyte destruction, or 4) a combination of the three. Anaemia caused by impaired 
erythrocyte production is secondary to a direct damage to the bone marrow and anaemia due 
to blood loss is an unspecific effect and therefore, not relevant for CAG level 2a and 
consequently, not relevant in terms of CRA for anaemia. 
Leucocytosis is a condition where the level of leucocytes (white blood cells) is higher than 
normal and leucopenia is a condition where the level of leucocytes is less than normal. CAGs 
at level 2 could be considered for both leucocytosis and for leucepenia. Alterations in white 
blood cells (WBC) are evaluated by measuring the total and differential leucocyte count 
(WBC count) in the haematological examination. In the DARs alterations in WBC are 
described in general terms such as e.g. increased/decreased WBC as well as in more specific 
terms such as increase / decrease in the various types of WBCs (neutrophils, eosinophils, 
basophils, monocytes, lymphocytes). Many of the active substances included in Annex I of 
Council Directive 91/414/EEC (up to 31st of May 2009) show an alteration in the WBC count 
and/or in one or more of the various types of WBCs. Generally, the alterations are only slight 
in comparison with the control group, within the normal range, not dose-related and/or only 
observed at very high doses. For some substances there is a general consistency in the findings 
across species and studies, but for most substances the alterations are only noted in one 
species and/or in one sex and/or only in one or a few of the studies. Furthermore, the 
alterations are often not consistent in terms of the direction of the alteration, e.g. increased 
count in one sex but decreased in the other sex, increased count in one study but decreased 
count in another study, and/or increased count in one species but decreased count in (an)other 
species. Therefore, the alterations in WBC counts are often considered in the DARs not to be 
treatment-related. Moreover, the descriptions in the various DARs are very different regarding 
details and preciseness. Finally, the alterations in WBC counts are generally not due to a direct 
damage of the WBCs in the blood but secondary to effects and disorders in other target organs 
and tissues such as the lymphoid organs and tissues. In conclusion, alterations in WBC counts 
for the active substances included in Annex I of Council Directive 91/414/EEC (up to 31st of 
May 2009) are considered either as being non-adverse effects and therefore, not relevant for 
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CAGs at level 2, or as not being applicable for a CAG at level 2 and consequently, not 
relevant in terms of CRA for either leucocytosis or leucopenia. 
Reticulocytopenia is observed in some forms of anaemias, e.g. pernicious anaemia (disease 
where an inability to absorb vitamin B12 prevents the production of red blood cells), folate 
deficiency anaemia and aplastic anaemia (anaemia caused by bone marrow failure). Of these 
types of anaemia, only aplastic anaemia is relevant for pesticidal active substances. 
Reticulocytopenia has been reported for one active substance (chlorothalonil) in a single 1-
year study on dogs whereas this effect was not reported in the other 1-year study on dogs as 
well as in the studies on rodent species. Reticulocytopenia has also been reported for a 
metabolite of an active substance (acibenzolar-S-methyl), a metabolite that is cytotoxic to the 
bone marrow. As aplastic anaemia is secondary to a direct damage to the bone marrow, this 
sign of anaemia is not considered relevant for CAG level 2a and consequently, not relevant in 
terms of CRA for anaemia. 
14.2.3. CAG level 3: Mode of action  
For a few of the active substances affecting the red blood cells and allocated to CAG level 2a, 
a mode of action has been proposed. For the remaining substances, no information regarding 
mode of action has been found and consequently, these substances cannot be allocated to a 
CAG level 3. 
14.2.3.1. CAG level 3a1: Haemolysis 
Anaemia caused by increased erythrocyte destruction is a direct effect on the red blood cells. 
Haemolytic anaemia is one form of anaemia in which the red blood cells are destroyed and 
removed from the bloodstream earlier than normally. Haemolytic anaemia can be 
intravascular (red blood cells in the blood stream) as well as extravascular (red blood cells 
outside the blood vessels).  
The reticulocyte count is usually increased in haemolytic anaemia and thus, reticulocytosis is a 
good indication whether anaemia could be considered as being due to haemolysis. Also 
increases in Heinz bodies and/or Howell-Jolly bodies are indications of haemolytic anaemia. 
However, reticulocytosis may also be solely due to a general bone marrow response in order 
to compensate for the anaemia. 
For the purpose of the CAG project, active substances causing anaemia accompanied by 
reticulocytosis, Heinz bodies and/or Howell-Jolly bodies in one or more of the studies of the 
active substances and/or their metabolite(s) are only allocated to CAG level 3a1 provided that 
haemolytic anaemia is justified based on information in the DAR or in the open literature.  
In haemolytic anaemia (intravascular), the concentration of methaemoglobin is generally 
increased. For the purpose of the CAG project, active substances causing 
methaemoglobinaemia are only allocated to CAG level 3a1 provided that haemolytic anaemia 
is justified based on information in the DAR or in the open literature.  
The active substances allocated to CAG level 3a1 are listed in Table 14.5. It should be noted 
that the CAG level 3a1 only covers substances inducing intravascular haemolytic anaemia. 
The substances causing methaemoglobinaemia are marked with the abbreviation ‘MetHb’ in 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
87 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
the table. One active substance also caused sulfhaemoglobinaemia; this substance is marked 
with the abbreviation ‘SulfHb’ in the table. 
 
Table 14.5. CAG level 3a1: Haemolysis  
1-Methyl-cyclopropene Famoxadone Methomyl 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Indoxacarb (MetHb) Metribuzin 
Benthiavalicarb Isoproturon (MetHb) Molinate 
Bifenazate Linuron (MetHb) Picolinafen (MetHb) 
Desmedipham (MetHb) MCPA Prosulfocarb 
Diflubenzuron MetHb, SulfHb) Metazachlor Triasulfuron 
Diuron   
 
 
14.2.3.2. CAG level 3a2: Oxidative stress 
For one active substance, methomyl, information in the open literature suggests that the 
haemolytic anaemia is caused by oxidative stress as indicated by increasing lipid peroxidation 
and perturbations in various antioxidant enzymes (Mansour et al. 2001). Garg et al. (2008) 
have noted that change in the membrane lipid composition is the key factor for deformations 
in blood-cell shape (e.g. spherocytosis and poikilocytosis) in response to various adverse 
treatments. The other factor might be the formation of active loci on the red blood cell 
membrane as a result of interaction with free radicals, thereby resulting in the alteration of the 
shape of red blood cells.  This is, according to the authors, consistent with the increase in lipid 
oxidation observed in their own study. It is not clear whether the haemolytic anaemia is 
intravascular or extravascular. 
For another active substance, acibenzolar-S-methyl, information in the DAR indicates that the 
haemolytic anaemia is caused by oxidative stress via metabolic release of methanethiol (an 
indirect mechanism) with the consequence of increased extravascular erythrocyte degradation.  
The active substances identified as inducing haemolytic anaemia by oxidative stress are 
allocated to CAG level 3a2 and are listed in Table 14.6. 
 
Table 14.6. CAG level 3a2: Oxidative stress  
Acibenzolar-S-methyl (benzothiadiazole) Methomyl  
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14.2.4. CAG level 4: Mechanism of action 
For a few of the active substances affecting the red blood cells, a mechanism of action has 
been proposed. For the remaining substances, no information regarding mechanisms has been 
found and consequently, these substances cannot be allocated to a CAG level 4. 
14.2.4.1. CAG level 4a1a: Reaction with sulfhydryl groups on the surface of erythrocytes 
For one active substance, 1-methylcyclopropene, information in the DAR indicates that the 
haemolytic anaemia is caused by a reaction of the ethylene bond in 1-methylcyclopropene 
with sulfhydryl groups on the surface of erythrocytes. This substance is allocated to CAG 
level 4a1a and is listed in Table 14.7. 
 
Table 14.7. CAG level 4a1a: Reaction with sulfhydryl groups on the surface of 
erythrocytes  
1-Methyl-cyclopropene   
 
 
14.2.4.2. CAG level 4d1a: Immune reaction 
For one active substance, azimsulfuron, information in the DAR indicates that the anaemia 
observed in dogs is due to azimsulfuron acting as a hapten to induce an immune reaction 
against the circulating blood cells, i.e. an immune mediated destruction of blood cells. This 
substance is allocated to CAG level 4d1a and is listed in Table 14.8. 
 
Table 14.8. CAG level 4d1a: Immune reaction  
Azimsulfuron   
 
 
14.3. Discussion of CAGs for the haematological system 
One hundred and twentyfour active substances were identified to affect the cellular elements 
of the blood and were allocated to CAG level 1. Three distinct CAGs at level 2 have been 
proposed. Information on mode/mechanism of action is available for only a few of the active 
substances. The information is summarised in Appendix T. 
Nineteen substances were identified as inducing haemolytic anaemia (CAG level 3a1, Table 
14.5). The CAG level 3a1 is recommended for CRA. Six of the substances also induced 
methaemoglobinanemia. In the clinic, one of the parameters examined in order to determine 
whether an anaemia is of the haemolysis is intravascular is methaemoglobinanemia. However, 
it is not clear whether haemolytic anaemia always is accompanied by methaemoglobinanemia. 
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Therefore, the other active substances identified as inducing methaemoglobinanemia were not 
included in the CAG level 3a1.  
In addition to the six substances identified to induce both haemolytic anaemia and 
methaemoglobinanemia, six other substances were identified as inducing 
methaemoglobinanemia: Beflubutamid, chlorpropham, clodinapob-prop, flufenacet, 
methoxyfenozide and phenmedipham. Whether these substances also induce haemolytic 
anaemia is not clear from neither the DAR nor the open literature. It has been considered 
whether a specific CAG for methaemoglobinanemia would be relevant. However, as 
mentioned, the available information is considered insufficient in order to conclude whether 
methaemoglobinanemia might be or might not be associated with haemolytic anaemia. 
Moreover, it is not clear whether methaemoglobinanemia is just a sign of anaemia in general 
and thus covered by CAG level 2a, or whether methaemoglobinanemia is a specific type of 
anaemia for which a specific CAG at level 3 would be relevant, i.e. it is not clear whether a 
CAG level 2 or a CAG level 3 would be the relevant one for methaemoglobinanemia. 
Therefore, a specific CAG for methaemoglobinanemia is not recommended for the time being. 
Two substances were identified as inducing anaemia via oxidative stress (CAG level 3a2, 
Table 14.6). For one substance, methomyl, it is not clear whether the oxidative stress is related 
to intravascular or extravascular haemolytic anaemia. For the other substance, acibenzolar-S-
methyl, the oxidative stress led to increased extravascular erythrocyte degradation. The CAG 
level 3a2 is therefore, not recommended for CRA for the time being. 
For iodosulfuron-methyl-sodium, the haematotoxicity in dogs was interpreted in the DAR as 
an interaction of the test compound at high concentrations with cell maturation in the 
haematopoietic tissues, mainly the bone marrow. Thus, the anaemia could be considered as 
secondary to the effect in the bone marrow and therefore, not relevant for CAG level 2a and 
consequently, not relevant in terms of CRA for anaemia. However, in the bone marrow, 
iodosulfuron-methyl-sodium was reported to increase in myeloid to erythroid ratio and to 
induce hyperplasia, effects which have been interpreted as being secondary to anaemia and 
consequently, not relevant in terms of CRA for effects on the bone marrow. As no further 
information has been located, iodosulfuron-methyl-sodium has not been allocated to a CAG 
level 3. 
For two substances, a mechanism of action has been proposed: 1-Methyl-cyclopropene (CAG 
level 4a1a, Table 14.7) and azimsulfuron (CAG level 4d1a, Table 14.8). However, as only one 
active substance is to each of these two CAGs at level 4, these two CAGs are not 
recommended for CRA for the time being. However, these CAGs may become relevant in the 
future provided that new information on other active substances reveals the mechanism of 
action forming the basis for the respective CAGs. 
For carfentrazone-ethyl it is noted in the DAR “It is believed to be an inhibitor of 
protoporphyrinogen oxidase and of heme synthesis in animals.” As no further information has 
been located, carfentrazone-ethyl can not been allocated to a CAG level 3 or 4. 
No information regarding the mode of action for the remaining active substances allocated to 
CAG level 2a has been found. Therefore, this CAG at level 2 could be considered for CRA for 
anaemia in general. 
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Regarding effects on the platelets, thrombocytosis (CAG level 2b) as well as 
thrombocytopenia (CAG level 2c), no information on mode/mechanism of action has been 
found except for benthiavalicarb where it has been indicated in the DAR that thrombocytosis 
may be linked to a chronic inflammatory response. Therefore, these CAGs at level 2 could be 
considered for CRA for effects on the platelets. 
14.4. Recommended CAGs for the haematological system 
The following CAGs are recommended for CRA for effects on the cellular elements in the 
blood, which is a part of the haematological system (the other part, the bone marrow, is 
addressed in chapter 8): 
• CAG level 3a1: Haemolysis, see Table 14.5. 
• CAG level 2a: Anaemia, see Table 14.2. 
• CAG level 2b: Thrombocytosis, see Table 14.3. 
• CAG level 2c: Thrombocytopenia, see Table 14.4. 
 
The following CAGs are not recommended for CRA for the time being. However, these 
CAGs may become relevant in the future provided that new information on other active 
substances justifies the mode of action / phenomenological effects forming the basis for the 
respective CAGs: 
• CAG level 3a2: Oxidative stress, see Table 14.6. 
• CAG level 4a1a: Reaction with sulfhydryl groups on the surface of erythrocytes, see 
Table 14.7. 
• CAG level 2b: Immune reaction, see Table 14.8. 
 
 
15. Immune system 
15.1. Introduction 
The immune system is represented in most tissues, organs and peripheral sites and is therefore 
readily accessible for toxic substances regardless of the route of exposure. It is designed to 
distinguish between self and non-self to provide host integrity against invading pathogens and 
emerging tumour cells as well as to respond to tissue damage and external potential host-
threatening stimuli. As the immune system works by means of recognition and response, it is 
important in toxicological risk assessment not only to consider whether chemical exposure 
may results in insufficient immune responses but also whether it may results in inappropriate 
immune responses in terms of disease risk. 
Bone marrow, liver, thymus and Peyer’s patches represent primary sites of the immune system 
that is important for immune cell maturation. Specific secondary lymphoid sites such as the 
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spleen, lymph nodes and tonsils are important for antigen presentation and initiation of 
adaptive immune responses. Mucosal-associated lymphoid tissue is regional organisations of 
immune cell populations that are important in local immunity; examples are the bronchus-
associated lymphoid tissue and gut-associated lymphoid tissue associated with respiratory and 
oral exposure, respectively.  
The mammalian immune system is composed of two cooperating subdivisions: The innate 
immune system and the adaptive immune system. These can be separated by the rapidity and 
specificity of the response. The innate immune system comprises of anatomical, humoral and 
cellular barriers and provides a rapid immediate defence with a low degree of specificity. On 
the other hand, adaptive immune responses have a much slower onset, a high degree of 
specificity, recognise a much broader range of foreign substances and produce signals and 
components that increase the innate response. Furthermore, adaptive immunity has three 
unique features: Diversity, immunological memory and self-nonself recognition; and can be 
divided into humoral immunity (response mediated by B cell-secreted antibodies) and cell-
mediated immunity (response mediated by antigen-specific T cells in collaboration with 
various non-specific immune cells). Contrary to innate immunity which is found in all classes 
of plant and animal life, adaptive immunity is only found in vertebrates.  
One way to evaluate immune system status is to examine the host response to challenge with 
an infectious agent or immunisation with a foreign antigen. Thus, it is fundamental to evaluate 
functional immune responses to antigenic challenge to detect chemically induced adverse 
effects (such as immune system impairment or dysfunction) influencing health risk. In 
general, evaluation of structural alterations of the resting/unchallenged immune system (e.g. 
immunopathological examination) is considered less sensitive to detect immunotoxic effects 
compared to measurement of the functional immune response to antigenic challenge. Finally, 
it is important to notice that dose sensitivity may be greater in early life than in adulthood as 
well as early-life immune insults may result in immune dysfunction affecting later-life host 
integrity and diseases. 
15.2. Establishment of CAGs for toxicity to the immune system 
Most of the immune system-related changes described in DARs are based on studies not 
conducted according to test guideline toxicity or immunotoxicity studies. In addition, most of 
the studies lack information about study design and examined parameters which complicate 
assessment of NOAELs and LOAELs. Thus, the effects on the immune system reported most 
probably reflect a state of physiological stress (in general most studies noted increased adrenal 
weights). A few studies demonstrated an immunomodulating effect but were not able to 
identify or clarify the underlying mechanism(s).  
Effects on the primary sites of the immune system, i.e. bone marrow, liver and thymus, and 
the lymph nodes are described in the sections of these organs, respectively. 
Therefore, the immune system is not considered further for CAGs in this report.  
15.3. Recommended CAGs for the immune system 
No CAGs for toxicity to the immune system are recommended. 
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16. Kidney 
16.1. Introduction 
The kidneys are paired organs. Each kidney has a bean-shaped structure and consists of a 
capsule, the outer renal cortex and the inner renal medulla (see Figure 16.1.) The medulla 
contains a number of cone-shaped renal pyramids. The tip of each pyramid is called the 
papilla. The functional unit of the kidney is the nephron (see Figure 16.2.). More than a 
million nephrons are located in each kidney in the cortex and medulla. The nephron consists 
of the glomerulus, which is a tuft of capillaries. The main function of the glomerulus is to 
filter the blood. The glomerulus is located in Bowman´s capsule. From Bowman´s capsule the 
filtered blood is lead into the tubules, which are subdivided into various segments such as the 
proximal tubule, loop of Henle and the distal tubule. The function of the tubules is to regulate 
the filtrate to maintain body fluid volume, electrolyte composition, and pH within narrow 
limits. The urine formed by the nephrons in the kidney flow from the distal tubules and 
collecting ducts through the renal papilla, and into the minor and major calyces, and is 
collected in the renal pelvis. From the renal pelvis, urine is funnelled into the ureters and on to 
the bladder. In addition to maintaining a stable internal environment, the kidneys also secrete 
hormones for regulation of blood pressure, erythrocyte production, and calcium metabolism. 
(McCance and Huether 1998). 
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Urinary%20system/The%20kidney,%20LS.jpg 
Figure 16.1. Anatomy of the kidney. 
apbio3.wikispaces.com/Kidney 
 
Figure 16.1. Structure of a nephron. 
 
 
The urinary passages, the renal pelvis, the ureters, the bladder and the urethra are histological 
similar to each other. They have a mucosal layer lined with transitional epithelium. 
Underlying the mucosal layer are muscle layers covered by a serous membrane or connective 
tissue. (Verlander 1998). Therefore the pathogenesis for effects in the renal pelvis and ureters 
may be the same as for effects in the urinary bladder and urethra (Cohen 1998). Effects in the 
urinary bladder and urethra have been included in the chapter about the urinary bladder. 
Any chemical in the blood will be delivered to the kidney in relatively high amounts as the 
kidneys receive about 25 percent of the resting cardiac output. In addition potential toxicants 
may be concentrated in the tubular fluid, thereby driving passive diffusion of toxicants into 
the tubular cells. Therefore, a non-toxic concentration of a chemical in the blood may reach 
toxic concentrations in the kidney.  Progressive concentration of toxicants along the nephron 
may result in precipitation and ultimately calculi, which may obstruct the renal flow of urine. 
Many nephrotoxicants have their primary effects on discrete regions of the nephron. The 
proximal tubule is the most common site of toxicant-induced renal injury. Part of the reason is 
that the proximal tubules compared to the distal tubules have a much more leaky epithelium 
favouring the flux of compounds into the proximal tubular cells. Furthermore, active transport 
of many molecules into the tubular cells is greater in the proximal tubules than in other 
segments of the tubules. (Klaassen 1996). 
 
 
16.2. Establishment of CAGs for toxicity to the kidney 
16.2.1. CAG level 1: Toxicity to the kidney 
The active substances identified as having an effect on the kidney in the toxicological studies 
included in the DARs are allocated to CAG level 1 and are listed in Table 16.1. 
Table 16.1. CAG level 1: Toxicity to the kidney. 
1-Methyl-cyclopropene Fenpropidin Pethoxamid 
2,4-D Fenpyroximate Phenmedipham 
2,4-DB Fipronil Picloram 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Flazasulfuron Pirimiphos-methyl 
Acetamiprid Florasulam Prohexadione-calcium 
Aclonifen Fludioxonil Propamocarb 
Azimsulfuron Flufenacet (formerly fluthiamide) Propaquizafop 
Beflubutamid Flumioxazin Propyzamide 
Benfluralin Fluopicolide Prosulfocarb 
Bentazone Fluoxastrobin Prothioconazole 
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Benthiavalicarb Fluroxypyr Pyraclostrobin 
Benzoic acid Folpet Pyraflufen-ethyl 
Beta-Cyfluthrin Forchlorfenuron Pyrimethanil 
Bifenox Fosetyl Pyriproxyfen 
Carbendazim Gibberellin Quinoclamine 
Chloridazon (aka pyrazone) Glufosinate Quizalofop-P-tefuryl 
Chlorothalonil Glyphosate Rimsulfuron (aka renriduron) 
Chlorotoluron Ioxynil S-Metolachlor 
Chlorpropham Iprodione Sodium 5-nitroguaiacolate 
Cinidon ethyl Isoxaflutole Sodium o-nitrophenolate 
Clodinafop Linuron Sodium p-nitrophenolate 
Clopyralid Lufenuron Spinosad 
Clothianidin MCPA Spiroxamine 
Copper compounds Mecoprop Sulcotrione 
Cyazofamid Mecoprop-P Sulfosulfuron 
Cyflufenamid Mepanipyrim Tebufenpyrad 
Cyhalofop-butyl Mesotrione Tepraloxydim 
Cymoxanil Metamitron Tetraconazole 
Cyprodinil Metazachlor Thiabendazole 
Cyromazine Metconazole Thiamethoxam 
Desmedipham Methomyl Thiophanate-methyl 
Dichlorprop-P Methoxyfenozide Tolylfluanid 
Dimethachlor Metrafenone Tri-allate 
Diquat (dibromide) Metribuzin Triasulfuron 
Diuron Milbemectin Tribenuron methyl 
Esfenvalerate Molinate Triclopyr 
Ethephon Oxadiazon Trifloxystrobin 
Etofenprox Oxamyl Trinexapac (aka cimetacarb ethyl) 
Fenhexamid Oxasulfuron Tritosulfuron 
Fenoxaprop-P Penconazole  
 
 
16.2.2. CAG level 2: Phenomenological / specific effects on the kidney 
Various types of effects on the kidney were identified as a basis for establishing CAGs at level 
2. Based on these effects, thirteen distinct CAGs at level 2 are proposed: Tubular hypertrophy 
/ hyperplasia, tubular fatty changes, tubular degeneration / death, tubular neoplasms, tubular 
hyaline droplets, chronic progressive nephropathy (CPN), alpha2u-globulin nephropathy, 
glomerular degeneration / death, glomerular inflammation, inflammation, papillary 
degeneration / death, papillary hypertrophy / hyperplasia, and pelvic hyperplasia. More 
information is given in Appendix U. 
16.2.2.1. CAG level 2a: Tubular cell degeneration / cell death 
This CAG level covers effects described as tubular nephropathy, tubular degeneration, tubular 
death, and tubular atrophy. Tubular nephropathy is unspecified damage to the tubular cells. 
Degeneration of cells reflects cytoplasmic alterations at the borderline between adaptation 
with resolution back to normal structure and function, and inability to adapt leading to cell 
death. It may be difficult to distinguish between different forms of degeneration, and early 
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necrosis. Cell death is the ultimate result of irreversible cellular injury. Tubular atrophy 
represents collapse of tubular structures, ultimately with disappearance and reduction of 
individual tubules (Hard et al 1999).  
Effects described by a term such as chronic nephropathy is included in this CAG at least if the 
effect occurred in other species than rats or in subchronic studies. For long-term rat studies the 
matter is more complicated as the DARs by the term chronic nephropathy may refer to CPN 
(see CAG level 2f). Chronic nephropathy in principle also may include damage to the 
glomerulus or other parts of the kidney. However, if the lesions in the chronic nephropathy 
have not been specified by the DARs they have just been included in this CAG. 
See Annex U for a list of all terms in the DARs interpreted to represent tubular cell 
degeneration / cell death. CAGs have not been created for damage to specific sites within the 
tubules as this information rarely has been noted in the DARs. 
The active substances identified as inducing tubular cell degeneration / cell death are allocated 
to CAG level 2a, termed ‘CAG level 2a: Tubular cell degeneration / cell death’ and are listed 
in Table 16.2. 
 
Table 16.2. CAG level 2a: Tubular cell degeneration / cell death  
2,4-D Fludioxonil Pyraclostrobin 
2-Phenylphenol Flufenacet  Pyrimethanil 
Aclonifen Fluoxastrobin Pyriproxyfen 
Carbendazim Fluroxypyr Quinoclamine 
Chloridazon (aka pyrazone) Forchlorfenuron Sodium 5-nitroguaiacolate 
Chlorothalonil MCPA Sodium o-nitrophenolate 
Cinidon ethyl Mecoprop-P Sodium p-nitrophenolate 
Copper compounds Mepanipyrim Spinosad 
Cyhalofop-butyl Metazachlor Sulfosulfuron 
Cyromazine Metrafenone Tetraconazole 
Dichlorprop-P Oxasulfuron Thiabendazole 
Dimethachlor Pethoxamid Thiamethoxam 
Etofenprox Pirimiphos-methyl Thiophanate-methyl 
Fenhexamid Propaquizafop Triasulfuron 
Fenoxaprop-P Propyzamide Triclopyr 
Flazasulfuron Prosulfocarb Tritosulfuron 
Florasulam Prothioconazole  
 
 
16.2.2.2. CAG level 2b: Tubular fatty changes 
This CAG level covers effects described as fatty changes and/or vacuolation. Tubular 
vacuolation is recognised as clear, round spaces of variable size within the cytoplasm. 
Vacuolation may be a transient physiological response or it may represent the initial stage 
preceding cell degeneration. The vacuoles may or may not contain accumulated fat. (Hard et 
al. 1999).  
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Most of the DARs do not detail the content of the vacuoles. Consequently it is probably not 
all the active substances included in this CAG that actually contain fat in the vacuoles.  
See Annex U for a list of all terms in the DARs interpreted to represent tubular fatty change. 
The active substances identified as inducing fatty change are allocated to CAG level 2b and 
are listed in Table 16.3. 
 
Table 16.3. CAG level 2b: Tubular fatty changes  
2,4-D Metazachlor Prosulfocarb 
Chloridazon (aka pyrazone) Metconazole Spinosad 
Cyflufenamid Oxadiazon Thiabendazole 
Dimethachlor Oxamyl Triclopyr 
Fenoxaprop-P Pethoxamid Tritosulfuron 
Flufenacet Prohexadione-calcium  
 
 
For twelve out of the seventeen active substances, which induce tubular fatty changes, tubular 
cell degeneration / cell death has also been noted.   
16.2.2.3. CAG level 2c: Tubular hypertrophy / hyperplasia 
Tubular hypertrophy / hyperplasia covers tubular hypertrophy, tubular regeneration, and 
tubular hyperplasia. Tubular hypertrophy is an increase in the size of the epithelial cells lining 
the renal tubules. It may develop after tubule cell necrosis as a compensatory response to 
transient loss of tubule function. Regenerating tubular epithelium is characterised by 
basophilia and a higher than normal proliferative rate. Tubule regeneration is the epithelial 
response to tubular necrosis. Tubular hyperplasia is an increase in the number of epithelial 
cells lining the renal tubules. It may develop following longstanding persistent tubule 
regeneration. (Hard et al. 1999). 
Tubules may be basophilic unrelated to regeneration. It is likely that chemically induced 
cytoplasmic basophilia in tubules is a reflection of an increase in ribosomal RNA. Basophilic 
tubules also characterise the early stages of CPN (see CAG level 2f). (Hard et al. 1999). Often 
it was not clear in the DARs whether the basophilic tubules were considered to be 
regenerating tubules, tubules in the early stage of CPN, or tubules unrelated to regeneration or 
CPN. In those cases the basophilic tubules have been included in this CAG for hypertrophy / 
hyperplasia. 
See Annex U for a list of all terms in the DARs interpreted to represent tubular hypertrophy / 
hyperplasia. 
The active substances identified as inducing tubular hypertrophy / hyperplasia are allocated to 
CAG level 2c and are listed in Table 16.4. 
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Table 16.4. CAG level 2c: Tubular hypertrophy / hyperplasia  
2,4-D Fenhexamid Prothioconazole 
2-Phenylphenol Florasulam Quinoclamine 
Aclonifen Fluroxypyr Sodium 5-nitroguaiacolate 
Chlorothalonil Forchlorfenuron Sodium o-nitrophenolate 
Cinidon ethyl MCPA Sodium p-nitrophenolate 
Copper compounds Metconazole Sulcotrione 
Cyazofamid Oxadiazon Tetraconazole 
Cyromazine Oxamyl Thiabendazole 
Desmedipham Pethoxamid Tolylfluanid 
Dichlorprop-P Prohexadione-calcium Triasulfuron 
Etofenprox Propaquizafop Triclopyr 
 
 
For 25 out of the 33 active substances, which induce tubular hypertrophy / hyperplasia, tubular 
cell degeneration / cell death has also been noted.  For 3 out of the 8 active substances that did 
not induce tubular cell degeneration / cell death, CPN was noted. 
16.2.2.4. CAG level 2d: Tubular neoplasms 
For the purpose of the CAG project, histopathological findings in the form of tubular adenoma 
and tubular carcinoma are interpreted, qualitatively but not quantitatively, as representing the 
same type of effect in the kidney and therefore, are allocated to a single CAG level 2, termed 
‘CAG level 2d: Tubular neoplasms’. See Annex U for a list of all terms in the DARs 
interpreted to represent tubular neoplasms. 
The active substances identified as inducing tubular neoplasms are allocated to CAG level 2d 
and are listed in Table 16.5. 
 
Table 16.5. CAG level 2d: Tubular neoplasms  
Benfluralin Chlorotoluron Molinate 
Chlorothalonil Forchlorfenuron  
 
 
16.2.2.5. CAG level 2e: Tubular hyaline droplets 
Hyaline droplets are lysosomes containing protein (Hard et al. 1999). Hyaline droplets solely 
in male rats may be part of alpha2u-globulin nephropathy (see CAG level 2g) and is not 
included in CAG level 2e. See Annex U for a list of all terms in the DARs interpreted to 
represent tubular hyaline droplets. 
The active substances identified as inducing tubular hyaline droplets in both sexes of rats or in 
other species are allocated to CAG level 2e and are listed in Table 16.6. 
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Table 16.6. CAG level 2e: Tubular hyaline droplets  
Azimsulfuron Benthiavalicarb Mesotrione 
Benfluralin Copper compounds  
 
 
16.2.2.6. CAG level 2f: Chronic progressive nephropathy (CPN) 
CPN is a common spontaneous disease of aging rats of unknown etiology. It occurs in both 
sexes but is more prevalent and more severe in male rats. Several physiological factors 
influence its incidence and severity, most prominently protein and caloric intake. Chemicals 
may also exacerbate CPN. In its early stages it has histological similarity to tubular 
degeneration from other causes. In its advanced stages it is associated with marginally 
increased renal tubule tumour incidences. The earliest change is foci of basophilic tubules 
with thickened basement membrane and hyaline casts. The first lesions may develop as early 
as 2-3 months in conventional strains of laboratory rats.  With progression affected tubules 
display both degenerative and regenerative changes including hyperplasia. Dilated tubules are 
filled with hyaline casts. With increasing severity tubular atrophy and glomerular changes 
become evident. The glomerular changes include collapse of capillary tufts, adhesions with 
Bowman´s capsule, glomerular atrophy and sclerosis. Interstitial changes include 
inflammation and fibrosis. In very advanced stages, little normal parenchyma remains in the 
cortex, the tubules are cystic and there may be mineralisation of the basement membranes 
(because of compensatory hyperplasia of the parathyroid gland with general mineralisation). 
Chemically induced exacerbation of CPN and increases in the incidence of CPN-related renal 
tumours is not considered relevant to humans. (Hard et al. 2009, Hard and Khan 2004, Hard et 
al. 1999). Most chemicals that induce alpha2u-globulin nephropathy also exacerbate CPN in 
male rats but no evidence suggests that the high level of alpha2u-globulin in male rats has any 
influence on the expression of CPN. It is however possible that the two modes of action, 
alpha2u-globulin and CPN, may work in concert to enhance the formation of renal tubule 
tumours. (Hard et al. 2009). 
Recently Hard and Seely (2005) have recommended criteria to assist pathologists in the 
discrimination between proliferative lesions found in advanced CPN and preneoplastic 
lesions. According to Hard et al. (1999), CPN should be identified by this term in safety 
evaluation studies and the lesion components of CPN should not be individually diagnosed. 
So it should be easy to go through the DARs and find the active substances that may 
exacerbate CPN. However, in practice the terms chronic progressive nephropathy or CPN 
have rarely been used in the DARs. Over the years CPN has been called several names e.g. 
glomeruloschlerosis, glomerulonephritis and chronic nephrosis (Hard et al. 2009). Sometimes 
the DARs specify the lesions covered e.g. by the term chronic nephropathy but just as often 
the terms are not specified. Consequently, it is not always clear whether the DARs mean CPN. 
See Annex U for a list of all terms in the DARs interpreted to represent CPN. In general, 
active substances have only been included in this CAG if CPN was noted in long time studies 
with rats. Some of the effects seen in the 90-day studies may be early indications of CPN but 
it is not clear from the DARs whether that is the case. For at least one active substance, 
dimethachlor, the DAR has used the term chronic progressive nephropathy for effects seen in 
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mouse studies. Hard et al. (2009) shortly mention that mice can develop a form of CPN that 
bears some resemblance to rat CPN. However, dimethachlor is not included in this CAG as it 
is not clear from the articles whether CPN in mice is without relevance for humans. 
The active substances identified as inducing CPN are allocated to CAG level 2f and are listed 
in Table 16.7. 
 
Table 16.7. CAG level 2f: Chronic progressive nephropathy (CPN)  
Beflubutamid Flumioxazin Picloram 
Benfluralin MCPA Pirimiphos-methyl 
Benthiavalicarb Mesotrione Prothioconazole 
Chlorothalonil Metazachlor Sulcotrione 
Cinidon ethyl Metconazole Thiamethoxam 
Clodinafop Methoxyfenozide Thiophanate-methyl 
Fipronil Metrafenone Tri-allate 
Flazasulfuron Milbemectin  
Fludioxonil Oxadiazon  
 
 
16.2.2.7. CAG level 2g: Alpha2u-globulin nephropathy 
Alpha2u-globulin nephropathy (where u is short for urinary) is a renal syndrome that occurs 
exclusively in male rats. The toxicity appears to be caused by the accumulation of the protein, 
alpha2U-globulin. The protein overload causes renal cell injury, compensatory cell 
proliferation and ultimately a low incidence of renal tubule tumours. Alpha2u-globulin is a 
protein that is only synthesised by adult male rats. Chemicals that cause alpha2u-globulin 
nephropathy (or their metabolites) bind to alpha2u-globulin. Because of this binding the rate 
of degradation of alpha2u-globulin is reduced and the protein begins to accumulate in the 
phagolysosomes. This accumulation of protein is histopathologically seen as hyaline droplets 
in the proximal tubular cells. Continued exposure to the chemical leads to single cell 
degeneration and necrosis in the tubular cells. Dead cells are sloughed into the tubular lumen 
and contribute to the development of granular casts. After several months of exposure, 
mineralisation occurs in the lumen of tubules in the renal papilla often accompanied by 
papillary hyperplasia. The mineralisation represents residues of the granular casts formed in 
more active stages of injury. As a result of the renal cell death and degeneration, tubular 
hyperplasia and ultimately tubular neoplasms may develop. There is no protein in humans that 
can contribute to a renal syndrome like alpha2u-globulin nephropathy. Thus alpha2u-globulin 
nephropathy and increases in the incidence of renal tumours related to alpha2u-globulin 
nephropathy is not considered relevant to humans. (Swenberg and Lehman-McKeeman 1999, 
Hard et al. 1999). 
IARC 1999 has developed criteria that need to be met to conclude that a chemical causes 
kidney tumours through an alpha2u-globulin mode of action.  
In this CAG for alpha2u-globulin nephropathy active substances, which induce hyaline 
droplets and sometimes one or more of the other characteristic lesions (single cell 
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degeneration and necrosis, granular casts, papillary mineralisation, tubular hyperplasia, 
tubular neoplasms) for alpha2u-globulin nephropathy only in male rats have been included. 
Thus the active substances in this CAG do not necessarily meet the IARC 1999 criteria 
(actually none of them do). 
The active substances identified as inducing alpha2u-globulin nephropathy are allocated to 
CAG level 2g and are listed in Table 16.8. 
 
Table 16.8. CAG level 2g: Alpha2u-globulin nephropathy 
1-Methyl-cyclopropene Fluopicolide Thiamethoxam 
Benfluralin Prosulfocarb Tri-allate 
Cyflufenamid Quinoclamine Trinexapac 
Flazasulfuron Tepraloxydim  
 
 
In the remarks column in the database it is noted which characteristic lesions the 11 active 
substances induce. Shortly 5 of the active substances (1-methyl-cyclopropene, benfluralin, 
cyflufenamid, flazasulfuron, and quinoclamine) only induce hyaline droplets. Thiamethoxam, 
tri-allate, and trinexapac induce hyaline droplets, granular casts, and tubular hyperplasia. 
Tepraloxydim induces hyaline droplets and single cell degeneration and necrosis. Prosulfocarb 
induces hyaline droplets, single cell degeneration and necrosis, and tubular hyperplasia. 
Fluopicolide as the only active substance induces almost the whole sequence of lesions 
(hyaline droplets, single cell degeneration and necrosis, granular casts, papillary 
mineralisation, and tubular hyperplasia). Only benfluralin induces tubular neoplasms but 
clearly not through an alpha2u-globulin mode of action (see the CAG for tubular neoplasms 
for further details). 
16.2.2.8. CAG level 2h: Glomerular cell degeneration / cell death 
The CAG level for glomerular degeneration / death mainly covers glomeruloschlerosis. 
Glomerulosclerosis represent progressive replacement of glomerular matrix with amorphous 
hyaline material. Early changes include a thickened basement membrane. Glomeruloschlerosis 
in rats is a component of advanced CPN but can also be induced experimentally by the 
administration of chemicals. (Hard et al. 1999). To complicate matter further, CPN has over 
the years been called several names of which glomeruloschlerosis is one (Hard et al. 2009). 
See Annex U for a list of all terms in the DARs interpreted to represent glomerular 
degeneration / death.  
The active substances identified as inducing glomerular degeneration / death are allocated to 
CAG level 2h and are listed in Table 16.9. 
Table 16.9. CAG level 2h: Glomerular cell degeneration / cell death 
Benthiavalicarb Ethephon Molinate 
Carbendazim Fludioxonil Propamocarb 
Chlorothalonil Fluroxypyr Propaquizafop 
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For two of the substances, benthiavalicarb and ethephon, the effect was noted in 2-year rat 
studies, and thus may represent CPN. 
16.2.2.9. CAG level 2i: Glomerular inflammation 
The CAG level for glomerular inflammation covers 2 active substances, which induce the 
effects glomerulonephritis or membranous glomerulonephritis in non-rat studies. In 
membranous glomerulonephritis, the glomerular basement membranes are thickened due to 
deposition of aggregates of immune complexes (Hard et al. 1999). To complicate matter 
further, CPN has over the years been called several names of which glomerulonephritis is one 
(Hard et al. 2009). Thus a few active substances where the terms glomerulonephritis or 
progressive glomerulonephritis have been used in the DARs for effects in long term rat 
studies have been allocated to the CAG for CPN. 
The active substances identified as inducing glomerular inflammation are allocated to CAG 
level 2i and are listed in Table 16.10. 
 
Table 16.10. CAG level 2i: Glomerular inflammation 
Chlorothalonil Sulfosulfuron  
 
 
16.2.2.10. CAG level 2j: Inflammation 
Infiltration of different inflammatory cells is typically a response to death of cells. Thus 
tubular or papillary necrosis may cause inflammation. Calculi in the pelvis may also be the 
cause of an inflammation in the kidney. In rats an infection with bacteria may easily ascend 
from the bladder to the kidney and cause inflammation. Inflammation between the tubules is 
common in advanced stages of CPN. (Hard et al. 1999). See Annex U for a list of all terms in 
the DARs interpreted to represent inflammation. 
The active substances identified as inducing inflammation are allocated to CAG level 2j and 
are listed in Table 16.11. 
 
Table 16.11. CAG level 2j: Inflammation 
2-Phenylphenol Fludioxonil Pyrimethanil 
Aclonifen Fluroxypyr Quinoclamine 
Azimsulfuron Forchlorfenuron Spinosad 
Benfluralin Fosetyl Sulfosulfuron 
Benthiavalicarb Iprodione Thiabendazole 
Bifenox Lufenuron Thiamethoxam 
Carbendazim Oxamyl Triasulfuron 
Chloridazon (metabolite) Oxasulfuron Tritosulfuron 
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Chlorothalonil Prothioconazole  
Desmedipham Pyraflufen-ethyl  
 
 
Calculi, tubular necrosis or papillary necrosis have been noted for almost all of the active 
substances, which induce inflammation. Thus for most of the active substances the 
inflammation is probably secondary to effects already covered in other CAGs. 
16.2.2.11. CAG level 2k: Papillary cell degeneration / cell death 
Papillary necrosis starts at the tip of the papilla and may progress to involve the full depth of 
the papilla. At first the degenerative change involves the interstitial cells and blood vessels. 
Later the degenerative change involves the tubules. The demarcation between necrotic papilla 
and the surviving medullary tissue may show infiltration of inflammatory cells and 
mineralisation. The necrotic papilla may undergo regeneration, which may result in papillary 
hyperplasia. Secondary changes of tubular dilation and inflammation may occur in the cortex. 
(Hard et al. 1999). See Annex U for a list of all terms in the DARs interpreted to represent 
papillary cell degeneration / cell death. 
The active substances identified as inducing papillary cell degeneration / cell death are 
allocated to CAG level 2k and are listed in Table 16.12. 
 
Table 16.12. CAG level 2k: Papillary cell degeneration / cell death 
2-Phenylphenol Fosetyl Quinoclamine 
Aclonifen Metamitron Sulcotrione 
Benfluralin Picloram Tetraconazole 
Florasulam Propaquizafop Tritosulfuron 
Fluroxypyr Pyraflufen-ethyl  
 
16.2.2.12. CAG level 2l: Papillary hypertrophy / hyperplasia 
As described above papillary hyperplasia may be a regenerative response to papillary necrosis 
(Hard et al. 1999). See Annex U for a list of all terms in the DARs interpreted to represent 
papillary hypertrophy / hyperplasia. 
The active substances identified as inducing papillary hypertrophy / hyperplasia are allocated 
to CAG level 2l and are listed in Table 16.13. 
 
Table 16.13. CAG level 2l: Papillary hypertrophy / hyperplasia 
2-Phenylphenol Fluopicolide Pyraflufen-ethyl 
Chlorothalonil Fluroxypyr Quinoclamine 
Florasulam Phenmedipham Thiabendazole 
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Five of the active substances (2-phenylphenol, florasulam, fluroxypyr, pyraflufen-ethyl, and 
quinoclamine) that induce papillary hypertrophy / hyperplasia also induce papillary 
degeneration / death. Thus for these five substances the hyperplasia is probably secondary to 
the papillary necrosis.  
Six of the active substances (2-phenylphenol, chlorothalonil, fluroxypyr, phenmedipham, 
pyraflufen-ethyl, quinoclamine and thiabendazole) that induce papillary hypertrophy / 
hyperplasia also induce pelvic hyperplasia. It makes one speculate whether the cause of the 
papillary hyperplasia at times may be related to the cause of the pelvic hyperplasia. 
16.2.2.13. CAG level 2m: Pelvic hyperplasia 
Hyperplasia is an increased number of cells. Hyperplasia of the pelvis may be a response to 
epithelial irritation, which in turn can be induced by urinary crystals, calculi or toxic 
chemicals (Cohen 1998, Hard et al. 1999). See Annex U for a list of all terms in the DARs 
interpreted to represent pelvic hyperplasia. 
The active substances identified as inducing pelvic hyperplasia are allocated to CAG level 2m 
and are listed in Table 16.14. 
Table 16.13. CAG level 2m: Pelvis hyperplasia 
2,4-D Desmedipham Methoxyfenozide 
2-Phenylphenol Diuron Oxasulfuron 
Aclonifen Flazasulfuron Phenmedipham 
Azimsulfuron Flufenacet Pyraflufen-ethyl 
Benfluralin Fluoxastrobin Quinoclamine 
Benthiavalicarb Fluroxypyr Spiroxamine 
Chloridazon (metabolite) Fosetyl Sulfosulfuron 
Chlorothalonil Glyphosate (metabolite) Thiabendazole 
Clothianidin Linuron Thiamethoxam 
Cyromazine  Mepanipyrim Triasulfuron 
 
 
16.2.2.14. Effects not considered relevant for CAGs at level 2 
Changes in blood and urine parameters indicative of kidney damage: 
Initially, nephrotoxicity can be assessed by evaluating serum chemistry and urinalyses 
following treatment with the toxicant. The standard battery of tests includes measurement of 
urine volume and osmolality, pH, and urinary composition (e.g. electrolytes, glucose, protein). 
The specificity of the tests often is poor. As examples, glucosuria may reflect chemically 
induced defects in the proximal tubules but may also be secondary to hyperglycemia. Urinary 
excretion of high molecular weight proteins such as albumin is suggestive of glomerular 
injury, whereas excretion of low molecular weight proteins suggests proximal tubular damage. 
Enzymes in the urine may reflect damage to more or less specific sites in the kidney (or in 
other organs). The absence of enzymuria does not necessarily reflect an absence of damage, as 
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it is often a transient phenomenon. Blood urea nitrogen (BUN) and/or creatinine are often 
measured in blood. These two substances are waste products that are normally excreted by the 
kidneys. Increases in the blood of BUN or creatinine suggest decreases in the glomerular 
filtration rate (GFR). However, both substances are rather insensitive indices of the GFR as a 
50 to 70 percent decrease in GFR must occur before increases in blood BUN and/or creatinine 
develop. Increases in BUN and /or creatinine may not necessarily reflect renal damage but 
rather may be secondary to dehydration, hypovolemia, and/or protein catabolism. (Klaassen 
1996). 
Changes in all of the above parameters thus are more or less specific indicators for damage to 
the kidney. However, the CAGs for different histopathological effects will cover the kidney 
injury indicated by these blood and urine parameters.   
 
Hypertrophy (collecting ducts): 
Florasulam induces various effects in the kidneys including tubular and papillary hypertrophy 
/ hyperplasia. In addition in most short and long term studies hypertrophy of the collecting 
ducts have been reported. The DAR speculates on possible mode of actions for the 
hypertrophy of the collecting ducts. Anyhow as florasulam is the only substance where 
hypertrophy of the collecting ducts have been noted and the possible mode of actions are 
speculations, a CAG has not been created for the effect, which is considered covered by either 
tubular or papillary hypertrophy / hyperplasia. 
 
Tubular karyomegaly: 
Tubular karyomegaly is an increase in the nuclear size of the tubular cells. The pathogenesis is 
not known but the presence generally implies a response to a variety of toxic agents. (Hard et 
al. 1999). Chlorothalonil is the only active substance where tubular karyomegaly have been 
noted in several studies. Chlorothalonil induces various other effects in the tubular cells 
(degeneration / death, hypertrophy / hyperplasia, and neoplasms). Thus the tubular 
karyomegaly is considered covered by other CAGs for tubular effects. 
 
Tubular dilation: 
Tubular dilation covers tubular dilation and tubular cysts. Tubular dilation is an increase in 
lumen diameter of the tubules. It may be induced e.g. by luminal obstruction by crystalline 
deposits, tubular hyperplasia, inflammation, or tubule cell degeneration/regeneration. Tubular 
cysts are marked focal distension of tubules. Causative factors are poorly understood, but 
tubular cysts may develop secondary to tubule obstruction by casts or interstitial fibrosis. 
(Hard et al. 1999). Thus tubular dilation is considered secondary to the effect already covered 
by other CAGs especially the CAGs for tubular degeneration / death, tubular hypertrophy / 
hyperplasia, and inflammation. 
 
Tubular casts: 
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Tubular casts cover hyaline casts and granular casts. Hyaline casts are homogeneous matter in 
the tubule lumen typically composed of protein. They are associated with increased protein in 
the glomerular filtrate, such as albumin, or with secretion into the lumen from tubule cells. 
Hyaline casts are a characteristic of CPN (see CAG level 2f). Granular casts are non-
homogenous particulate matter in the tubule lumen presenting cell breakdown products and 
debris. Typically they occur secondary to tubular necrosis or apoptosis, as in alpha2u-globulin 
nephropathy (see CAG level 2g). (Hard et al. 1999). Thus tubular casts are considered 
secondary to the effect already covered by other CAGs especially the CAGs for tubular 
degeneration / death, CPN and alpha2u-globulin nephropathy. 
 
Pelvic metaplasia: 
The epithelial cells are transformed into squamous epithelial cells typically as a response to 
irritation. Pelvic metaplasia has only been noted for 2 active substances (fluroxypyr and 
sulfosulfuron) where pelvic hyperplasia also was noted. Although pelvic metaplasia is not the 
same as pelvic hyperplasia, the pelvic metaplasia is considered covered by the CAG level 2m 
for pelvic hyperplasia. 
 
Pelvic cell degeneration / cell death: 
As the only active substance fluroxypyr induce pelvic degeneration / death. Fluroxopyr also 
induce glomerular, tubular and papillary degeneration / death, and in the pelvis hyperplasia 
and metaplasia have been noted. Thus the pelvic degeneration / death is considered covered by 
some of the other CAGs. 
 
Pelvic dilation: 
Pelvic dilation is dilation of the renal pelvis and calyces. Pelvic dilation may be secondary to 
urinary obstruction e.g. because of calculi. (Hard et al. 1999). Thus pelvic dilation is 
considered secondary to the effects already covered by other CAGs especially the CAG level 
3m1 for calculi. 
 
Ureter effects: 
Ureter effects cover epithelial cell death, hyperplasia, metaplasia and dilation. Only 4 active 
substances (benfluralin, chloridazon, fosetyl, and sulfosulfuron) induce effects on the ureters. 
Calculi have been found and pelvic hyperplasia noted for all 4 active substances. In addition 3 
of the substances also induce hyperplasia in the bladder and two of them neoplasms in the 
bladder. Thus the effects on the ureters are considered covered by other CAGs especially by 
the CAG level 2m: Pelvic hyperplasia, but also by CAGs for effects on the urinary bladder.   
 
Mineralisation: 
Mineralisation in the rat kidney mainly represents calcium salt deposition. The spontaneous 
occurrence often depends on the calcium-phosphorous ratio in the diet. Mineralisation may 
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occur in different locations in the kidney. Tubular mineralisation is usually a consequence of 
tubular degeneration. Papillary mineralisation may occur as part of the alpha2u-globulin 
nephropathy or may be secondary to papillary necrosis. Mineralisation may also occur in the 
pelvis. In renal failure e.g. in end-stage CPN, generalised mineralisation may occur because of 
compensatory hyperplasia of the parathyroid glands and release of calcium from the bones. 
(Hard et al. 1999). Thus mineralisation often seems to be secondary to effects already covered 
in other CAGs.  
 
Fibrosis: 
Fibrosis is the formation of excess connective tissue in a reaction to toxicity of the kidney. 
Fibrosis in the kidney has been found for about 15 substances. Fibrosis in the kidney is 
considered secondary to the effects already covered by other CAG´s especially the CAG level 
2a: Tubular degeneration / death.  
 
Pigmentation: 
The most commonly encountered pigments are hemosiderin, bilirubin or lipofuscin (Hard et 
al. 1999). Hemosiderin is precipitated iron following for instance hemolytic anemia. Bilirubin 
is a byproduct of destruction of (aged) red blood cells. An increased amount of bilirubin may 
appear in the kidneys following hepatic dysfunction. Lipofuscin represent a breakdown of cell 
membranes, and is often observed in aging rats. Thus pigmentation is either an indirect effect 
(hemosiderin, bilirubin) or should be covered by the CAG for tubular degeneration / death 
(lipofuscin). 
16.2.3. CAG level 3: Mode of action  
For some of the phenomenological / specific effects on the kidney described under CAG level 
2, a mode of action has been proposed. For the remaining substances, no information 
regarding mode of action has been found and consequently, these substances cannot be 
allocated to a CAG level 3. 
16.2.3.1. CAG level 3g1: Alpha2u-globulin 
One of the criteria that need to be met to conclude that a chemical causes kidney tumours 
through an alpha2u-globulin mode of action is that alpha2u-globulin is identified as the 
accumulating protein in tubule cells (IARC 1999). 
The active substances identified as increasing alpha2u-globulin in male rats are allocated to 
CAG level 3g1 and are listed in Table 16.16. 
 
Table 16.16. CAG level 3g1: Alpha2u-globulin 
Benfluralin Flazasulfuron Tri-allate 
Cyflufenamid Thiamethoxam  
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The standard toxicological guidelines do not include as a mandatory requirement analysis of 
alpha2u-globulin in tubule cells. Therefore, more active substances than those listed may 
induce accumulation of alpha2u-globulin. 
16.2.3.2. CAG level 3m1: Calculi 
Calculi are stones. Calculi in the kidney usually occur in the renal pelvis either attached to the 
epithelium or lying free in the pelvis (Hard et al 1999). In the bladder calculi may cause 
erosion and ulceration of the epithelium with hemorrhage, inflammation and regeneration. 
Severe damage to the epithelium may lead to hyperplasia and ultimately neoplasms. The 
pathogenesis appears to be similar for the renal pelvis (and ureter). Formation of calculi 
requires the concentration of the critical substances (e.g. active substance, metabolite, 
calcium) in the urine to be sufficiently high to lead to precipitate formation and ultimately to 
calculi. This can be influenced by specific chemical and physical condition of the urine (e.g. 
pH, volume). (Cohen 1998). Calculi in the pelvis, ureters or bladder may cause obstruction of 
the renal flow, which may lead to pelvic (and tubular dilation) and ultimately to damage to the 
cells in the kidney. See Annex U for a list of all terms in the DARs interpreted to represent 
calculi. 
The active substances identified as inducing calculi are allocated to CAG level 3m1 and are 
listed in Table 16.17. 
 
Table 16.17. CAG level 3m1: Calculi 
2,4-D Chloridazon (metabolite) Linuron 
2-Phenylphenol Clothianidin Oxasulfuron 
Benfluralin Desmedipham Sulfosulfuron 
Benthiavalicarb Fluoxastrobin Thiabendazole 
Bifenox Fosetyl Triasulfuron 
 
 
Calculi frequently are passed during the course of an experiment by the animals without being 
detected by the investigators because they are too small for gross visual detection or they have 
dissolved in the urine (Cohen 1998). Therefore, more active substances than those listed may 
cause pelvic hyperplasia by a calculi mode of action.  
All of the 15 active substances, which induce calculi, also induce pelvic hyperplasia - except 
one (bifenox). Most of these active substances also induce inflammation of the kidney (2-
phenylphenol, benfluralin, bifenox, chloridazon (metabolite), desmedipham, fosetyl, 
oxasulfuron, sulfosulfuron, thiabendazole, and triasulfuron).  
Even though studies with 2-phenylphenol have shown calculi in the bladder and in the kidney, 
calculi does not seem to be considered part of the mode of action for 2-phenylphenol by the 
DAR. For fluoxastrobin and fosetyl, calculi have been discussed as part of the 
mode/mechanism of action for these substances (see CAG level 4m). For benfluralin the DAR 
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suggests that calculi is the cause of the pelvic hyperplasia.  For the rest of the active 
substances, which induce calculi, no mode/mechanism of action for the pelvic hyperplasia was 
discussed in the DARs. 
Bifenox do not induce pelvic hyperplasia but inflammation. The DAR suggests that the calculi 
may have caused obstruction to renal flow, which subsequently led to infection. 
16.2.3.3. CAG level 3m2: Crystals 
Like calculi, crystals in the urine may lead to erosion of the epithelium in the pelvis, ureters 
and bladder that may result in regenerative hyperplasia and ultimately neoplasms usually 
without inflammation. (Cohen 1998). See Annex U for a list of all terms in the DARs 
interpreted to represent crystals.  
The active substances identified as inducing crystals are allocated to CAG level 3m2 and are 
listed in Table 16.18. 
 
Table 16.18. CAG level 3m2: Crystals 
Aclonifen Flazasulfuron Prothioconazole 
Azimsulfuron – in urinary bladder Fluoxastrobin – in urinary bladder Sulfosulfuron - in urinary bladder 
Chloridazon (metabolite) – in 
urinary bladder 
Iprodione  
 
 
Azimsulfuron, chloridazon (metabolite), fluoxastrobin, and sulfosulfuron have been included 
in CAG level 3m2 even though crystals have not been detected in the kidney but only in the 
bladder as the substances clearly have the potential to produce crystals. 
Six of the 8 active substances, which induce crystals, induce hyperplasia of the pelvis 
(aclonifen, azimsulfuron, chloridazon (metabolite), flazasulfuron, fluoxastrobin, and 
sulfosulfuron). Three of the substances also induce calculi (chloridazon (metabolite), 
fluoxastrobin, and sulfosulfuron). 
16.2.3.4. CAG level 3n1: Oxidative stress 
Oxidative stress occurs in cells when the concentration of reactive oxygen species (ROS) 
generated exceeds the antioxidant capability. ROS can be produced in normal cellular 
metabolism or by inflammatory cells. Reactive intermediate metabolites produced in the 
metabolism of xenobiotics may enhance the formation of ROS. Antioxidants such as vitamin 
C, vitamin E, glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GSH-
Px), and catalase normally inactivate ROS. With excessive formation of reactive intermediate 
metabolites and ROS the antioxidant capacity may be overloaded. The result is oxidative 
stress, which may result in damage to DNA, lipids, and proteins in the cell. Unrepaired DNA 
damage may lead to new mutations and potentially tumours. Oxidative injury may also 
produce cell death, which may lead to regenerative hyperplasia and ultimately tumours.  
(Klaunig et al. 1998). 
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Active substances, which induce oxidative stress measured as a decreased level of the 
antioxidant GSH are included in this CAG level. 
The active substances identified as inducing oxidative stress are allocated to CAG level 3n1 
and are listed in Table 16.15. 
Table 16.15. CAG level 3n1: Oxidative stress 
2-Phenylphenol   
 
The standard toxicological guidelines do not include as a mandatory requirement studies on 
oxidative stress. Therefore, more active substances than those listed may cause kidney toxicity 
by an oxidative stress mode of action. 
16.2.3.5. Other information reported 
Mode of action for kidney tumours: 
Lock and Hard 2004 have categorized 69 renal carcinogens based on mechanistic information. 
They have created the following categories that were based on the categories identified in 
IARC 1999:  
• Direct interaction of the chemical or metabolite with renal DNA 
• Indirect interaction with DNA mediated by oxidative stress leading to increased 
production of reactive oxygen species 
• Conjugation with gluthathion (GSH) and subsequent enzymatic activation to a reactive 
species 
• Sustained stimulation of tubule cell proliferation in response to cytotoxicity caused 
directly by the chemical 
• Sustained stimulation of tubule cell proliferation by indirect cytotoxicity involving 
hyaline droplets and alpha2u-globulin accumulation 
• Chemically induced exacerbation of chronic progressive nephropathy (CPN). 
 
As the DARs consider all the active substances non-genotoxic, none of the 5 active 
substances, which induce tumours in the kidney, act through the first mode of action. No 
mechanistic studies have been located on the second mode of action.  
As increases in the incidence of renal tumours related to alpha2u-globulin nephropathy are not 
considered relevant to humans, IARC 1999 has developed criteria that need to be met to 
conclude that a chemical causes kidney tumours through an alpha2u-globulin mode of action. 
Some of the criteria that need to be met are that the nephropathy and tumours are specific to 
the male rat, that the characteristic sequence of histopathological changes are induced, and 
that alpha2u-globulin is identified as the accumulating protein in tubule cells. 
As increases in the incidence of CPN-related renal tumours are not considered relevant to 
humans, criteria have also been developed for CPN as the underlying cause of tubular 
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tumours. First and foremost the chemical must have been shown to exacerbate CPN to very 
advanced stages of severity. Secondly the tumours must be of low incidence and 
predominantly adenomas of small size. The tumours must be restricted to the CPN-affected 
tissue. Finally the parts of the kidney not affected by CPN should reveal no evidence of 
compound-induced cellular injury that would suggest an alternative mode of action. (Lock and 
Hard 2004, Hard and Khan 2004). 
For two of the active substances (chlorotoluron and molinate) tumours are the only effect in 
the kidney in the long term studies. For chlorotoluron one of the DAR addenda speculates that 
kidney tumours may be related to excessive proliferation secondary to cytotoxicity resulting 
from the excretion of toxic glutathione related conjugates. However, neither tubular 
cytotoxicity nor tubular regeneration is described to occur in the study where tumours were 
noted, and no mechanistic studies seem to have been performed. For molinate the DAR 
speculates that the tumours may be caused by an alpha2u-globulin nephropathy as the tumours 
are only noted in male rats. However, none of the characteristic lesions of alpha2u-globulin 
nephropathy are described to occur in the study. 
For chlorothalonil and forchlorfenuron the most likely mode of action is cytotoxicity as 
tubular degeneration / death and tubular hypertrophy / hyperplasia have been noted for both 
active substances. For forchlorfenuron no signs of alpha2u-globulin nephropathy or CPN were 
noted. For chlorothalonil, CPN was noted in several rat studies. However, as kidney tumours 
also occurred in mice studies, CPN cannot be the only mode of action behind the tumours. In 
the list of endpoints for chlorothalonil the mechanistic studies on kidney lesions have been 
summarised: “The data indicate that kidney lesions are probably caused by thiol metabolites 
leading to cell-degeneration and subsequent cell-proliferation”. This is in line with Lock and 
Hard 2004, which places chlorothalonil in the third mode of action (conjugation with GSH) as 
the nephrotoxic thiol metabolites are formed after metabolism via conjugation with GSH.  
For benfluralin the most likely mode of action is number 6 (CPN) as the tumours only 
occurred in a rat study where CPN also was noted. Neither tubular cytotoxicity nor tubular 
regeneration was noted in that study. Increased alpha2u-globulin has been measured in one rat 
study with benfluralin. However, the only alpha2u-globulin nephropathy lesion noted was 
hyaline droplets and in the study with tumours the hyaline droplets were also noted in female 
rats. It cannot be concluded that the mode of action of tumour-formation is through CPN as 
the histopathology in the DAR was not described to an extent making it possible to decide 
whether benfluralin fulfil the criteria for that mode of action. 
Thus for two of the active substances inducing tubular neoplasms (chlorotoluron and 
molinate) the mode of action seem to be pure speculation that do not fit with the available 
data. For chlorothalonil the mode of action seems to be number 3 (conjugation with GSH 
followed by cytotoxicity). For forchlorfenuron the mode of action seems to be number 4 
(cytotoxicity). For benfluralin the mode of action seems to be number 6 (CPN) although it is 
not known whether benfluralin meet the criteria for this mode of action. 
 
Mode of action for tubular effects / increased kidney weight: 
For mesotrione and sulcotrione, it has been shown that corneal lesions can be attributed to 
increased plasma tyrosine levels following inhibition of HPPD, a key enzyme of the tyrosine 
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catabolic pathway. For mesotrione increased kidney weight correlated with plasma tyrosine 
levels and showed similar dose-response curves. It was not mentioned whether the other 
effects (hyaline droplets, CPN) correlated with the plasma tyrosin level. However for 
sulcotrione the effects on the kidney (increased weight, tubular hypertrophy / hyperplasia, 
papillary degeneration / death, CPN) did not correlate well with either blood or tissue tyrosine 
concentrations and were considered to be a direct consequence of sulcotrione exposure. Thus 
it seems that the tyrosine level is not part of the mode of action for kidney effects. 
 
Mode of action for tubular cell degeneration / cell death: 
For copper sulphate  (copper compounds) it has been shown that the copper accumulated in 
hyaline droplets in renal tubule epithelium. Accumulation eventually caused severe necrosis 
followed by regeneration and recovery. 
 
Mode of action for tubular hypertrophy / hyperplasia: 
2,4-D has been included both in CAG level 2a: Tubular degeneration / death and CAG level 
2c: Tubular hypertrophy / hyperplasia even though it is probably the same lesion that there is 
referred to. The authors of an article in the open literature are stating that the lesion described 
in another article (and in the DAR) as degeneration is morphologically similar to the lesion 
(few scattered foci of tubules with prominenet basophilia due to high nuclear density and 
decreased cytoplasmic volume of the epithelial cells) described in this paper as simple 
hyperplasia. The authors are interpreting the renal lesions to be the result of peroxisome 
proliferator activity although no increase in peroxisome number was detected in the affected 
tubules. In neighbouring cells to the hyperplastic cells increased activity of P450 4A and 
catalase (markers of peroxisome proliferation) was detected. The authors are speculating that 
the affected hyperplastic cells proliferated following a cytotoxic effect possibly related to 
peroxisome proliferation. 
 
Mode of action for hypertrophy of collecting ducts: 
For florasulam hypertrophy of the collecting ducts was reported in most short and long term 
studies. It is probably the type A intercalated cells that are hypertrophied in the collecting 
duct. The type A intercalated cells are involved in acid secretion into urine and HCO3 
resorption. Hypertrophy of type A intercalated cells has been reported as a physiological 
response to several factors affecting acid-base homeostasis. Other potential mechanisms of 
type A intercalated cell hypertrophy include hypokalaemia, altered levels of adrenal 
mineralocorticoids, carbonic anhydrase inhibition and HCO3/Cl exchange in the basolateral 
membrane. Florasulam may also have acted directly upon the type A intercalated cell by some 
unknown mechanism to cause the hypertrophy. 
 
Mode of action for pelvic hyperplasia: 
Many mechanistic studies have been conducted with 2-phenylphenol because of the tumours it 
produces in the urinary bladder. Despite the many studies the mode of action of urinary 
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bladder toxicity (and thus also pelvic hyperplasia) is not clear-cut. Calculi were produced in a 
couple of lifetime studies. However, according to the DAR, the mechanism of tumourigenesis 
in rats was assumed to be non-genotoxic, probably based on chronic irritation of the 
epithelium by a combination of high pH, high sodium-ion concentration and/or high 
concentration of free metabolites at high doses. In the studies there was e.g. a positive 
correlation between urinary pH and the incidence of hyperplasia of the urinary bladder. The 
tumourigenic potential of 2-phenylphenol was enhanced by co-administration of sodium 
bicarbonate as an alkalinising agent while the tumourigenesis by its sodium salt was 
attenuated by co-administration of ammonium chloride as an acidifier. 
16.2.4. CAG level 4: Mechanism of action 
For a few active substances affecting the kidney, information on the mechanism of action has 
been proposed. For the remaining substances, no information regarding mechanism of action 
has been found and consequently, these substances cannot be allocated to a CAG level 4.  
16.2.4.1. CAG level 4m1a: Increased calcium in urine 
Both fluoxastrobin and fosetyl induce calculi in the kidney and urinary bladder. For both 
substances mechanistic studies have shown an increased level of phosphorous in the faeces, a 
decreased level of phosphorous in the urine and an increased level of calcium in the urine. The 
two substances differed in that the urinary pH was increased for fluoxastrobin but decreased 
for fosetyl. For fluoxastrobin it was stated that fluoxastrobin resulted in reduced phosphate 
absorption in the intestine. A potential phosphate deficiency was counter-regulated by reduced 
renal excretion of phosphate and renal hyper-excretion of calcium. It is proposed by the DAR 
that increased calcium excretion in urine, together with an increase in urinary pH, led to 
calculi formation and following erosive and/or irritative effects of these foreign bodies in the 
urine, moderate to marked diffuse hyperplasia of the transitional epithelium of the urinary 
tract with inflammation developed.  
For 6 other of the active substances (2-phenylphenol, chloridazon, clothianidin, linuron, 
oxasulfuron, and sulfosulfuron), which induced calculi, mineralisation was noted in the 
kidney or urinary bladder. Mineralisation in the rat kidney mainly represents calcium salt 
deposition (Hard et al. 1999). Thus for these substances an increased level of calcium in the 
urine may also be part of the cause of bladder calculi. However, no mechanistic studies have 
been performed to confirm or reject that hypothesis.  
The active substances identified in mechanistic studies as inducing increased calcium in urine 
are allocated to CAG level 4m1a and are listed in Table 16.19. 
 
Table 16.19. CAG level 4m1a: Increased calcium in urine 
Fluoxastrobin Fosetyl  
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16.2.4.2. Other information reported 
Formation of calculi/crystals: 
For iprodione the crystals probably consisted of the metabolite 32490 RP. The information on 
the content of crystals for iprodione is of no relevance for CAGs at level 4 unless other active 
substances produce the same metabolite and that is not the case. For triasulfuron the calculi 
mainly contained triasulfuron. 
For thiabendazole the main component of calculi was protein. In order to create a CAG at 
level 4 for thiabendazole, more mechanistic studies are needed to explain whether protein is 
important for the formation of the calculi. 
16.3. Discussion of CAGs for the kidney 
One hundred and nineteen active substances were identified to have effects on the kidneys and 
were allocated to CAG level 1 (Table 16.1). Thirteen distinct CAGs at level 2 have been 
proposed. Information on mode / mechanism of action is available for only twenty-three of the 
active substances. The information is summarised in Appendix V. 
 
Ad CAG level 2a, 2b, 2c, and 3n1: Tubular cell degeneration / cell death, fatty changes, and 
hypertrophy / hyperplasia: 
Fifty active substances induce tubular degeneration / death. Thirty-three active substances 
induce tubular hypertrophy / hyperplasia. Tubular hypertrophy / hyperplasia may develop after 
tubular necrosis as a compensatory response to loss of tubule function.  Actually for 25 out of 
the 33 active substances, which induce tubular hypertrophy / hyperplasia, tubular degeneration 
/ death has also been noted. For these 25 active substances the tubular hypertrophy / 
hyperplasia is probably secondary to the tubular necrosis. As explained in the chapter on CAG 
level 2c, the CAG for tubular hypertrophy / hyperplasia may include some active substances 
where it is not regenerating tubules that have been noted in the DARs. For 3 out of the 8 
active substances that did not induce tubular degeneration / death, CPN was noted. For these 3 
active substances it may have been an early stage of CPN that was seen. 
Seventeen active substances induce fatty changes as defined in CAG level 2b. This CAG level 
covers effects described as fatty changes and/or vacuolation. As the vacuoles may or may not 
contain accumulated fat it may not be all the active substances in this category that actually 
accumulate fat. Vacuolation may be a transient physiological response or it may represent the 
initial stage preceding cell degeneration. For twelve out of the seventeen active substances, 
which induce tubular fatty changes, tubular degeneration / death has also been noted. Thus the 
fatty changes for these 12 active substances could be considered covered by the CAG for 
tubular degeneration / death.  
For CRA for effects on the kidney it is recommended to consider CAG level 2a: Tubular 
degeneration / death. It is not recommended to consider CAG level 2c for CRA as the 
hypertrophy or hyperplasia for most of the substances probably is secondary to the tubular 
necrosis. Neither is it recommended to consider CAG level 2b as the fatty changes for most of 
the active substances could be considered covered by CAG level 2a. As oxidative stress (CAG 
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level 3n1) only have been studied for 2-phenylphenol it is not possible to use CAG level 3n1 
for CRA. 
 
Ad CAG level 2d:Tubular neoplasms: 
Five substances induce tubular neoplasms. As the mode of action(s) for the tumour formation 
seem to be different for the five substances it is not recommended to consider CAG level 2d 
for CRA. 
 
Ad CAG level 2e, 2g, and 3g1: Tubular hyaline droplets and alpha2u-globulin nephropathy: 
The 11 active substances in CAG level 2g for alpha2u-globulin nephropathy have in common 
that they only in male rats induce hyaline droplets and sometimes one or more of the other 
characteristic lesions of the syndrome. For the 5 active substances in CAG level 3g1, an 
increased level of alpha2u-globulin has been measured. Thus the two different CAG levels 
provide different levels of support for the hypothesis that these active substances may induce 
alpha2u-globulin nephropathy. As alpha2u-globulin nephropathy is not considered relevant to 
humans, it is not recommended to consider CAG level 2g and 3g1 for CRA. 
Five active substances induce hyaline droplets (CAG level 2e) in other species than the rat or 
also in the female rat. Hyaline droplets are lysosomes containing protein. For one of these 
active substances, copper sulphate, it has been shown that the copper accumulated in the 
hyaline droplets. The accumulation eventually caused severe necrosis followed by 
regeneration and recovery. None of the other active substances in this CAG level induced 
tubular necrosis but three of them induced CPN. As there are only 5 active substances in this 
CAG level and the relevance of hyaline droplets in relation to other tubular effects is not 
known, it is not recommended to consider CAG level 2e for CRA. 
 
Ad CAG level 2f: CPN: 
As chemically induced exacerbation of CPN is not considered relevant to humans it is not 
recommended to consider CAG level 2f for CRA. 
 
Ad CAG level 2h and 2i: Glomerular degeneration / death and inflammation: 
Nine active substances induce glomerular degeneration / death and two glomerular 
inflammation. As discussed in the chapter on CAG level 2h, the effect may represent CPN for 
two of the active substances included in the CAG. For all but one of the active substances the 
glomerular effects have only been noted in one study. For all but two of the active substances 
the glomerular effects are seen together with tubular effects and thus may be secondary to the 
tubular effects.  
As glomerular effects have been noted for very few active substances and it is likely that the 
glomerular effects are secondary to tubular effects at least for some of the active substances it 
is not recommended to consider CAG level 2h and 2i for CRA. 
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Ad CAG level 2j: Inflammation: 
Tubular or papillary necrosis may cause inflammation. Calculi in the pelvis may also be the 
cause of an inflammation in the kidney. Calculi, tubular necrosis or papillary necrosis have 
been noted for almost all of the 28 active substances, which induce inflammation. As the 
inflammation probably is secondary to effects already covered in other CAGs for most of the 
active substances it is not recommended to consider CAG level 2j for CRA. 
 
Ad CAG level 2k and 2l: Papillary degeneration / death and hypertrophy / hyperplasia: 
Fourteen active substances induce papillary degeneration / death. The necrotic papilla may 
undergo regeneration, which may result in papillary hyperplasia. Nine active substances 
induce papillary hypertrophy / hyperplasia. Five of the active substances that induce papillary 
hypertrophy / hyperplasia also induce papillary degeneration / death. Thus for these five 
substances the hyperplasia is probably secondary to the papillary necrosis. Six of the active 
substances that induce papillary hypertrophy / hyperplasia also induce pelvic hyperplasia. It 
makes one speculate whether the cause of the papillary hyperplasia at times may be related to 
the cause of the pelvic hyperplasia. 
For CRA for effects on the kidney it is recommended to consider CAG level 2k: Papillary 
degeneration / death. It is not recommended to consider CAG level 2l for CRA as the 
hyperplasia for more than half of the substances probably is secondary to the papillary 
necrosis. 
 
Ad CAG level 2m, 3m1, 3m2, and 4m1a: Pelvic hyperplasia: 
Thirty active substances induce pelvic hyperplasia. Sixteen of those also induce hyperplasia in 
the bladder. Pelvic hyperplasia may be a response to epithelial irritation, which in turn can be 
induced by urinary crystals, calculi or toxic chemicals. For nineteen of the active substances 
the epithelial irritation may be explained by urinary crystals (CAG level 3m2) and/or calculi 
(CAG level 3m1). As calculi frequently are passed during the course of an experiment by the 
animals without being detected by the investigators, more active substances than those listed 
may cause pelvic hyperplasia by a calculi mode of action.  
For one of the active substances, 2-phenylphenol, where calculi have been found in a couple 
of studies, calculi does not seem to be considered part of the mode of action for 2-
phenylphenol by the DAR. For most of the active substances, mechanistic studies have not 
been performed, and the DAR has not elaborated on the mode or mechanism of action. For 
fluoxastrobin and fosetyl mechanistic studies have shown an increased level of calcium in the 
urine (CAG level 4m1a), which may explain the formation of calculi and the subsequent 
urinary bladder and pelvic toxicity. For benfluralin the DAR suggests that the calculi is the 
cause of the pelvic hyperplasia. Thus the DARs have no opinion on whether the calculi or 
crystals may be the cause of pelvic hyperplasia for 15 out of the 19 active substances that 
induce calculi or crystals. For 3 substances (fluoxastrobin, fosetyl, and benfluralin) the DAR 
consider the calculi the cause of the urinary bladder toxicity. And for 2-phenylphenol calculi 
does not seem to be considered part of the mode of action by the DAR.  
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For CRA for effects on the kidney it is recommended to consider CAG level 2m: Pelvic 
hyperplasia. The CAG level 2m may be subdivided into other CAGs at level 3 and 4 as 
explained in the text above. However, as found calculi and/or crystals not necessarily are the 
cause of the pelvic hyperplasia it may be wiser to stick to CAG level 2m. 
16.4. Recommended CAGs for the kidney 
The following CAGs at level 2 are recommended for CRA for effects on the kidney: 
• CAG level 2a: Tubular degeneration / death, see Table 16.2. 
• CAG level 2k: Papillary degeneration / death, see Table 16.12. 
• CAG level 2m: Pelvic hyperplasia, see Table 16.14. 
 
 
17. Liver 
17.1. Introduction 
The liver is the largest organ in the body. It is divided into lobes. Within the liver lobes are 
multiple, smaller anatomical units (hexagonal structures) called liver lobules, see Figure 17.1.  
The liver has a dual blood supply from the hepatic portal vein and from the hepatic artery. 
Branches of the hepatic portal vein and the hepatic artery are located in the corners of the 
hexagonal structure in the liver lobules. The blood flows through the sinusoids (small 
capillaries with highly permeable endothelium) to a central vein in the middle of each liver 
lobule. The highly permeable endothelium enhances the transport of nutrients and foreign 
compounds (xenobiotics) into the hepatocytes, which are located in between the sinusoids. 
The sinusoids are lined with phagocytic cells, Kupffer cells, which remove bacteria and 
foreign particles from the blood. One of the functions of hepatocytes is to produce bile. The 
bile flows through the bile canaliculi to bile ducts located in the portal triad together with the 
branches of the hepatic portal vein and the hepatic artery. 
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From:  http://www.harford.edu/faculty/wrappazzo/BIO204/lecture/bio204lecturematerials.htm 
Figure 17.1. Anatomy of the liver lobules.  
 
 
Functionally, periportal hepatocytes are specialized for oxidative liver functions such as 
gluconeogenesis, β-oxidation of fatty acids and cholesterol synthesis, while centrilobular 
hepatocytes are more important for glycolysis, lipogenesis and cytochrome P-450-based drug 
metabolism (Thoolen et al. 2010). 
The liver metabolizes (and stores) a variety of nutrients, endogenous compounds and foreign 
substances (xenobiotics) (McCance and Huether 1998). Some examples include: 
• Metabolism of carbohydrates. The liver contributes to the stability of blood glucose 
levels by releasing glucose during states of low blood sugar and taking up glucose 
during states of high blood sugar. When glucose is taken up it is stored as glycogen 
(glycogenesis) or converted to fat. Glucose is released by catabolism of glycogen 
(glycogenolysis) or by synthesis from amino acids or glycerol (gluconeogenesis).  
• Metabolism of proteins. Ammonia is released when amino acids are converted to 
carbohydrates. The liver converts ammonia to urea, which is excreted by the kidneys. 
The liver synthesizes the plasma carrier protein albumin and globulins (except gamma-
globulin). The liver synthesizes most of the coagulation factors, which are necessary 
for effective blood clotting. The liver also synthesizes a number of enzymes such as 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate 
dehydogenase (LDH), and alkaline phosphatase (ALP). 
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• Metabolism of lipids. Triglycerides are synthesized from carbohydrates and protein in 
the liver (lipogenesis). Absorbed lipids enter the liver primarily as triglycerides. The 
triglycerides may be hydrolyzed and used to produce metabolic energy, or they may be 
released into the bloodstream as lipoproteins and carried to adipose cells for storage. 
The liver synthesizes phospholipids and cholesterol, which are needed e.g. for the 
hepatic production of bile acids, steroid hormones and components of plasma 
membranes.   
• Production of bile. Bile is necessary for the digestion of lipids in the intestine. The bile 
is produced in the liver, stored in the gallbladder, and released into the intestine during 
digestion of food. Bile consists of bile salts, cholesterol, phospholipids, bilirubin, 
electrolytes, and water. Bilirubin is a byproduct of destruction of (aged) red blood 
cells. In the plasma bilirubin binds to albumin (free bilirubin). In the liver the free 
bilirubin is conjugated to make it a water soluble substance that can be excreted in the 
bile. Bilirubin gives bile a yellowish green colour. In the intestine the conjugated 
bilirubin is deconjugated by bacteria and converted to urobilinogen. Some of the 
urobilinogen is excreted in feces giving it a brown colour. Some of the urobilinogen is 
reabsorbed and excreted in urine. 
• Storage of minerals and vitamins. In times of excessive intake the liver stores the 
vitamins A, B12, D, E and K, and the minerals iron and copper. 
• Metabolism of xenobiotics (Liska 1998). The liver contains complex enzyme systems 
for the metabolism of drugs, chemicals in food and environment, and endogenous 
molecules such as hormones. The purpose of the metabolism of xenobiotics is to 
create water-soluble compounds that can be excreted in urine. The metabolism often 
consists of two phases – see Figure 17.2. Phase II reactions are conjugations where a 
water-soluble molecule such as glutathione, glucuronic acid, or sulphuric acid is added 
to the molecule.  However, many molecules do not have a reactive site that can bind to 
the water-soluble group. The purpose of phase I reactions are to create metabolites that 
contain such reactive sites. The phase I reactions are carried out by different 
cytochrome P450 enzymes. 
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Figure 17.2. Metabolism of xenobiotics 
 
 
17.2. Establishment of CAGs for toxicity to the liver 
17.2.1. CAG level 1: Toxicity to the liver 
The active substances identified as having an effect on the liver in the toxicological studies 
included in the DARs are allocated to CAG level 1 and are listed in Table 17.1. 
 
Table 17.1. CAG level 1: Toxicity to the liver 
1-Methyl-cyclopropene Ethofumesate Molinate 
2,4-D Ethoprophos Nicosulfuron 
2,4-DB Ethoxysulfuron Oxadiazon 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Etofenprox Penconazole 
Abamectin (aka avermectin) Etoxazole Pendimethalin 
Acetamiprid Famoxadone Pethoxamid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Fenamidone Phosmet 
Aclonifen Fenhexamid Picloram 
Alpha-Cypermethrin (aka 
alphamethrin) 
Fenoxaprop-P Propaquizafop 
Amitrole (aminotriazole) Fenpropidin Propiconazole 
Azimsulfuron Fenpropimorph Propineb 
Azoxystrobin Fenpyroximate Propoxycarbazone 
Beflubutamid Fipronil Propyzamide 
Benalaxyl Flazasulfuron Prosulfocarb 
Benfluralin Florasulam Prosulfuron 
Bensulfuron Fluazinam Prothioconazole 
Bentazone Fludioxonil Pymetrozine 
Benthiavalicarb Flufenacet (formerly fluthiamide) Pyraclostrobin 
Benzoic acid Flumioxazin Pyraflufen-ethyl 
Beta-Cyfluthrin Fluopicolide Pyrethrins 
Bifenazate Fluoxastrobin Pyrimethanil 
Bifenox Flupyrsulfuron-methyl (DPX KE 459) Pyriproxyfen 
Boscalid Flusilazole Quinoclamine 
Bromoxynil Flutolanil Quinoxyfen 
Captan Formetanate Quizalofop-P-ethyl 
Carbendazim Fuberidazole Quizalofop-P-tefuryl 
Carfentrazone-ethyl Gibberellin Rimsulfuron (aka renriduron) 
Chloridazon (aka pyrazone) Glyphosate (incl trimesium aka 
sulfosate) 
Silthiofam 
Chlorothalonil Imazalil (aka enilconazole) S-Metolachlor 
Chlorotoluron Imazosulfuron Sodium 5-nitroguaiacolate 
Chlorpropham Imidacloprid Sodium o-nitrophenolate 
Chlorsulfuron Iodosulfuron-methyl-sodium Sodium p-nitrophenolate 
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Cinidon ethyl Ioxynil Spinosad 
Clodinafob-prop Iprodione Spiroxamine 
Clofentezine Iprovalicarb Sulcotrione 
Clomazone Isoproturon Tebuconazole 
Clopyralid Isoxaflutole Tebufenpyrad 
Clothianidin Kresoxim-methyl Teflubenzuron 
Copper compounds lambda-Cyhalothrin Tepraloxydim 
Cyclanilide Lenacil Tetraconazole 
Cyflufenamid Linuron Thiabendazole 
Cyfluthrin Lufenuron Thiacloprid 
Cyhalofop-butyl Magnesium phosphide Thiamethoxam 
Cymoxanil Maleic hydrazide Thiophanate-methyl 
Cypermethrin Mancozeb Thiram 
Cyprodinil Maneb Tolclofos-methyl 
Cyromazine MCPA Tolylfluanid 
Deltamethrin MCPB Tralkoxydim 
Desmedipham Mecoprop Triadimenol 
Dicamba Mecoprop-P Tri-allate 
Dichlorprop-P Mepanipyrim Triasulfuron 
Difenoconazole Mesotrione Tribenuron (aka metometuron) 
Diflubenzuron Metalaxyl-M Triclopyr 
Diflufenican Metamitron Trifloxystrobin 
Dimethachlor Metazachlor Triflusulfuron 
Dimethenamid-P Metconazole Trinexapac (aka cimetacarb 
ethyl) 
Dimethomorph Methiocarb (aka mercaptodimethur) Triticonazole 
Dinocap Methoxyfenozide Tritosulfuron 
Diuron Metiram zeta-Cypermethrin 
Dodemorph Metrafenone Ziram 
Epoxiconazole Metribuzin Zoxamide 
Ethephon Milbemectin  
 
 
17.2.2. CAG level 2: Phenomenological / specific effects on the liver 
The hepatocytes have the flexibility to adapt to changing physiological demands with 
reversible alterations. However, sufficient stress or injurious stimuli may lead to irreversible 
changes. Often at high doses, targeted cells go through a sequence of cellular degeneration 
followed by cell death, but at lower doses degenerative changes do not necessarily lead to cell 
death. Cellular adaptations may lead to increases in cellular organelles and intracellular 
accumulations of a variety of substances. (Thoolen et al. 2010) 
Various types of effects on the liver were identified as a basis for establishing CAGs at level 
2. Based on these effects, eleven distinct CAGs at level 2 are proposed. More information is 
given in Appendix X. 
17.2.2.1. CAG level 2a: Hypertrophy 
The term hepatocellular hypertrophy is most commonly used to describe the changes in the 
liver cell following induction of the metabolic enzymes. The increased enzyme activity in the 
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cell following the induction causes an increase in cell organelles (endoplasmic reticulum, 
peroxisomes, and mitochondria). Hepatocellular hypertrophy following enzyme induction is 
considered an adaptive response to chemical stress. However, excessive hypertrophy from 
enzyme induction may lead to degeneration and cell death. Hepatocellur hypertrophy often is 
associated with increased liver weight. (Thoolen et al. 2010). 
For the purpose of the CAG project, a number of histopathological findings described in the 
DARs are interpreted to represent hepatocellular hypertrophy and are allocated to a single 
CAG level 2, termed ‘CAG level 2a: Hypertrophy’. See Appendix X for a list of all terms in 
the DARs interpreted to represent hepatocellular hypertrophy. 
The active substances identified as inducing hepatocellular hypertrophy are allocated to CAG 
level 2a and are listed in Table 17.2. 
 
Table 17.2. CAG level 2a: Hepatocellular hypertrophy 
1-Methyl-cyclopropene Ethoxysulfuron Penconazole 
2,4-D Etofenprox Pendimethalin 
2,4-DB Etoxazole Pethoxamid 
Acetamiprid Famoxadone Picloram 
Aclonifen Fenamidone Propaquizafop 
Amitrole (aminotriazole) Fenoxaprop-P Propiconazole 
Azimsulfuron Fenpropidin Propyzamide 
Azoxystrobin Fenpropimorph Prosulfocarb 
Beflubutamid Fenpyroximate Prosulfuron 
Benfluralin Fipronil Prothioconazole 
Bensulfuron Flazasulfuron Pymetrozine 
Benthiavalicarb Fluazinam Pyraclostrobin 
Benzoic acid Fludioxonil Pyraflufen-ethyl 
Bifenazate Flufenacet (formerly fluthiamide) Pyrethrins 
Bifenox Flumioxazin Pyrimethanil 
Boscalid Fluopicolide Pyriproxyfen 
Bromoxynil Fluoxastrobin Quinoxyfen 
Captan Flupyrsulfuron-methyl (DPX KE 
459) 
Quizalofop-P-ethyl 
Carbendazim Flusilazole Quizalofop-P-tefuryl 
Carfentrazone-ethyl Flutolanil Rimsulfuron (aka renriduron) 
Chloridazon (aka pyrazone) Fuberidazole Silthiofam 
Chlorothalonil Glyphosate (incl trimesium aka 
sulfosate) 
S-Metolachlor 
Chlorsulfuron Imazalil (aka enilconazole) Spinosad 
Cinidon ethyl Imazosulfuron Spiroxamine 
Clodinafob-prop Imidacloprid Sulcotrione 
Clofentezine Iodosulfuron-methyl-sodium Tebuconazole 
Clomazone Ioxynil Tebufenpyrad 
Clopyralid Iprodione Teflubenzuron 
Clothianidin Iprovalicarb Tepraloxydim 
Copper compounds Isoproturon Tetraconazole 
Cyclanilide Isoxaflutole Thiabendazole 
Cyflufenamid Kresoxim-methyl Thiacloprid 
Cyhalofop-butyl Lenacil Thiamethoxam 
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Cymoxanil Linuron Thiophanate-methyl 
Cypermethrin Lufenuron Tolclofos-methyl 
Cyprodinil Mancozeb Tolylfluanid 
Desmedipham Maneb Tralkoxydim 
Dicamba Mepanipyrim Triadimenol 
Dichlorprop-P Mesotrione Tri-allate 
Difenoconazole Metalaxyl-M Triasulfuron 
Diflubenzuron Metamitron Tribenuron (aka metometuron) 
Diflufenican Metazachlor Triclopyr 
Dimethachlor Metconazole Trifloxystrobin 
Dimethenamid-P Methoxyfenozide Triflusulfuron 
Dimethomorph Metiram Trinexapac (aka cimetacarb ethyl) 
Dinocap Metrafenone Triticonazole 
Diuron Metribuzin Tritosulfuron 
Dodemorph Milbemectin Ziram 
Epoxiconazole Molinate Zoxamide 
Ethofumesate Oxadiazon  
 
 
17.2.2.2. CAG level 2b: Fatty changes 
Hepatocellular fatty change is an accumulation of lipid in the hepatocytes because of 
perturbations in lipid metabolism and disposition. In macrovesicular fatty change the 
hepatocytes contain a large well-defined single rounded vacuole within each cell. In 
microvesicular fatty change the hepatocytes are filled with numerous small lipid vacuoles and 
the affected hepatocytes may have a foamy appearance. In animal studies, it is common to see 
a mixture of macrovesicular and microvesicular fatty change. Macrovesicular fatty change can 
be regarded as a physiological adaptation whereas microvesicular fatty change is usually 
indicative of more serious hepatic dysfunction. (Thoolen et al. 2010). 
For the purpose of the CAG project, histopathological findings described as fatty change, lipid 
droplets, fat in hepatocytes, vacuolation, steatosis, foamy hepatocytes, fatty degeneration, and 
fatty liver metamorphosis are allocated to a single CAG level 2, termed ‘CAG level 2b: Fatty 
changes’. See Appendix X for a list of all terms in the DARs interpreted to represent 
hepatocellular fatty change. 
The active substances identified as inducing hepatocellular fatty changes are allocated to CAG 
level 2b and are listed in Table 17.3. 
 
Table 17.3. CAG level 2b: Hepatocellular fatty changes 
1-Methyl-cyclopropene Dodemorph Metrafenone 
Abamectin (aka avermectin) Epoxiconazole Oxadiazon 
Acetamiprid Ethofumesate Pethoxamid 
Alpha-Cypermethrin (aka 
alphamethrin) 
Ethoprophos Phosmet 
Amitrole (aminotriazole) Ethoxysulfuron Picloram 
Benalaxyl Etoxazole Propaquizafop 
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Benfluralin Famoxadone Propiconazole 
Bensulfuron Fenamidone Prosulfocarb 
Bentazone Fenpropimorph Prothioconazole 
Benthiavalicarb Fipronil Pyraflufen-ethyl 
Benzoic acid Florasulam Pyrethrins 
Bifenazate Fluazinam Quinoxyfen 
Bromoxynil Flufenacet (formerly fluthiamide) Quizalofop-P-tefuryl 
Captan Flusilazole Rimsulfuron (aka renriduron) 
Carbendazim Flutolanil Silthiofam 
Chloridazon (aka pyrazone) Formetanate Spinosad 
Chlorothalonil Gibberellin Spiroxamine 
Chlorotoluron Imazalil (aka enilconazole) Tebuconazole 
Clofentezine Iodosulfuron-methyl-sodium Teflubenzuron 
Clothianidin Iprodione Tepraloxydim 
Copper compounds Iprovalicarb Tetraconazole 
Cyflufenamid Isoproturon Thiacloprid 
Cymoxanil Isoxaflutole Thiamethoxam 
Cypermethrin Lenacil Tolylfluanid 
Deltamethrin Lufenuron Tralkoxydim 
Desmedipham Mepanipyrim Triadimenol 
Difenoconazole Mesotrione Tri-allate 
Diflubenzuron Metalaxyl-M Triasulfuron 
Diflufenican Metazachlor Trifloxystrobin 
Dimethenamid-P Metconazole Triticonazole 
Dimethomorph Methoxyfenozide Ziram 
 
 
17.2.2.3. CAG level 2c: Cell degeneration / cell death 
Degeneration of hepatocytes reflects cytoplasmic alterations at the borderline between 
adaptation with resolution back to normal structure and function, and inability to adapt 
leading to cell death. It may be difficult to distinguish between hepatocellular hypotrophy, 
different forms of degeneration, and early necrosis. Degenerated hepatocytes may show 
increased cytoplasmic granularity, cell swelling, and eosinophilia. Glycogen accumulation and 
spongiosis hepatis are types of degeneration. (Thoolen et al. 2010). 
For the purpose of the CAG project, histopathological findings described as hepatocellular 
degeneration, hepatocytes with granular cytoplasm, glycogen deposition in liver, and 
spongiosis hepatis are interpreted as representing degeneration of hepatocytes. See Appendix 
X for a list of all terms in the DARs interpreted to represent degeneration. 
Cell death of the hepatocytes is the ultimate result of irreversible cellular injury. (Thoolen et 
al. 2010). 
For the purpose of the CAG project, histopathological findings described as necrosis and 
apoptosis are interpreted as representing the same type of effect in the liver. See Appendix X 
for a list of all terms in the DARs interpreted to represent cell death of hepatocytes. 
Very few of the active substances induce degeneration without inducing cell death. Therefore, 
for the purpose of the CAG project, histopathological findings in the form of degeneration and 
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cell death in the hepatocytes are allocated to a single CAG level 2, termed ‘CAG level 2c: Cell 
degeneration / cell death’.  
The active substances identified as inducing cell degeneration and/or cell death of hepatocytes 
are allocated to CAG level 2c and are listed in Table 17.4. 
 
Table 17.4. CAG level 2c: Hepatocellular cell degeneration / cell death 
2,4-D Epoxiconazole Oxadiazon 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Ethoprophos Penconazole 
Alpha-Cypermethrin (aka 
alphamethrin) 
Ethoxysulfuron Pendimethalin 
Amitrole (aminotriazole) Famoxadone Pethoxamid 
Azimsulfuron Fenhexamid Phosmet 
Azoxystrobin Fenoxaprop-P Picloram 
Beflubutamid Fipronil Propaquizafop 
Benfluralin Flazasulfuron Propiconazole 
Bensulfuron Florasulam Propyzamide 
Bentazone Fluazinam Prosulfocarb 
Benthiavalicarb Fludioxonil Pymetrozine 
Benzoic acid Flufenacet (formerly fluthiamide) Pyraclostrobin 
Bifenazate Flumioxazin Pyraflufen-ethyl 
Bifenox Fluopicolide Pyriproxyfen 
Bromoxynil Flupyrsulfuron-methyl (DPX KE 
459) 
Quinoxyfen 
Carbendazim Flusilazole Quizalofop-P-ethyl 
Carfentrazone-ethyl Flutolanil Quizalofop-P-tefuryl 
Chloridazon (aka pyrazone) Formetanate Silthiofam 
Chlorothalonil Fuberidazole Spinosad 
Cinidon ethyl Gibberellin Spiroxamine 
Clodinafob-prop Imazalil (aka enilconazole) Sulcotrione 
Clofentezine Imidacloprid Tebuconazole 
Copper compounds Iprovalicarb Teflubenzuron 
Cyclanilide Isoproturon Tetraconazole 
Cyflufenamid Isoxaflutole Thiacloprid 
Cyhalofop-butyl Kresoxim-methyl Thiamethoxam 
Cymoxanil lambda-Cyhalothrin Thiram 
Cypermethrin Linuron Tolylfluanid 
Cyprodinil Lufenuron Tralkoxydim 
Cyromazine Magnesium phosphide Triadimenol 
Deltamethrin Mancozeb Tri-allate 
Desmedipham Maneb Triasulfuron 
Dicamba MCPA Triclopyr 
Dichlorprop-P MCPB Trifloxystrobin 
Difenoconazole Mepanipyrim Triflusulfuron 
Diflubenzuron Metamitron Triticonazole 
Dimethachlor Metazachlor Tritosulfuron 
Dinocap Metconazole Ziram 
Diuron Metrafenone  
Dodemorph Molinate  
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17.2.2.4. CAG level 2d: Inflammation 
Infiltration of different inflammatory cells is typically a response to death of hepatocytes. 
Therefore, inflammatory cell infiltrates may be secondary to the effects already covered in the 
CAG level 2c for cell degeneration and/or cell death. (Thoolen et al. 2010). However, for 
about 25% of the active substances where inflammatory cell infiltrates are noted in the DAR 
this is not accompanied by cell death. Therefore, active substances inducing inflammatory cell 
infiltrates form their own CAG. As increased activity of Kupffer cells may be seen following 
inflammatory conditions, increased activity of Kupffer cells is included in this CAG. 
For the purpose of the CAG project, histopathological findings described as inflammation, 
inflammatory foci, liver tissue infiltration, hepatitis, mononuclear cell aggregation, Kupffer 
cell activity increased, histiocytic hepatic infiltration, reticulo-endothelial system activated, 
microgranuloma, lymphocyte infiltration, cholangiohepatitis, and cholangitis are allocated to a 
single CAG level 2, termed ‘CAG level 2d: Inflammation’. See Appendix X for a list of all 
terms in the DARs interpreted to represent inflammation. 
The active substances identified as inducing inflammation are allocated to CAG level 2d and 
are listed in Table 17.5. 
 
Table 17.5. CAG level 2d: Inflammation in the liver 
2,4-D Epoxiconazole Oxadiazon 
2,4-DB Ethoxysulfuron Penconazole 
Abamectin (aka avermectin) Etoxazole Pendimethalin 
Acetamiprid Fenhexamid Propaquizafop 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Fenpropidin Propiconazole 
Alpha-Cypermethrin (aka 
alphamethrin) 
Flazasulfuron Propyzamide 
Azimsulfuron Florasulam Pymetrozine 
Azoxystrobin Fluazinam Pyraflufen-ethyl 
Beflubutamid Fludioxonil Pyriproxyfen 
Benfluralin Flusilazole Quinoclamine 
Benthiavalicarb Gibberellin Quizalofop-P-ethyl 
Carbendazim Imazosulfuron Quizalofop-P-tefuryl 
Carfentrazone-ethyl Imidacloprid Silthiofam 
Chlorothalonil Iodosulfuron-methyl-sodium Sodium 5-nitroguaiacolate 
Chlorotoluron Iprodione Sodium o-nitrophenolate 
Clodinafob-prop Iprovalicarb Sodium p-nitrophenolate 
Copper compounds Isoproturon Spinosad 
Cyclanilide Isoxaflutole Tebuconazole 
Cyflufenamid lambda-Cyhalothrin Teflubenzuron 
Cyhalofop-butyl Linuron Tetraconazole 
Cymoxanil Maleic hydrazide Thiamethoxam 
Cypermethrin MCPA Thiram 
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Cyromazine MCPB Tralkoxydim 
Deltamethrin Mepanipyrim Triadimenol 
Desmedipham Mesotrione Triasulfuron 
Difenoconazole Metamitron Triclopyr 
Diflubenzuron Metazachlor Triticonazole 
Dimethachlor Metconazole Tritosulfuron 
Dimethenamid-P Metribuzin Ziram 
 
 
17.2.2.5. CAG level 2e: Foci of cellular alteration 
Foci of hepatocellular alteration are localized increased numbers of hepatocytes. The altered 
hepatocytes are phenotypically different from surrounding hepatocyte parenchyma.  Foci of 
hepatocellular alteration may be potential precursors of neoplastic transformation but can also 
be found as non-neoplastic end-stage lesions. (Thoolen et al. 2010). 
For the purpose of the CAG project, histopathological findings described as foci of cellular 
change, cell alteration, eosinophilic foci, and aberrant hepatocytes are allocated to a single 
CAG level 2, termed ‘CAG level 2e: Foci of cellular alteration’. See Appendix X for a list of 
all terms in the DARs interpreted to represent foci of hepatocellular alteration. 
The active substances identified as inducing foci of hepatocellular alteration are allocated to 
CAG level 2e and are listed in Table 17.6. 
 
Table 17.6. CAG level 2e: Foci of cellular alteration in the liver 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Famoxadone Propiconazole 
Abamectin (aka avermectin) Fenamidone Propyzamide 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Fenoxaprop-P Prothioconazole 
Benthiavalicarb Fluazinam Pymetrozine 
Benzoic acid Fluopicolide Pyraflufen-ethyl 
Boscalid Flusilazole Pyrimethanil 
Bromoxynil Fuberidazole Silthiofam 
Carbendazim Imazalil (aka enilconazole) S-Metolachlor 
Cinidon ethyl Isoproturon Tebuconazole 
Clodinafob-prop Isoxaflutole Teflubenzuron 
Clofentezine Kresoxim-methyl Tepraloxydim 
Clothianidin Linuron Tetraconazole 
Cyhalofop-butyl Mancozeb Thiacloprid 
Deltamethrin Maneb Thiamethoxam 
Dichlorprop-P Mecoprop-P Thiram 
Diflubenzuron Metamitron Tolylfluanid 
Dimethomorph Metconazole Triadimenol 
Dodemorph Metiram Tri-allate 
Epoxiconazole Metrafenone Triclopyr 
Ethofumesate Oxadiazon Triflusulfuron 
Etofenprox Propaquizafop  
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17.2.2.6. CAG level 2f: Neoplasms 
For the purpose of the CAG project, histopathological findings in the form of hepatocellular 
adenoma, hepatocellular carcinoma and hepatoblastoma are allocated to a single CAG level 2, 
termed ‘CAG level 2f: Neoplasms’.  
The active substances identified as inducing hepatocellular neoplasms are allocated to CAG 
level 2f and are listed in Table 17.7. 
 
Table 17.7. CAG level 2f: Neoplasms 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Imazalil (aka enilconazole) Propaquizafop 
Benfluralin Ioxynil Propiconazole 
Benthiavalicarb Iprodione Propineb 
Bromoxynil Isoproturon Propyzamide 
Carbendazim Isoxaflutole Pymetrozine 
Cinidon ethyl Kresoxim-methyl Pyraflufen-ethyl 
Clodinafob-prop Lenacil Pyrethrins 
Clofentezine Linuron Quizalofop-P-tefuryl 
Cyflufenamid Mancozeb Silthiofam 
Difenoconazole Maneb Tebuconazole 
Dimethachlor Mecoprop-P Tebufenpyrad 
Dimethenamid-P Mepanipyrim Teflubenzuron 
Epoxiconazole Metazachlor Tepraloxydim 
Fenoxaprop-P Metconazole Tetraconazole 
Fluazinam Metiram Thiamethoxam 
Fluopicolide Metrafenone Thiophanate-methyl 
Flupyrsulfuron-methyl (DPX KE 
459) 
Nicosulfuron Thiram 
Flusilazole Oxadiazon Triflusulfuron 
Fuberidazole Pethoxamid  
 
 
17.2.2.7. CAG level 2g: Lesions of biliary epithelium 
Lesions of biliary epithelium following exposure to the active substances are mainly seen as 
bile duct hyperplasia. Bile duct hyperplasia is a spontaneous change in portal areas of older 
animals that may be induced or exacerbated after exposure to chemicals. It may be a 
consequence of hepatic injury and repair, and obstruction of bile flow. (Thoolen et al. 2010). 
For the purpose of the CAG project, histopathological findings described as bile duct 
hyperplasia, bile duct proliferation, portal triad proliferation and bile duct epithelial 
hypertrophy are interpreted as representing bile duct hyperplasia. See Appendix X for a list of 
all terms in the DARs interpreted to represent bile duct hyperplasia. 
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Cholangiofibrosis, biliary cysts, and bile duct lipid vacuolation are other lesions of biliary 
epithelium. Cholangiofibrosis is an inflammatory, proliferative, and metaplastic reaction 
involving bile duct epithelium. The reaction is seen in response to pronounced hepatic 
parenchymal necrosis. Biliary cysts occur as a dilation of biliary structures and are common in 
older rats. (Thoolen et al. 2010). 
For the purpose of the CAG project, histopathological findings in the form of bile duct 
hyperplasia, cholangiofibrosis, biliary cysts and bile duct lipid vacuolation are are allocated to 
a single CAG level 2, termed ‘CAG level 2g: Lesions of biliary epithelium’.  
The active substances identified as inducing lesions of biliary epithelium are allocated to CAG 
level 2g and are listed in Table 17.8. 
 
Table 17.8. CAG level 2g: Lesions of biliary epithelium 
2,4-DB Florasulam Prothioconazole 
Azoxystrobin Fluazinam Pymetrozine 
Beflubutamid Fludioxonil Pyraflufen-ethyl 
Benthiavalicarb Flufenacet (formerly fluthiamide) Pyriproxyfen 
Carbendazim Flumioxazin Quinoclamine 
Cinidon ethyl Fuberidazole Quizalofop-P-ethyl 
Clodinafob-prop Iprovalicarb Silthiofam 
Clothianidin Isoproturon Sulcotrione 
Copper compounds Kresoxim-methyl Tebuconazole 
Cyclanilide Magnesium phosphide Teflubenzuron 
Cyflufenamid MCPA Tetraconazole 
Cyhalofop-butyl MCPB Thiabendazole 
Desmedipham Metamitron Thiamethoxam 
Dimethenamid-P Metazachlor Thiram 
Dodemorph Metconazole Tolylfluanid 
Epoxiconazole Metrafenone Tralkoxydim 
Ethephon Oxadiazon Trinexapac (aka cimetacarb ethyl) 
Ethoprophos Pendimethalin Triticonazole 
Fenamidone Propaquizafop Ziram 
Flazasulfuron Propyzamide  
 
 
17.2.2.8. CAG level 2h: Porphyria 
In porphyria the active substance interfere with the heme metabolism. The result is deposition 
of pigments of porphyrin, which is a precursor of heme protein. (Thoolen et al. 2010). 
The active substances identified as inducing porphyria are allocated to CAG level 2h and are 
listed in Table 17.9. 
 
Table 17.9. CAG level 2h: Porphyria 
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Bifenox Oxadiazon Tralkoxydim 
Carfentrazone-ethyl Pyraflufen-ethyl  
 
 
17.2.2.9. CAG level 2i: Cholestasis 
Cholestasis is decreased bile flow resulting from reduced secretion or from obstruction of the 
biliary tree. The cause of cholestasis may range from hepatocyte injury leading to defective 
formation and secretion of bile to interference with bile flow along its excretory pathways. For 
example, chemicals may selectively block uptake of bile components, interfere with the 
canalicular excretion of bile, or destroy or distort the membranes, organelles, or ductules 
responsible for normal bile flow (Mohi-ud-din and Lewis 2004). By obstructing the biliary 
tree, gallbladder calculi may also be the cause of cholestasis. 
Bile pigment is a common finding when there is cholestasis secondary to obstruction of bile 
flow or when there is perturbation in bile metabolism (Thoolen et al. 2010). Therefore for the 
purpose of the CAG project, increased bile pigment is interpreted as representing cholestasis.  
The active substances identified as inducing cholestasis are allocated to CAG level 2i and are 
listed in Table 17.10. 
 
Table 17.10. CAG level 2i: Cholestasis 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Famoxadone Quinoxyfen 
Bensulfuron Florasulam Quizalofop-P-ethyl 
Chlorothalonil Pendimethalin Quizalofop-P-tefuryl 
Clodinafob-prop Propyzamide Tepraloxydim 
Copper compounds Prosulfocarb Triflusulfuron 
Desmedipham Prothioconazole Triticonazole 
Difenoconazole Pymetrozine  
 
 
17.2.2.10. CAG level 2j: Inclusions 
Inclusions in the hepatocytes are protrusions of cytoplasm into an invagination of the 
hepatocyte nuclear membrane (Thoolen et al. 2010). 
The active substances identified as inducing inclusions in the hepatocytes are allocated to 
CAG level 2j and are listed in Table 17.11. 
Table 17.11. CAG level 2j: Inclusions in hepatocytes 
Beflubutamid Flupyrsulfuron-methyl (DPX KE 
459) 
Pethoxamid 
Benfluralin Flusilazole Propaquizafop 
Benthiavalicarb Imazalil (aka enilconazole) S-Metolachlor 
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Cyprodinil Iprovalicarb Tetraconazole 
Dimethachlor Mancozeb Tolylfluanid 
Fenpropidin Maneb  
 
 
17.2.2.11. CAG level 2k: Karyocytomegaly 
Hepatocellular karyocytomegaly is an increase in the number of diploid nuclei per hepatocyte 
or an increase in the ploidy level of a single hepatocyte nucleus. Karyocytomegaly may be an 
age-related phenomenon but can also be induced by xenobiotics. (Thoolen et al. 2010). 
The active substances identified as inducing hepatocellular karyocytomegaly are allocated to 
CAG level 2k and are listed in Table 17.12. 
Table 17.12. CAG level 2k: Karycytomegaly 
Amitrole (aminotriazole) Flufenacet (formerly fluthiamide) Metamitron 
Benthiavalicarb Flupyrsulfuron-methyl (DPX KE 
459) 
Metazachlor 
Carbendazim Flusilazole Metrafenone 
Carfentrazone-ethyl Iprovalicarb Penconazole 
Cinidon ethyl Isoxaflutole Prothioconazole 
Cyflufenamid Linuron Silthiofam 
Cypermethrin Mancozeb Tepraloxydim 
Etofenprox Maneb Tri-allate 
Fenamidone MCPA Triticonazole 
Fenpropimorph MCPB  
Fludioxonil Mepanipyrim  
 
 
17.2.2.12. Effects not considered relevant for CAGs at level 2 
Changes in blood and urine parameters indicative of liver damage: 
Liver related blood and urine parameters can be divided into three groups (Ramaiah 2007): 
• Hepatic leakage enzymes 
• Cholestatic induction parameters 
• Liver function parameters 
 
Hepatic leakage enzymes in blood include alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), lactate dehydrogenase (LDH), ornithine carbamyltransferase (OCT), 
and sorbitol dehydrogenase (SDH). These enzymes are produced by the liver and will leak out 
of the membrane into the blood following injury to the liver (due to e.g. hepatitis or necrosis) 
or alterations in the liver membrane permeability (due to e.g. hepatic glycogen or lipid 
accumulation).   
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Cholestatic induction parameters in blood include alkaline phosphatise (ALP), gamma 
glutamyltransferase (GGT), and bilirubin. The enzymes ALP and GGT show minimal activity 
in normal hepatic tissue. Following cholestasis the enzyme synthesis increase and they will 
occur in blood in increased amounts. GGT can also be elevated in cases of bile duct 
hyperplasia. If the function of the liver is impaired or when biliary drainage is blocked, some 
of the conjugated bilirubin leaks out of the hepatocytes and appears in the blood and urine. In 
hemolytic anemia, an increased number of red blood cells are broken down, causing an 
increase in the amount of free bilirubin in the blood. An increased level of bilirubin in the 
blood causes the yellow discoloration in jaundice. In standard toxicological studies only total 
bilirubin (free and conjugated) is measured in blood. Thus it is not possible to distinguish 
between hemolytic anemia and hepatobiliary injury based on total bilirubin. However, as the 
free bilirubin is not water soluble, bilirubin will not increase in the urine following hemolytic 
anemia. The excess free bilirubin will go through all of the normal processing mechanisms in 
the liver and intestine and will show up as an increase in urine urobilinogen.  
Liver function parameters in blood include albumin, coagulation times, urea, bilirubin, 
triglycerides, and bromosulphophtalein (BSP) retention. Decreased albumin, increased 
coagulation times, and decreased urea may indicate a decrease in the capacity of the liver to 
synthesize albumin, coagulation factors and urea (from ammonia). Coagulation times may be 
measured as activated partial thromboplastin time (APTT) or prothrombin time (PT). 
Decreases in plasma triglycerides have been noted in several tested hepatotoxic chemicals. 
BSP is a dye that is injected into study animals. With loss of secretory function of the liver, 
the dye will be retained in the blood. 
Changes in all of the above parameters are more or less specific indicators for damage to the 
liver. However, the CAGs for different histopathological effects will cover the liver injury 
indicated by these blood and urine parameters.   
 
Hepatocellular atrophy: 
The sizes of the hepatocytes are decreased in hepatocellular atrophy because of too little food 
intake, hemodynamic changes, or the pressure from neoplasia (Thoolen et al. 2010). Atrophy 
caused by pressure from neoplasia is secondary to the effect already covered in the CAG level 
2f for neoplasms of hepatocytes. Hepatocellular atrophy caused by too little food intake or 
hemodynamic changes is an indirect effect and therefore not considered relevant in terms of 
CRA for direct effects on the liver. 
 
Hepatocellular hyperplasia: 
Hepatocellular hyperplasia is an increased number of normal hepatocytes. Hepatocellular 
hyperplasia is often a regenerative response to prior or continuous hepatocellular damage.  
(Thoolen et al. 2010). Therefore, hepatocellular hyperplasia in almost all cases is secondary to 
the effects already covered by other CAG´s especially the CAG level 2c for degeneration 
and/or cell death of hepatocytes. 
 
Fibrosis: 
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Fibrosis in the liver is the formation of excess connective tissue as a reaction to hepatotoxicity 
(Thoolen et al. 2010). Therefore, fibrosis in the liver is secondary to the effects already 
covered by other CAG´s especially the CAG level 2c for degeneration and/or cell death of 
hepatocytes. 
 
Haemorrhage: 
Haemorrhage in the liver is found for very few active substances together with necrosis and 
inflammation. For these substances hemorrhage in the liver is secondary to the effects already 
covered in the CAG level 2c for degeneration and/or cell death of hepatocytes or in the CAG 
level 2d for inflammatory cell infiltrates. 
 
Angiectasis: 
Angiectasis is multiple blood-filled cystic spaces in the liver occurring after weakening of 
sinusoidal walls and/or supporting tissue. Angiectasis is a consequence of perturbations in 
blood flow and/or drainage e.g. following hepatocellular neoplasms or heart failure. 
Angiectasis may also be chemically induced. (Thoolen et al. 2010). For most of the active 
substances inducing angiectasis the effect is probably secondary to the effect already covered 
in the CAG level 2f for neoplasms of hepatocytes. For the rest of the active substances 
inducing angiectasis the effect may be either a direct effect or an indirect effect. Indirect 
effects are not considered relevant in terms of CRA for direct effects on the liver. As it is 
relatively few active substances that induce angiectasis and it is not possible to distinguish 
between direct and indirect effects it is not considered relevant to create a CAG for 
angiectasis. 
 
Lipofuscin pigment: 
Lipofuscin pigment represents a breakdown of cell membranes, and is often observed in older 
animals. Lipofuscin accumulation in the liver may be augmented by certain chemicals.  
(Thoolen et al. 2010). As it is very few active substances that induce accumulation of 
lipofuscin pigment, and they all induce other effects on the liver such as cell death it is not 
considered relevant to create a CAG for lipofuscin pigment. 
 
Extramedullary heamatopoiesis in the liver: 
Extramedullary heamatopoiesis in the liver is the production of blood cells in the liver. 
Extramedullary haematopoiesis is a response to an increased haematopoietic demand for 
instance following hemolytic anaemia. Both erythroid and granulocytic cells may be present in 
the aggregates; rarely megakaryocytes may be present. (Thoolen et al. 2010). Extramedullary 
haematopoiesis is therefore an indirect effect and therefore not considered relevant in terms of 
CRA for direct effects on the liver. 
 
Haemosiderosis: 
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Haemosiderosis is accumulation of hemosiderin (precipitated iron) in hepatocytes and Kupffer 
cells following for instance hemolytic anemia (Thoolen et al. 2010). Haemosiderosis is 
therefore an indirect effect and therefore not considered relevant in terms of CRA for direct 
effects on the liver. 
17.2.3. CAG level 3: Mode of action  
For some of the phenomenological / specific effects on the liver described under CAG level 2, 
a mode of action has been proposed for several active substances. For the remaining 
substances, no information regarding mode of action has been found and consequently, these 
substances cannot be allocated to a CAG level 3. 
17.2.3.1. CAG level 3a: Phase I enzyme induction 
The enzymes involved in the phase I reactions are mainly different cytochrome P450 
enzymes. When the body is faced with a high load of an active substance, the phase I and/or 
phase II enzymes involved in the metabolism of this active substance can be induced, leading 
to higher amounts of enzymes being present and a higher rate of metabolism. If Phase I 
metabolism is induced relatively more than Phase II, the level of potential reactive 
intermediates may increase. The reactive intermediate metabolites may cause toxicities by 
damaging to proteins, RNA, and DNA (Liska 1998). As an example from humane medicine, 
the analgesic paracetamol is known to be activated by hepatic CYP2E1 to a reactive 
metabolite. Chronic administration of ethanol can result in hepatic CYP2E1 induction and 
hence enhance the hepatotoxicity of paracetamol in humans. (Graham and Lake 2008). 
Drugs may lose their desired pharmacological effect when their metabolism is enhanced 
because of simultaneously exposure to other substances that induce CYPs. Induction of 
hepatic CYPs in humans may also lead to an increased metabolism of endogenous compounds 
such as folic acid, steroids steroid hormones, prostaglandins, fatty acids, cholesterol, bile 
acids,and vitamin D. Thus, induction of hepatic CYPs by xenobiotics may in some cases lead 
to profound pertubation of endogenous regulatory circuits with associated pathofysiological 
consequences in other organs and tissues than the liver (Waxman, 1999).  
Most CYP forms are induced by receptor-mediated mechanisms leading to an increase in gene 
transcription. Three nuclear receptor superfamily members, designated CAR (constitutive 
androstane receptor), PXR (pregnane X receptor), and PPARα (peroxisome proliferator-
activated receptor alpha, are mediating induction of hepatic CYP450’s belonging to the 
families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital 
(CAR), pregnenolone 16-alpha-carbonitrile and rifampicin (PXR), and clofibrate (PPAR). 
Induction of CYPs belonging to the family CYP1 is mediated by the AhR (aryl hydrocarbon 
receptor; Ah receptor) which is member of the PAS transcription family, not a nuclear 
receptor. The activation of certain receptors also leads to responses that produce effects on 
genes other than those involved in phase I and II metabolism which in rodent may lead to liver 
toxicity, including tumours (Waxman, 1999) (see CAG level 4a3 and CAG level 4a6 for 
further details). 
In rodents, the CYP1A, CYP2B, CYP2E, CYP3A and CYP4A families are the main CYPs 
that may be induced. Induction of hepatic CYPs in rodents may indicate a potential for 
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induction of CYPs in human liver, although pronounced species differences have been 
reported in the occurrence of specific CYPs and their induction  (Graham and Lake 2008). 
Induction of CYP450 species is normally measured as an increased activity of specific 
biotransformation reactions that are catalysed by the individual CYPs. 
Active substances where induction of phase I enzymes has been measured are included in this 
CAG level. See Appendix X for a list of all terms in the DARs interpreted to represent phase I 
enzyme induction. In CAG level 4, active substances have been further sub-grouped according 
to induction of specific CYPs.  
The active substances identified as increasing phase I enzymes are allocated to CAG level 3a 
and are listed in Table 17.13. 
 
Table 17.13. CAG level 3a: Increase in phase I enzymes in the liver 
2,4-D Fluopicolide Propaquizafop 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Fluoxastrobin Propiconazole 
Alpha-Cypermethrin (aka 
alphamethrin) 
Flupyrsulfuron-methyl (DPX KE 
459) 
Propoxycarbazone 
Benfluralin Flusilazole Propyzamide 
Benthiavalicarb Flutolanil Prothioconazole 
Beta-Cyfluthrin Imazalil (aka enilconazole) Pymetrozine 
Bifenox Imidacloprid Pyraflufen-ethyl 
Boscalid Iprodione Pyrethrins 
Chlorpropham Iprovalicarb Pyrimethanil 
Clodinafob-prop Isoproturon Quinoxyfen 
Clofentezine Isoxaflutole Quizalofop-P-tefuryl 
Clothianidin Kresoxim-methyl S-Metolachlor 
Cyflufenamid lambda-Cyhalothrin Spiroxamine 
Cyfluthrin Linuron Tebuconazole 
Cypermethrin Mancozeb Tebufenpyrad 
Deltamethrin Maneb Tetraconazole 
Dicamba MCPA Thiabendazole 
Difenoconazole Mecoprop Thiacloprid 
Diflubenzuron Mecoprop-P Thiamethoxam 
Dimethenamid-P Mepanipyrim Thiophanate-methyl 
Diuron Mesotrione Thiram 
Epoxiconazole Metalaxyl-M Tolclofos-methyl 
Ethoprophos Metconazole Tralkoxydim 
Etofenprox Metrafenone Triadimenol 
Famoxadone Metribuzin Tri-allate 
Fenamidone Oxadiazon Triflusulfuron 
Fenoxaprop-P Penconazole zeta-Cypermethrin 
Fenpropimorph Pendimethalin  
Fipronil Pethoxamid  
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The standard toxicological guidelines do not include as a mandatory requirement analysis of 
the phase I enzymes. Therefore, more active substances than those listed may induce phase I 
enzymes. 
The ‘CAG level 2a: Hepatocellular hypertrophy’ may be used as an indication for phase I 
enzyme induction, as the term hepatocellular hypertrophy is most commonly used to describe 
the changes in the cell following enzyme induction. 
17.2.3.2. CAG level 3b: Oxidative stress 
Oxidative stress occurs in cells when the concentration of reactive oxygen species (ROS) 
generated exceeds the antioxidant capability. ROS can be produced in normal cellular 
metabolism or by inflammatory cells. Reactive intermediate metabolites produced in the 
metabolism of xenobiotics may enhance the formation of ROS. Antioxidants such as vitamin 
C, vitamin E, glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GSH-
Px), and catalase normally inactivates ROS. With excessive formation of reactive intermediate 
metabolites and ROS the antioxidant capacity may be overloaded. The result is oxidative 
stress which may result in damage to DNA, lipids, and proteins in the cell. Unrepaired DNA 
damage may lead to mutations and potentially tumours. Oxidative injury may also produce 
cell death and tumours by the cytotoxic mode of action (see CAG level 3c). (Klaunig et al. 
1998). 
Active substances which induce oxidative stress measured as increased ROS, free radicals, or 
malondialdehyde (marker for oxidised lipid) and/or a decreased level of the antioxidants GSH, 
GSH-Px, SOD or catalase are included in this CAG level. 
The active substances identified as inducing oxidative stress are allocated to CAG level 3b 
and are listed in Table 17.14. 
 
Table 17.14. CAG level 3b: Oxidative stress 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Deltamethrin Methiocarb (aka mercaptodimethur) 
Captan Gibberellin Propiconazole 
Chlorothalonil Imazalil (aka enilconazole) Pyraflufen-ethyl 
Cypermethrin lambda-Cyhalothrin Thiram 
 
 
The standard toxicological guidelines do not include as a mandatory requirement studies on 
oxidative stress. Therefore, more active substances than those listed may cause hepatotoxicity 
by an oxidative stress mode of action. 
17.2.3.3. CAG level 3c: Cytotoxicity 
Cytotoxicity is a generally accepted mode of action for development of liver tumours. 
Continued hepatocyte death can cause compensatory regenerative hyperplasia aimed at 
maintaining the overall liver mass. Such growth results in more opportunities for 
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“spontaneous” DNA mutations, allowing mutated cells to accumulate and grow. The mutated 
cells may give rise to foci of cellular alterations and ultimately liver tumours. Liver tumours 
formed as a result of sustained cytotoxicity and regenerative hyperplasia are considered 
relevant for evaluating human cancer risk. (Holsapple et al. 2006). 
Active substances which induce degeneration and/or cell death of hepatocytes and foci of 
cellular alteration and/or liver neoplasms in the same study are included in this CAG level.  
The active substances identified as inducing foci of cellular alteration and/or liver neoplasms 
which may be caused by cytotoxicity are allocated to CAG level 3c and are listed in Table 
17.15. 
 
Table 17.15. CAG level 3c: Foci of cellular alteration and/or liver neoplasms which maay 
be caused by cytotoxicity 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Famoxadone Metconazole 
Benfluralin Fenoxaprop-P Metrafenone 
Benthiavalicarb Fluopicolide Oxadiazon 
Benzoic acid Flupyrsulfuron-methyl (DPX KE 
459) 
Propaquizafop 
Bromoxynil Flusilazole Propyzamide 
Carbendazim Fuberidazole Pyraflufen-ethyl 
Cinidon ethyl Imazalil (aka enilconazole) Silthiofam 
Clodinafob-prop Isoproturon Tebuconazole 
Cyflufenamid Isoxaflutole Teflubenzuron 
Cyhalofop-butyl Kresoxim-methyl Tetraconazole 
Dichlorprop-P Mepanipyrim Thiamethoxam 
Difenoconazole Metamitron Triadimenol 
Epoxiconazole Metazachlor Triflusulfuron 
 
 
17.2.3.4. CAG level 3d: Hormonal changes 
The liver is responsive to sex hormones. Epidemiological studies have shown a small 
increased risk of hepatocellular adenomas following use of long-term estrogen-containing 
contraceptives. The key events in liver tumour development in rodents following exposure to 
estrogenic agents are changes of hormone level or function, altered balance between cell 
proliferation and apoptosis, and development of foci of cellular alteration. (Holsapple et al. 
2006). 
Active substances where in vitro studies have shown aromatase induction and/or estrogenicity 
(see Table 25.78.) and in vivo studies have shown foci of cellular alteration and/or liver 
tumours are included in this CAG level. 
The active substances identified as inducing foci of cellular alteration and/or liver neoplasms 
which may be caused by hormonal changes are allocated to CAG level 3d and are listed in 
Table 17.16. 
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Table 17.16. CAG level 3d: Foci of cellular alteration and/or liver neoplasms which may 
be caused by hormonal changes 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Dodemorph Thiacloprid 
Clodinafop Iprodione Triadimenol 
Deltamethrin Oxadiazon  
 
 
The standard toxicological guidelines do not include as a mandatory requirement in vitro 
studies of aromatase induction and/or estrogenicity. Therefore, more active substances than 
those listed may cause foci of cellular alteration and/or liver tumours by a hormonal mode of 
action. 
17.2.4. CAG level 4: Mechanism of action 
For some active substances, a mechanism of action has been proposed.  
17.2.4.1. CAG level 4a1: CYP1A enzyme increased 
Induction of the cytochrome P450 enzymes of the CYP1A (CYP1A1 and CYP1A2) family 
involves activation of the aryl hydrocarbon receptor (AhR), which results in an increase in 
gene transcription. In addition CYP1A enzymes can be induced by AhR-independent 
pathways possible involving protein stabilisation. (Graham and Lake 2008, Lake 2009). 
The active substances identified as increasing CYP1A enzymes are allocated to CAG level 
4a1 and are listed in Table 17.17. 
 
Table 17.17. CAG level 4a1: Increase in CYP1A enzymes 
Benthiavalicarb Imazalil (aka enilconazole) Quinoxyfen 
Clothianidin Iprodione S-Metolachlor 
Cypermethrin Isoxaflutole Spiroxamine 
Deltamethrin Linuron Tetraconazole 
Difenoconazole Mesotrione Thiabendazole 
Diflubenzuron Metrafenone Thiacloprid 
Dimethenamid-P Pethoxamid Thiamethoxam 
Diuron Propiconazole Thiophanate-methyl 
Etofenprox Prothioconazole Tralkoxydim 
Fipronil Pymetrozine Triadimenol 
Fluopicolide Pyrimethanil  
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17.2.4.2. CAG level 4a2: CYP2A enzyme increased 
Induction of the cytochrome P450 enzymes of the CYP2A family (CYP2A1 testosterone 7-
alpha-hydroxylase) involves activation of the CAR receptor, which results in an increase in 
gene transcription (Waxman 1999). 
Two active substances identified as increasing CYP2A enzymes are allocated to CAG level 
4a2 and are listed in Table 17.18. 
 
Table 17.18. CAG level 4a2: Increase in CYP2A enzymes 
Diflubenzuron Propaquizafop  
 
 
17.2.4.3. CAG level 4a3: CYP2B enzyme increased 
Phenobarbital is the prototype of several rodent hepatocarcinogens that induce tumours by a 
non-genotoxic mechanism. The mechanism of action involves activation of the nuclear 
receptor, constitutive androstane receptor (CAR), which results in a pleiotropic response 
including induction of the cytochrome P450 enzymes of the CYP2B (CYP2B1, CYP2B2), 
family, increased cell proliferation, inhibition of apoptosis, and liver hypertrophy. Prolonged 
treatment results in the formation of foci of cellular alteration and subsequently of liver 
tumours. Phenobarbital is not cytotoxic to the liver cells. In addition to CYP2B enzymes, 
phenobarbital induces other hepatic CYPs together with phase II enzymes. (Graham and Lake 
2008, Holsapple et al. 2006). 
Scientists have concluded that rodent CYP2B enzymes inducers would not be expected to 
produce any increased risk of liver tumours in humans. However, an increased liver size has 
been noted in humans after prolonged treatment with phenobarbital. (Graham and Lake 2008, 
Holsapple et al. 2006). 
Active substances where induction of CYP2B enzymes has been measured are included in this 
CAG level. Hepatocellular hypertrophy was noted for most of these substances. Foci of 
cellular alteration and/or neoplasms of hepatocytes were also noted for most of these 
substances. Contrary to phenobarbital, many of the substances included in this CAG produce 
liver cell death, and thus also may be acting through a cytotoxic mode of action. 
The active substances identified as increasing CYP2B enzymes are allocated to CAG level 
4a3 and are listed in Table 17.19. 
 
Table 17.19. CAG level 4a3: Increase in CYP2B enzymes (phenobarbital-like P450 
inducers) 
Benthiavalicarb Iprodione Pyrethrins 
Clothianidin Isoxaflutole Pyrimethanil 
Cypermethrin Kresoxim-methyl S-Metolachlor 
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Deltamethrin Mesotrione Tetraconazole 
Difenoconazole Metconazole Thiabendazole 
Diflubenzuron Penconazole Thiacloprid 
Dimethenamid-P Pethoxamid Thiamethoxam 
Fenamidone Propaquizafop Thiophanate-methyl 
Fipronil Propiconazole Triadimenol 
Fluopicolide Prothioconazole  
Imazalil (aka enilconazole) Pymetrozine  
 
 
17.2.4.4. CAG level 4a4: CYP2E enzyme increased 
Induction of the cytochrome P450 enzymes of the CYP2E family (CYP2E enzymes are 
induced by ethanol) involves a posttranslational mechanism by stabilisation of the enzyme 
mRNA and protein. (Graham and Lake 2008). 
Two active substances identified as increasing CYP2E enzymes are allocated to CAG level 
4a4 and are listed in Table 17.20. 
 
Table 17.20. CAG level 4a4: Increase in CYP2E enzymes 
Deltamethrin Thiophanate-methyl  
 
 
17.2.4.5. CAG level 4a5: CYP3A enzyme increased 
Induction of the cytochrome P450 enzymes of the CYP3A family involves activation of the 
nuclear receptor, pregnane X receptor (PXR), which results in an increase in gene 
transcription (Graham and Lake 2008, Lake 2009). The prototype rat liver CYPs are CYP3A1, 
CYP3A2 and CYP3A23 (Waxman 1999). 
The active substances identified as increasing CYP3A enzymes are allocated to CAG level 
4a5 and are listed in Table 17.21. 
 
Table 17.21. CAG level 4a5: Increase in CYP3A enzymes 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Etofenprox Propiconazole 
Benthiavalicarb Fipronil Propyzamide 
Bifenox Flutolanil Pymetrozine 
Chlorpropham Imazalil (aka enilconazole) Pyrethrins 
Cyfluthrin lambda-Cyhalothrin Tetraconazole 
Cypermethrin Linuron Thiophanate-methyl 
Deltamethrin Mecoprop Thiram 
Diflubenzuron Mesotrione Tolclofos-methyl 
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Diuron Metconazole Tralkoxydim 
Epoxiconazole Pendimethalin zeta-Cypermethrin 
Ethoprophos Propaquizafop  
 
 
17.2.4.6. CAG level 4a6: CYP4A enzymes increased  
A wide range of non-genotoxic chemicals have been shown to produce liver enlargement and 
peroxisome proliferation in rats and mice. Peroxisome proliferation is associated with a 
marked induction of enzymes of the peroximal fatty acid β-oxidation cycle. The mechanism of 
action involves activation of the nuclear receptor, peroxisome proliferator activated receptor 
alpha (PPARα), which results in a pleiotropic response including induction of the cytochrome 
P450 enzymes of the CYP4A family, and similar key effects as the effects leading to liver 
tumours in the CYP2B enzymes inducers. The prototype rat liver CYPs are CYP4A1, 
CYP4A2 and CYP4A3 (Waxman 1999). Peroxisome proliferation may lead to oxidative 
stress which may contribute to liver tumours by causing indirect DNA damage and/or by 
contributing to the stimulation of cell proliferation. PPARα agonists also inhibit gap junction 
intercellular communication and stimulate hepatic Kupffer cells. Both of these effects also 
may contribute to the induction of cell proliferation (Graham and Lake 2008, Klaunig et al. 
2003). 
It has been concluded that rodent CYP4A enzymes inducers would not be expected to produce 
any increased risk of liver tumours in humans. Humans are relatively insensitive or non-
responsive to peroxisome proliferation at dose levels that produce a marked response in 
rodents. However, a reduction in serum lipids, which is the primary therapeutic value of the 
peroxisome proliferators used as drugs in humans, occurs in all species tested to date. 
(Graham and Lake 2008, Klaunig et al. 2003). 
Active substances where induction of CYP4A enzymes and/or increased activity of palmitoyl 
CoA oxidase, acyl CoA oxidase, and/or catalase (markers of peroxisome proliferation) have 
been measured are included in this CAG level.  
The active substances identified as increasing CYP4A enzymes are allocated to CAG level 
4a6 and are listed in Table 17.22. 
 
Table 17.22. CAG level 4a6: Increase in CYP1A enzymes (peroxisome proliferator 
activated receptor alpha (PPARα) agonists) 
2,4-D Mecoprop Pyrethrins 
Clodinafob-prop Mecoprop-P Quizalofop-P-tefuryl 
Dicamba Oxadiazon Tebufenpyrad 
Famoxadone Propaquizafop Tri-allate 
Fenoxaprop-P Propiconazole  
MCPA Pyraflufen-ethyl  
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17.2.4.7. CAG level 4c1: Porphyria and cytotoxicity 
In porphyria the active substance interfere with the heme metabolism. The result is deposition 
of pigments of porphyrin, which is a precursor of heme protein. (Thoolen et al. 2010). 
Porphyria may be the cause of persistent hepatocellular injury. Some porphyrinogenic 
chemicals cause liver tumours by this cytotoxic mode of action. Liver tumours formed as a 
result of porphyria resulting in sustained cytotoxicity are considered relevant for evaluating 
human cancer risk. (Holsapple et al. 2006). 
Active substances which induce degeneration and/or cell death of hepatocytes and porphyria 
in the same study are included in this CAG level. Only one of the active substances, 
Oxadiazon, inducing porphyria induce foci of cellular alteration and/or liver tumours. 
The active substances identified as inducing degeneration and/or cell death of hepatocytes and 
porphyria are allocated to CAG level 4b1 and are listed in Table 17.23. 
 
Table 17.23. CAG level 4c1: Degeneration and/or cell death which may be caused by 
porphyria 
Carfentrazone-ethyl Oxadiazon Tralkoxydim 
 
 
17.3. Discussion of CAGs for the liver 
17.3.1. Studies on effects on the liver in experimental animals 
The pesticide active substances on the European market typically have been tested in a battery 
of standard toxicological tests.  In the standard guidelines for testing of repeated dose toxicity 
including chronic toxicological studies in rodents, histopathological changes in the liver such 
as hepatocellular hypertrophy, fatty change, death, and tumours will be revealed.  In addition 
it is a requirement to measure certain clinical biochemical parameters such as liver enzymes 
which when increased in the blood indicate liver damage. It is also a requirement to record the 
liver weight. However, the standard guidelines do not include as a mandatory requirement 
analysis of the enzymes involved in detoxification in the liver such as the cytochromes P450s. 
Neither do the standard guidelines require analysis of oxidative stress or hormonal changes 
that may contribute to liver toxicity. Therefore, for several of the CAG levels more active 
substances may cause liver toxicity by those mode or mechanisms of action. 
17.3.2. Species differences in toxicity to the liver 
Although species differences exist, Holsapple et al. 2006 have evaluated that liver tumours 
caused by a cytotoxic (including porphyria) or hormonal mode of action are relevant for 
humans. Liver tumours caused by PPAR alpha agonists or phenobarbital-like P450 inducers 
are not relevant for humans. However, other liver effects may still be relevant for humans 
exposed to PPAR alpha agonists or phenobarbital-like P450 inducers. It is known that PPAR 
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alpha agonists lower serum lipids in humans, and phenobarbital may increase the liver size 
after prolonged treatment in humans (Graham and Lake 2008). 
Humans and animals have different hepatic CYPs. However, induction of hepatic CYPs in 
animals may indicate a potential for induction of CYPs in human liver (Graham and Lake 
2008). 
17.3.3. Discussion of which CAGs to recommend 
One hundred and ninety-five active substances were identified to have effects on the liver and 
were allocated to CAG level 1. Eleven distinct CAGs at level 2 have been proposed. 
Information on modes/mechanisms of action is available for a number of the active 
substances. The information is summarised in Appendix Y. 
Foci of cellular alteration and neoplasms of hepatocytes (CAG level 2e and 2f) can be 
explained by different mode or mechanisms of actions for about 2/3 of the active substances. 
Cytotoxicity (CAG level 3c), sometimes together with induction of CYP2B enzymes (CAG 
level 4a3) or CYP4A enzymes (CAG level 4a6), may account for about half of the cases of 
foci of cellular alteration and/or neoplasms. A possible association between induction of 
CYP2B enzymes, induction of CYP4A enzymes, or hormonal changes (CAG level 3d) and 
foci of cellular alteration and/or neoplasms have been found for far less active substances 
probably because it is not a requirement to study these mode or mechanisms of actions in the 
standard guidelines. Porphyria may cause neoplasms by a cytotoxic mode of action. However, 
although porphyria for some of the active substances is associated with cytotoxicity (CAG 
level 4c), only one of the included active substances which induce porphyria induce neoplasm.  
Cell degeneration and/or cell death (CAG level 2c) can be explained by different mode or 
mechanisms of actions for about 1/3 of the active substances. Phase I enzyme induction (CAG 
level 3a), sometimes together with oxidative stress (CAG level 3b), may account for about 1/3 
of the cases of cell degeneration and/or cell death. A possible association between oxidative 
stress or porphyria (CAG level 4c) and cell degeneration and/or cell death have been found for 
very few active substances. Oxidative stress has only been studied for very few active 
substances as it is not a requirement to study this mode of actions in the standard guidelines. 
Porphyria is a relatively seldom finding in the studies and thus only may be responsible for 
cytotoxicity for very few active substances.  
Eleven CAG level 2 have been proposed. It should be noted that some of the effects allocated 
to these CAGs may be interrelated. As the mode or mechanisms of action only may explain a 
few of the phenomenological effects in the liver for some of the active substances, it is 
recommended also to consider the eleven CAG level 2 for cumulative risk assessment for 
effects on the liver.  
17.3.4. Chemical classes as basis for CAGs for the liver 
Active substances belonging to the same chemical class may have similar toxicological 
effects. Information in the DARs on effects on the liver is evaluated for similarity of 
toxicological effects within the relevant chemical classes, i.e. the chemical classes containing 
more than one active substance. The evaluation includes the active substances allocated to 
CAG level 1 and the CAG level 2 groups for phenomenological/specific effects. A 
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comparison of the compounds allocated to CAGs at level 3 and 4 would probably be 
misleading because only a limited amount of active substances have been studied for 
mode/mechanism of action. 
17.3.4.1. Amides 
Both amides, beflubutamid and cyflufenamid, had effects on the liver and induced 
hypertrophy (CAG level 2a), cell degeneration / cell death (CAG level 2c), inflammation 
(CAG level 2d), and lesions of biliary epithelium (CAG level 2g). Only cyflufenamid 
produced fatty changes in the liver (CAG level 2b), liver tumours (CAG level 2f), and 
karyocytomegaly (CAG level 2k), and only beflubutamid produced inclusions (CAG level 2j). 
Taken together, the two amides produced a number of similar effects on the liver, but the 
information in the DARs does not allow a firm conclusion that they as a group always have 
similar effects on the liver.  
17.3.4.2. Anilinopyrimidines 
All three anilinopyrimidines, cyprodinil, mepanipyrim, and pyrimethanil, had effects on the 
liver and induced hypertrophy (CAG level 2a). Cyprodinil and mepanipyrim induced liver cell 
degeneration / cell death (CAG level 2c). Only mepanipyrim produced fatty changes in the 
liver (CAG level 2b), inflammation (CAG level 2d), and liver tumours (CAG level 2f) and 
only cyprodinil induced inclusions (CAG level 2j). Taken together, the three 
anilinopyrimidines produced hypertrophy (CAG level 2a), but the information in the DARs 
does not allow the conclusion that they as a group always have similar effects on the liver.  
17.3.4.3. Aryloxyalkanoic acids 
All seven aryloxyalkanoic acids (2,4-D, 2,4-DB, dichlorprop-P, MCPA, MCPB, , mecoprop, 
and mecoprop-P) were identified as having effects on the liver at CAG level 1. However, only 
2,4-D, 2,4-DB, and dichlorprop-P induced liver hypertrophy (CAG level 2a), whereas none of 
the aryloxyalkanoic acids produced fatty changes in the liver (CAG level 2b). 2,4-D, 
dichlorprop-P, MCPA and MCPB produced liver cell degeneration / cell death (CAG level 
2c). 2,4-D, 2,4-DB, MCPA and MCPB produced inflammation (CAG level 2d) whereas only 
dichlorprop-P and mecoprop-P induced foci of cellular alteration (CAG level 2e) and only 
mecoprop-P induced liver tumours (CAG level 2f). Lesions of biliary epithelium (CAG level 
2g) was seen after 2,4-DB, MCPA and MCPB but none of the substances produced porphyria 
(CAG level 2h) and cholestasis (CAG level 2i). None of the aryloxyalkanoic acids gave 
inclusions (CAG level 2j) but MCPA and MCPD induced karyocytomegaly (CAG level 2k), 
Taken together, the information in the DARs indicate that although all the aryloxyalkanoic 
acids have effects on the liver, this does not allow the conclusion that the aryloxyalkanoic 
acids as a group have similar toxic effects on the liver. 
17.3.4.4. Aryloxyphenoxypropionates 
All five aryloxyphenoxypropionates (clodinafop-P, cyhalofop-butyl, fenoxaprop-P, 
propaquizafop, and quizalofop-P) were identified as having effects on the liver at CAG level 
1. All induced liver hypertrophy (CAG level 2a) but only propaquizafop and quizalofop-P 
produced fatty changes in the liver (CAG level 2b). All the aryloxyphenoxypropionates 
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produced liver cell degeneration / cell death (CAG level 2c) and all except fenoxaprop-P 
produced inflammation (CAG level 2d). Clodinafop-P, cyhalofop-butyl, fenoxaprop-P, and 
propaquizafop induced foci of cellular alteration (CAG level 2e). Clodinafop-P, fenoxaprop-
P, propaquizafop, and quizalofop-P induced liver tumours (CAG level 2f). Lesions of biliary 
epithelium (CAG level 2g) was seen after clodinafop-P, cyhalofop-butyl, propaquizafop, and 
quizalofop-P, but none of the substances produced porphyria (CAG level 2h). Cholestasis was 
induced by clodinafop-P and quizalofop-P (CAG level 2i). Propaquizafop was reported to 
induce inclusions (CAG level 2j). None of the substances induced karyocytomegaly (CAG 
level 2k), Taken together, the information in the DARs indicate that all the 
aryloxyphenoxypropionates have effects on the liver and all produced liver hypertrophy and 
liver cell degeneration / cell death. However, the information does not allow the conclusion 
that the aryloxyphenoxypropionates have similar toxic effects on the liver. 
17.3.4.5. Benzenamides 
All three benzamides (fluopicolide, propyzamide and zoxamide) were identified as having 
effect on the liver (CAG level 1) and all induced liver hypertrophy (CAG level 2a). 
Fluopicolide and propyzamide produced liver cell degeneration / cell death (CAG level 2c) 
and foci of cellular alteration (CAG level 2e). Only propyzamide produced inflammation 
(CAG level 2d), liver tumours (CAG level 2f), lesions of biliary epithelium (CAG level 2g) 
and cholestasis (CAG level 2i). Taken together, the information in the DARs indicate that the 
benzamides have effects on the liver and all produced liver hypertrophy. However, the 
information does not allow the conclusion that the benzamides as a group have similar toxic 
effects on the liver. 
17.3.4.6. Benzimidazoles 
All three benzimidazoles (fuberidazole, thiabendazole, and thiophanate-methyl) were 
identified as having effect on the liver (CAG level 1) and all induced liver hypertrophy (CAG 
level 2a), Only fuberidazole produced liver cell degeneration / cell death (CAG level 2c) and 
foci of cellular alteration (CAG level 2e). Fuberidazole and thiophanate-methyl were reported 
to induce liver tumours (CAG level 2f). Fuberidazole and thiabendazole produced lesions of 
biliary epithelium (CAG level 2g). No other effects on the liver were found. Taken together, 
the information in the DARs indicate that the benzimidazoles have effects on the liver and all 
produced liver hypertrophy. However, the information does not allow the conclusion that the 
benzimidazoles as a group have other similar toxic effects on the liver. 
17.3.4.7. Benzoic acid and dicamba (aromatic carboxylic acids) 
Dicamba classified as a benzoic acid and benzoic acid itself, being classified as an aromatic 
carboxylic acid, both had effects on the liver (CAG level 1) and both compounds induced 
liver hypertrophy (CAG level 2a) and liver cell degeneration / cell death (CAG level 2c). Only 
benzoic acid was reported to produce fatty changes in the liver (CAG level 2b)and foci of 
cellular alteration (CAG level 2e). None of the compounds produced inflammation (CAG 
level 2d), liver tumours (CAG level 2f), lesions of biliary epithelium (CAG level 2g), 
porphyria (CAG level 2h), cholestasis (CAG level 2i), inclusions (CAG level 2j), or 
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karyocytomegaly (CAG level 2k), Taken together, the information in the DARs indicate that 
benzoic acid and dicamba have similar toxic effect on the liver. 
17.3.4.8. Benzoylureas 
All three benzoylureas (diflubenzuron, lufenuron, and teflubenzuron) were identified as 
having effect on the liver (CAG level 1) and all induced liver hypertrophy (CAG level 2a), 
fatty changes in the liver (CAG level 2b) and liver cell degeneration / cell death (CAG level 
2c). Only diflubenzuron showed inflammation (CAG level 2d) and foci of cellular alteration 
(CAG level 2e) and only teflubenzuron was reported to induce liver tumours (CAG level 2f). 
Teflubenzuron also produced lesions of biliary epithelium (CAG level 2g). None of the 
compounds produced porphyria (CAG level 2h), cholestasis (CAG level 2i), inclusions (CAG 
level 2j), or karyocytomegaly (CAG level 2k). Taken together, the information in the DARs 
indicate that the benzoylureas have effects on the liver and all produced liver hypertrophy, 
fatty changes and liver cell degeneration / cell death. However, the information does not allow 
a firm conclusion that the benzoylureas have similar toxic effects on the liver. 
17.3.4.9. Biscarbamates 
Two active substance are biscarbamates (desmedepham and phenmedipham). Desmedipham 
was identified as having effect on the liver and induced liver hypertrophy (CAG level 2a), 
fatty changes in the liver (CAG level 2b), liver cell degeneration / cell death (CAG level 2c), 
inflammation (CAG level 2d), liver tumours (CAG level 2f), lesions of biliary epithelium 
(CAG level 2g), cholestasis (CAG level 2i) and inclusions (CAG level 2j). None of the 
compounds were found to induce foci of cellular alteration (CAG level 2e), porphyria (CAG 
level 2h) and karyocytomegaly (CAG level 2k). Taken together, the information in the DARs 
does not allow the conclusion that the biscarbamates as a group have similar toxic effects on 
the liver. 
17.3.4.10. Carbamates 
Eight active substances are carbamates (carbamate esters or urethanes) (benthiavalicarb, 
chlorpropham, iprovalicarb, methiocarb, methomyl, oxamyl, pirimicarb, and propamocarb). 
Benthiavalicarb, chlorpropham, iprovalicarb and methiocarb were reported to have effect on 
the liver (CAG level 1). Benthiavalicarb and iprovalicarb induced liver hypertrophy (CAG 
level 2a), fatty changes in the liver (CAG level 2b), liver cell degeneration / cell death (CAG 
level 2c), inflammation (CAG level 2d), lesions of biliary epithelium (CAG level 2g), 
inclusions (CAG level 2j and karyocytomegaly (CAG level 2k). Only benthiavalicarb induced 
foci of cellular alteration (CAG level 2e) and liver tumours (CAG level 2f), None of the 
compounds induced cholestasis (CAG level 2i) and porphyria (CAG level 2h). Taken 
together, the information in the DARs does not allow the conclusion that the carbamates as a 
group have similar toxic effects on the liver. 
17.3.4.11. Carboxamides 
Both carboxamides, boscalid and diflufenican, had effects on the liver and induced 
hypertrophy (CAG level 2a). Diflufenican induced fatty changes in the liver (CAG level 2b) 
and boscalid gave foci of cellular alteration (CAG level 2e). No other effects were noted. 
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Taken together, the two carboxamides produced hypertrophy (CAG level 2a), but the 
information in the DARs does not allow the conclusion that they as a group have similar 
effects on the liver. 
17.3.4.12. Dicarboximides 
All three dicarboximides, cinidon ethyl, flumioxazin, and iprodione, had effects on the liver 
and induced hypertrophy (CAG level 2a). Cinidon ethyl and flumioxazin induced liver cell 
degeneration / cell death (CAG level 2c) and lesions of biliary epithelium (CAG level 2g), 
Cinidon ethyl and iprodione induced liver tumours (CAG level 2f), Only iprodione produced 
fatty changes in the liver (CAG level 2b) and inflammation (CAG level 2d) and only cinidon 
ethyl produced foci of cellular alteration (CAG level 2e) and karyocytomegaly (CAG level 
2k). Taken together, the three dicarboxamides produced hypertrophy (CAG level 2a), but the 
information in the DARs does not allow the conclusion that they as a group have similar 
effects on the liver. 
17.3.4.13. Chloroacetamides 
All five chloracetamides (dimethachlor, dimethenamid-P, metazachlor, pethoxamid, S-
metolachlor) were reported to have effect on the liver (CAG level 1) and all induced 
hypertrophy (CAG level 2a), Dimethenamid-P, metazachlor and pethoxamid produced fatty 
changes in the liver (CAG level 2b). Dimethachlor, metazachlor and pethoxamid induced liver 
cell degeneration / cell death (CAG level 2c). Dimethachlor, dimethenamid-P and metazachlor 
produced inflammation (CAG level 2d). S-metolachlor induced foci of cellular alteration 
(CAG level 2e). Dimethachlor, dimethenamid-P, metazachlor and pethoxamid induced liver 
tumours (CAG level 2f), Dimethenamid-P and metazachlor produced lesions of biliary 
epithelium (CAG level 2g), dimethachlor and pethoxamid induced inclusions (CAG level 2j), 
and metazachlor produced karyocytomegaly (CAG level 2k). Taken together, the five 
chloracetamides  produced hypertrophy (CAG level 2a), but the information in the DARs does 
not allow the conclusion that they as a group have similar effects on the liver. 
17.3.4.14. Diphenylethers 
Both diphenylethers, aclonifen and bifenox, had effects on the liver and induced hypertrophy 
(CAG level 2a). Bifenox induced cell degeneration / cell death (CAG level 2c) and porphyria 
(CAG level 2h). No other effects in the liver were noted. Taken together, the two 
diphenylethers produced hypertrophy (CAG level 2a), but the information in the DARs does 
not allow the conclusion that they as a group have similar effects on the liver. 
17.3.4.15. Dithiocarbamates 
Four of the five dithiocarbamates (mancozeb, maneb, propineb, and thiram) and the 
dimethyldithiocarbamate ziram were identified as having effects on the liver (CAG level 1). 
Mancozeb, maneb, and ziram induced liver hypertrophy (CAG level 2a), Only ziram produced 
fatty changes in the liver (CAG level 2b) and inflammation (CAG level 2d). Mancoseb, 
maneb and ziram induced liver cell degeneration / cell death (CAG level 2c) and mancozeb, 
maneb, and thiram induced foci of cellular alteration (CAG level 2e). Liver tumours (CAG 
level 2f) were induced by mancozeb, maneb and thiram. Only thiram and ziram produced 
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lesions of biliary epithelium (CAG level 2g), Mancoseb and Maneb induced inclusions (CAG 
level 2j) and karyocytomegaly (CAG level 2k). None of the compounds were found to induce 
cholestasis (CAG level 2i) and porphyria (CAG level 2h). Taken together, the information in 
the DARs does not allow the conclusion that the dithiocarbamates as a group have similar 
toxic effects on the liver. 
17.3.4.16. Hydroxybenzonitrils 
Both hydroxybenzonitrils, bromoxynil and ioxynil, had effects on the liver and induced 
hypertrophy (CAG level 2a) and liver tumours (CAG level 2f). Only bromoxynil produced 
fatty changes in the liver (CAG level 2b), liver cell degeneration / cell death (CAG level 2c), 
inflammation (CAG level 2d), and foci of cellular alteration (CAG level 2e). No other effects 
in the liver were noted. Taken together, the two hydroxybenzonitrils produced hypertrophy 
and liver tumours, but the information in the DARs does not allow a firm conclusion that they 
as a group have similar effects on the liver. 
17.3.4.17. Imidazoles 
Both imidazoles, fenamidone and imazalil (aka enilconazole), had effects on the liver and 
induced hypertrophy (CAG level 2a), fatty changes in the liver (CAG level 2b), foci of cellular 
alteration (CAG level 2e). Only imazalil produced liver cell degeneration / cell death (CAG 
level 2c) and inclusions (CAG level 2j), and only fenamidone produced lesions of biliary 
epithelium (CAG level 2g) and karyocytomegaly (CAG level 2k). Taken together, the two 
imidazoles produced hypertrophy, fatty changes in the liver (CAG level 2b) and foci of 
cellular alteration (CAG level 2e), but the information in the DARs does not allow a firm 
conclusion that they as a group have similar effects on the liver. 
17.3.4.18. Morpholines 
All four morpholines (dimethomorph, dodemorph, fenpropimorph and spiroxamine) were 
identified as having an effect on the liver (CAG level 1). All produced liver hypertrophy 
(CAG level 2a) and fatty changes in the liver (level 2b CAG), Dodemorph and spiroxamine 
induced liver cell degeneration / cell death (CAG level 2c). Dimethomorph and dodemorph 
induced foci of cellular alteration (CAG level 2e). Dodemorph induced lesions of biliary 
epithelium (CAG level 2g), while fenpropimorph induced karyocytomegaly (CAG level 2k). 
None of the substances induced inflammation (CAG level 2d), liver tumours (CAG level 2f), 
cholestasis (CAG level 2i), porphyria (CAG level 2h) or inclusions (CAG level 2j). Taken 
together, the information in the DARs does not allow the conclusion that the morpholines as a 
group have similar toxic effects on the liver. 
17.3.4.19. Neonicotinoids 
All five neonicotinoids (acetamiprid, clothianidin, imidacloprid, thiacloprid and 
thiamethoxam) were identified as having effects onthe liver (CAG level 1). All five 
substances induced liver hypertrophy (CAG level 2a). Acetamiprid, clothianidin, thiacloprid 
and thiamethoxam produced fatty changes in the liver (level 2b CAG) and imidacloprid 
thiacloprid and thiamethoxam showed liver cell degeneration / cell death (CAG level 2c). 
Inflammation (CAG level 2d) was reported after acetamiprid, imidacloprid and 
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thiamethoxam. Foci of cellular alteration (CAG level 2e) were induced by clothianidin, 
thiacloprid and thiamethoxam.Only thiamethoxam was reported to induce liver tumours 
(CAG level 2f). Lesions of biliary epithelium (CAG level 2g) were induced by clothianidin, 
and thiamethoxam, None of the compounds showed cholestasis (CAG level 2i), porphyria 
(CAG level 2h), inclusions (CAG level 2j and karyocytomegaly (CAG level 2k). Taken 
together, all five neonicotinoids showed effects onthe liver. However, the information in the 
DARs does not allow a firm conclusion that the neonicotinoids as a group have similar toxic 
effects on the liver. 
17.3.4.20. Organophosphates 
Of the nine organophosphates (chlorpyrifos, chlorpyrifos-methyl, dimethoate, ethoprophos, 
fenamiphos (aka phenamiphos), fosthiazate, glufosinate, phosmet, pirimiphos-methyl) two 
(ethoprophos and phosmet) were identified as having effects on the liver (CAG level 1). 
Ethoprophos and phosmet induced fatty changes in the liver (CAG level 2b) and liver cell 
degeneration / cell death (CAG level 2c) and ethoprophos induced lesions of biliary 
epithelium (CAG level 2g). No other specific effects on the liver were reported. Therefore, the 
information in the DARs does not allow the conclusion that the organophosphates as a group 
have similar toxic effects on the liver. 
17.3.4.21. Oxidazoles 
One oxidazole, oxadiazon, had effects on the liver and induced hypertrophy (CAG level 2a), 
fatty changes in the liver (level 2b CAG), liver cell degeneration / cell death (CAG level 2c). 
inflammation (CAG level 2d), foci of cellular alteration (CAG level 2e), liver tumours (CAG 
level 2f), lesions of biliary epithelium (CAG level 2g), and porphyria (CAG level 2h). The 
other active substance being a oxidazole, oxadiargyl, had no effects on the liver. Taken 
together, the information in the DARs does not allow the conclusion that the oxidazoles as a 
group have similar effects on the liver. 
17.3.4.22. Phenylureas 
One phenylurea, diuron, had effects on the liver and induced hypertrophy (CAG level 2a) and 
liver cell degeneration / cell death (CAG level 2c). The other active substance being a 
phenylurea, forchlorfenuron, had no effects on the liver. Taken together, the information in the 
DARs does not allow the conclusion that the phenylureas as a group have similar effects on 
the liver. 
17.3.4.23. Phthalimides 
One phthalamide, captan, had effects on the liver and induced hypertrophy (CAG level 2a) 
and fatty changes in the liver (level 2b CAG). The other active substance being a phthalamide, 
folpet, had no effects on the liver. Taken together, the information in the DARs does not allow 
the conclusion that the phthalamides as a group have similar effects on the liver. 
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17.3.4.24. Phenylpyrazoles 
Both phenylpyrazoles (fibronil and pyraflufen-ethyl) were identified as having an effect on the 
liver (CAG level 1). Both induced liver hypertrophy (CAG level 2a), fatty changes in the liver 
(level 2b CAG) and liver cell degeneration / cell death (CAG level 2c). Only pyraflufen-ethyl 
produced inflammation (CAG level 2d), foci of cellular alteration (CAG level 2e), liver 
tumours (CAG level 2f), lesions of biliary epithelium (CAG level 2g) and porphyria (CAG 
level 2h). No other specific effects were reported on the liver. Therefore, the information in 
the DARs does not allow the conclusion that the phenylpyrazoles have similar toxic effects on 
the liver. 
17.3.4.25. Pyrazoles 
Both pyrazoles (fenpyroximate and tebufenpyrad) were identified as having an effect on the 
liver (CAG level 1). Both induced liver hypertrophy (CAG level 2a) but only tebufenpyrad 
induced liver tumours (CAG level 2f), No other specific effects were reported on the liver. 
The information in the DARs does not allow a firm conclusion that the phenylpyrazoles have 
similar toxic effects on the liver. 
17.3.4.26. Pyrethroids and pyrethrin 
For eight (alpha-cypermethrin, beta-cyfluthrin, cyfluthrin, cypermethrin, deltamethrin, , 
etofenprox, lambda-cyhalothrin and zeta-cypermethrin)of the nine active substances classified 
as pyrethroids effects on the liver were reported in the DARs. For esfenvalerate no effects on 
the liver were reported. Esfenvalerate lacks the (vinyl)cyclopropanecarboxylate moity 
characteristic for the majority of the pyrethroid active substances. Cypermethrin and 
etofenprox were allocated to CAG level 2a: Hypertrophy. Alpha-cypermethrin, cypermethrin, 
and deltamethrin induced fatty changes in the liver (CAG level 2b). Alpha-cypermethrin, 
cypermethrin,deltamethrin, and lambda-cyhalothrin produced liver cell degeneration / cell 
death (CAG level 2c) and inflammation (CAG level 2d). and deltamethrin produced foci of 
cellular alteration (CAG level 2e). None of the pyrethroids induced neoplasms (CAG level 
2f), lesions of biliary epithelium (CAG level 2g), porphyria (CAG level 2h), Cholestasis) 
(CAG level 2i), or inclusions (CAG level 2j). However, cypermethrin was found to induce 
karyocytomegaly (CAG level 2k). Taken together, the information in the DARs do not allow 
the conclusion that the pyrethroids that are cyclopropanecarboxylate esters as a group have 
similar toxic effects on the liver. 
It is noted that pyrethrins are classified as a biopesticide. However, as the pyrethroids are 
structural derivatives of the naturally occurring pyrethrins, the latter could be considered 
together with the pyrethroids. According to the DAR pyrethrins produced hypertrophy (CAG 
level 2a), fatty changes in the liver (CAG level 2b) and liver tumours (CAG level 2f). In 
conclusion, the information in the DARs do not allows the conclusion that the pyrethroids and 
pyrethrins as a group have similar toxic effects on the liver. 
17.3.4.27. Pyridazones 
One pyridazinone, chloridazon, had effects on the liver and induced hypertrophy (CAG level 
2a), fatty changes in the liver (level 2b CAG) and liver cell degeneration / cell death (CAG 
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level 2c). The other active substance being a pyridazinone, flurtamone, had no effects on the 
liver. Taken together, the information in the DARs does not allow the conclusion that the 
pyridazones as a group have similar effects on the liver. 
17.3.4.28. Pyridine compounds 
Four of six pyridine compounds, clopyralid, picloram, pymetrozine, and triclopyr, were 
identified as having an effect on the liver (CAG level 1). Fluroxypyr and picolinafen had no 
effects on the liver. Clopyralid, picloram, pymetrozine, and triclopyr induced hypertrophy 
(CAG level 2a). Only picloram induced fatty changes in the liver (level 2b CAG). Picloram, 
pymetrozine, and triclopyr produced liver cell degeneration / cell death (CAG level 2c) and 
pymetrozine and triclopyr induced inflammation (CAG level 2d) and foci of cellular alteration 
(CAG level 2e). No other effects on the liver were noted. Taken together, the information in 
the DARs does not allow the conclusion that the pyridine compounds as a group have similar 
effects on the liver. 
17.3.4.29. Sulfonylureas 
Fifteen sulfonylureas (azimsulfuron, bensulfuron, chlorsulfuron, ethoxysulfuron, 
flazasulfuron, flupyrsulfuron-methyl, imazosulfuron, iodosulfuron-methyl-sodium, 
nicosulfuron, prosulfuron, rimsulfuron, triflusulfuron, triasulfuron, tribenuron, and 
tritosulfuron) were identified as having effects on the liver. Mesosulferon, metsulfuron-
methyl, oxasulfuron, and sulfosulfuron had no effect on the liver. Azimsulfuron, bensulfuron, 
chlorsulfuron, ethoxysulfuron, flazasulfuron, flupyrsulfuron-methyl, imazosulfuron, 
iodosulfuron-methyl-sodium, prosulfuron, rimsulfuron, triflusulfuron, triasulfuron, tribenuron, 
and tritosulfuron induced hypertrophy (CAG level 2a). Bensulfuron, ethoxysulfuron, 
iodosulfuron-methyl-sodium, rimsulfuron, and triasulfuron induced fatty changes in the liver 
(CAG level 2b). Cell degeneration / cell death (CAG level 2c) was induced by azimsulfuron, 
bensulfuron, ethoxysulfuron, flazasulfuron, flupyrsulfuron-methyl, triflusulfuron, triasulfuron, 
and tritosulfuron. Inflammation (CAG level 2d) was produced by azimsulfuron, 
ethoxysulfuron, flazasulfuron, imazosulfuron, iodosulfuron-methyl-sodium, triasulfuron, and 
tritosulfuron, whereas foci of cellular alteration (CAG level 2e) was only induced by 
triflusulfuron. Flupyrsulfuron-methyl, nicosulfuron and triflusulfuron induced liver neoplasms 
(CAG level 2f). Lesions of biliary epithelium (CAG level 2g) were seen after flazasulfuron, 
porphyria (CAG level 2h), Bensulfuron and triflusulfuron induced cholestasis (CAG level 2i) 
and flupyrsulfuron-methyl produced inclusions (CAG level 2j), and karyocytomegaly (CAG 
level 2k). Although 15 of 21 sylfonylureas were reported to affect the liver, the information in 
the DARs does not allow the conclusion that the sulfonylureas as a group have similar toxic 
effects on the liver. 
17.3.4.30. Strobilurines 
Five of seven strobilurines were identified as having an effect on the liver. Azoxystrobin, 
fluoxastrobin, kresoxim-methyl, pyraclostrobin, and trifloxystrobin all induced hypertrophy 
(CAG level 2a). For the remaining two strobilurines, dimoxystrobin and picoxystrobin, no 
effects on the liver were reported in the DARs. Fatty changes in the liver (CAG level 2b) were 
only seen after trifloxystrobin, while azoxystrobin, kresoxim-methyl, pyraclostrobin, and 
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trifloxystrobin produced cell degeneration / cell death (CAG level 2c). Only azoxystrobin 
produced inflammation (CAG level 2d) while kresoxim-methyl induced foci of cellular 
alteration (CAG level 2e) and neoplasms (CAG level 2f). Lesions of biliary epithelium (CAG 
level 2g) was seen after azoxystrobin and kresoxim-methyl, None of the compound induced 
porphyria (CAG level 2h), cholestasis (CAG level 2i), inclusions (CAG level 2j), or 
karyocytomegaly (CAG level 2k). Taken together, the information in the DARs does not 
allow the conclusion that the strobilurines as a group have similar toxic effects on the liver. 
17.3.4.31. Thiocarbamates 
All three thiocarbamates (molinate, prosulfocarb, and tri-allate) were identified as having 
effects on the liver. All three substances produced hypertrophy (CAG level 2a) and cell 
degeneration / cell death (CAG level 2c), but only prosulfocarb and tri-allate induced fatty 
changes in the liver (CAG level 2b) and only tri-allate induced foci of cellular alteration 
(CAG level 2e). Prosulfocarb gave cholestasis (CAG level 2i) and tri-allate induced 
karyocytomegaly (CAG level 2k). None of the compounds showed inflammation (CAG level 
2d), neoplasms (CAG level 2f), lesions of biliary epithelium (CAG level 2g), porphyria (CAG 
level 2h), and inclusions (CAG level 2j). Taken together, the information in the DARs does 
not allow the conclusion that the thiocarbamates as a group have similar toxic effects on the 
liver. 
17.3.4.32. Triazoles 
All 11 triazoles (amitrole, difenoconazole, epoxiconazole, flusilazole, metconazole, 
penconazole, propiconazole, tebuconazole, tetraconazole, triadimenol, and triticonazole) had 
effects on the liver: They all induced hypertrophy (CAG level 2a) and cell degeneration / cell 
death (CAG level 2c). All except penconazole were reported to produce fatty changes in the 
liver (CAG level 2b) and all except amitrol were reported to produce inflammation (CAG 
level 2d). Epoxiconazole, flusilazole, metconazole, tebuconazole, tetraconazole, and 
triadimenol were reported to produce foci of cellular alteration (CAG level 2e). Neoplasms 
(CAG level 2f) were induced by difenoconazole, epoxiconazole, flusilazole, metconazole, 
propiconazole, tebuconazole, and tetraconazole. Lesions of biliary epithelium (CAG level 2g) 
were seen after epoxiconazole, metconazole, tebuconazole, tetraconazole,and triticonazole, 
cholestasis (CAG level 2i) after difenoconazole and triticonazole. Inclusions (CAG level 2j) 
were reported after flusilazole and tetraconazole while flusilazole, penconazole and 
triticonazole induced karyocytomegaly (CAG level 2k). None of the compounds induced 
porphyria (CAG level 2h). Taken together, all 11 triazoles as a group produced hypertrophy 
(CAG level 2a) and cell degeneration / cell death (CAG level 2c), 10 produced fatty changes 
in the liver (CAG level 2b) and another 10 produce inflammation (CAG level 2d). However, 
the information in the DARs does not allow a firm conclusion that the triazoles as a group 
have similar effects on the liver. 
17.3.4.33. Triazinones 
Both triazinones, metamitron, triazinone (metribuzin), had effects on the liver and induced 
hypertrophy (CAG level 2a), inflammation (CAG level 2d). Metamitron produced cell 
degeneration / cell death (CAG level 2c), foci of cellular alteration (CAG level 2e), lesions of 
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biliary epithelium (CAG level 2g), and karyocytomegaly (CAG level 2k). No other effects in 
the liver were noted. Taken together, the two triazinones produced hypertrophy (CAG level 
2a), but the information in the DARs does not allow the conclusion that the triazinones as a 
group have other similar effects on the liver. 
17.3.4.34. Triketones 
Both triketones, Mesotrione and sulcotrione, had effects on the liver and induced hypertrophy 
(CAG level 2a). Mesotrione produced fatty changes in the liver (CAG level 2b) and 
inflammation (CAG level 2d) while sulcotrione induced cell degeneration / cell death (CAG 
level 2c), No other effects in the liver were noted. Taken together, the two triketones produced 
hypertrophy (CAG level 2a), but the information in the DARs does not allow the conclusion 
that the triketones as a group have other similar effects on the liver. 
17.3.4.35. Ureas 
Two of three ureas were identified as having an effect on the liver. Isoproturon and linuron 
induced hypertrophy (CAG level 2a), cell degeneration / cell death (CAG level 2c), 
inflammation (CAG level 2d), foci of cellular alteration (CAG level 2e), neoplasms (CAG 
level 2f). For the remaining compound being an urea, chlorotoluron, no effects on the liver 
were reported in the DARs. Only isoproturom produced fatty changes in the liver (CAG level 
2b) and lesions of biliary epithelium (CAG level 2g) whereas linuron induced 
karyocytomegaly (CAG level 2k). Taken together, the information in the DARs does not 
allow the conclusion that the ureas as a group have similar toxic effects on the liver. 
17.3.4.36. Conclusion: Chemical classes as basis for CAGs for the liver 
Based on the analysis whether active substances belonging to the same chemical class may 
have similar effects on the liver it is concluded that active substances belonging to the same 
chemical class in general do not have similar effects on the liver.  
17.4. Recommended CAGs for the liver 
The following CAGs are recommended for CRA for effects on the liver: 
• CAG level 2a: Hypertrophy, see Table 17.2. 
• CAG level 2b: Fatty changes, see Table 17.3. 
• CAG level 2c: Cell degeneration / cell death, see Table 17.4. 
• CAG level 2d: Inflammation, see Table 17.5. 
• CAG level 2e: Foci of cellular alteration, see Table 17.6. 
• CAG level 2f: Neoplasms, see Table 17.7. 
• CAG level 2g: Lesions of biliary epithelium: see Table 17.8. 
• CAG level 2h: Porphyria, see Table 17.9. 
• CAG level 2i: Cholestasis, see Table 17.10. 
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• CAG level 2j: Inclusions, see Table 17.11. 
• CAG level 2k: Karyocytomegaly, see Table 17.12. 
• CAG level 3a: Phase I enzyme induction, see Table 17.13. 
• CAG level 4a1: CYP1A increased, see Table 17.17. 
• CAG level 4a2: CYP2A increased, see Table 17.18. 
• CAG level 4a3: CYP2B increased, see Table 17.19. 
• CAG level 4a4: CYP2E increased, see Table 17.20. 
• CAG level 4a5: CYP3A increased, see Table 17.21. 
• CAG level 4a6: CYP4A increased, see Table X.22. 
• CAG level 3b: Oxidative stress, see Table 17.14. 
• CAG level 3c: Cytotoxicity, see Table 17.15. 
• CAG level 4c: Porphyria and cytotoxicity, see Table 17.23. 
• CAG level 3d: Hormonal changes, see Table 17.16. 
 
 
18. Lung 
18.1. Introduction 
The principal function of the lungs is to transport oxygen from the atmosphere into the 
bloodstream, and to release carbon dioxide from the bloodstream into the atmosphere.  
The trachea in humans divides into the two main bronchi that enter the roots of the lungs. The 
bronchi continue to divide within the lung, and after multiple divisions, give rise to 
bronchioles. The bronchial tree continues branching until it reaches the level of terminal 
bronchioles, which lead to alveolar sacs. Alveolar sacs are made up of clusters of alveoli. The 
individual alveoli are tightly wrapped in blood vessels and it is here that the gas exchange 
occurs. 
There are three major cell types in the walls of the alveoli: 
• Type I epithelial cells that form the structure of the alveoli walls.  
• Type II epithelial cells that are responsible for the production and secretion of 
surfactants. The surfactants consists of a group of phospholipids that reduce the 
alveolar surface tension thus increasing the capability to exchange gases. Type II cells 
also repair the endothelium of the alveolus when it becomes damaged. 
• Macrophages that destroy foreign material, such as bacteria.  
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18.2. Establishment of CAGs for toxicity to the lungs 
Many active substances were identified to affect the skin. The predominant effects include: 
• Increased (relative) weight 
• Alveolar histiocytosis / alveolar foam cells 
• Inflammation 
• Neoplasms 
• Vacuoles 
 
Some of these effects are non-specific. Other effects are considered as being non-adverse. For 
the majority of the substances, the overall study NOAELs and LOAELs are lower than for the 
specific ‘lung NOAEL’ and ‘lung LOAEL’. Moreover, effects on the lungs were generally 
observed only in one study for a particular active substance – often a long-term study and 
therefore, the findings were often considered in the DARs to be age-related – not treatment-
related. Thus, the lungs seem not to be primary target organs for the active substances 
included in this project. 
Moreover, it is plausible that the effects reported are caused by local irritant properties of the 
active substances due to that the active substances in the diet (dust) may come in direct 
contact with the epithelium in the respiratory tract rather than caused following systemic 
uptake of the substance.  
Overall, CRA for the abovementioned effects on the lungs are not considered relevant. 
Therefore, the lungs are not considered further for CAGs in this project. 
18.3. Recommended CAGs for the lungs  
No CAGs for toxicity to the lungs are recommended. 
 
 
19. Lymph node 
19.1. Introduction 
The main functions of the lymph nodes are to filter pathogens from the afferent lymph and 
then to initialise immune reactions. A lymph node is enclosed by a capsule and is comprised 
of various compartments or microenvironments; the outer cortex with primary and secondary 
follicles (B-lymphocyte areas), the inner cortex or paracortex (T lymphocyte area) and the 
medulla, with medullary cords and medullary sinuses (contains both T and B lymphocytes). 
Lymphocytes and antigens pass into the lymph node via the afferent lymphatics. The lymph 
(fluid and lymphocytes) drains through the node and passes out of the medulla through the 
efferent lymphatic vessel. In addition, lymphocytes can enter the organ by the lymph node 
blood supply. In lymph nodes, antigen presenting cells (APCs) and reactive lymphocytes are 
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in close contact in the same microenvironment. Upon antigenic stimulation, proliferating cells 
in the lymph node (clonal expansion) form lymphoid follicles containing foci (germinal 
centres) of antibody producing B cells, T cells and dendritic cells. The nature of antigenic 
stimulus and duration of immune response direct the types and composition of T cell subsets 
in stimulated lymphoid tissues. 
After birth, exposure to many new exogenous antigens promotes lymph nodes to develop 
quickly. Due to the continuously exposure to antigens via the digestive tract, sinal 
histiocytosis (considerable numbers of macrophages in the sinuses) and accumulations of 
pigmented macrophages are often present in the mesenteric lymph nodes. 
19.2. Establishment of CAGs for toxicity to the lymph nodes 
Many active substances were identified to affect the lymph nodes. The predominant effects 
reported include: 
• Increased (relative) weight 
• Hypertrophy / hyperplasia 
• Decreased (relative) weight 
• Atrophy 
• Inflammation 
• Haemorrhage 
• Congestion 
 
Most of the studies describing effects on lymph nodes are test guideline toxicity studies where 
haematological parameters such as white blood cells (WBC) and/or lymphoid cells are 
recorded together with macroscopical and/or microscopical changes. The predominant lymph 
node related phenomenological effects reported in the DARs are increased/decreased weight 
and hypertrophy/atrophy. For some of the active substances, such effects were regarded as a 
critical effect and together with critical effects reported for other organs formed the basis of 
study NOAELs. But for the majority of the substances, the overall study NOAELs and 
LOAELs are lower than for the specific ‘lymph node NOAEL’ and ‘lymph node LOAEL’. 
Moreover, effects on the lymph nodes were generally observed only in one study for a 
particular active substance – often a long-term study and therefore, the findings were often 
considered in the DARs to be age-related – not treatment-related. Thus, the lymph nodes seem 
not to be primary target organs for the active substances included in this project.  
Overall, CRA for effects on the lymph nodes are not considered relevant. Therefore, the 
lymph nodes are not considered further for CAGs in this project. 
19.3. Recommended CAGs for the lymph nodes 
No CAGs for toxicity to the lymph nodes are recommended. 
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20. Muscles 
20.1. Introduction 
The function of muscles is to produce force and cause motion.  Muscles can cause either 
locomotion of the organism itself or movement of organs.  
Each muscle fibre is a single muscle cell. The muscle fibres contain bundles of myofibrils 
which are the functional units of muscle contraction. Myofibrils are composed of two 
contractile proteins, actin and myosin.  
In skeletal muscles, contraction is stimulated by electrical impulses transmitted by the efferent 
nerves in the peripheral nerve system. All skeletal muscle contractions are facilitated by the 
neurotransmitter acetylcholine. 
20.2. Establishment of CAGs for toxicity to the muscles 
20.2.1. CAG level 1: Toxicity to the muscles 
The active substances identified as having an effect on the muscles in the toxicological studies 
included in the DARs are allocated to CAG level 1 and are listed in Table 20.1. 
Table 20.1. CAG level 1: Toxicity to the muscles 
Benfluralin Mancozeb Spinosad 
Chloridazon (aka pyrazone) Maneb Thiacloprid 
Dimethachlor Metiram Thiram 
Fosthiazate Molinate Trifloxystrobin 
Imazaquin Pirimicarb Ziram 
Isoxaflutole Propineb  
 
 
20.2.2. CAG level 2: Phenomenological / specific effects on the muscles 
Only one type of effect on muscles was identified as the basis for establishing CAGs at level 
2. More information is given in Appendix Z. 
20.2.2.1. CAG level 2a: Weakness 
The active substances included in the CAG level 2a for muscle weakness produced 
histopathological effects described as muscle atrophy, muscle dystrophy, muscle fibre 
degeneration, and myopathy. Muscle atrophy is a decrease in the mass of the muscle; muscle 
dystrophy is progressive skeletal muscle weakness, defects in muscle proteins, and the death 
of muscle cells and tissue; myopathy is a functional defect of muscle fibres. 
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The active substances identified as inducing muscle weakness are allocated to CAG level 2a 
and are listed in Table 20.2. 
For some of the substances muscle fibres were replaced by connective tissue (spinosad and 
probineb) or adipose tissue (metiram and ziram). For other substances the muscles were 
infiltrated with macrophages (spinosad, benfluralin, and thiacloprid). 
 
Table 20.2. CAG level 2a: Muscle weakness 
Benfluralin Mancozeb Spinosad 
Chloridazon (aka pyrazone) Maneb Thiacloprid 
Dimethachlor Metiram Thiram 
Fosthiazate Molinate Trifloxystrobin 
Imazaquin Pirimicarb Ziram 
Isoxaflutole Propineb  
 
 
20.2.3. CAG level 3: Mode of action  
Two different modes of action (nerve degeneration, and formation of a common intermediate 
metabolite: CS2) were identified for some of the active substances allocated to CAG level 2. 
20.2.3.1. CAG level 3a1: Nerve degeneration 
The muscles are enervated by efferent nerves such as the sciatic nerve. When the nerves 
enervating the muscles are degenerated, the muscles will atrophy and weaken.  
The active substances for which muscle weakness is related to nerve degeneration are 
allocated to CAG level 3a1 and are listed in Table 20.3. 
Both for benfluralin and thiacloprid, the DAR suggests that the sciatic nerve degeneration was 
attributed to the extremely high toxicity rather than to a specific neuropathy. As thiacloprid is 
a nicotinergic acetylcholine receptor agonist, the DAR is also suggesting that this may be the 
cause of the exacerbated normal age-related processes in the nerve and muscle tissues. Like 
thiacloprid, isoxaflutole is a nicotinergic acetylcholine receptor agonist. 
 
Table 20.3. CAG level 3a1: Muscle weakness related to nerve degeneration 
Benfluralin Molinate Thiram 
Isoxaflutole Thiacloprid Ziram 
Mancozeb   
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20.2.3.2. CAG level 3a2: Formation of carbon disulphide 
Inhalation studies with propineb suggest that its muscle toxicity appear to be associated with 
the intermediary breakdown product carbon disulphide (CS2).  
The active substances (dithiocarbamates) having carbon disulphide as a common intermediate 
metabolite are allocated to CAG level 3b and are listed in Table 20.4 
 
Table 20.4. CAG level 3a2: Muscle weakness related to formation of carbon disulphide 
Mancozeb Metiram Thiram 
Maneb Propineb Ziram 
 
 
20.2.4. CAG level 4: Mechanism of action  
No mechanism of actions were identified to form the basis for CAG level 4 for toxicity to the 
muscles. 
20.3. Discussion of CAGs for the muscles 
Seventeen active substances were identified to have effects on the muscles and were allocated 
to CAG level 1. One distinct CAG at level 2 have been proposed. Information on mode of 
action is available for a number of the active substances. No information on the mechanism(s) 
of action is available for any of them. The information is summarised in Appendix AA. 
Two different modes of action (CAG level 3a1: Nerve degeneration, and CAG level 3a2: 
Formation of carbondisulphide) were identified for some of the active substances allocated to 
CAG level 2. 
For seven of the seventeen active substances allocated to CAG level 2a, the available 
information on mode of action (CAG level 3a1) indicates that the effects are indirect effects in 
the muscles, i.e., are secondary to effects on the nervous system. The CAG level 3a1 as well 
as the CAG level 2a for these substances are therefore, not considered relevant in terms of 
CRA for a direct effect on the muscles. 
For six of the seventeen active substances allocated to CAG level 2a, the available 
information on mode of action (CAG level 3a2) indicates that the effects in the muscles are 
associated with the intermediary breakdown product carbon disulphide (CS2). This is 
considered as being a direct effect of these substances on the muscles and therefore, relevant 
for CRA. 
As no information regarding the mode / mechanism(s) of action for the remaining active 
substance allocated to CAG level 2a has been found, the CAG level 2a could be considered 
for CRA for effects on the muscles for these substances.  
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20.4. Recommended CAGs for the muscles  
The following CAGs are recommended for CRA for effects on the muscles: 
• CAG level 3a2: Formation of carbon disulphide, see Table 20.4. 
• CAG level 2a: Weakness, see Table 20.2 (only if no information on the mode / 
mechanism of action is available). 
 
 
21. Nervous system 
21.1. Introduction 
The nervous system is responsible for the body’s ability to interact with the environment and 
for the regulation and coordination of activities involving internal organs. It is a network 
composed of complex structures that transmit electric and chemical signals between the brain 
and the body’s many organs and tissues. 
Structurally, the nervous system is divided into the central nervous system and the peripheral 
nervous system.  
The central nervous system (CNS) consists of the brain and the spinal cord, enclosed within 
the protective cranial vault and the vertebral column, respectively. 
The three major divisions of the brain are: 
• The forebrain (telencephalon), formed by the two cerebral hemispheres 
• The midbrain (mesencephalon) 
• The hindbrain (metencephalon), which includes the cerebellum, pons, and medulla 
oblongata.  
 
The midbrain, medulla oblongata, and pons make up the brain stem, which connects the 
hemispheres of the brain, cerebellum, and spinal cord.  
The peripheral nervous system (PNS) is composed of the cranial nerves, which project from 
the brain and pass through foramina (openings) in the skull, and the spinal nerves, which 
project from the spinal cord and pass through intervertebral foramina of the vertebrae. 
Peripheral nerve pathways are differentiated into afferent pathways that carry sensory 
impulses toward the CNS (sensory division), and efferent pathways that innervate effector 
organs (organs innervated by specific components of the nervous system), such as skeletal, 
cardiac, and smooth muscles, as well as glands, by transmitting motor impulses away from the 
CNS (motor division).  
Clinically, the nervous system can be divided into the somatic nervous system and the 
autonomic nervous system. The somatic nervous system consists of motor and sensory 
pathways regulating voluntary motor control of skeletal muscles. The autonomic nervous 
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system also consists of motor and sensory components and is involved in regulation of the 
body’s internal environment (viscera) through involuntary control of organ systems.  
The autonomic nervous system is further divided into sympathetic and parasympathetic 
systems. Many organs are innervated by both the sympathetic and parasympathetic systems 
and the two systems frequently cause opposite responses. 
The two basic types of cells that make up the nervous tissue are neurons and supporting cells, 
such as neuroglial cells of the CNS and Schwann cells of the PNS. 
Neurons are the primary cells of the nervous system and generate and conduct electrical and 
chemical impulses. Impulses are transmitted across a synapse (the region between adjacent 
neurons) by chemical conduction. The conducting substance is called a neurotransmitter. 
More than 30 substances are thought to be neurotransmitters, including norepinephrine, 
acetylcholine, dopamine, histamine, and serotonin. Several neurotransmitters are amino acids, 
including gamma-aminobutyric acid (GABA), glutamic acid, and aspartic acid. Many of these 
transmitters have more than one function.  
Neurotoxicity is any adverse effect on the structure or function of the nervous system related 
to exposure to a chemical substance. Neurotoxicity may be indicated by morphological 
(structural) changes in the central or peripheral nervous system or in special sense organs, 
neurophysiological changes (e.g., electroencephalographic changes), behavioural (functional) 
changes, and/or neurochemical changes (e.g., neurotransmitter levels). Symptoms of 
neurotoxicity may appear immediately after exposure or be delayed.  
They may include limb weakness or numbness, loss of memory, vision, and/or intellect, 
uncontrollable obsessive and/or compulsive behaviors, delusions, headache, cognitive and 
behavioral problems. 
This section deals with neurotoxicity to both the peripheral and central parts of the nervous 
systems. 
21.2. Establishment of CAGs for toxicity to the nervous system 
21.2.1. CAG level 1: Toxicity to the nervous system 
The active substances identified as having an effect on the nervous system in the toxicological 
studies included in the DARs are allocated to CAG level 1 and are listed in Table 21.1.  
 
Table 21.1. CAG level 1: Toxicity to nervous system 
2,4-D Ethoprophos Oxamyl 
Abamectin (aka avermectin) Fenamiphos (aka phenamiphos) Oxasulfuron 
Acetamiprid Fenpropidin Phenmedipham 
Alpha-Cypermethrin (aka alphamethrin) Fenpropimorph Phosmet 
Benfluralin Fipronil Pirimicarb 
Benzoic acid Florasulam Pirimiphos-methyl 
Beta-Cyfluthrin  Flufenacet (formerly fluthiamide), 
and metabolite 
Propamocarb 
Chlormequat (chloride) Formetanate Propineb 
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Chlorpropham Fosetyl Prosulfocarb 
Chlorpyrifos Fosthiazate Pyrethrins 
Chlorpyrifos-methyl Glufosinate Quinoclamine 
Clothianidin Imidacloprid Spinosad 
Cyfluthrin Indoxacarb  Sulcotrione 
Cymoxanil Isoxaflutole Thiacloprid 
Cypermethrin Lufenuron Thiram 
Deltamethrin Mancozeb Tolclofos-methyl 
Desmedipham Maneb Triadimenol 
Dicamba Mepiquat Tri-allate 
Dimethoate Methiocarb (aka 
mercaptodimethur) 
Triflusulfuron 
Dimoxystrobin Methomyl Ziram 
Dinocap, and metabolites Metiram lambda-Cyhalothrin 
Esfenvalerate Molinate  zeta-Cypermethrin 
Ethephon   
 
 
21.2.2. CAG level 2: Phenomenological / specific effects on the nervous system 
Various types of effects on the nervous system were identified as a basis for establishing 
CAGs at level 2. These effects concern functional changes related to the motor division, 
effects on reflex action, effects on cognition, hypertrophy / hyperplasia in the brain, cell 
degeneration / cell death in the brain, and neoplasms in the brain. Based on these effects, three 
distinct CAGs at level 2 are proposed. More information is given in Appendix AB. 
21.2.2.1. CAG level 2a: Functional changes related to the motor division 
A number of different functional changes in the motor division of the nervous system have 
been reported in the toxicological studies with active substances. These changes involve 
effects on the movement of muscles, effects on locomotion, and neuropathy. 
Effects related to the movement of muscles include: 
• Effects on motor activity - effects on the activity of a muscle, nerve, or centre that 
affects or produces movement 
• Ataxia - lack of control of muscular coordination / irregularity of muscular action due 
to defects in the nervous system 
• Choreoathetosis - a condition marked by choreic and athetoid movements, i.e. 
involuntary movements 
• Abnormal gait - abnormal walking 
• Paralysis - condition where the muscles in a part of the body become weak and cannot 
be moved because the motor nerves have been damaged 
• Neuromuscular dysfunction - abnormal functioning of nerves and muscles 
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The above-mentioned effects related to the movement of muscles could to some extent be 
considered as a single group of effects and/or some of the effects could be considered as a 
subgroup of others. For the purpose of the CAG project, these effects are allocated to a single 
CAG level 2, termed ‘CAG level 2a: Functional changes related to the motor division’. 
Locomotion is movement or the ability to move from one place to another. Locomotor activity 
is pertaining to or affecting the locomotive apparatus of the body. Decreased locomotion 
could be due to decreased ability to move e.g. because of disturbances in the above mentioned 
functional changes related to the motor division. But it is also noted that decreased locomotor 
activity could also be due to effects such as pain, exhaustion, or decreased activity in centres 
regulating locomotion. However for the purpose of the CAG project, effects on locomotion 
are allocated to ‘CAG level 2a: Functional changes related to the motor division’. 
Neuropathy is a general term denoting functional disturbances and/or pathological changes in 
the peripheral nervous system. Organophosphate-induced delayed neuropathy (OPIDN) is a 
neuropathy caused by destruction of neurons in the central nervous system, especially in the 
spinal cord, as a result of acute or chronic organophosphate poisoning. The exact OECD TG 
418/419 definition is: “Delayed neurotoxicity is a syndrome associated with prolonged 
delayed onset of ataxia, distal axonopathies in spinal cord and peripheral nerve, and inhibition 
and aging of neuropathy target esterase in neural tissue”. For the purpose of the CAG project, 
neuropathy and OPIDN are allocated to the CAG level 2a: ‘Functional changes related to the 
motor division’.  
The active substances identified as inducing one or more of the abovementioned effects and 
allocated to CAG level 2a are listed in Table 21.2. 
 
Table 21.2. CAG level 2a: Functional changes related to the motor division 
2,4-D Fenpropidin Molinate  
Abamectin (aka avermectin) Fenpropimorph Oxamyl 
Acetamiprid Fipronil Oxasulfuron 
Alpha-Cypermethrin (aka alphamethrin) Florasulam Phosmet 
Benfluralin Flufenacet (formerly fluthiamide), 
and metabolite 
Pirimicarb 
Beta-Cyfluthrin  Formetanate Propineb 
Chlormequat (chloride) Fosetyl Prosulfocarb 
Chlorpropham Fosthiazate Pyrethrins 
Chlorpyrifos Glufosinate Spinosad 
Chlorpyrifos-methyl Imidacloprid Sulcotrione 
Clothianidin Indoxacarb  Thiacloprid 
Cyfluthrin Isoxaflutole Thiram 
Cypermethrin Lufenuron Triadimenol 
Deltamethrin Mancozeb Tri-allate 
Dicamba Maneb Ziram 
Dinocap, and metabolites Mepiquat lambda-Cyhalothrin 
Esfenvalerate Methomyl zeta-Cypermethrin 
Ethephon Metiram  
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21.2.2.2. CAG level 2b: Effects on reflex action 
A reflex is defined as an involuntary, almost instantaneous, movement in response to a 
stimulus. Reflexes are dependent on the sensory (afferent) division of the nervous system to 
detect and conduct impulses in response to a stimulus, and subsequently the motor (efferent) 
division to conduct impulses to muscles, so that movement occurs. Substances having effects 
on reflex action could potentially have effects on the sensory and/or motor division of the 
nervous system. Thus substances in this CAG could very well overlap with the previous CAG 
“Functional changes related to the motor division”. However for the purpose of the CAG 
project, a distinct CAG on reflex action was established as substances with effects on reflex 
action could be acting on the sensory division of the nervous system. In the present CAG 
substances having effects on the righting reflex and/or on the acoustic startle reflex and/or the 
patellar reflex were included. The righting reflex is the ability to assume an optimal position 
when there has been a departure from it. Acoustic startle response latency is the response to a 
sudden unexpected stimulus such as a loud noise. The patellar reflex helps maintain balance 
and posture 
The active substances identified as inducing effects on reflex action, and allocated to CAG 
level 2b are listed in Table 21.3. 
 
Table 21.3. CAG level 2b: Effects on reflex action 
2,4-D Fenpropimorph Molinate 
Abamectin (aka avermectin) Fipronil Phosmet 
Clothianidin Florasulam Thiram 
Cyfluthrin Flufenacet Triadimenol 
Deltamethrin Mepiquat zeta-Cypermethrin 
Esfenvalerate   
 
 
21.2.2.3. CAG level 2c: Effects on cognition 
Cognitive function is an intellectual process by which one becomes aware of, perceives, or 
comprehends ideas. It involves all aspects of perception, thinking, reasoning, and 
remembering. It should be noted that only few investigations on learning and memory 
performance have been performed with the active substances included in this project. Thus, 
this group is potentially larger than described here 
The active substances identified as inducing effects on cognition and allocated to CAG level 
2c are listed in Table 21.4. 
 
Table 21.4. CAG level 2c: Effects on cognition 
Beta-Cyfluthrin Clothianidin Maneb 
Chlorpropham Fipronil Molinate 
Chlorpyrifos   
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21.2.2.4. Effects not considered relevant for CAGs at level 2 
The presence of vacuoles in the brain is considered as being a non-adverse effect and 
therefore, not relevant for CAGs at level 2 and consequently, not relevant in terms of CRA for 
effects on the nervous system. 
Many active substances were reported to increase or decrease the relative weight of the brain. 
In general, the changes were small in comparison to the control group, did not reach 
statistically significance, were not dose-related, increased weights were related to an increased 
incidence of masses (noted in the macroscopic examination) and/or neoplasms (noted in the 
microscopic examination), observed in only one or a few studies, and/or findings were not 
consistent across studies, sex and/or species. Therefore, the changes in relative brain weight 
were often considered in the DARs not to be treatment-related. Moreover, the description in 
the various DARs are very different regarding details and exactness. In conclusion, increased 
and decreased relative brain weight for the active substances included in Annex I of Council 
Directive 91/414/EEC (up to 31st of May 2009) are considered as not being applicable for a 
CAG at level 2 and consequently, not relevant in terms of CRA for effects on the nervous 
system. 
Several active substances were evaluated for induction of neoplasms (predominantly 
astrocytoma) in the brain of experimental animals. In general, the incidences of tumours at the 
highest dose levels tested did not reach statistically significance and was within the historical 
control range. Therefore, no CAG level 2 was suggested for brain neoplasms. 
21.2.3. CAG level 3: Mode of action  
For a number of the active substances having phenomenological / specific effects on the 
nervous system as described under CAG level 2, a mode of action has been proposed. For the 
remaining substances, no information regarding mode of action has been found and 
consequently, these substances cannot be allocated to a CAG level 3. 
21.2.3.1. CAG level 3a1: Modulation of the cholinergic system 
Several of the active substances reported to affect the nervous system in experimental studies 
have shown that they are able to modulate the cholinergic transmission of nerve impulses. 
This mode of action is associated with the effects seen at CAG level 2a. 
Acetylcholine is a neurotransmitter released from nerve endings, which allows nerve impulses 
to move from one nerve to another or from a nerve to the organ it controls. It is a 
neurotransmitter in both the peripheral nervous system (PNS) and the central nervous system 
(CNS) in many organisms including humans. Acetylcholine is one of many neurotransmitters 
in the autonomic nervous system (ANS) and the only neurotransmitter used in the motor 
division of the somatic nervous system (sensory neurons use glutamate and various peptides at 
their synapses).  
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In the peripheral nervous system acetylcholine acts as a transmitter between motor nerves and 
the fibres of skeletal muscles at all neuromuscular junctions. On release, acetylcholine acts 
almost instantly, to cause a sequence of chemical and physical events which cause contraction 
of the muscle fibre. The action of acetylcholine is terminated rapidly following its inactivation 
by the enzyme acetylcholineesterase (AChE).  
These same principles apply to cholinergic transmission at sites other than neuromuscular 
junctions, although the structure of the synapses differs. In the autonomic nervous system 
these include nerve-to-nerve synapses at the ganglia in both the sympathetic and the 
parasympathetic division, and the endings of parasympathetic nerve fibres on non-voluntary 
organs and tissues such as (smooth) muscle, the heart, and glandular cells. In response to 
activation of this nerve supply, smooth muscle contracts (notably in the gut), the frequency of 
heart beat is slowed, and glands secrete. Acetylcholine is also an important transmitter at 
many sites in the brain at nerve-to-nerve synapses. 
For numerous active substances, including carbamates and organophosphates, the pesticidal 
mode of action for killing insects is an inhibition of this enzyme. Because there is a structural 
similarity between insect and mammalian AChE, the insect AchE inhibiting active substances 
can also affect mammalian AChE.  
There are two main types of cholinergic receptors, nicotinic and muscarinic acetylcholine 
receptors. Nicotinic acetylcholine receptors (nAChR) are located at synapses between two 
neurons and at synapses between neurons and skeletal muscle cells. Muscarinic acetylcholine 
receptors (mAChr) are located at the synapses of nerves with smooth or cardiac muscles. Each 
type is also located in the brain. 
The active substances identified as affecting the cholinergic transmission by either inhibiting 
the acetylcholinesterase activity or being direct ligands of the nicotinic or muscarinic 
acetylcholine receptors are allocated to CAG level 3a1 ‘Modulation of the cholinergic 
transmission’ and are listed in Table 21.5. 
Table 21.5. CAG level 3a1: Modulation of the cholinergic transmission 
Acetamiprid  Fenpropidin  Phosmet 
Chlormequat  Fenpropimorph Pirimicarb 
Chlorpropham Formetanate Pirimiphos-methyl 
Chlorpyrifos  Fosthiazate Propamocarb  
Chlorpyrifos-methyl Imidacloprid  Propineb 
Deltamethrin Indoxacarb Prosulfocarb 
Desmedipham Mepiquat Spinosad 
Dimethoate  Methiocarb (aka 
mercaptodimethur) 
Thiacloprid  
Dimoxystrobin Methomyl Thiram 
Ethephon (both inhibition of acetyl and 
buturyl-choline esterase) 
Molinate Tolclofos-methyl 
Ethoprophos Oxamyl Ziram 
Fenamiphos (aka phenamiphos) Phenmedipham  
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21.2.3.2. CAG level 3a2: Modulation of the GABA system 
Gamma-aminobuturic acid (GABA) is the main inhibitory neurotransmitter in the CNS. It is 
formed from glutamate. GABA contributes to motor control, vision, and many other cortical 
functions. It also regulates anxiety. In accordance with this all substances in this group are 
also members of CAG level 2a (active substances that have effects on functional changes in 
the nervous system). 
The active substance identified as affecting the GABA system is allocated to CAG level 3a2 
‘Modulation of the GABA system’ and are listed in Table 21.6. 
Table 21.6. CAG level 3a2: Modulation of the GABA system 
Abamectin   
 
 
21.2.3.3. CAG level 3a3: Modulation of the dopaminergic system 
Dopamine is an inhibitory neurotransmitter involved in controlling movement and posture. It 
also modulates mood and plays a central role in positive reinforcement and dependency. In 
accordance with this all substances in this group are also members of CAG level 2a (active 
substances that have effects on functional changes in the nervous system). 
The active substances identified as affecting the dopaminergic system are allocated to CAG 
level 3a3 ‘Modulation of the dopaminergic system’ and are listed in Table 21.7. 
 
Table 21.7. CAG level 3a3: Modulation of the dopaminergic system  
2,4-D Triadimenol Ziram 
Glufosinate   
 
 
21.2.3.4. CAG level 3c1: Modulation of the glutamate system 
Glutamate is a major excitatory neurotransmitter in the CNS that is associated with learning 
and memory. It is also thought to be associated with Alzheimer’s disease, whose first 
symptoms include memory malfunctions. In accordance with this substances in this group 
should also be members of CAG level 2c (active substances that have effects on cognition). 
However, as already mentioned under CAG level 2c only few investigations on learning and 
memory performance have been performed with the active substances included in this project. 
Thus, the number of substances included in CAG level 3c1 is larger than described in CAG 
level 2c. 
The active substances identified as affecting the glutamate system are allocated to CAG level 
3c1 ‘Modulation of the glutamate system’ and are listed in Table 21.8. 
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Table 21.8. CAG level 3c1: Modulation of the glutamate system  
Glufosinate Maneb Ziram 
Mancozeb Thiram  
 
 
21.2.3.5. CAG level 3d1: Modulation of mitochondrial function  
Several active substances (also implicated in dysregulation of the dopaminergic system) affect 
the function of mitochondria in vitro, mainly in an inhibitory fashion (Thrash et al. 2007).  
The active substances identified as affecting the mitochondrial function are allocated to CAG 
level 3d1 and are listed in Table 21.9. It should be noted that the CAG level 3d1 is not 
allocated to a specific CAG level 2. 
 
Table 21.9. CAG level 3d1: Modulation of michondrial function  
2,4-D Cypermethrin Maneb 
Chlorpropham Mancozeb Pyrethrins 
Chlorpyrifos   
 
 
21.2.3.6. CAG level 3e1: Demyelination 
Demyelination is the loss of the myelin sheath insulating the nerves and results in disruption 
of signals between the brain and other parts of the body. 
The active substances identified as inducing demyelination are allocated to CAG level 3e1 
and are listed in Table 21.10. It should be noted that the CAG level 3e1 is not allocated to a 
specific CAG level 2. 
 
Table 21.10. CAG level 3e1: Demyelination  
2,4-D Fenpropidin Maneb 
Cymoxanil Isoxaflutole Molinate 
Cypermethrin Mancozeb  
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21.2.3.7. CAG level 3f1: Neuronal degeneration 
A neuron is defined as a signal conducting cell of the nervous system. Typically a neuron 
consists of a cell body with short radiating processes called dendrites and most neurons also 
possess a long projection called the axon. The axon with its sheath constitutes the nerve fiber. 
Neuron degeneration is the progressive loss of function or structure of this cell type.  
The active substances identified as inducing neuronal degeneration are allocated to CAG level 
3f1 and are listed in Table 21.11. It should be noted that the CAG level 3f1 is not allocated to 
a specific CAG level 2. 
 
Table 21.11. CAG level 3f1: Neuronal degeneration  
Alpha-Cypermethrin (aka 
alphamethrin) 
Isoxaflutole Thiacloprid 
Chlorpyrifos Maneb Thiram 
Cypermethrin Molinate Tri-allate 
Dinocap Oxasulfuron Triflusulfuron 
Flufenacet Quinoclamine Ziram 
 
 
21.2.4. CAG level 4: Mechanism of action 
For some of the phenomenological / specific effects on the nervous system described under 
CAG level 2 and the mode of actions indicated at CAG level 3, respectively, a mechanism of 
action has been proposed. For the remaining substances, no information regarding mechanism 
of action has been found and consequently, these substances cannot be allocated to a CAG 
level 4. 
21.2.4.1. CAG level 4a1a: Acetylcholinesterase inhibition  
A number of the active substances identified as affecting the cholinergic system (CAG level 
3a1) were identified as being acetylcholinesterase inhibitors. These substances are allocated to 
CAG level 4a1a ‘Acetylcholinesterase inhibition’ and are listed in Table 21.12. 
 
Table 21.12. CAG level 4a1a: Acetylcholinesterase inhibition  
Chlorpropham Fenpropidin Pirimicarb 
Chlorpyrifos Fenpropimorph Pirimiphos-methyl 
Chlorpyrifos-methyl Formetanate Propamocarb 
Desmedipham Fosthiazate Prosulfocarb 
Dimethoate Methiocarb (aka mercaptodimethur) Thiram 
Dimoxystrobin Methomyl Tolclofos-methyl 
Ethephon Molinate  Ziram 
Ethoprophos Oxamyl  
Fenamiphos (aka phenamiphos) Phosmet  
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21.2.4.2. CAG level 4a1b: Nicotinic acetylcholine receptor agonist  
Some of the active substances identified as inhibiting AChE and being direct ligands of the 
nicotinic acetylcholine receptor (nAChR) (CAG level 3a1) were identified as being nicotinic 
acetylcholine receptor agonists. These substances are allocated to CAG level 4a1b ‘Nicotinic 
acetylcholine receptor agonist’ and are listed in Table 21.13. 
 
Table 21.13. CAG level 4a1b: Nicotinic acetylcholine receptor agonist  
Acetamiprid  Imidacloprid Propineb 
Chlormequat Indoxacarb Thiacloprid 
 
 
21.2.4.3. CAG level 4a1c: Muscarinic acetylcholine receptor agonist  
Two of the active substances identified as inhibiting AChE and being direct ligands of the 
muscarinic acetylcholine receptor (mAChR) (CAG level 3a1) were identified as being 
muscarinic acetylcholine receptor agonists. These substances are allocated to CAG level 4a1c 
‘Muscarinic acetylcholine receptor agonist’ and are listed in Table 21.14. 
 
Table 21.14. CAG level 4a1c: Muscarinic acetylcholine receptor agonist  
Chlormequat Mepiquat  
 
 
21.2.4.4. CAG level 4a2a: GABA gated chloride channel blocker 
The GABAA receptor is an ionotropic receptor and ligand-gated ion channel. Its endogenous 
ligand is γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central 
nervous system. Upon activation, the GABAA receptor selectively conducts chloride ions (Cl-) 
through its pore, resulting in hyperpolarisation of the neuron. This causes an inhibitory effect 
on neurotransmission. Ligands which decrease receptor activation usually have opposite 
effects, including anxiogenesis and convulsion. 
Three of the active substances identified as affecting the GABA system (CAG level 3a2) were 
identified as being GABA gated chloride channel blockers. These substance are allocated to 
CAG level 4a2a ‘GABA receptor agonist’ and are listed in Table 21.15. 
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Table 21.15. CAG level 4a2a: GABA gated chloride channel blocker 
Abamectin Deltamethrin Fipronil 
 
 
It should be noted that abamectin has been reported to act both as a GABA receptor agonist 
and a GABA gated chloride channel blocker. These two mechanisma potentially act against 
each other with the former acting GABA like and the latter opposing the effect of GABA. 
21.2.4.5. CAG level 4c1a: Glutamate NMDA receptor modulation 
Glutamate acts via two classes of receptors, ligand gated ion channels (ionotropic receptors) 
and G-protein coupled (metabotropic) receptors. The ionotropic glutamate receptors are 
subdivided into three groups (AMPA, NMDA and Kainate receptors). 
N-Methyl-D-aspartate (NMDA) is the specific agonist at the NMDA receptor mimicking the 
action of glutamate, the neurotransmitter which normally acts at that receptor. Two of the 
active substances identified as affecting the glutamate system (CAG level 3c1) were identified 
as being NMDA receptor modulators. These substances are allocated to CAG level 4c1a and 
are listed in Table 21.16. 
 
Table 21.16. CAG level 4c1a: Glutamate NMDA receptor modulation  
Glufosinate Triadimenol  
 
 
21.2.4.6. CAG level 4c1b: Glutamate vesicular transport interference 
Some of the active substances identified as affecting the glutamate system (CAG level 3d) 
were identified asfound to interfering with the vesicular transport of glutamate. These 
substances are allocated to CAG level 4dc2 and are listed in Table 21.17. 
Table 21.17. CAG level 4c1b: Glutamate vesicular transport interference  
Mancozeb Thiram Ziram 
Maneb   
 
 
21.2.4.7. CAG level 4g1a: Voltage-gated sodium channel blocker 
Voltage-gated ion channels are a class of transmembrane ion channels that are activated by 
changes in electrical potential difference near the channel and mediate a rapid and co-
ordinated depolarisation.  
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Voltage-gated ion channels are especially critical in neurons, but are common in many types 
of cells. They have a crucial role in excitable neuronal and muscle tissues, allowing a rapid 
and co-ordinated depolarisation in response to triggering voltage change. Found along the 
axon and at the synapse, voltage-gated ion channels directionally propagate electrical signals.  
Voltage-gated ion channels are composed of several subunits arranged in such a way that there 
is a central pore through which ions can travel down their electrochemical gradients. The 
channels tend to be ion-specific, although similarly sized and charged ions may sometimes 
travel through them. 
Examples include the sodium and potassium voltage-gated channels of nerve and muscle, and 
the voltage-gated calcium channels that play a role in neurotransmitter release in pre-synaptic 
nerve endings. 
Some of the active substances affecting the nervous system belonging to the pyrethroids were 
identified as blocking the voltage-gated sodium channel (Shafer et al. 2004). These substances 
are allocated to CAG level 4g1a and are listed in Table 21.18. It should be noted that the CAG 
level 4g1a is not allocated to a specific CAG level 2. 
 
Table 21.18. CAG level 4g1a: Voltage-gated sodium channel blocker 
Alpha-cypermethrin (aka alphamethrin) Cypermethrin Indoxacarb 
Beta-cyfluthrin Deltamethrin Lambda-Cyhalothrin 
Cyfluthrin Esfenvalerate  
 
 
21.2.4.8. CAG level 4h1a: Voltage-gated delayed rectifier of potassium channels 
One of the active substances affecting the nervous system was identified as a voltage-gated 
delayed rectifier of potassium channels. This substance is allocated to CAG level 4h1a and is 
listed in Table 21.19. It should be noted that the CAG level 4h1a is not allocated to a specific 
CAG level 2.  
 
Table 21.19. CAG level 4h1a: Voltage-gated delayed rectifier of potassium channels 
Alpha-cypermethrin (aka alphamethrin)   
 
 
21.2.4.9. CAG level 4i1a: Voltage-gated calcium channel interference 
Some of the active substances affecting the nervous system belonging to the pyrethroids were 
identified as interfering with voltage-gated calcium channels. These substance are allocated to 
CAG level 4i1a and are listed in Table 21.20. It should be noted that the CAG level 4i1a is not 
allocated to a specific CAG level 2. 
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Table 21.20. CAG level 4i1a: Voltage-gated calcium channel interference 
Alpha-cypermethrin (aka alphamethrin) Cyfluthrin Deltamethrin 
Beta-cyfluthrin Cypermethrin  
 
 
21.3. Discussion of CAGs for the nervous system 
Sixty-seven active substances were identified to affect the nervous system and were allocated 
to CAG level 1. Three distinct CAGs at level 2 have been proposed. Information on 
modes/mechanisns of action is available for a number of the active substances. The 
information is summarised in Appendix AC. 
The phenomenological / specific effects on the nervous system that are proposed at CAG level 
2 may to some extent be interrelated and the individual modes of action identified at CAG 
level 3 may play roles in several (or sometimes all) of these effects. Although, the 
mechanisms of action identified at CAG level 4 constitute optimal criteria for creating CAGs, 
with the exception of CAG level 4a1a: Acetylcholineesterase inhibition, only a limited 
number of active substances have been studied for the other specific mechanisms. Therefore 
the CAGs at level 3 and 2 are also recommended for consideration in CRA. 
21.3.1. Chemical classes as basis for CAGs for the nervous system 
Active substances belonging to the same chemical class may have similar toxicological 
effects. Information in the DARs on effects on the nervous system  is summarised below for 
evaluation of similarity of toxicological effects within the relevant chemical classes, i.e. the 
chemical classes containing more than one active substance. 
21.3.1.1. Aryloxyalkanoic acids 
One aryloxyalkanoic acid was identified as having a specific chronic effect on the nervous 
system: 2,4-D (decreased response to sharp noise and swollen axons in brain and spinal cord). 
After injection into basal ganglia of rats 2,4-D produced decreased locomotor activity, 
postural effects, increased serotonin (5-HT) and homovanillic acid (HVA) levels and 
diminished levels of striatal 5-HT and dopamine). The remaining aryloxyalkanoic acids (2,4-
DB, dichlorprop-P, MCPA, MCPB, mecoprop, and mecoprop-P) all show similar acute 
clinical signs as 2,4-D, however, no specific effects on the nervous system were seen for 
dichlorprop-P and MCPA in the neurotoxicity studies reported in the DARs. For 2,4-DB, 
MCPB, mecoprop and mecoprop-P no specific studies on neurotoxicity were available. 
Therefore, the information in the DARs does not allow the conclusion that aryloxyalkanoic 
acids have similar toxic effects on the nervous system. 
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21.3.1.2. Benzoic acids (aromatic carboxylic acids) 
Dicamba classified as a benzoic acid was identified as having an effect on the nervous system 
(abnormal locomotion and gait, ataxia, sporadic muscle spasms, uncoordinated movements). 
Benzoic acid itself, being classified as an aromatic carboxylic acid, show similar effects on the 
nervous system (aggressiveness, hypersensitivity, tremor, convulsions, uncoordinated 
movement and depression).  
21.3.1.3. Benzylureas 
One benzylurea was identified as having a specific effect on the nervous system: Lufenuron 
(episodes of spontaneous clonic-tonic convulsion or fasciculations and facilitated 
pentylenetetrazol-induced generalised convulsions was the only effect reported in a 
neurotoxicity study). For the remaining benzylureas (diflubenzuron, teflubenzuron), this effect 
has not been investigated. For both compounds the DARs state that special testing for 
neurotoxicity is not deemed necessary. Therefore, the information in the DARs does not allow 
the conclusion that the benzylureas have similar toxic effects on the nervous system. 
21.3.1.4. Biscarbamates 
Two active substance are biscarbamates. Phenmedipham was identified to increase choline 
esterase activity in rat brain, red blood cells and plasma. For the other biscarbamate, 
desmedipham, which is structurally closely related to phenmedipham, conflicting results were 
reported. In one study, rat brain, red blood cell and plasma choline esterase activities were 
reported to be reduced whereas in another (similar) rat study reduced brain activity and 
increased plasma activities were noted. It has to be noted that these biscarbamates are used as 
herbicides and although they upon metabolism have the potential to yield the structurally 
closely related (mono)-carbamates, they seem to increase cholinesterase activity in rats. This 
is in contrast to the (mono)-carbamates that are mainly insecticides that act by inhibiting the 
activity of cholinesterase. 
21.3.1.5. Carbamates 
Six carbamates (carbamate esters or urethanes) were identified as having effects in the 
nervous system in mammals: Chlorpropham (decreased choline esterase activity, affected 
surface righting, axonal degeneration, abnormal gait), methiocarb (choline esterase activity 
inhibition), methomyl (decreased grip strength, functional observational battery parameters, 
acetylcholine esterase inhibition), oxamyl (decreased forelimb and hind limb grip strength, 
tremor, acetylcholine esterase inhibition), pirimicarb (acetylcholine esterase inhibition), 
propamocarb (vacuolization of the choroid plexus, acetylcholine esterase inhibition). The 
remaining active substances being carbamates (benthiavalicarb, iprovalicarb) included in the 
CAG project had no effects on the nervous system in mammals. These two carbamates are 
used as fungicides in contrast to the six carbamate esters identified as having effects in the 
nervous system which are mainly used as insecticides and all displayed effects as 
acetylcholine esterase inhibitors. In addition, the carbamate moities of benthiavalicarb and 
iprovalicarb are very similar, but distinctly different from the carbamate moieties of the six 
neurotoxic carbamates. These findings suggests that being a carbamate ester does not 
automatically make a substance an acetylcholine esterase inhibitor.  
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21.3.1.6. Dithiocarbamates 
Five dithiocarbamates were identified as having effects in the nervous system: Mancozeb 
(ataxia, abnormal gait or mobility, tremors and hindlimb paralysis, myelin damage, Schwann 
cells proliferation), maneb (abnormal gait and hind limb paralysis, axonal shrinkage, 
neurofibrillary degeneration, myelin sheath thickening, demyelination, myelin phagocytosis, 
myelin bubbles and Schwann cell proliferation), metiram (reduced grip strength, hind limb 
weakness, ataxia, increased incidence of meningo-encephalocele, hydrocephaly, obstructed 
neural tube), propineb (propreoceptive deficits and hind-limb wheelbarrowing), thiram (ataxia 
or paralysis of the hind legs, chromatolysis of motor neurones, hyperactivity, abnormal gait, 
demyelination, degeneration of the axis cylinders, and presence of macrophages in the nerve 
bundle of the sciatic nerve). Mancozeb, maneb and thiram (together with the 
dimethyldithiocarbamate, ziram) all interfere with vesicular transport of glutamate. Maneb 
and mancozeb both have effects on demyelination and neuronal degeneration. In addition 
mancozeb and maneb have effects on mitochondrial function and concomitantly on the 
dopaminergic system. Therefore, the information in the DARs allows the conclusion that the 
dithiocarbamates have similar toxic effects (neuropathy) on the nervous system. 
21.3.1.7. Dimethyldithiocarbamates 
The dimethyldithiocarbamate ziram (could also be classified as a dithiocarbamate) was 
identified as having an effect on the nervous system (ataxia, muscle tremors and convulsions, 
posture abnormalities, decreased grip strength). It is noted that ziram interfere with vesicular 
transport of glutamate and that this effect is analogous to the effect of the dithiocarbamates 
Mancozeb, maneb and thiram. In addition ziram in parallel to maneb and mancozeb have 
effects on the dopaminergic system. Thus, this indicates that the six dithiocarbamates could be 
considered together when reviewing similar nervous system effects (neuropathy) in relation to 
chemical groups.  
21.3.1.8. Morpholines 
One morpholine was identified as having an effect on the nervous system: Fenpropimorph. 
(reduced serum choline esterase, postural effects, decreased grip strength). For the remaining 
morpholines (dimethomorph, dodemorph, spiroxamine), no effects on the nervous system 
were reported in the DAR. Therefore, the information in the DARs does not allow the 
conclusion that morpholines have similar toxic effects on the nervous system. 
21.3.1.9. Neonicotinoids 
Four neonicotinoids were identified as having effects in the nervous system: Acetamiprid 
(decreased food consumption, nicotinic receptor agonist), clothianidin (increased startle 
reflex, convulsions, and stiff movements, increased motor activity), imidacloprid (functional 
observational battery effects, nicotinic receptor agonist), thiacloprid  (nerve degeneration, 
nicotinic receptor agonist). For the remaining neonicotinoid (thiamethoxam) no effects on the 
nervous system was reported in the DAR. In conclusion, the information in the DARs indicate 
that neonicotinoids to some extent have similar toxic effects on the nervous system 
(functional observational battery effects, nicotinic receptor agonists). 
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21.3.1.10. Organophosphates 
Nine organophosphates were identified as having effects in the nervous system: Chlorpyrifos, 
chlorpyrifos-methyl, dimethoate, ethoprophos, fenamiphos (aka phenamiphos), fosthiazate, 
glufosinate, phosmet, pirimiphos-methyl. For the remaining active substance classified as an 
organophosphate (fosetyl) no effects on the nervous system was reported in the DAR. 
However, fosetyl is the aluminium salt of ethyl hydrogen phosphonate and is therefore an 
organometallic compound and not a “true” organophosphate. Eight of the nine 
organophosphates identified as having effects in the nervous system displayed effects as 
acetylcholine esterase inhibitors. The remaining organophosphate (glufosinate) interacts with 
the glutamate system. In contrast to the eight organophosphates with acetylcholine esterase 
inhibiting properties that are used as insecticides/nematicides/acaricides, glufosinate is used as 
a herbicide. Therefore, the information in the DARs allows the conclusion that the 
organophosphates that are used as insecticides/nematicides/acaricides have similar toxic 
effects (neuropathy) on the nervous system. 
Regarding choline esterase inhibition there has been some debate as to whether to include 
carbamates and organophosphates in a common assessment group (UK Science Group 2004). 
The United States Environmental Protection Agency (US EPA) has decided to group the 
carbamates (N-methyl carbamates) and the organophosphates into separate common 
mechanism groups. This was done on the basis of differences in kinetics of the carbamylation 
and the phosphorylation of the acethylcholine esterase protein. In contrast to this, the UK 
Science Group found the use of separate groups highly questionable. The argument for having 
a common assessment group including both carbamates and organophosphates was that there 
is a potential for concurrent exposure to substances from both groups from various sources in 
the diet.  
In agreement with the reasoning by the UK Science Group it has propsed to group the 
carbamates, organophosphates, morpholines, strobilurines, thiocarbamates and fenpropidin 
causing acetylcholinesterase inhibition into a common assessment group: CAG level 4a1a 
‘Acetylcholineesterase inhibition’. 
21.3.1.11. Phenylpyrazoles 
One phenylpyrazole was identified as having an effect on the nervous system: Fipronil. 
(postural abnormalities, abnormal reflex action, aggressivity or irritability, convulsions, 
increased motor activity). For the remaining phenylpyrazole (pyraflufen-ethyl), no effects on 
the nervous system were reported in the DAR. Therefore, the information in the DARs does 
not allow the conclusion that the phenylpyrazoles have similar toxic effects on the nervous 
system. 
21.3.1.12. Pyrethroids and pyrethrin 
For eight of the nine active substances classified as pyrethroids effects on the nervous system 
were reported in the DARs: Alpha-cypermethrin (ataxia/abnormal gait, over-activity or 
hunched posture, increased sensitivity to noise), beta-cyfluthrin (temor, uncoordinated gait, 
axonal degeneration, motor disturbances), cyfluthrin (tremor, altered gait,  brain 
haemorrhages, increased salivation, tremor,uncoordinated gait), cypermethrin (impaired gait, 
ataxia, paralysis, hypersensitivity to external stimuli, gross disorientation and convulsions, 
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axonal damage), deltamethrin (  impaired mobility and gait, stereotypic behaviour, altered air 
righting reflex, altered hindlimb extensor strength, reduced grip strength, increased motor 
activity, choreoathetosis and effects on muscarinic and nicotinic brain receptors), 
esfenvalerate (hyperactivity, abnormal limb movements, tremors, seizures, ataxia, decreased 
grip strength, decreased ease of removal from the home cage, decreased motor activity, bizarre 
reactions to tail pinch and to startle response) lambda-cyhalothrin (ataxia, muscle tremors and 
convulsions, decreased grip strength), zeta-cypermethrin (reduction in locomotor activity, 
ataxia, tremors, convulsions and hypersensitivity to touch). The remaining pyrethroid 
(etofenprox) had no effects on the nervous system  according to the DAR. However, 
etophenprox lacks the (vinyl)cyclopropanecarboxylate moity characteristic for the majority of 
the active pyrethroids. Therefore, the information in the DARs allows the conclusion that the 
pyrethroids that are cyclopropanecarboxylate esters have similar toxic effects on the nervous 
system.  
The effects described in the DARs, such as motor disturbances, decreased grip strength, 
voltage gated sodium channel blockade and voltage sensitive calcium channel interference are  
in accordance with reports from the open literature. Thus, Wolansky and Harill (2008) in a 
review reported that all pyrethroids investigated (20 substances), regardless of structure, 
produced a decrease in motor activity in a variety of test protocols and six substances showed 
a decrease in grip strength.  
It is noted that pyrethrins are classified as a biopesticide. However, as the pyrethroids are 
structural derivatives of the naturally occurring pyrethrins, the latter could be considered 
together with the pyrethroids. According to the DAR pyrethrins produces tremor and postural 
disturbances. Thus they have toxic effects similar to the pyrethroids on the nervous system. It 
is noted that the primary neurotoxic site of action for pyrethroids is the voltage dependent 
sodium channels in excitable membranes. In conclusion, the information in the DARs allows 
the conclusion that the pyrethroids and pyrethrins have similar toxic effects on the nervous 
system. 
21.3.1.13. Quarternary ammonium compounds 
Two quarternary ammonium compounds were identified as having effects on the nervous 
system: Chlormequat (salivation, transient inhibitory action on the neuromuscular junction) 
and mepiquat (tremors, impaired gait, ataxia, posture abnormalities, decreased motor activity, 
sedation, salivation). There are no other quarternary ammonium compounds in the CAG 
project. Although salivation occurs with both substances, the limited amount of data and 
number of quarternary ammonium compounds in the CAG project makes it difficult to make a 
firm conclusion on similar toxic effects of quarternary ammonium compounds.  
21.3.1.14. Sulfonylureas 
Two sulfonylureas were identified as having effects on the nervous system: Oxasulfuron,      
(axonal degeneration, findings in functional observational battery parameters) and 
triflusulfuron. (nerve degeneration). For the remaining sulfonylureas (amidosulfuron, 
azimsulfuron, bensulfuron, chlorsulfuron, ethoxysulfuron, flazasulfuron, flupyrsulfuron-
methyl, imazosulfuron, iodosulfuron-methyl-sodium, metsulfuron-methyl, nicosulfuron, 
prosulfuron, rimsulfuron, sulfosulfuron, thifensulfuron-methyl, triflusulfuron, tribenuron, 
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tritosulfuron) no effects on the nervous system were reported in the DAR. Therefore, the 
information in the DARs does not allow the conclusion that the sulfonylureas have similar 
toxic effects on the nervous system.  
21.3.1.15. Strobilurines 
One strobilurine was identified as having an effect on the nervous system: Dimoxystrobin 
(decreased choline esterase activity, nerve degeneration). For the remaining strobilurines 
(azoxystrobin, fluoxastrobin, kresoxim-methyl, pyraclostrobin, trifloxystrobin), no effects on 
the nervous system were reported in the DAR. Therefore, the information in the DARs does 
not allow the conclusion that the sulfonylureas have similar toxic effects on the nervous 
system. 
21.3.1.16. Thiocarbamates 
All three thiocarbamates included were identified as having an effect on the nervous system: 
molinate (demyelination, nerve lesions, impaired gait, ataxia, abnormal reflex function), 
prosulfocarb (lower choline esterase activity, decreased activity, hunched posture), and tri-
allate (impaired gait, reduced grip strength). There are no other thiocarbamates in the CAG 
project. Therefore, the information in the DARs indicate that the thiocarbamates have similar 
toxic effects on the nervous system. However, only prosulfocarb has an effect on acetyl 
choline esterase inhibition which would suggest a common toxic mechanism in the nervous 
system parallel to that seen for carbamates but the lack of this effect for molinate and tri-
allate, does not substantiate a firm conclusion on a similar mode/mechanism if action of 
thiocarbamates on the nervous system. 
21.3.1.17. Triazoles 
One triazole was identified as having an effect on the nervous system: Triadimenol 
(dopamine-reuptake, increased motor activity, hyperactivity, decreased grip strength and foot 
splay). For the remaining triazoles (amitrole, difenoconazole, epoxiconazole, flusilazole, 
metconazole, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole), no 
effects on the nervous system were reported in the DAR. Therefore, the information in the 
DARs does not allow the conclusion that the triazoles have similar toxic effects on the 
nervous system. 
21.3.1.18. Triketones 
One triketone was identified as having an effect on the nervous system: Sulcotrione (ataxia, 
abnormal gait and posture, reduced activity). For the remaining triketone (mesotrione), no 
effects on the nervous system were reported in the DAR. Therefore, the information in the 
DARs does not allow the conclusion that the triketones have similar toxic effects on the 
nervous system. 
21.3.1.19. Chemical class not specified/unclassified 
Two of seven unclassified substances were reported to have effect on the nervous system: 
Fenpropidin (decreased acetylcholine esterase activity, demyelination, hind limb paralysis), 
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quinoclamine (nerve degeneration). As these substances are unclassified no conclusion can be 
drawn on their similarity to other chemical classes  in the CAG project. 
21.3.1.20. Conclusion: Chemical classes as basis for CAGs for the nervous system 
Based on the analysis whether active substances belonging to the same chemical class may 
have similar effects on the nervous system it is concluded that active substances belonging to 
the same chemical class in general do not have similar effects on the nervous system.  
However, the active substances in the following chemical classes have similar toxic effects on 
the nervous system: Dithiocarbamates, organophosphates, and pyrethroids and pyrethrins. 
Therefore, CAG for each of these three chemical classes could be proposed.  
21.4. Recommended CAGs for the nervous system 
The following CAGs are recommended for CRA for effects on the nervous system: 
• CAG level 4a1a: Acetylcholinesterase inhibition, see Table 21.12. 
• CAG level 4a1b: Nicotinic receptor agonist, see Table 21.14. 
• CAG level 4a1c: Muscarinic receptor agonist, see Table 21.19. 
• CAG level 4a2a: GABA gated chloride channel blocker, see Table 21.15. 
• CAG level 4c1a: Glutamate NMDA receptor modulation, see Table 21.16. 
• CAG level 4c1b: Glutamate vesicular transport interference, see Table 21.17. 
• CAG level 4g1a: Voltage gated sodium channel blocker, see Table 21.18. 
• CAG level 4i1a: Voltage gated calcium channel interference, see Table 21.20. 
• CAG level 3a1: Modulation of the cholinergic system, see Table 21.5. 
• CAG level 3a3: Modulation of the dopaminergic system, see Table 21.7. 
• CAG level 3c1: Modulation of the glutamate system, see Table 21.8. 
• CAG level 3d1: Mitochondrial function, see Table 21.9. 
• CAG level 3e1: Demyelination, see Table 21.10. 
• CAG level 3f1: Neuronal degeneration, see Table 21.11. 
• CAG level 2a: Functional changes related to the motor division, see Table 21.2. 
• CAG level 2f: Effects of reflex action, see Table 21.3. 
• CAG level 2c: Effects on cognition, see Table 21.4. 
 
The following CAG is not recommended for CRA for the time being. However, this CAG 
may become relevant in the future provided that new information on other active substances 
justifies the mode of action / phenomenological effects forming the basis for this CAG: 
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• CAG level 4h1a: Voltage gated delayed rectifier of potassium channels, see Table 
21.19. 
• CAG level 3a2: Modulation of the GABA system, see Table 21.12. 
 
 
22. Pancreas 
22.1. Introduction 
The pancreas serves as an endocrine gland that produces hormones and as an exocrine gland 
that produces digestive enzymes. The pancreas is located behind the stomach between the 
spleen and the duodenum. 
 
 
From http://www.gopetsamerica.com/anatomy/pancreas.aspx 
Figure 22.1. Anatomy of the pancreas 
 
 
As can be seen in Figure 22.1 the exocrine pancreas is composed of acinar cells that secrete 
digestive enzymes and a network of ducts that secrete alkaline fluids. The digestive enzymes 
pass to the small intestine where they help to break down carbohydrates, proteins, and fats in 
the chyme. The major proteases are trypsinogen and chymotrypsinogen. Secreted to a lesser 
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degree are pancreatic lipase and pancreatic amylase. Trypsinogen is an inactivated form of 
trypsin, and chymotrypsinogen is an inactivated form of chymotrypsin. The pancreas 
synthesizes and stores these inactive enzymes in zymogen granules to avoid autodegradation. 
Once released in the intestine, an intestinal enzyme activates the inactive proteases. The 
exocrine pancreas also secretes alkaline fluids in order to neutralize the acidic chyme that the 
stomach releases into the duodenum. 
Control of the exocrine function of the pancreas is both via hormones and the nervous system. 
Cholecystokinin is the primary hormone signaling for secretion of digestive enzymes and 
secretin is the primary hormone signaling for secretion of alkaline fluids. The parasympathetic 
nerveous system generally stimulates pancreatic secretion whereas the sympathetic nerveous 
system inhibits it. 
Regions of endocrine cells are found within the exocrine pancreas. These regions are termed 
the islets of Langerhans named after the pathologists that discovered them. The islets of 
Langerhans constitute only a few percent of the mass of the pancreas. Hormones produced in 
the islets of Langerhans are secreted directly into the blood flow by at least five different types 
of cells. The hormones of which insulin is the most well know help to regulate the 
carbohydrate, fat and protein metabolism within the body. The secretion of insulin is regulated 
by chemical, hormonal and neural control.  One of the effects of insulin is to facilitate uptake 
of glucose into the cells. 
22.2. Establishment of CAGs for toxicity to the pancreas 
Several active substances were identified to affect the pancreas. The effects reported include: 
• Increased (relative) weight 
• Hypertrophy / hyperplasia 
• Atrophy / cell degeneration / necrosis 
• Inflammation 
 
The predominant effects reported in the DARs are increased weight and hypertrophy. 
Generally, the overall study NOAELs and LOAELs are lower than for the specific ‘pancreatic 
NOAEL’ and ‘pancreatic LOAEL’. Moreover, effects on the pancreas were generally 
observed only in one study for a particular active substance – often a long-term study and 
therefore, the findings were often considered in the DARs to be age-related – not treatment-
related. Thus, the pancreas seems not to be a primary target organ for the active substances 
included in this project.  
Overall, CRA for effects on the pancreas are not considered relevant. Therefore, the pancreas 
is not considered further for CAGs in this project. 
22.3. Recommended CAGs for the pancreas 
No CAGs for toxicity to the pancreas is recommended. 
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23. Parathyroid glands 
23.1. Introduction 
The parathyroid glands are small endocrine glands that produce parathyroid hormone. Humans 
usually have four parathyroid glands, which are usually located on the rear surface of the 
thyroid gland – see Figure 23.1. 
 
 
From: http://en.wikipedia.org/wiki/Parathyroid_gland 
Figure 23.1. The thyroid and parathyroid glands 
 
 
Parathyroid hormone takes part in controlling the amount of calcium in the blood and within 
the bones. As can be seen from Figure 9.1 (in chapter 9) the metabolism of calcium and 
phosphate is regulated by a complex interplay mainly between parathyroid hormone, vitamin 
D and calcitonine. Acting together, these substances determine the amount of dietary calcium 
and phosphate absorbed from the intestine, the reabsorption and excretion of calcium and 
phosphate by the kidney, and the deposition and release of calcium and phosphate from the 
bone. Both parathyroid hormone and active vitamin D stimulate osteoclasts to resorb bone 
(and release calcium and phosphate from bone) whereas calcitonin suppresses calcium release 
from bone by suppression of osteoclasts. 
The production of parathyroid hormone, active vitamin D and calcitonin is mainly regulated 
by the serum level of calcium but also by other minerals and other substances. 
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23.2. Establishment of CAGs for toxicity to the parathyroid glands 
23.2.1. CAG level 1: Toxicity to parathyroid glands 
The active substances identified as having an effect on the parathyroid glands in the 
toxicological studies included in the DARs are allocated to CAG level 1 and are listed in 
Table 23.1. 
 
Table 23.1. CAG level 1: Toxicity to the parathyroid glands 
Cinidon ethyl Mepanipyrim Sulfosulfuron 
Desmedipham Metconazole Thiophanate-methyl 
Dimethenamid-P Picloram  
Flazasulfuron Quinoclamine  
 
 
23.2.2. CAG level 2: Phenomenological / specific effects on the parathyroid glands 
Two types of effects on the parathyroid glands were identified as a basis for establishing 
CAGs at level 2. Based on these effects, two distinct CAGs at level 2 are proposed. More 
information is given in Appendix AD. 
23.2.2.1. CAG level 2a: Hypertrophy / hyperplasia 
Hypertrophy is an increased size of cells and hyperplasia is an increased number of cells. 
Hypertrophy and hyperplasia frequently occur together and for the purpose of the CAG project 
these terms are allocated to a single CAG level 2, termed ‘CAG level 2a: Hypertrophy / 
hyperplasia’. 
The active substances identified as inducing hyperplasia (hypertrophy was not reported) are 
allocated to CAG level 2a ‘Hypertrophy / hyperplasia’ and are listed in Table 23.2. 
 
Table 23.3. CAG level 2a: Hypertrophy / hyperplasia in the parathyroid glands 
Cinidon ethyl Mepanipyrim Sulfosulfuron 
Desmedipham Metconazole Thiophanate-methyl 
Dimethenamid-P Picloram  
Flazasulfuron Quinoclamine  
 
 
23.2.2.2. CAG level 2b: Neoplasms 
One active substance was identified as inducing tumours in the parathyroid glands. This 
substance is allocated to CAG level 2b and is listed in Table 23.3. 
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Table 23.3. CAG level 2b: Neoplasms in the parathyroid glands 
Cinidon ethyl   
 
 
23.2.3. CAG level 3: Mode of action  
23.2.3.1. CAG level 3: Chronic nephropathy 
In early chronic renal failure, excreted phosphate levels decrease and the plasma phosphate 
concentration increases. Plasma phosphate binds calcium resulting in hypocalcaemia. As a 
consequence, the parathyroids start to secrete parathyroid hormone to try to get the calcium 
and phosphate levels back to normal. The increased activity of the parathyroid gland may lead 
to hyperplasia and tumours. 
For eight of the active substances identified as inducing hyperplasia in the parathyroid gland 
and allocated to CAG level 2a, as well as for the active substance inducing tumours in the 
parathyroid glands and allocated to CAG level 2b, the mode of action is considered to be 
secondary to chronic nephropathy and is thus an indirect effect. These substances are allocated 
to CAG level 3 and is listed in Table 23.4. 
 
Table 23.4. CAG level 3: Hyperplasia / neoplasms secondary to chronic nephropathy 
Cinidon ethyl Metconazole Sulfosulfuron 
Flazasulfuron Picloram Thiophanate-methyl 
Mepanipyrim Quinoclamine  
 
 
For the two remaining substances, desmedipham and dimethenamid-P, no mode of action was 
identified to form the basis for a CAG level 3 for toxicity to the parathyroid gland. 
23.2.4. CAG level 4: Mechanism of action 
No information on mechanism(s) of action have been found for any of the active substances 
identified as having an effect on the parathyroid glands. 
23.3. Discussion of CAGs for the parathyroid glands 
Ten active substances were identified to have effects on the parathyroid glands and were 
allocated to CAG level 1. Two distinct CAGs at level 2 have been proposed. Information on 
mode of action is available for most of the active substances. No information on the 
mechanism(s) of action is available for any of them. The information is summarised in 
Appendix AE. 
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For eight of the ten active substances allocated to CAG level 2a, as well as for the active 
substance allocated to CAG level 2b, the available information on mode of action indicates 
that the hyperplasia / neoplasms is an indirect effect in the parathyroid glands, i.e., are 
secondary to chronic nephropathy (CAG level 3). The CAG level 3 as well as the CAG level 
2a for these substances are therefore, not considered relevant in terms of CRA for a direct 
effect on the parathyroid glands. 
As no information regarding the mode / mechanism(s) of action for the remaining two active 
substance allocated to CAG level 2a has been found, the CAG level 2a could be considered 
for CRA for effects on the parathyroid glands for these two substances.   
23.4. Recommended CAGs for the parathyroid glands 
The following CAG at level 2 is recommended for CRA for effects on the parathyroid glands 
(only for desmedipham and dimethenamid-P for the time being): 
• CAG level 2a: Hypertrophy / hyperplasia, see Table 23.2. 
 
 
24. Pituitary gland 
24.1. Introduction 
The pituitary gland (or hypophysis) is an endocrine gland located at the base of the brain and 
is attached to the hypothalamus (a part of the brain that affects the pituitary gland) by nerve 
fibers. While the pituitary gland sometimes is called the ‘master’ gland of the endocrine 
system, because it controls the functions of the other endocrine glands, the pituitary gland is 
under the control of the hypothalamus. The pituitary gland consists of three parts: 
• The anterior lobe 
• The intermediate lobe 
• The posterior lobe 
 
The pituitary gland secretes nine endocrine hormones that regulate homeostasis. 
The anterior lobe (or adenohypophysis) secretes the following hormones: 
• Growth hormone (or somatotropin) – to stimulate growth 
• Prolactin – to stimulate milk production after giving birth 
• ACTH (adrenocorticotropic hormone) – to stimulate the adrenal glands 
• TSH (thyroid-stimulating hormone) – to stimulate the thyroid gland 
• FSH (follicle-stimulating hormone) – to stimulate the ovaries and testes 
• LH (luteinizing hormone) – to stimulate the ovaries or testes 
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The intermediate lobe secretes the following hormone: 
• Melanocyte-stimulating hormone – to control skin pigmentation 
 
The posterior lobe (or neurohypophysis) secretes the following hormones: 
• ADH (antidiuretic hormone) – to increase absorption of water into the blood by the 
kidneys 
• Oxytocin – to contract the uterus during childbirth and stimulate milk production 
 
24.2. Establishment of CAGs for toxicity to the pituitary gland 
Many active substances were identified to affect the pituitary gland. The effects reported 
include: 
• Increased (relative) weight 
• Hypertrophy / hyperplasia 
• Decreased (relative) weight 
• Atrophy / cell degeneration 
• Cysts 
• Neoplasms 
 
The predominant effects reported in the DARs are increased weight, hypertrophy, cysts and 
neoplasms. Generally, the overall study NOAELs and LOAELs are lower than for the specific 
‘pituitary gland NOAEL’ and ‘pituitary gland LOAEL’. Moreover, effects on the pituitary 
gland were generally observed only in one study for a particular active substance – often a 
long-term study and therefore, the findings were often considered in the DARs to be age-
related – not treatment-related. Thus, the pituitary gland seems not to be primary target organ 
for the active substances included in this project.  
Overall, CRA for effects on the pituitary gland are not considered relevant. Therefore, the 
pituitary gland is not considered further for CAGs in this project. 
24.3. Recommended CAGs for the pituitary gland 
No CAGs for toxicity to the pituitary gland is recommended. 
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25. Reproductive and developmental toxicity 
25.1. Introduction 
Reproductive toxicity at large includes both male and female fertility effects and 
developmental toxicity effects. In some cases it is not possible to decide whether an observed 
effect is a sign of impaired fertility or developmental toxicity (or both). Therefore, it is 
decided to describe reproductive and developmental effects together in this section. As 
tumours in reproductive organs may be caused by similar modes of action as other effects in 
reproductive organs (endocrine related effects), tumours are also included in this section.  
This section presents first an overview of studies on reproductive and developmental 
endpoints, and then an introduction to methods applied in the determination of CAGs 
followed by a presentation of CAGs at level 2. CAGs at level 3 and level 4 are presented 
subsequently together with an overview of modes and mechanisms of action leading to effects 
on reproduction and development. Finally, a discussion and some concluding remarks on 
CAGs for reproductive and developmental effects are presented. 
Developmental toxicity is investigated in prenatal developmental (teratology) studies and in 
one- or multi-generation studies.  
Reproductive toxicity i.e. effects on reproductive organs and fertility is investigated in one- or 
multi-generation studies. Such studies may also reveal developmental toxicity of a test 
substance. In addition, some of the repeated dose studies also include end points relevant for 
reproductive effects. 
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Modified from Figure 20-1 in Foster et al., 2008  
Figure 25.1. The reproductive cycle. Modified from Foster et al., 2008. 
 
 
Figure 25.1 illustrates how reproductive studies in various periods of life can be applied to 
examine effects on different endpoints. Chemical exposure during mating or early gestation 
may reveal effects on fertilization, implantation and early embryogenesis, whereas chemical 
exposure in late gestation reveals effects on foetal development. Effects of gestational 
exposure may be apparent not only in foetal life, but also in the postnatal period and 
adulthood. Chemical exposure during weaning and/or maturation may also influence adult 
reproductive function. In repeated dose studies chemical exposure can start before or after 
sexual maturation, and may reveal effects on reproductive organs and -function. It is important 
to keep in mind that the reproductive cycle starts at gamete production in the parents, when 
they were foetuses and ends after sexual maturation. 
Various guideline studies are used to test effects on development and reproduction. The 
purpose of prenatal developmental toxicological studies (e.g. OECD 414) is to evaluate 
compounds for their effect on the developing foetus. The rat and rabbit are the preferred 
species for these studies. These tests may be integrated into the multigenerational tests (e.g. 
OECD TG 416) during the evaluation of reproductive toxicity.  Manifestations of toxicity to 
the foetus are categorized as death, structural anomaly, altered or retarded growth, or 
functional deficiencies. At necropsy, reproductive tracts and foetuses are collected for counts 
of live/dead foetus and for gross and histological examination of the foetus and reproductive 
organs (Hamm et al., 2006).  
The general purpose of generation studies is to examine successive generations to identify 
possible increased sensitivity to a chemical, effects on the fertility of male and female 
animals, pre-, peri- and postnatal effects on the mother. There are some limitations in 
generation studies concerning end points such as neonatal death and malformations which 
may not be detected, since the rat may eat dead or serious malformed pups subsequent to 
birth. The effect may therefore only be indirectly indicated by a decrease in litter size (Hass, 
1992). In a prenatal developmental toxicity study the demonstration that intra-uterine death 
after implantation has occurred (resorptions) could be detected. Two-generation reproduction 
studies are aimed to provide general information concerning the effects of a test substance on 
the integrity and performance of the male and female reproductive systems, including gonadal 
function, the oestrus cycle, mating behaviour, conception, gestation, parturition, lactation, and 
weaning, and the growth and development of the offspring (OECD TG 416). The study may 
also provide information about the effects of the test substance on neonatal morbidity, 
mortality, and preliminary data on prenatal and postnatal developmental toxicity and serve as 
a guide for subsequent tests. In addition to studying growth and development of the F1 
generation, studies are intended to assess the integrity and performance of the male and female 
reproductive systems as well as growth and development of the F2 generation. Some of the 
DARs contain old two generation studies (before update in 2001) meaning that e.g. 
assessment of oestrus cycle and semen quality is not included. 
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Repeated dose studies may also contribute with information on toxicological effects on the 
reproductive system, as they are intended to investigate effects on a very broad variety of 
potential targets of toxicity. Short-term (28-day) studies provides information on the possible 
health hazards likely to arise from repeated exposure over a relatively limited period of time, 
including effects on the nervous, immune and endocrine systems (OECD TG 407, Repeated 
Dose 28-Day Oral Toxicity Study in Rodents, updated in 2008). Sub-chronic (90-day) studies 
provide information on the possible health hazards likely to arise from repeated exposure over 
a prolonged period of time covering post-weaning maturation and growth well into adulthood 
(OECD TG 408, updated 1998). Chronic toxicity (1 or 2 years) studies are aimed at providing 
information on chronic toxicological effects and tumour development including tumours in 
the reproductive system. 
25.2. Establishment of CAGs for reproductive and developmental toxicity  
25.2.1. CAG level 1: Reproductive and developmental toxicity 
Reproductive toxicity at large includes both male and female fertility effects and 
developmental toxicity effects. In some cases it is not possible to decide whether an observed 
effect is a sign of impaired fertility or developmental toxicity (or both). One example is 
decreased litter size observed in two-generation studies as this may be due to e.g. decreased 
fertilization (fertility effect) or foetal death (developmental toxicity). Another example is peri-
natal mortality, which may be due to impaired parturition in the dams (fertility effect) or 
effects on the foetus/new born offspring (developmental toxicity). Consequently, it was 
decided to evaluate reproductive toxicity overall and not divide this into separate columns 
with fertility and developmental toxicity. This results in one “level 1” category for 
reproductive toxicity including both effects on fertility and developmental toxicity.  
A total of 196 active substances have shown reproductive and/or developmental toxicity 
and/or induction of tumours in reproductive organs in experimental animals and thus could 
form a CAG level 1. However, as this CAG comprises several different types of specific 
effects with varying modes of action, the usefulness of this CAG is limited to very general 
first-steps in cumulative risk assessment. 
 
Table 25.1. CAG level 1: Reproductive and developmental toxicity and tumours in 
reproductive organs  
1-Methyl-cyclopropene 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. 
sodium salt orthophenyl 
phenol) 
Abamectin (aka avermectin) 
Acetamiprid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Aclonifen 
Amidosulfuron 
Deltamethrin 
Desmedipham 
Dicamba 
Dichlorprop-P 
Difenoconazole 
Diflubenzuron 
Diflufenican 
Dimethachlor 
Dimethenamid-P 
Dimethoate 
Dimethomorph 
Dimoxystrobin 
Glyphosate (incl trimesium 
aka sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imazosulfuron 
Imidacloprid 
Indoxacarb# 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Iprovalicarb 
Isoproturon 
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Pyriproxyfen 
Quinoclamine 
Quinoxyfen 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Rimsulfuron (aka renriduron) 
S-Metolachlor 
Silthiofam 
Sodium 5-nitroguaiacolate 
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Amitrole (aminotriazole) 
Azimsulfuron 
Azoxystrobin 
Beflubutamid 
Benalaxyl 
Benfluralin 
Bensulfuron 
Bentazone 
Benthiavalicarb 
Benzoic acid 
Beta-Cyfluthrin 
Bifenox 
Boscalid 
Bromoxynil 
Calcium phosphide 
Captan 
Carbendazim 
Carfentrazone-ethyl 
Chloridazon (aka pyrazone) 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Chlorpyrifos 
Chlorpyrifos-methyl 
Chlorsulfuron 
Cinidon ethyl 
Clodinafop 
Clofentezine 
Clomazone 
Clopyralid 
Clothianidin 
Copper compounds 
Cyazofamid 
Cyclanilide 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Cyprodinil 
Cyromazine 
Dinocap 
Diuron 
Dodemorph 
Epoxiconazole 
Esfenvalerate 
Ethephon 
Ethofumesate 
Ethoprophos 
Ethoxysulfuron 
Etofenprox 
Etoxazole 
Famoxadone 
Fenamidone 
Fenamiphos (aka 
phenamiphos) 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Fipronil 
Flazasulfuron 
Fluazinam 
Fludioxonil 
Flufenacet (formerly 
fluthiamide) 
Flumioxazin 
Fluopicolide 
Fluoxastrobin 
Flupyrsulfuron-methyl 
(DPX KE 459) 
Fluroxypyr 
Flusilazole 
Folpet 
Forchlorfenuron 
Formetanate 
Fosetyl 
Fosthiazate 
Fuberidazole 
Gibberellin 
Glufosinate 
Isoxaflutole 
Lenacil 
Linuron 
Lufenuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mepanipyrim 
Mepiquat 
Mesotrione 
Metamitron 
Metconazole 
Methiocarb (aka 
mercaptodimethur) 
Metiram 
Metrafenone 
Metribuzin 
Metsulfuron-methyl 
Milbemectin 
Molinate 
Oxadiazon 
Oxamyl 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Pirimicarb 
Pirimiphos-methyl 
Propamocarb 
Propaquizafop 
Propiconazole 
Propineb 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Sodium hypochlorite 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Tribenuron (aka 
metometuron) 
Triclopyr 
Trifloxystrobin 
Triflusulfuron 
Trinexapac (aka cimetacarb 
ethyl) 
Triticonazole 
Tritosulfuron 
Ziram 
Zoxamide 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
25.2.2. CAG level 2: Phenomenological / specific effects for reproductive and developmental 
toxicity  
The above mentioned CAG level 1 active substances were allocated to various CAGs at level 
2 based on their ‘specific effects’. In order to facilitate this sorting of the substances, the 
following terminology for specific effect groups was developed: 
• Body weight + decreased/increased + foetus/pups + age (e.g. birth weight, from PND 
14 etc.). Only effects in offspring were included 
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• Delayed development + type + foetus/pups + male/female if relevant (e.g. delayed 
ossification, foetus GD 21; delayed sexual maturation, pups, female etc.) 
• Malformations + type of malformation + foetus/pups + age (e.g. hydrocephalus, foetus 
GD 21; hypospadias, adult male offspring etc.) 
• Variations + type + foetus/pups (e.g. extra ribs, GD 21 foetus etc.) 
• Death + foetus/pups + type/age (e.g. post implantation loss; pups, during lactation etc.) 
• Offspring, other effects + type (e.g. histopathology; functional effects etc.) 
• Fertility + type + male/female (e.g. fertility index; time to pregnancy; semen quality; 
effect on weight or histopathology of reproductive organs; impaired parturition etc.). 
Only effects in adult animals, e.g. parental generation (F0) or in repeated dose toxicity 
studies, were included 
• Tumour + site + type (e.g. tumour, testes, Leydig cell) 
 
Each of these specific effect groups were further subdivided into CAGs at level 2 as outlined 
in the following. 
For each study, species, strain and mode of administration was noted together with a note on 
either study duration (for repeated dose studies, e.g. 28 days, 90 days, 2 years) or type of study 
(two-generation study, one-generation study, prenatal developmental toxicity study). For non-
guideline studies the dosing period was noted (e.g. GD 13-18, GD 7-PND 16). This 
information can be found in the Access database, but is not included for each category. 
All effects listed are in vivo effects from studies accepted by the DAR and related documents 
(ECCO, EFSA peer review) and mainly statistically significant effects are noted. However, in 
some cases the DAR did not contain sufficient information on statistical analyses, and effects 
considered relevant by the DAR are listed anyway. Also effects that were considered relevant 
by the DAR but were not statistically significant were included.  
For some studies the describtion in DARs did not note NOAELs/LOAELs in mg/kg bw/day 
but as ppm in diet. In those cases NOAELs/LOAELs were converted as described in the above 
general section on collection of information, and the remark “converted from ppm” was 
included in the Remarks column of the Access database. 
For developmental studies it may be relevant to consider whether effects on offspring are seen 
above, below or at maternal effect levels, i.e. whether developmental NOAELs are above, 
below or at maternal NOAELs. The letter “t” is used in the CAG tables in Appendices AP to 
AX as an indication of cases where the relevant developmental NOAEL is at or above the 
maternal NOAEL most often for decreased body weight and/or decreased food consumption.  
The letter “m” is presented in the CAG table in Appendices AP to AX for studies performed 
on metabolites. In some cases, both mother compound and metabolite have the same effect, 
and therefore two lines are presented for one active substance in the CAG table. 
Studies from the open literature are included when these appeared to be of a sufficient quality 
and relevance. Mainly Pubmed was used for literature searches as this is the most 
comprehensive database covering topics relevant for human health. When no or little 
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information was found for a certain substance, further searches were performed in DTU 
digital library, a search machine collecting abstracts from Biosis, Food Science and 
Technology Abstracts, Web of Science, Pubmed, Inspec, Compendex, Academic Search 
Elite/Ebsco, and Business Source Premier/Ebsco. 
The search strategy for studies on reproduction and development in open literature was as 
follows: 
 1. Search compound name 
  a. If few hits (less than 100): check for studies on reproductive and 
developmental toxicity. 
  b. If many hits (more than 100): go to 2 
 2. Search compound name and one of the following words: rats, mice, in vitro, 
endocrine, reproduction, fertility, development 
  a. Check for studies on reproductive and developmental toxicity or 
mechanisms of action relevant to reproduction and development 
 
This approach resulted in a number of “level 2” categories that can be used for selection of 
CAGs. Six major groups were identified, some of them containing more than one major CAG 
at level 2:  
• 2a: Delayed development and decreased (increased) body weight 
• 2b: Malformations and variations 
• 2c: Pre- and postnatal death 
• 2d: Other effects in offspring 
• 2e: Fertility  
• 2f: Tumours in reproductive organs 
 
An observed effect can be included in more than one “level 2” category (e.g. decreased litter 
size can be found in both the “death” and the “fertility” or the “offspring, other effects” 
categories). Using the above terminology, effect categories could be made and grouped in 
“tree structures” representing various levels of detail. For some level 2 effect categories it was 
possible to make level 3 subgroups based on knowledge of chemical mode of action. 
Examples are delayed development and low body weight in offspring caused by thyroid 
disruption, or male reproductive effects caused by anti-androgenicity. For some anti-
androgenic chemicals, organ weight changes and offspring effects the mechanism of action 
could be attributed to androgen receptor antagonism (based on data from open literature), and 
this would be an example of a level 4 subgroup. 
The following figure (Figure 25.2) presents CAG level 2 categories for specific effects within 
reproductive and developmental toxicity. Some of the level 2 categories are grouped, as these 
categories are likely to be interrelated. 
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Figure 25.2. Main CAGs for reproductive and developmental toxicity. 
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These main CAGs are further subdivided. In the following text CAGs are numbered 
systematically with the first letter indicating main the level 2 CAG (e.g. 2a “Delayed 
development and decreased body weight”); the following number indicating main subgroup 
(e.g. 2a1 “Delayed development”); the following letter indicating further subgrouping (e.g. 
2a1a “Delayed prenatal development” and 2a1b “Delayed postnatal development”), and in 
some cases yet another number indicates additional subgrouping (e.g. 2a1b1 “Delayed sexual 
maturation” and 2a1b2 “Delayed eye opening”).  
Each section on main CAGs contains tables describing these subdivisions listing which 
specific effects are included in each CAG. However, the following list shows all level 2 
subgroups for use as an overview and reference for the section on Reproductive and 
developmental toxicity as a whole. CAG names in italics are searchable in the Access 
database (in column “phenomenological/specific effect CAG level 2”) using specifically the 
listed words. 
 
2a. Delayed development and decreased body weight 
1. Delayed development 
a. Delayed prenatal development 
1. Delayed ossification 
2. Delayed tooth eruption 
3. Delayed development (other) 
b. Delayed postnatal development 
1. Delayed sexual maturation 
2. Delayed eye opening 
3. Delayed auditory canal opening 
4. Delayed pinna unfolding 
5. Delayed tooth eruption 
6. Delayed development (other) 
2. Decreased body weight 
a. Prenatal body weight decrease 
b. Postnatal body weight decrease 
c. Decreased body weight of adult offspring 
3. Increased body weight 
a. Prenatal body weight increase 
b. Postnatal body weight increase 
c. Increased body weight of adult offspring 
 
2b. Malformations and variations 
1. Malformations 
a. Skeletal malformations 
b. Cleft palate 
c. Hydrocephalus 
d. Excencephaly 
e. Kidney malformations 
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f. Eye malformations 
g. Heart malformations 
2 Variations 
a. Skeletal variations 
b. Urinary tract variations 
c. Heart variations 
d. Eye variations 
e. Dilated brain vesicles 
3 Runts 
 
2c. Pre- and postnatal death 
1. Prenatal death 
2. Postnatal death 
 
2d. Other effects in offspring 
1. Male offspring 
a. Changes in reproductive organs of male offspring 
1. Decreased weight of male reproductive organs of offspring  
2. Reduced semen quality of offspring 
3. Change in anogenital distance of male offspring 
4. Nipple retention in male offspring 
b. Impaired fertility of male offspring 
2. Female offspring 
a. Changes in reproductive organs of female offspring 
b. Impaired fertility of female offspring 
3. Male and/or female offspring 
a. Impaired fertility of male and/or female offspring 
4. Effects on non-reproductive organs or endpoints in offspring 
a. Changes in other organs of offspring 
b. Changes in non-reproductive endpoints in offspring 
5.  Altered sex ratio 
 
2e. Fertility 
1. Male  
a. Changes in male reproductive organs 
1. Decreased weight of male reproductive organs and Small male 
reproductive organs 
2. Decreased weight of male reproductive organs in Hershberger 
assay 
3. Reduced semen quality 
4. Leydig cell hyperplasia 
b. Impaired male fertility 
2. Female 
a. Changes in female reproductive organs 
b. Impaired female fertility  
3. Male and/or female  
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a. Impaired male and/or female fertility 
 
2f. Tumours in reproductive organs 
1. Mamma tumours 
2. Ovary tumours 
3. Testis tumours 
4. Uterus tumours 
 
25.2.2.1. CAG level 2a: Delayed development and decreased body weight  
These two main CAGs are interrelated, as decreases in offspring body weights often may 
cause delay in pre- or postnatal development. Furthermore, decreases in offspring body 
weights and delayed development may have the same underlying causes. Increased offspring 
body weights have been found after exposure to a few active substances, which forms its own 
CAG. 
 
Table 25.2. CAG level 2a: Delayed development and decreased body weight (194 
compounds) 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Acetamiprid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Aclonifen 
Amidosulfuron 
Amitrole (aminotriazole) 
Azimsulfuron 
Azoxystrobin 
Beflubutamid 
Benalaxyl 
Benfluralin 
Bensulfuron 
Bentazone 
Benthiavalicarb 
Benzoic acid 
Beta-Cyfluthrin 
Bifenox 
Boscalid 
Bromoxynil 
Captan 
Carbendazim 
Carfentrazone-ethyl 
Chloridazon (aka pyrazone) 
Chlormequat (chloride) 
Chlorothalonil 
Ethofumesate 
Ethoprophos 
Ethoxysulfuron 
Etofenprox 
Etoxazole 
Famoxadone 
Fenamidone 
Fenamiphos (aka phenamiphos) 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Fipronil 
Flazasulfuron 
Fluazinam 
Fludioxonil 
Flufenacet (formerly fluthiamide) 
Flumioxazin 
Flupyrsulfuron-methyl (DPX KE 
459) 
Fluroxypyr 
Flusilazole 
Folpet 
Forchlorfenuron 
Formetanate 
Fosetyl 
Fosthiazate 
Fuberidazole 
Gibberellin 
Oxadiazon 
Oxamyl 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Pirimicarb 
Pirimiphos-methyl 
Propamocarb  
Propaquizafop 
Propiconazole 
Propineb 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Pyriproxyfen 
Quinoclamine 
Quinoxyfen  
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Rimsulfuron (aka renriduron) 
S-Metolachlor 
Silthiofam 
Sodium 5-nitroguaiacolate 
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Chlorotoluron 
Chlorpropham 
Chlorpyrifos 
Chlorpyrifos-methyl 
Chlorsulfuron 
Cinidon ethyl 
Clodinafop 
Clofentezine 
Clomazone 
Clopyralid 
Clothianidin 
Copper compounds 
Cyazofamid 
Cyclanilide 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Cyprodinil 
Cyromazine 
Deltamethrin 
Desmedipham 
Dicamba 
Difenoconazole 
Diflubenzuron 
Diflufenican 
Dimethachlor 
Dimethenamid-P 
Dimethoate 
Dimethomorph 
Dimoxystrobin 
Dinocap 
Diuron 
Dodemorph  
Epoxiconazole  
Esfenvalerate 
Ethephon 
Glufosinate 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imidacloprid 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Fluopicolide 
Fluoxastrobin 
Ioxynil 
Iprodione 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Lenacil 
Linuron 
Lufenuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mepanipyrim 
Mepiquat 
Mesotrione 
Metamitron 
Metconazole 
Methiocarb (aka 
mercaptodimethur) 
Metiram 
Metrafenone 
Metribuzin 
Metsulfuron-methyl 
Milbemectin 
Molinate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Tribenuron (aka metometuron) 
Triclopyr 
Trifloxystrobin 
Triflusulfuron 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
Ziram 
Zoxamide 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
The above CAG level 2a for “Delayed development and decreased offspring body weight” 
comprises different specific effects with varying mode of action and may mainly be useful for 
general first-step risk assessments. This main CAG can be subdivided into the following level 
2 CAGs: 
 
Table 25.3. Overview of CAGs within CAG level 2a “Delayed development and 
decreased body weight” 
Level 2 CAGs within “Decreased 
offspring body weight and 
delayed development” 
Subgroups, Level 2 CAGs Specific effects included in the 
CAG 
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Delayed development (CAG level 
2a1) 
Prenatal (CAG level 2a1a) Delayed ossification 
Delayed tooth eruption (rabbit)  
Other (no information on specific 
effects) 
Postnatal (CAG level 2a1b) Delayed sexual maturation  
Delayed eye opening  
Delayed auditory canal opening  
Delayed pinna unfolding  
Delayed tooth eruption (rat, mouse) 
Other (e.g. no information on 
specific effects, delayed grip reflex, 
delayed hair growth) 
Decreased body weight (CAG level 
2a2) 
Prenatal (CAG level 2a2a) Foetal weight 
Birth weight 
Postnatal (CAG level 2a2b) Weight during lactation 
Weight at weaning 
Adult (CAG level 2a2c) Weight adult offspring 
Increased body weight (CAG level 
2a3) 
Prenatal (CAG level 2a3a) Foetal weight 
Postnatal (CAG level 2a3b) Weight during lactation 
Adult (CAG level 2a3c) Weight adult offspring 
 
 
One CAG level 3 is presented within “Delayed development and decreased body weight” for 
substances that are also known to affect the thyroid hormone system, as this is a likely cause 
of delayed development and decreased body weight of offspring (see below in section on 
CAGs at level 3). 
25.2.2.2. CAG level 2a1: Delayed development 
Appendix AF lists substances with effects on delayed development in offspring. This table 
collects the information also presented in the Access database in order to give an overview of 
how one substance can affect more than one endpoint within this main CAG level 2. As 
delayed development and/or decreased offspring body weights are often seen at doses that also 
induce maternal toxicity, e.g. decreased body weight of the dams, this is indicated with the 
letter “t” in the CAG list. More than one line may be presented for the same substance, as a 
compound may have effects on a certain endpoint (e.g. delayed ossification of foetuses) in one 
study at a dose at or above the dose causing maternal toxicity, and in another study at a dose 
for which maternal toxicity is not noted. One such example is Boscalid, see Appendix AF. 
Another reason why two lines are presented for a compound is when one study describes a 
specific effect of the parent compound, and another study describes the same effect for a 
metabolite. One example of this is 2,4 D, see Appendix AF.  
The majority of the active substances in the CAG level 2a1 “Delayed development” affect 
foetal development, whereas fewer active substances affect postnatal development (see 
Appendix AF). This may in part reflect that postnatal development has not always been 
examined in detail in one- and/or multi-generation studies, whereas the prenatal development 
studies always/often include assessment of ossification of foetuses. 
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Two CAG level 2a1 subgroups CAG level 2a1a “Delayed prenatal development” and CAG 
level 2a1b “Delayed postnatal development” are established and presented in the following 
Tables 25.4 and 25.5: 
 
Table 25.4. CAG level 2a1a: Delayed prenatal development (at dose levels with or 
without maternal toxicity) 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Amitrole (aminotriazole) 
Azoxystrobin 
Beflubutamid 
Benalaxyl 
Bensulfuron 
Bentazone 
Benthiavalicarb 
Beta-Cyfluthrin 
Bifenox 
Boscalid 
Captan 
Carbendazim 
Carfentrazone-ethyl 
Chloridazon (aka pyrazone) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Chlorpyrifos-methyl 
Chlorsulfuron 
Clodinafop 
Clomazone 
Clothianidin 
Copper compounds 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cyprodinil 
Cyromazine 
Deltamethrin 
Desmedipham 
Dichlorprop-P 
Dimethachlor 
Dinocap 
Diuron 
Dodemorph 
Ethoxysulfuron 
Etofenprox 
Fenamidone 
Fenhexamid 
Fenoxaprop-P 
Flazasulfuron 
Fluazinam 
Flumioxazin 
Fluopicolide 
Fluoxastrobin 
Fluroxypyr 
Flusilazole 
Folpet 
Forchlorfenuron 
Fuberidazole 
Glufosinate 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imidacloprid 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Isoproturon 
Isoxaflutole 
Linuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mesotrione 
Metconazole 
Metribuzin 
Metsulfuron-methyl 
Molinate 
Oxadiazon 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Pirimicarb 
Pirimiphos-methyl 
Propamocarb  
Propaquizafop 
Propoxycarbazone 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Quinoclamine 
Quizalofop-P-ethyl 
S-Metolachlor 
Silthiofam 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Tribenuron (aka metometuron) 
Triclopyr 
Triflusulfuron 
Triticonazole 
Ziram 
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Table 25.5. CAG level 2a1b: Delayed postnatal development (at dose levels with or 
without maternal toxicity) 
Amitrole (aminotriazole) 
Beflubutamid 
Bromoxynil 
Chlorothalonil 
Clodinafop 
Clothianidin 
Cypermethrin 
Dicamba 
Dimethomorph 
Dodemorph 
Ethofumesate 
Fenpropidin 
Fipronil 
Fluazinam 
Fluoxastrobin  
Fosthiazate 
Glyphosate (incl trimesium aka 
sulfosate) 
Iprodione 
Lufenuron 
Mancozeb 
Mecoprop 
Mepiquat 
Mesotrione 
Metconazole 
Metrafenone 
Molinate 
Propaquizafop 
Propiconazole 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Spiroxamine 
Sulcotrione 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiophanate-methyl 
Triadimenol 
Trifloxystrobin 
Tritosulfuron 
 
 
 
Delayed foetal ossification was observed for all substances shown to delay prenatal 
development. Delayed ossification should be interpreted in the context of other maternal and 
foetal findings. In many cases this effect was only seen at dose levels at or above those leading 
to maternal toxicity (most often reduced body weight and/or food consumption, but also 
clinical signs, and in some cases abortions or maternal death) and was likely associated with 
this and it may be argued that these should not be included in a CAG. When leaving out 
substances for which maternal toxicity is noted, this leaves the following substances in a 
modified CAG level 2a1a “Delayed prenatal development”: 
 
Table 25.6. Modified CAG level 2a1a: Delayed prenatal development (at dose levels 
without maternal toxicity) 
Abamectin (aka avermectin) 
Bensulfuron 
Bifenox 
Boscalid 
Carbendazim 
Carfentrazone-ethyl 
Cyfluthrin 
Cymoxanil 
Deltamethrin 
Fenoxaprop-P 
Flumioxazin 
Fluoxastrobin 
Flusilazole 
Folpet 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Ioxynil 
Isoxaflutole 
MCPA 
Mesotrione 
 
Metribuzin 
Penconazole 
Phenmedipham 
Prothioconazole 
Tetraconazole 
Thiacloprid 
Thiophanate-methyl 
Tralkoxydim 
Triclopyr 
 
 
 
 
The applicability of the modified CAG level 2a1a in Table 25.6 may be discussed as 
decreased maternal body weight gain may in some cases be secondary to reduced weight of 
foetuses. Additionally, mild maternal toxicity elicited as decreased food intake, decreased 
body weight gain or clinical signs may not always be clearly associated with delayed 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
200 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
ossifications, and compounds with these maternal effects may be relevant to include in a CAG 
for specific effects on skeletal ossification. Importantly, the DARs often use effects on 
prenatal development, e.g. delayed ossification, for determination of developmental NOAELs 
also in the presence of mild maternal toxicity (decreased body weight gain, decreased food 
intake or clinical signs). To use the same principles as applied by the DAR, it would not be 
appropriate to exclude all compounds having effects at maternal toxic doses. It is therefore 
recommended to use the broader CAG level 2a1a presented in Table 25.4 for cumulative risk 
assessment. As a refinement of this CAG, only compounds with marked maternal toxicity such 
as maternal body weight loss during gestation or maternal death may be excluded.  
In the case of delayed postnatal development the association to maternal toxicity (e.g. 
decreased body weight) is not so clear. Before removing the active substances for which the 
effects are seen at or above maternal toxicity the effect should be checked for e.g. endocrine 
causes of the delayed development. 
A number of compounds (ethofumesate, fipronil, fluazinam, mancozeb, mepiquat, 
metconazole, pyrimetrozine, tepraloxydim, and trifloxystrobin) all caused delayed 
development at maternal toxic doses and are removed from Table 25.5 to form the modified 
CAG level 2a1b below (Table 25.7). The effects caused by these substances were not 
endocrine related (i.e. they did not affect sexual maturation). Propiconazole and triadimenol 
also caused delayed development at maternal toxic doses, but as the specific effects of these 
substances were delayed sexual maturation, which may be considered an endocrine-related 
effect, these substances are not removed from the modified CAG below. Compounds with 
endocrine-related effects at doses at or above maternal toxicity levels are therefore included in 
Table 25.7. 
 
Table 25.7. Modified CAG level 2a1b: Delayed postnatal development (at dose levels 
without maternal toxicity).  
Amitrole (aminotriazole) 
Beflubutamid 
Bromoxynil 
Chlorothalonil 
Clodinafop 
Clothianidin 
Cypermethrin 
Dicamba 
Dimethomorph 
Dodemorph 
Fenpropidin 
Fluoxastrobin 
Fosthiazate 
Glyphosate (incl trimesium aka 
sulfosate) 
Iprodione 
Mecoprop 
Mesotrione 
Metrafenone 
Molinate 
Propaquizafop 
Propiconazole 
Prothioconazole 
Pyraclostrobin 
Spiroxamine 
Sulcotrione 
Tebufenpyrad 
Tetraconazole 
Thiophanate-methyl 
Triadimenol 
Tritosulfuron 
 
 
The same line of arguments applies for delayed postnatal development as for delayed prenatal 
development. It cannot be determined whether mild maternal effects have any causative role 
in relation to the observed delayed postnatal development, and DARs often use postnatal 
developmental effects for determination of offspring NOAELs. It is recommended to use the 
broader CAG level 2a1b which includes compounds with effects at doses showing mild 
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maternal toxicity (Table 25.5) for cumulative risk assessment. As a refinement of this CAG, 
only compounds with marked maternal toxicity such as maternal body weight loss during 
gestation or maternal death may be excluded. 
The tables below present subgroups of the CAG level 2a1b “Delayed postnatal development” 
(including effects at dose levels inducing maternal toxicity). 
 
Table 25.8. CAG level 2a1b1: Delayed sexual maturation 
Beflubutamid 
Chlorothalonil 
Clothianidin 
Dicamba 
Fenpropidin 
Fluoxastrobin 
Glyphosate (incl trimesium aka 
sulfosate) 
Iprodione 
Mesotrione 
Metrafenone 
Molinate 
Propiconazole 
Prothioconazole 
Pyraclostrobin 
Spiroxamine 
Tebufenpyrad 
Tetraconazole 
Triadimenol 
 
 
Table 25.9. CAG level 2a1b2: Delayed eye opening 
Bromoxynil 
Clodinafop 
Cypermethrin 
Dodemorph 
Fluazinam 
Fosthiazate 
Lufenuron 
Mancozeb 
Metconazole 
Propaquizafop 
Pymetrozine 
 
Sulcotrione 
Tepraloxydim 
Thiophanate-methyl 
Trifloxystrobin 
Tritosulfuron 
 
 
 
Table 25.10. CAG level 2a1b3: Delayed auditory canal opening 
Amitrole (aminotriazole) 
Cypermethrin 
Dodemorph 
Mecoprop 
Propaquizafop 
Tritosulfuron 
 
 
Table 25.11. CAG level 2a1b4: Delayed pinna unfolding 
Clodinafop 
Dodemorph 
Fipronil 
Fluazinam 
Mecoprop 
 
Thiophanate-methyl 
Tritosulfuron 
 
 
 
Table 25.12. CAG level 2a1b5: Delayed tooth eruption 
Clodinafop Dimethomorph  Fosthiazate 
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Cypermethrin Fipronil  
 
 
25.2.2.3. CAG level 2a2: Decreased body weight 
Appendix AG lists the compounds that have decreased offspring body weights and/or 
decreased weight gain of offspring prenatally, postnatally (= during weaning) and/or in 
adulthood. Appendix AG reveals that several active substances decrease both prenatal and 
postnatal body weight, and that these effects are often seen at maternal toxic dose levels, i.e. 
doses at which reduced maternal body weight, food consumption and/or other effects are seen. 
Table 25.13 presents CAG level 2a2a “Prenatal body weight decrease” and in Table 25.14 this 
CAG is modified by removing those compounds for which the effects are only seen at 
maternal toxic doses: 
 
Table 25.13. CAG level 2a2a: Prenatal body weight decrease (including compounds at 
doses showing maternal effects) 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Acetamiprid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Aclonifen 
Amidosulfuron 
Amitrole (aminotriazole) 
Azimsulfuron 
Benalaxyl 
Bensulfuron 
Bentazone 
Benzoic acid 
Beta-Cyfluthrin 
Bromoxynil 
Captan 
Carbendazim 
Chloridazon (aka pyrazone) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Chlorpyrifos 
Chlorpyrifos-methyl 
Chlorsulfuron 
Clodinafop 
Clofentezine 
Clomazone 
Clopyralid 
Clothianidin 
Copper compounds 
Diuron 
Dodemorph 
Esfenvalerate 
Ethephon 
Ethofumesate 
Ethoxysulfuron 
Etofenprox 
Fenamidone 
Fenamiphos (aka phenamiphos) 
Fenoxaprop-P 
Fenpropimorph 
Flazasulfuron 
Fluazinam 
Flufenacet (formerly fluthiamide) 
Flumioxazin 
Fluopicolide 
Flupyrsulfuron-methyl (DPX KE 
459) 
Flusilazole 
Folpet 
Forchlorfenuron 
Fosthiazate 
Fuberidazole 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imidacloprid 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Metribuzin  
Milbemectin 
Molinate 
Oxadiazon 
Oxamyl 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Pirimicarb 
Propamocarb  
Propaquizafop 
Propineb 
Propoxycarbazone 
Prosulfocarb 
Prothioconazole 
Pyrimethanil 
Quinoclamine 
Quizalofop-P-tefuryl 
S-Metolachlor 
Silthiofam 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
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Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cyprodinil 
Cyromazine 
Deltamethrin 
Desmedipham 
Dichlorprop-P 
Difenoconazole 
Dimethoate 
Dimethomorph 
Dinocap 
Isoproturon 
Isoxaflutole 
Linuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mesotrione 
Metconazole 
Methiocarb (aka 
mercaptodimethur) 
Metiram 
Metrafenone 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Tribenuron (aka metometuron) 
Triclopyr 
Triticonazole 
Ziram 
 
 
Table 25.14. Modified CAG level 2a2a: Prenatal body weight decrease (excluding 
compounds at doses showing maternal effects) 
Bentazone 
Carbendazim 
Chlorpropham 
Chlorpyrifos-methyl? 
Copper compounds? 
Deltamethrin 
Desmedipham 
Dichlorprop-P 
Difenoconazole? 
Dimethoate 
Dinocap 
Esfenvalerate 
Ethofumesate 
Fluazinam 
Flumioxazin 
Fluopicolide 
Fosthiazate 
Ioxynil 
Isoproturon 
Isoxaflutole 
MCPA 
Mecoprop 
Mecoprop-P 
Mesotrione 
Metiram 
Metrafenone 
Oxamyl 
Penconazole 
Phenmedipham 
Phosmet 
Propamocarb  
Propineb? 
Quizalofop-P-tefuryl 
Tepraloxydim 
Tetraconazole 
Thiophanate-methyl 
Thiram? 
Triclopyr 
? = Not clear from DARs whether maternal effects are observed at same dose levels 
 
 
Decreases in prenatal body weight may be related to decreases in dam body weight, but the 
same line of arguments applies for decreased prenatal body weight as for delayed prenatal 
development. It cannot be determined whether mild maternal effects have any causative role 
in relation to the observed decreased prenatal body weight, and DARs often use effects on 
prenatal body weight for determination of developmental NOAELs. It is recommended to use 
the broader CAG level 2a2a which includes compounds with effects at doses showing mild 
maternal toxicity (Table 25.13) for cumulative risk assessment. As a refinement of this CAG, 
only compounds with marked maternal toxicity such as maternal body weight loss during 
gestation or maternal death may be excluded. 
Decreases in prenatal body weight may be related to decreases in dam body weight, whereas 
decreases in postnatal body weight may also be caused by postnatal malnourishment (e.g. 
impaired lactation or lack of maternal care). The two tables below (Tables 25.15 and 15.16) 
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present two possible CAGs at level 2a2b “Postnatal body weight decrease”. The CAG level 
2a2b1 includes active substances that affect postnatal body weight irrespective of whether 
prenatal body weight is affected, whereas the CAG level 2a2b2 presents only active 
substances for which no prenatal body weight (but only postnatal bodyweight) reduction was 
noted. The CAG level 2a2b1 in Table 25.15 thus includes both prenatal and postnatal causes 
of the observed low postnatal body weight, and the CAG level 2a2b in Table 25.16 includes 
only postnatal causes of the observed low postnatal body weight. Both CAGs at level 2a2b 
include substances having effects at doses showing maternal effects. 
 
Table 25.15. CAG level 2a2b: Postnatal body weight decrease (prenatal and/or postnatal 
causes of effect) 
2,4-D 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Acetamiprid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Amidosulfuron 
Amitrole (aminotriazole) 
Azimsulfuron 
Azoxystrobin 
Beflubutamid 
Benalaxyl 
Benfluralin 
Bensulfuron 
Bentazone 
Benthiavalicarb 
Beta-Cyfluthrin 
Bifenox 
Boscalid 
Bromoxynil 
Captan 
Carbendazim 
Chloridazon (aka pyrazone) 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Cinidon ethyl 
Clodinafop 
Clofentezine 
Clothianidin 
Cyazofamid 
Cyclanilide 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Cyprodinil 
Cyromazine 
Esfenvalerate  
Ethephon 
Ethofumesate 
Ethoprophos 
Ethoxysulfuron 
Etofenprox 
Etoxazole 
Famoxadone 
Fenamidone 
Fenamiphos (aka phenamiphos) 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Fipronil 
Fludioxonil 
Fluopicolide 
Fluoxastrobin 
Flupyrsulfuron-methyl (DPX KE 
459) 
Flusilazole 
Folpet 
Forchlorfenuron 
Formetanate 
Fosetyl 
Gibberellin 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imidacloprid 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Iprovalicarb 
Isoproturon 
Lenacil 
Linuron 
Lufenuron 
Metsulfuron-methyl 
Milbemectin 
Molinate 
Oxamyl 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Pirimicarb 
Propamocarb  
Propiconazole 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Pyriproxyfen 
Quinoxyfen  
Quinoclamine 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Rimsulfuron (aka renriduron) 
S-Metolachlor 
Silthiofam 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tolylfluanid 
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Deltamethrin 
Desmedipham 
Dicamba 
Dichlorprop-P 
Difenoconazole 
Diflubenzuron 
Diflufenican 
Dimethachlor 
Dimethenamid-P 
Dimethoate 
Dimoxystrobin 
Dinocap 
Diuron 
Dodemorph 
Epoxiconazole 
MCPA 
MCPB 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mepanipyrim 
Mepiquat 
Mesotrione 
Metamitron 
Metconazole 
Methiocarb (aka 
mercaptodimethur) 
Metiram 
Metrafenone 
Metribuzin 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Tribenuron (aka metometuron) 
Triclopyr 
Trifloxystrobin 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
Ziram 
Zoxamide 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
Table 25.16. CAG level 2a2b: Postnatal body weight decrease without decreased 
prenatal body weight (postnatal cause of effect, e.g. malnutrition) 
Abamectin (aka avermectin) 
Azoxystrobin 
Beflubutamid 
Benfluralin 
Bensulfuron 
Benthiavalicarb 
Beta-Cyfluthrin 
Bifenox 
Boscalid 
Captan 
Chloridazon (aka pyrazone) 
Chlormequat (chloride) 
Chlorothalonil 
Cinidon ethyl 
Clodinafop 
Cyazofamid 
Cyclanilide 
Cyfluthrin 
Cypermethrin 
Deltamethrin 
Dicamba 
Diflubenzuron 
Diflufenican 
Dimethachlor 
Dimethenamid-P 
Dimethoate 
Dimoxystrobin 
Dodemorph 
Epoxiconazole 
Esfenvalerate 
Ethoprophos 
Etoxazole 
Famoxadone 
Fenhexamid 
Fenpropidin 
Fenpyroximate 
Fipronil 
Fludioxonil 
Fluoxastrobin 
Flusilazole 
Folpet 
Forchlorfenuron 
Formetanate 
Fosetyl 
Gibberellin 
Imazalil (aka enilconazole) 
Imidacloprid 
Iprovalicarb 
Lenacil 
Lufenuron 
Mancozeb 
Mecoprop 
Mepanipyrim 
Mepiquat 
Metamitron 
Metconazole 
Metsulfuron-methyl 
Oxamyl 
Propiconazole 
Propoxycarbazone 
Propyzamide 
Prosulfuron 
Pymetrozine 
Pyraclostrobin 
Pyriproxyfen 
Quinoxyfen  
Quizalofop-P-ethyl 
Rimsulfuron (aka renriduron) 
Sulcotrione 
Tebuconazole 
Tepraloxydim 
Thiamethoxam 
Thiophanate-methyl 
Tribenuron (aka metometuron) 
Trifloxystrobin 
Trinexapac (aka cimetacarb ethyl) 
Tritosulfuron 
Zoxamide 
lambda-Cyhalothrin 
zeta-Cypermethrin  
 
 
The CAG level 2a2b without prenatal causes presented in Table 25.16 has some limitations:  
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• When active substances with prenatal effects are omitted (Table 25.16) there is a risk 
of excluding some relevant active substances, e.g. active substances for which the 
postnatal effect is more marked than the prenatal effect although both effects are 
statistically significant. 
• The opposite problem is also present: this CAG may include some irrelevant active 
substances, e.g. active substances for which effects would indeed be seen on both pre- 
and postnatal body weight if the same doses had been applied in both prenatal and 
postnatal studies.  
 
Therefore, this subdivision of the CAG for postnatal body weight decrease may be of limited 
usefulness and the broader CAG level 2a2b for postnatal body weight decrease presented in 
Table 25.15 is recommended for cumulative risk assessment. 
A number of active substances also affected body weight in adult offspring. As this was 
observed in multigeneration studies with continuous dosing of offspring in feed it cannot be 
determined whether this is caused by pre-/postnatal body weight decreases persisting into 
adulthood or caused by direct effects of exposure to the active substance in adulthood. These 
substances are allocated to CAG level 2a2c “Decreased body weight of adult offspring: 
 
Table 25.17. CAG level 2a2c: Decreased body weight of adult offspring 
Cyfluthrin 
Dimethoate 
Dodemorph 
Esfenvalerate 
Ethephon 
Etofenprox 
Flumioxazin 
Ioxynil 
Isoproturon 
Isoxaflutole 
Mancozeb 
MCPB 
Penconazole 
Propamocarb  
Prothioconazole 
 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Sulcotrione 
Thiabendazole 
Tolylfluanid 
Triadimenol 
 
 
As those substances that also affect pre- or postnatal offspring body weight are already 
presented in the above recommended CAGs (Table 25.13 and Table 25.15), and direct effects 
on body weight are considered non-specific and excluded from this project, it is not 
recommend to use the CAG level 2a2c “Decreased body weight of adult offspring” for 
cumulative risk assessment. 
25.2.2.4. CAG level 2a3: Increased body weight 
Exposure to a few of the active substances resulted in increased body weight of the offspring 
either prenatally or postnatal as presented in Appendix AG and listed in the tables below. 
Generally, DARs question the toxicological relevance of these effects, and it is not 
recommended to apply CAGs for increased offspring body weight for cumulative risk 
assessment. 
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Table 25.18. CAG level 2a3a: Prenatal body weight increase 
Flusilazole 
Phenmedipham 
Propamocarb 
Prothioconazole 
 
 
Table 25.19. CAG level 2a3b: Postnatal body weight increase 
Deltamethrin 
 
 
Table 25.20. CAG level 2a3c: Increased body weight of adult offspring 
Lufenuron 
 
 
25.2.2.5. CAG level 2b: Malformations and variations  
Malformations are defined as structural changes considered detrimental to the animal (may 
also be lethal) and is usually rare. Variations are defined as structural changes considered to 
have little or no detrimental effect on the animal. Variations may be transient and may occur 
relatively frequently in the control population. (ref. OECD TG 414 (Prenatal Developmental 
Toxicity Study)). 
The main CAG level 2b “Malformations and variations” is only subdivided to 2 CAGs at 
level 2, i.e. CAG level 2b1 “Malformations” and CAG level 2b2 “Variations” although it may 
be possible to also subdivide into e.g. skeletal malformations, skeletal variations, visceral 
malformations and visceral variations and “other”. 
 
Table 25.21. Overview of CAGs within CAG level 2b “Malformations and Variations” 
CAG level 2 within 
“Malformations and variations” 
Subgroup, CAG level 2 CAG includes the following 
specific effects 
Malformations (CAG level 2b1) Skeletal malformations (CAG level 
2b1a) 
E.g. fused ribs, malformed bones 
Cleft palate (CAG level 2b1b)  
Hydrocephalus (CAG level 2b1c)  
Excencephaly (CAG level 2b1d)  
Kidney malformations (CAG level 
2b1e) 
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Eye malformations (CAG level 
2b1f) 
E.g. anopthalmia, microophthalmia 
Heart malformations (CAG level 
2b1g) 
 
Variations (CAG level 2b2) Skeletal variations 
 
E.g. extra ribs, wavy ribs, fused 
sternebrae 
Urinary tract variations E.g. dilated renal pelvis, small renal 
papillae and distended ureter  
Dilated brain vesicles  
Heart variations E.g. dilated heart ventricles 
Eye variations E.g. corneal opacity 
Runts (CAG level 2b3)  Runt defined as animal significantly 
smaller than siblings 
 
 
Variations and malformations are often seen at doses inducing maternal toxicity, e.g. 
decreased body weight of dams, as indicated with the letter “t” in Appendix AH. However, 
this does not imply that the developmental toxicity effects are unspecific effects of maternal 
toxicity. Also, the effects on the foetus, especially in cases of malformations, are more severe 
than the effect on the dam.  
Appendix AH presents substances for which malformations and variations are seen. From this 
table a main CAG for all substances inducing malformations and/or variations was created 
(Table 25.22) as well as CAGs for substances inducing either malformations (Table 25.23) or 
variations (Table 25.24). The Access database contains information on the specific types of 
malformations and variations, and this information has been applied to define some subgroups 
which are presented in Tables 25.25 to 25.37 below. 
 
Table 25.22. CAG level 2b: Malformations and Variations 
2,4-D 
2,4-DB 
Abamectin (aka avermectin) 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Amitrole (aminotriazole) 
Azimsulfuron 
Beflubutamid 
Bensulfuron 
Benthiavalicarb 
Benzoic acid 
Beta-Cyfluthrin 
Bifenox 
Bromoxynil 
Captan 
Carbendazim 
Carfentrazone-ethyl 
Chloridazon (aka pyrazone) 
Chlorothalonil 
Chlorotoluron 
Ethofumesate 
Ethoxysulfuron 
Etofenprox 
Etoxazole Fenamiphos (aka 
phenamiphos) 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Flazasulfuron 
Fluazinam 
Flufenacet (formerly fluthiamide) 
Flumioxazin 
Fluoxastrobin 
Flusilazole 
Folpet 
Fosetyl 
Glufosinate 
Glyphosate (incl trimesium aka 
Picolinafen 
Pirimicarb 
Pirimiphos-methyl 
Propamocarb  
Propaquizafop  
Propiconazole 
Propineb 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Pyriproxyfen 
Quinoclamine 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Rimsulfuron (aka renriduron) 
S-Metolachlor 
Silthiofam 
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Chlorpropham 
Chlorpyrifos 
Chlorpyrifos-methyl 
Cinidon ethyl 
Clodinafop 
Clomazone 
Clopyralid 
Clothianidin 
Copper compounds 
Cyclanilide 
Cyfluthrin 
Cymoxanil 
Cyromazine 
Deltamethrin 
Desmedipham 
Dichlorprop-P 
Difenoconazole 
Diflufenican 
Dimethoate 
Dimoxystrobin 
Dinocap 
Diuron 
Dodemorph 
Epoxiconazole 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imidacloprid 
Iodosulfuron-methyl-sodium 
Ioxynil 
Isoxaflutole 
Linuron 
MCPA 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mepanipyrim 
Mesotrione 
Metconazole 
Metiram 
Metribuzin 
Metsulfuron-methyl 
Molinate 
Oxamyl 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Sodium hypochlorite 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Tribenuron (aka metometuron) 
Triclopyr 
Trifloxystrobin 
Triflusulfuron 
Triticonazole 
Tritosulfuron 
Ziram 
 
 
Table 25.23. CAG level 2b1: Malformations 
2,4-D 
2,4-DB 
Abamectin (aka avermectin) 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Amitrole (aminotriazole) 
Beflubutamid 
Benthiavalicarb 
Benzoic acid 
Bromoxynil 
Carbendazim 
Chlorpropham 
Chlorpyrifos 
Chlorpyrifos-methyl 
Cinidon ethyl 
Clopyralid 
Clothianidin 
Copper compounds 
Cyclanilide 
Cymoxanil 
Cyromazine 
Desmedipham 
Dichlorprop-P 
Diflufenican 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Flazasulfuron 
Fluazinam 
Flumioxazin 
Flusilazole 
Fosetyl 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazaquin 
Ioxynil 
MCPA 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mepanipyrim 
Mesotrione 
Metconazole 
Metiram 
Metribuzin 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Quinoclamine 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
S-Metolachlor 
Silthiofam 
Sodium hypochlorite 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tepraloxydim 
Thiabendazole 
Thiacloprid 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
210 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
Dimethoate 
Dimoxystrobin 
Dinocap 
Dodemorph 
Ethofumesate 
Metsulfuron-methyl 
Oxamyl 
Penconazole 
Pirimicarb 
Pirimiphos-methyl 
Propaquizafop 
Propiconazole 
Propineb 
Triadimenol 
Tribenuron (aka metometuron) 
Triclopyr 
Trifloxystrobin 
Triflusulfuron 
Ziram 
 
 
Table 25.24. CAG level 2b2: Variations 
2,4-D 
2,4-DB 
Azimsulfuron 
Bensulfuron 
Beta-Cyfluthrin 
Bifenox 
Bromoxynil 
Captan 
Carfentrazone-ethyl 
Chloridazon (aka pyrazone) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Clodinafop 
Clomazone 
Deltamethrin 
Desmedipham 
Difenoconazole 
Dimoxystrobin 
Diuron 
Dodemorph 
Epoxiconazole 
Ethoxysulfuron 
Etofenprox 
Etoxazole 
Fenamiphos (aka phenamiphos) 
Fluazinam 
Flufenacet (formerly fluthiamide) 
Flumioxazin 
Fluoxastrobin 
Flusilazole 
Folpet 
Glufosinate 
Imazalil (aka enilconazole) 
Imidacloprid 
Iodosulfuron-methyl-sodium 
Ioxynil 
Isoxaflutole 
Linuron 
Mancozeb 
Mecoprop-P 
Mesotrione 
Metconazole 
Molinate 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Pirimiphos-methyl 
Propamocarb  
Pyriproxyfen 
Quizalofop-P-ethyl 
Rimsulfuron (aka renriduron) 
Sulcotrione 
Tebufenpyrad 
Tetraconazole 
Thiamethoxam 
Tralkoxydim 
Triadimenol 
Triasulfuron 
Trifloxystrobin 
Triticonazole 
Tritosulfuron 
 
 
Table 25.25. CAG level 2b1a: Skeletal malformations 
2,4-D 
2,4-DB 
Amitrole (aminotriazole) 
Bromoxynil 
Carbendazim 
Chlorpropham 
Cinidon ethyl 
Cymoxanil 
Cyromazine 
Desmedipham 
Dimethoate 
Dimoxystrobin 
Dinocap 
Ethofumesate 
Fenhexamid 
Fenpropidin 
Fenpropimorph 
Flusilazole 
Fosetyl 
Ioxynil  
MCPA 
Maneb 
Mepanipyrim 
Metconazole 
Metiram 
Metribuzin 
Prothioconazole  
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Quinoclamine 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl  
S-Metolachlor 
Tebuconazole 
Tepraloxydim 
Thiacloprid 
Thiram 
Tralkoxydim 
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Pirimicarb 
Pirimiphos-methyl 
Propaquizafop 
Propineb 
Triadimenol  
Triclopyr 
Trifloxystrobin 
 
 
Table 25.26. CAG level 2b1b: Cleft palate 
Abamectin (aka avermectin) 
Chlorpyrifos-methyl 
Cymoxanil 
Dinocap 
Fenpropimorph 
Flusilazole 
Imazaquin 
MCPA 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Penconazole 
 
Propiconazole 
Prothioconazole 
Quizalofop-P-tefuryl 
Silthiofam 
Thiabendazole 
Thiram 
Triadimenol 
 
 
Table 25.27. CAG level 2b1c: Hydrocephalus 
Carbendazim 
Cymoxanil 
Dinocap 
Ioxynil 
Maneb 
Metconazole 
Metiram 
Penconazole 
Propineb 
Quizalofop-P-tefuryl 
Spiroxamine 
Thiabendazole 
Thiophanate-methyl 
Thiram 
 
 
 
Table 25.28. CAG level 2b1d: Exencephaly 
Abamectin (aka avermectin) 
Carbendazim 
Chlorpyrifos 
Cymoxanil 
Dinocap 
Maneb 
Propineb 
Thiophanate-methyl 
 
 
Table 25.29. CAG level 2b1e: Kidney malformations 
Beflubutamid 
Benzoic acid 
Dinocap 
Fluazinam 
 
Flusilazole 
Glyphosate (incl trimesium aka 
sulfosate) 
Propineb 
 
Quinoclamine  
Sulcotrione 
Tebuconazole 
Thifensulfuron-methyl 
Tritosulfuron 
 
 
Table 25.30. CAG level 2b1f: Eye malformations 
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Abamectin (aka avermectin) 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Benzoic acid 
Carbendazim  
Dodemorph 
Fenhexamid 
Fenpyroximate 
Ioxynil 
Penconazole  
Propineb 
 
Prosulfocarb 
Prothioconazole 
Quinoclamine 
Thiophanate-methyl 
Triclopyr 
 
 
Table 25.31. CAG level 2b1g: Heart malformations 
Cyclanilide 
Flazasulfuron 
 
Flumioxazin 
Glyphosate (incl trimesium aka 
sulfosate) 
Quinoclamine 
Thiram 
 
 
Table 25.32. CAG level 2b2a: Skeletal variations 
2,4-D 
2,4-DB 
Abamectin (aka avermectin) 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Amitrole (aminotriazole) 
Azimsulfuron 
Bensulfuron 
Benthiavalicarb 
Beta-Cyfluthrin 
Bifenox 
Bromoxynil 
Captan 
Carbendazim 
Carfentrazone-ethyl 
Chloridazon (aka pyrazone) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Chlorpyrifos 
Cyclanilide 
Cymoxanil 
Cyromazine 
Deltamethrin 
Desmedipham 
Dichlorprop-P 
Difenoconazole 
Diflufenican 
Dimethoate 
Dimoxystrobin 
Dinocap 
Diuron 
Dodemorph 
Epoxiconazole 
Ethoxysulfuron  
Etofenprox 
Etoxazole 
Fenamiphos (aka phenamiphos) 
Fenoxaprop-P 
Fenpyroximate 
Flazasulfuron 
Fluazinam 
Flufenacet (formerly fluthiamide) 
Flumioxazin 
Fluoxastrobin 
Flusilazole 
Folpet 
Fosetyl 
Glufosinate 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imidacloprid 
Ioxynil 
Isoxaflutole 
Linuron 
Mancozeb 
Mecoprop-P 
Mesotrione 
Metconazole 
Metiram 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet  
Picolinafen  
Pirimicarb  
Pirimiphos-methyl 
Propamocarb  
Propiconazole 
Propineb 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Pyriproxyfen 
Quizalofop-P-ethyl 
Rimsulfuron (aka renriduron) 
Silthiofam 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Triclopyr 
Trifloxystrobin 
Triticonazole 
Tritosulfuron 
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Table 25.33. CAG level 2b2b: Urinary tract malformations 
2,4-DB 
Clodinafop 
Clomazone 
Difenoconazole 
Flusilazole 
Glufosinate 
Iodosulfuron-methyl-sodium 
Ioxynil 
Isoxaflutole 
Mesotrione 
Metconazole 
Propamocarb  
Propaquizafop 
Prosulfocarb 
Prothioconazole 
Pyraclostrobin 
Pyriproxyfen 
Quinoclamine 
Quizalofop-P-tefuryl 
Thiacloprid 
Thifensulfuron-methyl 
Triticonazole 
Tritosulfuron 
 
 
Table 25.34. CAG level 2b2c: Dilated brain vesicles 
Ethoxysulfuron 
Fluoxastrobin 
Mancozeb 
Metiram 
Molinate 
 
 
 
Table 25.35. CAG level 2b2d: Heart variations 
Cyclanilide 
Cymoxanil 
 
Ethofumesate  
Glyphosate (incl trimesium aka 
sulfosate) 
Metribuzin 
 
 
Table 25.36. CAG level 2b2e: Eye variations 
Metconazole Sulcotrione  
 
 
Table 25.37. CAG level 2b3: Runts 
Benthiavalicarb 
Flusilazole 
Folpet 
Imazalil (aka enilconazole) 
Isoproturon 
Molinate 
Penconazole 
Pyrimethanil 
Tebuconazole 
Thiram 
 
 
Recommendations concerning malformations and variations: The main level 2 CAGs 2b1 
Malformations and 2b2 Variations are recommended, but also the subgroups are 
recommended. 
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25.2.2.6. CAG level 2c: Pre- and postnatal death  
The main CAG level 2c “Pre- and postnatal death” can be subdivided to two CAGs at level 2, 
i.e. CAG level 2c1 “Prenatal death” and CAG level 2c2 “Postnatal death”. 
 
Table 25.38. Overview of CAGs within CAG level 2c “Pre- and postnatal death” 
Level 2 CAG Subgroup, Level 2 CAG CAG includes the following specific effects 
Death of 
offspring (CAG 
level 2c) 
Prenatal death (CAG level 
2c1) 
Resorptions 
Postimplantation loss 
Abortions 
Stillborns 
Decreased litter size (some also in CAG for female fertility 
or offspring, other effects, see below) 
Total litter loss 
Postnatal death (CAG level 
2c2) 
During lactation 
At weaning 
 
 
Postnatal death of pups generally covers the lactation period. An active substance affecting 
litter size can be placed in both the CAG for fertility and the CAG for prenatal death, if there 
is no clear indication of the cause of the decreased litter size in generation F1 of a 
multigeneration study. In prenatal developmental studies where dams are dosed after 
implantation of foetuses, decreased litter size is only categorized as death of foetus, and 
decreased litter size in generation F2 of a multigeneration study is categorized as “other 
effects on offspring”. 
Appendix AI presents level 2 CAGs for pre- and postnatal death. Fetal death is often seen at 
doses inducing maternal toxicity, e.g. decreased body weight of dams, as indicated with the 
letter “t” in Appendix AI. However, this does not imply that the developmental toxicity effects 
are unspecific effects of maternal toxicity. Also, the effect on the offspring, death, is more 
severe than the effect on the dam. Therefore, no CAGs excluding compounds with effects at 
doses showing maternal toxicity are presented. 
A main CAG for all substances inducing prenatal and/or postnatal death was created (Table 
25.39) together with CAGs for substances inducing either prenatal (Table 25.40) or postnatal 
(Table 25.41) death. 
 
Table 25.39. CAG level 2c: Prenatal and postnatal death 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Ethofumesate 
Ethoprophos 
Ethoxysulfuron 
Famoxadone 
Fenhexamid 
Milbemectin  
Molinate 
Oxadiazon 
Oxamyl 
Oxasulfuron 
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Acetamiprid 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Aclonifen 
Amitrole (aminotriazole) 
Azimsulfuron 
Benfluralin 
Bensulfuron 
Bentazone 
Benthiavalicarb 
Benzoic acid 
Beta-Cyfluthrin 
Boscalid 
Captan 
Carbendazim 
Chloridazon (aka pyrazone) 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Chlorpyrifos 
Clodinafop 
Clomazone 
Clopyralid 
Clothianidin 
Copper compounds 
Cyclanilide 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Cyromazine 
Deltamethrin 
Desmedipham 
Dicamba 
Dichlorprop-P 
Difenoconazole 
Diflufenican 
Dimethenamid-P 
Dimethoate 
Dimethomorph 
Dimoxystrobin 
Dinocap 
Diuron 
Dodemorph 
Epoxiconazole 
Esfenvalerate 
Ethephon 
Etofenprox 
Etoxazole 
Fenoxaprop-P 
Fenpropimorph 
Fipronil 
Flazasulfuron 
Fluazinam 
Flumioxazin 
Fluopicolide 
Flupyrsulfuron-methyl (DPX KE 
459) 
Fluroxypyr 
Flusilazole 
Folpet 
Forchlorfenuron 
Formetanate 
Fosetyl 
Fosthiazate 
Fuberidazole 
Gibberellin 
Glufosinate 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imazosulfuron 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Linuron 
Lufenuron 
MCPA 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mepanipyrim 
Mepiquat 
Mesotrione 
Metamitron 
Metconazole 
Methiocarb (aka 
mercaptodimethur) 
Metiram 
Metrafenone 
Metribuzin 
Metsulfuron-methyl 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Propamocarb  
Propaquizafop 
Propiconazole 
Propineb 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prothioconazole 
Quinoxyfen  
Pymetrozine 
Pyraclostrobin 
Pyriproxyfen 
Quinoclamine 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Silthiofam 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Tribenuron (aka metometuron) 
Triclopyr 
Triflusulfuron 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
Ziram 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
Table 25.40. CAG level 2c1: Prenatal death 
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2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Acibenzolar-S-methyl 
(benzothiadiazole) 
Aclonifen 
Amitrole (aminotriazole) 
Bensulfuron 
Bentazone 
Benthiavalicarb 
Beta-Cyfluthrin 
Boscalid 
Captan 
Carbendazim 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Chlorpyrifos 
Clomazone 
Clopyralid 
Clothianidin 
Copper compounds 
Cyclanilide 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Cyromazine 
Desmedipham 
Dicamba 
Dichlorprop-P 
Difenoconazole 
Diflufenican 
Dimethenamid-P 
Dimethoate 
Dimethomorph 
Dimoxystrobin 
Dinocap 
Diuron 
Dodemorph 
Epoxiconazole 
Esfenvalerate 
Ethephon 
Ethofumesate 
Ethoprophos 
Ethoxysulfuron 
Etofenprox 
Famoxadone 
Fenhexamid 
Fenoxaprop-P 
Fenpropimorph 
Fipronil 
Flazasulfuron 
Fluazinam 
Flumioxazin 
Fluopicolide 
Flupyrsulfuron-methyl (DPX KE 
459) 
Fluroxypyr 
Flusilazole 
Folpet 
Forchlorfenuron 
Fosetyl 
Fosthiazate 
Gibberellin 
Glufosinate 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Isoproturon 
Isoxaflutole 
Linuron 
Lufenuron 
MCPA 
Mancozeb 
Maneb 
Mecoprop 
Mecoprop-P 
Mepanipyrim 
Mepiquat 
Mesotrione 
Metconazole 
Methiocarb (aka 
mercaptodimethur) 
Metiram 
Metrafenone 
Metribuzin 
Metsulfuron-methyl 
Milbemectin 
Molinate 
Oxadiazon 
Oxamyl 
Oxasulfuron 
Penconazole 
Phosmet 
Picolinafen 
Propamocarb  
Propaquizafop 
Propiconazole 
Propineb 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Pyriproxyfen 
Quinoclamine 
Quinoxyfen  
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Silthiofam 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tolylfluanid 
Tralkoxydim 
Triadimenol 
Tribenuron (aka metometuron) 
Triclopyr 
Triflusulfuron 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
Ziram 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
 
Table 25.41. CAG level 2c2: Postnatal death 
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2,4-D 
2,4-DB 
Abamectin (aka avermectin) 
Acetamiprid 
Amitrole (aminotriazole) 
Azimsulfuron 
Benfluralin 
Benzoic acid 
Beta-Cyfluthrin 
Boscalid 
Captan 
Chloridazon (aka pyrazone) 
Chlorothalonil 
Chlorpyrifos 
Clodinafop 
Cyfluthrin 
Cymoxanil 
Deltamethrin 
Diflufenican 
Dimethoate 
Dinocap 
Dodemorph 
Epoxiconazole 
Esfenvalerate 
Ethephon 
Ethofumesate 
Ethoprophos 
Ethoxysulfuron 
 
Etofenprox 
Etoxazole 
Famoxadone 
Fipronil 
Flumioxazin 
Flusilazole 
Forchlorfenuron 
Formetanate 
Fosthiazate 
Fuberidazole 
Imazalil (aka enilconazole) 
Imazosulfuron 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Iprovalicarb 
Isoxaflutole 
Linuron 
Mecoprop 
Mecoprop-P 
Mepiquat 
Metamitron 
Metiram 
Milbemectin 
Molinate 
Oxamyl 
 
Oxasulfuron 
Phenmedipham 
Phosmet 
Propamocarb  
Propaquizafop 
Propoxycarbazone 
Prothioconazole 
Pyriproxyfen 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tetraconazole 
Thiacloprid 
Thiram 
Tolylfluanid 
Tri-allate 
Triadimenol 
Tribenuron (aka metometuron) 
Triclopyr 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
zeta-Cypermethrin 
 
 
Effects on pre- or postnatal death are often used by DARs for determination of developmental 
or offspring NOAELs. The two CAGs for prenatal death (Table 25.40) and for postnatal death 
(Table 25.41) are recommended for cumulative risk assessment. 
A CAG level 3 “Coagulation inhibitors” can be presented within the CAG level 2 for foetal 
death, as coagulation inhibition leading to excess bleeding can induce abortions, which are in 
the current project included in the CAG for fetal death (see below in section on CAGs at level 
3).  
25.2.2.7. CAG level 2d: Other effects in offspring  
The main CAG level 2d “Other effects in offspring” can be subdivided to four main CAGs at 
level 2 and a number of subgroups, see Table 25.42. 
 
Table 25.42. Overview of CAGs within CAG level 2d “Other effects in offspring” 
CAG level 2 within “Other 
effects in offspring” 
Subgroup, CAG level 2 CAG includes the following 
specific effects 
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Male offspring (CAG level 2d1)  Changes in reproductive organs of 
male offspring (CAG level 2d1a) 
Organ weight changes 
Gross pathology 
Histolopathology  
Semen quality 
Altered anogenital distance 
Impaired fertility of male offspring 
(CAG level 2d1b) 
Decreased fertility (e.g. fertility 
index and copulation index)  
Female offspring (CAG level 2d2) Changes in reproductive organs of 
female offspring (CAG level 2d2a) 
Organ weight changes 
Gross pathology 
Histolopathology  
Impaired fertility of female 
offspring (CAG level 2d2b) 
Decreased fertility (e.g. fertility 
index)) 
Disturbed oestrus cyclicity 
Prolonged gestation 
Impaired parturition 
Male and/or female offspring 
(CAG level 2d3) 
Imparied fertility of male and/or 
female offspring (CAG level 2d3a) 
Decreased fertility (e.g. fertility 
index and litter size (some also in 
CAG for prenatal death)) 
Decreased number of implantations  
Effects on non-reproductive organs 
or endpoints in offspring (CAG 
level 2d4) 
Changes in other organs of 
offspring (CAG level 2d4a) 
Organ weight changes 
Gross pathology 
Histopathology  
Changes in non-reproductive 
endpoints in offspring (CAG level 
2d4b) 
Clinical signs (e.g. tremor, head tilt, 
torticollis, bloody nose, polyuria, 
cyanosis, laboured breathing) 
Other (e.g. altered  food 
consumption, haematological 
changes, neurological effects in 
offspring) 
 
 
Table 25.42 describes one suggested subdivision of the main CAG level 2d in Table 25.43. 
This subdivision is based on a grouping of effects on reproductive organs and fertility for 
males and females separately. 
The effects included in CAG level 2d4 “Effects on non-reproductive organs or endpoints in 
offspring” are diverse and are intended to reflect mainly developmental changes due to the 
exposure during gestation and lactation. Also non-developmental changes may be included in 
this subgroup, e.g. target organ effects seen in offspring.  
Direct effects on parental fertility or reproductive organs are presented in the section below on 
“Fertility”. The data on reproductive and fertility effects within CAG level 2d “Other effects 
in offspring” may need to be combined with data from the CAG for “Fertility” to determine 
CAG level 3 effects. A CAG level 3 has been made for substances acting via antiandrogenic 
modes of action within the main CAG for Offspring or the CAG for Fertility (see below in 
section on CAGs at level 3). 
Using the available data from the Access database numerous further subdivisions can be made 
e.g. substances with common histological effects in reproductive organs or substances with 
effect on the same reproductive organ. Suggested subgroups of the main CAG level 2d are 
presented in Appendix AJ and in Table 25.44 to 25.50. 
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Table 25.43. CAG level 2d: Other effects in offspring 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Acetamiprid 
Amidosulfuron 
Amitrole (aminotriazole) 
Azimsulfuron 
Beflubutamid 
Benthiavalicarb 
Beta-Cyfluthrin 
Carbendazim 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpropham 
Chlorpyrifos 
Chlorpyrifos-methyl 
Chlorsulfuron 
Clodinafop 
Clomazone 
Clothianidin 
Copper compounds 
Cyfluthrin 
Cypermethrin 
Deltamethrin 
Desmedipham 
Diflubenzuron 
Dimethoate 
Dimoxystrobin 
Dinocap 
Epoxiconazole 
Esfenvalerate 
Ethephon 
Ethofumesate 
Ethoxysulfuron 
Etofenprox 
Fenamidone 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fenpyroximate 
Fipronil 
Fluazinam 
Flumioxazin 
Fluoxastrobin 
Forchlorfenuron 
Fosetyl 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Lenacil 
Linuron 
Lufenuron 
Mancozeb 
Maneb 
Mecoprop 
Mepanipyrim 
Mepiquat 
Mepiquat 
Metamitron 
Metconazole 
Metiram 
Metrafenone 
Metribuzin 
Metsulfuron-methyl 
Milbemectin 
Molinate 
Oxamyl 
Penconazole 
Penconazole 
Phenmedipham 
Picolinafen 
Pirimiphos-methyl 
Propamocarb  
 
Propaquizafop 
Propiconazole 
Propineb 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prothioconazole 
Pyraclostrobin 
Pyrimethanil 
Pyriproxyfen 
Quinoclamine 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
S-Metolachlor 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triclopyr 
Trifloxystrobin 
Triticonazole 
Tritosulfuron 
Ziram 
Zoxamide 
zeta-Cypermethrin 
 
 
Table 25.44. CAG level 2d1a: Changes in reproductive organs of male offspring 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Esfenvalerate 
Ethephon 
Ethoxysulfuron 
Propamocarb  
Propaquizafop 
Propiconazole 
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Amidosulfuron 
Azimsulfuron 
Chlorothalonil 
Chlorotoluron 
Chlorpyrifos-methyl 
Clodinafop 
Clothianidin 
Cypermethrin 
Deltamethrin 
Desmedipham 
Dimethoate 
Epoxiconazole 
Fenoxaprop-P 
Fenpropidin 
Fenpyroximate 
Fipronil 
Isoproturon 
Isoxaflutole 
Linuron 
Mepanipyrim 
Metamitron 
Metrafenone 
Penconazole 
Pirimiphos-methyl 
Prosulfocarb 
Prothioconazole 
Quizalofop-P-ethyl 
Spinosad 
Spiroxamine 
Tebuconazole 
Thiacloprid 
Thiamethoxam 
Thifensulfuron-methyl 
Tolylfluanid 
Triadimenol 
Ziram 
 
 
For the purpose of identifying active substances with possible similar modes of action, 
substances with effects on male reproductive organs in offspring (CAG level 2d1a, Table 
25.44) are subgrouped into the following CAGs at level 2 for substances with effects 
indicating impaired male reproductive development or function (Table 25.45 to 25.48). These 
subgroups are used further in the section presenting CAGs at level 3. 
 
Table 25.45. CAG level 2d1a1: Decreased weight of male reproductive organs of 
offspring 
Amidosulfuron 
Chlorothalonil 
Chlorotoluron 
Clodinafop 
Cypermethrin 
Deltamethrin 
Desmedipham 
Dimethoate 
Esfenvalerate 
Fenoxaprop-P 
Fipronil 
Isoxaflutole 
Linuron 
Metamitron 
Propamocarb  
Propaquizafop 
Spiroxamine 
Thiamethoxam 
Thifensulfuron-methyl 
 
 
 
Table 25.46. CAG level 2d1a2: Reduced semen quality of offspring 
Azimsulfuron 
Chlorpyrifos-methyl 
Clothianidin 
Dimethoate 
Epoxiconazole 
Esfenvalerate 
Fenpropidin 
Glyphosate (incl trimesium aka 
sulfosate) 
Isoproturon 
Linuron 
 
Metrafenone 
Propamocarb  
Prothioconazole 
Quizalofop-P-ethyl 
Thiamethoxam 
 
 
 
Table 25.47. CAG level 2d1a3: Change in anogenital distance of male offspring 
Deltamethrin 
Dimethoate 
Epoxiconazole 
Esfenvalerate  
Propiconazole 
Prothioconazole 
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 Linuron 
 
Tebuconazole 
Triadimenol 
 
 
Three of the compounds in the CAG in 25.47 for level 2d1a3 for change in anogenital 
distance of male offspring also induce nipple retention in male offspring as listed in CAG 
level 2d1a4, Table 25.48. 
Table 25.48. CAG level 2d1a4: Nipple retention in male offspring 
Epoxiconazole Linuron Tebuconazole 
 
 
Table 25.49. CAG level 2d1b: Impaired fertility of male offspring 
Flumioxazin 
Propamocarb  
Quizalofop-P-tefuryl 
 
Triclopyr 
 
 
 
Table 25.50. CAG level 2d2a: Changes in reproductive organs of female offspring 
Carbendazim 
Chlorsulfuron 
Cypermethrin 
Deltamethrin 
Desmedipham 
Diflubenzuron 
Epoxiconazole 
Ethephon 
Ethoxysulfuron 
Fenoxaprop-P 
Fipronil 
Fosetyl 
Lenacil 
Linuron 
Metconazole 
Penconazole 
Prosulfocarb 
 
Prothioconazole 
Quizalofop-P-ethyl 
Spinosad 
Spiroxamine 
Tebuconazole 
Thiacloprid 
Triadimenol 
Triticonazole 
 
 
 
Table 25.51. CAG level 2d2b: Impaired fertility of female offspring 
2,4-D 
Amitrole (aminotriazole) 
Fluazinam 
Imazalil (aka enilconazole) 
Isoproturon 
Metconazole 
Penconazole 
Propamocarb  
Propiconazole 
Prothioconazole 
Quizalofop-P-tefuryl 
Spinosad 
Tri-allate 
Triadimenol 
 
 
Table 25.52. CAG level 2d3a: Impaired fertility of male and/or female offspring 
2,4-D Mepiquat Prothioconazole 
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Amitrole (aminotriazole) 
Dimethoate 
Ethofumesate 
Fenpropidin 
Fipronil 
Fluazinam 
Flumioxazin 
Forchlorfenuron 
Fosetyl 
Imazalil (aka enilconazole) 
Isoproturon 
Linuron 
Metamitron 
Metconazole 
Metrafenone 
Metribuzin 
Metsulfuron-methyl 
Milbemectin 
Molinate 
Oxamyl 
Penconazole 
Propineb 
Propyzamid 
Quinoclamine 
Quizalofop-P-ethyl 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Tolylfluanid 
Tri-allate 
Triadimenol 
Triticonazole 
 
 
 
Table 25.53. CAG level 2d4a: Changes in other organs of offspring 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Acetamiprid 
Amidosulfuron 
Amitrole (aminotriazole) 
Beflubutamid 
Benthiavalicarb 
Carbendazim 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpyrifos 
Chlorpyrifos-methyl 
Clodinafop 
Clomazone 
Clothianidin 
Copper compounds 
Cyfluthrin 
Desmedipham 
Diflubenzuron 
Dimoxystrobin 
Etofenprox 
Fenamidone 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fluazinam 
Fluoxastrobin 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Lenacil 
Linuron 
Mancozeb 
Maneb 
Mecoprop 
Mepanipyrim 
Metamitron 
Metiram 
Metrafenone 
Penconazole 
Propamocarb  
Propaquizafop 
Propiconazole 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prothioconazole 
Pyraclostrobin 
Pyriproxyfen 
Quinoclamine 
Quizalofop-P-ethyl 
S-Metolachlor 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Thiophanate-methyl 
Thiram 
Triadimenol 
Trifloxystrobin 
Zoxamide 
 
 
 
The CAG leve 2d4a “Changes in other organs of offspring” includes various effects and will 
need further subgrouping before being useful for cumulative risk assessment. It may also be 
possible to form CAGs for 2d4b “Changes in non-reproductive endpoints in offspring”, but at 
this covers a rather heterogeneous group of endpoints, CAGs have not been formed. Further 
information on effects included in CAG 2d4 “Changes in non-reproductive organs or 
endpoints in offspring” can be found in the “Remarks” column of the Access database and 
may be applicable for further subgrouping if this is considered relevant. 
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CAG level 2d4 for changes in non-reproductive organs or endpoints in offspring” and 
subgroups are not recommended for cumulative risk assessment. 
 
Table 25.54. CAG level 2d4b: Altered sex ratio of offspring 
2,4-D 
Abamectin (aka avermectin) 
Ethofumesate 
Iprovalicarb 
Penconazole 
Phenmedipham 
Propamocarb  
Propoxycarbazone 
Tetraconazole 
Thiacloprid 
Thifensulfuron-methyl 
Tralkoxydim 
Triadimenol 
Triclopyr 
 
 
Altered sex ratio often appears to be a chance finding and does not appear to be related to 
dosing, and the CAG 2d4b is not recommended for cumulative risk assessment. 
The CAGs at level 2d including subgroups presented in Tables 25.43 to 25.52 are relevant for 
cumulative risk assessment at level 2, and are all recommended for cumulative risk 
assessment. It is not recommended to use CAGs level 2d4 for changes in non-reproductive 
organs or endpoints in offspring presented in Tables 25.53 and 15.54, for cumulative risk 
assessment. 
25.2.2.8. CAG level 2e: Fertility  
The main CAG level 2e “Fertility” can be subdivided to five CAGs at level 2, see Table 25.55 
and Appendix AK. 
 
Table 25.55. Overview of CAGs within CAG level 2e “Fertility” 
CAG level 2 
within “Fertility” 
Subgroup, CAG level 2 CAG includes the following specific effects 
Male (CAG level 
2e1) 
 
Changes in male 
reproductive organs (CAG 
level 2e1a) 
Organ weight changes  
Gross pathology 
Histolopathology  
Semen quality 
Impaired male fertility 
(CAG level 2e1b) 
Decreased fertility (e.g. fertility index) 
Decreased number of pregnant unexposed females 
Altered sexual behaviour 
Female (CAG 
level 2e2) 
 
Changes in female 
reproductive organs (CAG 
level 2e2a) 
Organ weight changes 
Gross pathology 
Histolopathology  
Impaired female fertility 
(CAG level 2e2b) 
Decreased fertility  (e.g. fertility index), exposed females 
(e.g. prenatal developmental studies) 
Disturbed oestrus cyclicity 
Decreased number of implantations 
Prolonged gestation 
Premature delivery 
Impaired parturition 
Male and/or Impaired male and/or Decreased fertility (e.g. fertility index and litter size (some 
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female (CAG level 
2e3) 
female fertility (CAG level 
2e3a) 
also in CAG for prenatal death)) when both males and 
females are exposed (e.g. one-/multigeneration studies) 
Preimplantation loss/decreased number of implantations 
when both males and females are exposed 
 
 
The effects listed here are all direct effects in males or females, i.e. effects in repeated dose 
studies and effects on parental animals in generation studies. Effects in the reproductive 
system of offspring were presented in the section above on the CAG Level 2d “Other effects 
in offspring”. 
In addition, various relevant subgroups of the CAG level 2e “Fertility” in Table 25.56 can be 
proposed, e.g. decreased male reproductive organ weights, decreased male fertility and semen 
quality, decreased female fertility, increased male reproductive organ weights, decreased 
female reproductive organ weights, decreased female fertility, increased female reproductive 
organ weights. Using the available data from the Access database numerous subdivisions can 
be made, e.g. active substances with common histological effects in reproductive organs or 
substances with effect on the same reproductive organ. Appendix AL and Table 25.57 to 
25.65 present relevant subgroups. When evaluating mode of action of substances the 
information on reproductive and fertility effects within the CAG level 2e “Fertility” may need 
to be combined with information from the CAG level 2d “Other effects in offspring”, see the 
section on CAGs at level 3 and level 4 for mode and mechanism of action below.  
Table 25.56. CAG level 2e: Fertility 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Acetamiprid 
Aclonifen 
Amidosulfuron 
Amitrole (aminotriazole) 
Azimsulfuron 
Beflubutamid 
Benalaxyl 
Benfluralin 
Bentazone 
Benthiavalicarb 
Beta-Cyfluthrin 
Bifenox 
Bromoxynil 
Carbendazim 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpyrifos 
Chlorpyrifos-methyl 
Chlorsulfuron 
Cinidon ethyl 
Fenamidone 
Fenamiphos (aka phenamiphos) 
Fenhexamid 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Fipronil 
Fluazinam 
Fludioxonil 
Flufenacet (formerly fluthiamide) 
Flumioxazin 
Fluopicolide 
Fluoxastrobin 
Flupyrsulfuron-methyl (DPX KE 
459) 
Flusilazole 
Folpet 
Forchlorfenuron 
Formetanate 
Fosetyl 
Fosthiazate 
Fuberidazole 
Gibberellin 
Glufosinate 
Glyphosate (incl trimesium aka 
Oxamyl 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Propamocarb  
Propaquizafop 
Propiconazole 
Propineb 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
Pyraclostrobin 
Pyrimethanil 
Pyriproxyfen 
Quinoclamine 
Quinoxyfen 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Rimsulfuron (aka renriduron) 
S-Metolachlor 
Silthiofam 
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Clodinafop 
Clomazone 
Clothianidin 
Cyazofamid 
Cyclanilide 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Cyromazine 
Deltamethrin 
Desmedipham 
Dicamba 
Dichlorprop-P 
Difenoconazole 
Diflubenzuron 
Diflufenican 
Dimethoate 
Dimethomorph 
Dimoxystrobin 
Dinocap 
Diuron 
Dodemorph 
Epoxiconazole 
Esfenvalerate 
Ethephon 
Ethofumesate 
Ethoprophos 
Ethoxysulfuron 
Etoxazole 
Famoxadone 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imidacloprid 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Lenacil 
Linuron 
Lufenuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Mepanipyrim 
Mepiquat 
Mesotrione 
Metamitron 
Metconazole 
Methiocarb (aka mercaptodimethur) 
Metiram 
Metrafenone 
Metribuzin 
Metribuzin 
Milbemectin 
Molinate 
Molinate 
Oxadiazon 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Tribenuron (aka metometuron) 
Triclopyr 
Trifloxystrobin 
Triflusulfuron 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
Warfarin (aka coumaphene) 
Ziram 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
Main subdivisions of the CAG level 2e “Fertility” are presented in Tables 25.57 to 25.61: 
Table 25.57. CAG level 2e1a: Changes in male reproductive organs 
2,4-D 
2,4-DB 
2-Phenylphenol (incl. sodium salt 
orthophenyl phenol) 
Abamectin (aka avermectin) 
Acetamiprid 
Amidosulfuron 
Azimsulfuron 
Beflubutamid 
Benalaxyl 
Benfluralin 
Bentazone 
Benthiavalicarb 
Bromoxynil 
Ethoxysulfuron 
Etoxazole 
Famoxadone 
Fenamidone 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Fluazinam 
Fludioxonil 
Flufenacet (formerly fluthiamide) 
Fluoxastrobin 
Flupyrsulfuron-methyl (DPX KE 
459) 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Propamocarb  
Propaquizafop 
Propineb 
Propyzamide 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
Quinoclamine 
Quinoxyfen 
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Carbendazim 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpyrifos 
Chlorsulfuron 
Cinidon ethyl 
Clodinafop 
Clothianidin 
Cyazofamid 
Cyclanilide 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Cyromazine 
Deltamethrin 
Desmedipham 
Dichlorprop-P 
Difenoconazole 
Diflubenzuron 
Diflufenican 
Dimethoate 
Dimethomorph 
Dimoxystrobin 
Dinocap 
Diuron 
Esfenvalerate 
Ethephon 
Ethoprophos 
 
Flusilazole 
Folpet 
Forchlorfenuron 
Formetanate 
Fosetyl 
Fuberidazole 
Gibberellin 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Imazaquin 
Imidacloprid 
Indoxacarb 
Iodosulfuron-methyl-sodium 
Iprodione 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Linuron 
Lufenuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Mepiquat 
Mesotrione 
Metamitron 
Metconazole 
Methiocarb (aka mercaptodimethur) 
Metiram 
Molinate 
Oxasulfuron 
 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Rimsulfuron (aka renriduron) 
Silthiofam 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tebufenpyrad 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triasulfuron 
Tribenuron (aka metometuron) 
Triclopyr 
Trifloxystrobin 
Triflusulfuron 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
 
Table 25.58. CAG level 2e1b: Impaired male fertility 
Abamectin (aka avermectin) 
Amitrole (aminotriazole) 
Carbendazim 
Cypermethrin  
Dimethoate 
Thiram 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
 
Table 25.59. CAG level 2e2a: Changes in female reproductive organs 
2,4-D 
2,4-DB 
Aclonifen 
Amitrole (aminotriazole) 
Azimsulfuron 
Benfluralin 
Fenpyroximate  
Fipronil 
Fluazinam 
Flufenacet (formerly fluthiamide) 
Fluoxastrobin 
Flupyrsulfuron-methyl (DPX KE 
Propoxycarbazone 
Propyzamide 
Prosulfocarb 
Prosulfuron 
Prothioconazole 
Pymetrozine 
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Benthiavalicarb 
Beta-Cyfluthrin 
Carbendazim 
Chlormequat (chloride) 
Chlorothalonil 
Clodinafop 
Clomazone 
Clothianidin 
Cyclanilide 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cyromazine 
Deltamethrin 
Desmedipham 
Dicamba 
Difenoconazole 
Diflubenzuron 
Diflufenican 
Dimethoate 
Dimoxystrobin 
Dinocap 
Ethephon 
Ethofumesate 
Ethoxysulfuron 
Etoxazole 
Fenamiphos (aka phenamiphos) 
Fenpropidin 
Fenpropimorph 
459) 
Flusilazole 
Fosetyl 
Fuberidazole 
Gibberellin 
Glufosinate 
Imazalil (aka enilconazole) 
Imazaquin 
Iprodione 
Isoproturon 
Isoxaflutole 
Lenacil 
Linuron 
Lufenuron 
Mancozeb 
Mesotrione 
Metamitron 
Metconazole 
Metiram 
Metribuzin 
Milbemectin 
Molinate 
Molinate 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Propamocarb  
Propaquizafop 
Pyriproxyfen 
Quinoclamine 
Quizalofop-P-ethyl 
Silthiofam 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Tebuconazole 
Tepraloxydim 
Tetraconazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tolylfluanid 
Tralkoxydim 
Tri-allate 
Triadimenol 
Tribenuron (aka metometuron) 
Triclopyr 
Trifloxystrobin 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
Ziram 
zeta-Cypermethrin 
 
 
Table 25.60. CAG level 2e2b: Impaired female fertility 
Amitrole (aminotriazole) 
Beflubutamid 
Carbendazim 
Dichlorprop-P 
Difenoconazole 
Diflufenican 
Dimethoate 
Dinocap 
Epoxiconazole 
Fenamiphos (aka phenamiphos) 
Fenhexamid 
Fenpropimorph 
Fluazinam 
Fluopicolide 
Flusilazole 
Fosthiazate 
Glufosinate 
Imazalil (aka enilconazole) 
Iprodione 
Mancozeb 
Mepanipyrim 
Mesotrione 
Metconazole 
Metrafenone 
Molinate 
Oxadiazon 
Penconazole 
Propamocarb  
Propaquizafop 
Propiconazole 
Prothioconazole 
Quinoclamine 
Quizalofop-P-ethyl 
Rimsulfuron (aka renriduron) 
S-Metolachlor 
Spinosad 
Tebuconazole 
Tetraconazole 
Thiacloprid 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tralkoxydim 
Tribenuron (aka metometuron) 
Triclopyr 
Triticonazole 
Tritosulfuron 
lambda-Cyhalothrin 
zeta-Cypermethrin 
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Table 25.61. CAG level 2e3a: Impaired male and/or female fertility 
Aclonifen 
Amitrole (aminotriazole) 
Beta-Cyfluthrin 
Bifenox 
Chlormequat (chloride) 
Chlorotoluron 
Chlorpyrifos-methyl 
Chlorsulfuron 
Clodinafop 
Clomazone 
Cyclanilide 
Cymoxanil 
Cypermethrin 
Cyromazine 
Dimethoate 
Dodemorph 
Esfenvalerate 
Ethofumesate 
Ethoprophos 
Flumioxazin 
Flusilazole 
Formetanate 
Fosthiazate 
Glufosinate 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Iodosulfuron-methyl-sodium 
Ioxynil 
Iprodione 
Isoproturon 
Linuron 
Lufenuron 
Mesotrione 
Metamitron 
Metconazole 
Methiocarb (aka mercaptodimethur) 
Metiram 
Metribuzin 
Molinate 
Oxamyl 
Oxasulfuron 
Penconazole 
Phosmet 
Propamocarb  
Propiconazole 
Propineb 
Propoxycarbazone 
Prothioconazole 
Pyraclostrobin 
Pyrimethanil 
Quizalofop-P-ethyl 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Tebuconazole 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiophanate-methyl 
Thiram 
Triadimenol 
Triticonazole 
zeta-Cypermethrin 
 
 
For the purpose of identifying active substances with possible similar modes of action, 
substances with effects on male reproductive organs (Table 25.57) are subgrouped further into 
the following CAGs at level 2 for substances with effects indicating impaired male 
reproductive function (Tables 25.62 to 25.65): 
 
Table 25.62. CAG level 2e1a1: Decreased weight of male reproductive organs” and 
“Small male reproductive organs 
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2,4-D 
2,4-DB 
Acetamiprid 
Azimsulfuron 
Beflubutamid 
Bentazone 
Benthiavalicarb 
Bromoxynil 
Carbendazim 
ChlorothalonilChlorotoluron 
Chlorpyrifos 
Cyclanilide 
Cyflufenamid 
Cymoxanil 
Cypermethrin 
Desmedipham 
Dichlorprop-P 
Difenoconazole 
Dimethoate 
Dimethomorph 
Dinocap 
Esfenvalerate 
Ethephon 
Ethoxysulfuron 
Etoxazole 
Famoxadone 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Flufenacet (formerly fluthiamide)? 
Fluoxastrobin 
Folpet 
Formetanate? 
Gibberellin 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Iprodione 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Linuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Metconazole 
Molinate 
Oxasulfuron 
Phenmedipham 
Phosmet 
Propamocarb  
Prothioconazole 
Pymetrozine 
Quinoxyfen 
Quinoclamine 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Silthiofam 
Sodium 5-nitroguaiacolate 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Tebuconazole 
Tepraloxydim 
Tetraconazole 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tralkoxydim 
Tri-allate 
Triasulfuron 
Trifloxystrobin 
Triflusulfuron 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
The CAG level 2e1a1 in Table 15.62 includes both the specific effect “decreased weight of 
male reproductive organs” and the specific effect “small reproductive organs”. 
 
Table 25.63. CAG level 2e1a2: Decreased weight of male reproductive organs in 
Hershberger assay 
Beta-Cyfluthrin 
Chlorpyrifos-methyl 
Cyfluthrin 
Iprodione 
Linuron 
 
 
Table 25.64. CAG level 2e1a3: Reduced semen quality 
 
2,4-D 
2,4-DB 
Abamectin (aka avermectin) 
Amidosulfuron 
Azimsulfuron 
Carbendazim 
Diuron 
Esfenvalerate 
Fluoxastrobin 
Folpet 
Iprodione 
Isoproturon 
Prothioconazole 
Pymetrozine 
Quinoclamine 
Quinoxyfen 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
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Chlormequat (chloride) 
Chlorotoluron 
Chlorpyrifos 
Clothianidin 
Cymoxanil 
Cypermethrin 
Deltamethrin 
Desmedipham 
Difenoconazole 
Dimethoate 
Dimoxystrobin 
Linuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Metconazole 
Molinate 
Oxasulfuron 
Penconazole 
Picolinafen 
Propamocarb  
Propaquizafop 
 
Spinosad 
Sulcotrione 
Tebuconazole 
Tepraloxydim 
Tetraconazole 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tralkoxydim 
Triflusulfuron 
Tritosulfuron 
lambda-Cyhalothrin 
zeta-Cypermethrin 
 
 
 
Table 25.65. CAG level 2e1a4: Leydig cell hyperplasia 
Cyflufenamid 
Flusilazole 
Iprodione 
 
Iprovalicarb 
Linuron 
Metamitron 
Metconazole 
Propaquizafop 
Tepraloxydim 
Tralkoxydim 
Triflusulfuron 
 
 
The CAG level 2e1a4 “Leydig cell hyperplasia” is combined with the CAG level 2f3 “Leydig 
cell tumours”, see next section on Tumours. 
The CAGs for fertility at level 2e including subgroups presented in Tables 25.57 to 25.65 are 
all relevant for cumulative risk assessment at level 2, and are all recommended for cumulative 
risk assessment. 
25.2.2.9. CAG level 2f: Tumours in reproductive organs  
As noted elsewhere, genotoxic pesticides are not authorized for use in the EU. Therefore, 
tumours described in DARs can be considered non-genotoxic. Non-genotoxic tumours in 
reproductive organs can be related to disruption of the endocrine system. For example, some 
anti-androgenic chemicals are known to induce Leydig cell tumours. The human relevance of 
Leydig cell tumours is debated, but nevertheless, the detection of Leydig cell tumours in 
animal studies are a clear indication of endocrine disrupting effects of a chemical (Cook et al., 
1999). Therefore CAGs for Leydig cell tumours are relevant.  
Also other tumours may be indicative for a putative endocrine related mode of action. 
Importantly, tumours in reproductive organs may be closely related to other effects in those 
organs, and compounds listed in CAGs for tumours are likely to be present also in the CAGs 
for effects on reproductive organs (see section on Fertility) due to e.g. histological or 
functional effects.  
The main CAG level 2f “Tumours in reproductive organs” can be subdivided, see Table 
25.66. 
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Table 25.66. Overview of CAGs within CAG level 2f “Tumours in reproductive organs” 
CAG level 2 Subgroup, CAG level 2 CAG includes the following specific effects 
Tumours in 
reproductive organs 
(CAG level 2f) 
Mammary gland tumour 
(CAG level 2f1) 
Adenocarcinoma 
Ovarian tumour (CAG 
level 2f2) 
Adenoma 
Granulosa-theca cell blastoma 
Granulosa-theca cell tumour 
Luteoma 
Testis tumour (CAG level 
2f3) 
Leydig cell tumour (interstitial cell adenoma) 
Uterus tumour (CAG level 
2f4) 
Endometrial polyps 
Adenoma 
Adenocarcinoma 
Mixed Müllerian tumours 
Sarcoma 
 
 
As presented in Appendix AM some active substances may induce more than one type of 
tumours in reproductive organs. A collective CAG for tumours in reproductive organs and 
CAGs for each tumour type are presented below: 
 
Table 25.67. CAG level 2f: Tumours in reproductive organs (including all subtypes) 
Benfluralin 
Benthiavalicarb 
Chlorpropham 
Chlorsulfuron 
Dimethomorph 
Diuron 
Epoxiconazole 
Ethoprophos 
Ethoxysulfuron 
Etoxazole 
Flusilazole 
Fuberidazole 
Ioxynil 
Iprodione 
Iprovalicarb 
Lenacil 
Linuron 
Pirimicarb 
Propaquizafop 
Prosulfuron 
Quizalofop-P-tefuryl 
Thiacloprid 
Tolylfluanid 
Tralkoxydim 
Tribenuron (aka metometuron) 
Triflusulfuron 
Tritosulfuron 
Ziram 
 
 
Table 25.68. CAG level 2f1: Mamma tumours 
Diuron 
Lenacil  
Tribenuron (aka metometuron) 
Tritosulfuron 
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Table 25.69. CAG level 2f2: Ovary tumours 
Diuron 
Epoxiconazole 
Linuron 
Thiacloprid 
Tolylfluanid 
Tralkoxydim 
 
 
Table 25.70. CAG level 2f3: Testis tumours (Leydig cell tumours) 
Benfluralin 
Chlorpropham 
Chlorsulfuron 
Dimethomorph 
Etoxazole 
Flusilazole 
Iprodione 
Linuron 
Propaquizafop 
Prosulfuron 
Quizalofop-P-tefuryl 
Tralkoxydim 
Triflusulfuron 
Ziram 
 
 
Table 25.71. CAG level 2f4: Uterus tumours 
Benthiavalicarb 
Epoxiconazole 
Ethoprophos 
Ethoxysulfuron 
Fuberidazole 
Ioxynil 
Iprovalicarb 
Linuron 
Pirimicarb 
Thiacloprid 
Tolylfluanid 
Tralkoxydim 
 
 
A CAG at level 2 can be made for active substances inducing Leydig cell hyperplasia (see 
section on Fertility, Table 25.65) and Leydig cell tumours. The inclusion of Leydig cell 
hyperplasia in the CAG for Leydig cell tumours adds three more active substances to this 
CAG (metamitron, metconazole and tepraloxydim). 
 
Table 25.72. Modified CAG 2f3: Leydig cell hyperplasia and/or Leydig cell tumours 
Benfluralin 
Chlorpropham 
Chlorsulfuron 
Cyflufenamid 
Dimethomorph 
Etoxazole 
Flusilazole 
Iprodione 
Iprovalicarb 
Linuron 
Metamitron 
Metconazole 
 
Propaquizafop 
Prosulfuron 
Quizalofop-P-tefuryl 
Tepraloxydim 
Tralkoxydim 
Triflusulfuron 
Ziram 
 
 
All the CAGs level 2f for tumours including subgroups (Table 25.67 to 25.71) can be 
recommended for cumulative risk assessment. The modified CAG 2f3 for Leydig cell 
hyperplasia and/or Leydig cell tumours (Table 25.72) can also be recommended. 
 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
233 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
25.2.3. CAGs level 3 and level 4: Mode / mechanism of action 
Although genotoxicity is a relevant mechanism for a number of potent developmental and 
reproductive toxicants, this mechanism is not considered relevant for this project as it is 
assumed that none of the pesticides authorized in the EU have any genotoxic potential.  
In contrast, all modes of action which result in effects on the endocrine system could be 
important and relevant for the effects seen in reproductive toxicity studies. Certain active 
substances can interfere with the action of steroidal androgens in foetal life, with irreversible 
consequences for later life stages. 
Examples on mode of actions are:  
• Anticoagulants inducing excess bleeding may induce abortions when administered to 
pregnant dams and developmental effects in offspring 
• Inhibition of/interference with the thyroid hormone homeostasis in pregnant dams may 
lead to delayed development of offspring (reviewed by Boas et al., 2009 and Brucker-
Davis et al., 1998) 
• Inhibition of/interference with the steroid hormone homeostasis (in foetal life) may 
lead to altered development of the reproductive system in males and females (reviewed 
in e.g. Waring and Harris, 2011 and Gray et al., 2006) 
  (anti)androgenic compounds may 
  inhibit 5α-reductase, thereby blocking the conversion of testosterone to DHT 
  act as androgen receptor antagonists 
  decrease androgen levels due to inhibitions of enzymes involved in steroid 
hormone synthesis, e.g. Star,P450c17, P450scc and others (mechanism of action). 
  decrease androgen levels due to increased catabolism of steroid hormones 
  (anti)estrogenic compounds may 
  act as oestrogen receptor agonism/antagonists 
  inhibit aromatase activity (resulting in decreased oestrogen levels) 
  induce aromatase activity (resulting in increased oestrogen levels) 
  decrease oestrogen levels due to decreased steroid synthesis or increased 
catabolism of steroid hormones 
 
These modes of action may lead to changes in reproductive organ weight and histology 
(including endocrine-related tumours) or alter the function of reproductive organs leading to 
e.g. impaired fertility. Some of the modes of action mentioned above are not detected in the 
studies described in the old DARs. The reason is that the applied test guidelines were not 
aimed at detecting effects on endocrine sensitive endpoints and mechanistic studies on 
endocrine effects were rarely performed. The open literature shows several examples of 
endocrine effects of active substances for which the DARs revealed no clear effects on 
fertility/reproduction. 
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The CAGs for reproduction/fertility and development as listed in the previous sections are all 
at level 2. For many endpoints, level 3 (mode of action) or level 4 (mechanism of action) 
categories are not presented as it is difficult to pinpoint exact modes or mechanisms of action 
for many of the effects described in the DARs. However, inclusion of data from other target 
organ systems collected in the current project may contribute with knowledge on mode of 
action. For example, knowledge on active substance effects on the thyroid hormone system 
has been compared with knowledge on active substances resulting in delayed development, 
and for this mode of action (interference with thyroid hormone system) a CAG level 3 has 
been made.  
CAGs at level 3 (mode of action) can be subdivided into the following CAGs at level 4 
(mechanism of action) on the basis of in vitro effects of these active substances. CAGs at level 
3 combine findings in DARs with findings in the open literature. CAGs at level 4 are mainly 
based on information found in the open literature, as DARs reveal little mechanistic 
information on these endpoints.  
 
Table 25.73. CAGs at level 3 and 4 for reproductive and developmental toxicity 
Level 2 effect Level 3 – Mode of action Level 4 – Mechanism of action 
Delayed development Interruption of thyroid hormone 
homeostasis  
Various, see section on thyroid 
Developmental effects Anticoagulants  Inhibition of vitamin K epoxide reductase 
Altered reproductive organ 
weight or fertility in male and 
females following direct 
exposure (parental generation 
or repeated dose studies) or 
indirect exposure (offspring) 
 
Anti-androgenic  
 
AR antagonists (e.g. determined in reporter 
gene assays) 
Steroid synthesis inhibitors 
Estrogenic Estrogenic in vitro (e.g. proliferation assays)  
Aromatase inducers 
Anti-estrogenic Anti-estrogenic in vitro 
Aromatase inhibitors 
Steroid synthesis inhibitors 
 
 
The OECD “Guidance Document on Standardised Test Guidelines for Evaluating Chemicals 
for Endocrine Disruption” describes endocrine disrupting effects and is intended as a “tool to 
support regulatory authorities by helping to interpret assay results and suggesting possible 
additional studies for reducing uncertainty”. This document lists possible modes of action of 
chemicals and for each type of guideline study (e.g. 28 day study test guideline 407 or 2-
generation study test guideline 416) the possible effects related to each mode of action is 
listed. For anti-androgenic compounds, typical effects in 28 day studies, pubertal male studies, 
Hershberger studies and 1- or 2-generation studies include decreases in weights of 
epididymides, prostate and seminal vesicles with coagulating glands, accompanied by 
histopathological changes in those organs. However, similar effects may also be seen with 
estrogenic compounds (OECD 2011).  
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In the current project, active substances inducing a decrease in male reproductive organ 
weights are included in the CAG for substances with effects that “may be related to” an anti-
androgenic mode of action. It should be noted, however, that this grouping does not take into 
account other mechanistic information, and that the effects may be caused by other modes of 
action than anti-androgenicity.   
For females, the OECD “Guidance Document on Standardised Test Guidelines for Evaluating 
Chemicals for Endocrine Disruption” describes that changes in uterus or ovary weight are 
seen with estrogenic as well as anti-androgenic compounds in assays such as 28 day studies, 
pubertal female studies, uterotrophic assays and 1- or 2-generation studies (OECD 2011). 
However, changes in uterus or ovary weight are also seen with androgenic or antiandrogenic 
chemicals, and further mechanistic knowledge may be needed to be able to categorize 
chemicals with effects on females depending on their mode of action. 
CAGs at level 3 for anti-androgenic substances, thyroid hormone active substances and 
anticoagulants are presented below. No CAGs at level 3 were made for estrogenic or anti-
estrogenic substances, although this might have been possible based on the information 
available. For these mechanism of action CAGs at level 4 were established. 
25.2.3.1. CAG level 3a: Anti-androgenic mode of action 
A CAG level 3a for active substances with effects that may be related to an anti-androgenic 
mode of action was established (Table 25.74). This CAG combines several previously 
presented CAGs and includes active substances which  
• Reduce male reproductive organ weights in exposed males (presented within the 
Fertility CAG, see Table 25.62)  
• And/or reduce male reproductive organ weights in offspring of exposed dams (within 
Offspring CAG, see Table 25.45) 
• And/or reduce semen quality in exposed males or male offspring of exposed dams, see 
Table 25.64 and Table 25.46 
• And/or reduce male reproductive organ weights in the Hershberger assay (see Table 
25.63) 
 
Table 25.74. CAG level 3a: Anti-androgenic mode of action (see text for explanation) 
2,4-D 
2,4-DB 
Abamectin (aka avermectin) 
Acetamiprid 
Amidosulfuron 
Amitrole (aminotriazole) 
Azimsulfuron 
Beflubutamid 
Beta-Cyfluthrin 
Bentazone 
Benthiavalicarb 
Esfenvalerate 
Ethephon 
Ethoxysulfuron 
Etoxazole 
Famoxadone 
Fenoxaprop-P 
Fenpropidin 
Fenpropimorph 
Fenpyroximate 
Fipronil 
Flufenacet (formerly fluthiamide)? 
Propamocarb  
Propaquizafop 
Propiconazole 
Prothioconazole 
Pymetrozine 
Quinoclamine 
Quinoxyfen 
Quizalofop-P-ethyl 
Quizalofop-P-tefuryl 
Silthiofam 
Sodium 5-nitroguaiacolate 
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Bromoxynil 
Carbendazim 
Chlormequat (chloride) 
Chlorothalonil 
Chlorotoluron 
Chlorpyrifos 
Chlorpyrifos-methyl 
Clodinafop 
Clothianidin 
Cyclanilide 
Cyflufenamid 
Cyfluthrin 
Cymoxanil 
Cypermethrin 
Deltamethrin 
Desmedipham 
Dichlorprop-P 
Difenoconazole 
Dimethoate 
Dimethomorph 
Dimoxystrobin 
Dinocap 
Diuron 
Epoxiconazole 
Fluoxastrobin 
Folpet 
Formetanate? 
Gibberellin 
Glyphosate (incl trimesium aka 
sulfosate) 
Imazalil (aka enilconazole) 
Iprodione 
Iprovalicarb 
Isoproturon 
Isoxaflutole 
Linuron 
MCPA 
MCPB 
Mancozeb 
Maneb 
Metamitron 
Metconazole 
Metrafenone 
Molinate 
Oxasulfuron 
Penconazole 
Phenmedipham 
Phosmet 
Picolinafen 
Sodium o-nitrophenolate 
Sodium p-nitrophenolate 
Spinosad 
Spiroxamine 
Sulcotrione 
Tebuconazole 
Tepraloxydim 
Tetraconazole 
Thiamethoxam 
Thifensulfuron-methyl 
Thiophanate-methyl 
Thiram 
Tolclofos-methyl 
Tralkoxydim 
Tri-allate 
Triadimenol 
Triasulfuron 
Trifloxystrobin 
Triflusulfuron 
Trinexapac (aka cimetacarb ethyl) 
Triticonazole 
Tritosulfuron 
lambda-Cyhalothrin 
zeta-Cypermethrin 
? = No information on whether the testes weight is increased or decreased 
 
 
It may be debated whether active substances inducing a decrease in sperm quality should be 
included in the CAG for anti-androgenic mode of action, as decreased sperm quality could 
have many other causes than and if this is decided it may also be relevant to include active 
substances decreasing male fertility. The data available in the Appendices AP to AX and in 
the Access database makes it possible to modify the above CAG by including or excluding 
e.g. semen quality or fertility effects.  
The CAG level 3a presented in Table 25.74 is recommended for cumulative risk assessment. 
25.2.3.2. CAG level 3b: Interruption of maternal thyroid hormone homeostasis as potential mode of 
action for observed delayed development of offspring 
Sixty active substances were identified as having effects on the thyroid gland as presented in 
the section on thyroid toxicity. Of these active substances, 41 active substances also affect 
pre- or postnatal development, and the following CAG level 3b for thyroid interrupting active 
substances have been made within the CAG level 2 for delayed development: 
 
Table 25.75. CAG level 3b: Interruption of maternal thyroid hormone homeostasis as 
potential mode of action for observed delayed development of offspring 
(including compounds having effects at maternal toxic doses) 
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2,4-D 
2,4-DB 
Amitrole (aminotriazole) 
Beflubutamid 
Benalaxyl 
Benthiavalicarb 
Boscalid 
Chlorpropham 
Clodinafop 
Cyflufenamid 
Cyprodinil 
Desmedipham 
Dinocap 
Etofenprox 
Fenamidone 
Fipronil 
Flumioxazin 
Fluoxastrobin 
Fuberidazole 
Imidacloprid 
Ioxynil 
Isoxaflutole 
Lufenuron 
Mancozeb 
Maneb 
MCPA 
MCPB (metabolized to MCPA) 
Metribuzin 
Prothioconazole 
Pymetrozin 
Silthiofam 
Tepraloxydim 
Tetraconazole 
Thiabendazole 
Thiacloprid 
Thiamethoxam 
Thiophanate-methyl 
Thiram 
Tribenuron (aka metometuron) 
Tritosulfuron 
Ziram 
 
 
It should be noted that for the above 41 compounds it is not definitive that interruption of 
thyroid hormone homeostasis is the mode of action for the observed delayed development. For 
some of the above compounds, effects on delayed development appear at doses affecting 
maternal body weight or food consumption. Those compounds are excluded in the modified 
CAG level 3b: 
Table 25.76. Modified CAG level 3b for interruption of maternal thyroid hormone 
homeostasis as possible mode of action for delayed development of offspring 
(excluding compounds having effects on maternal body weight or food 
consumption) 
Amitrole (aminotriazole) 
Beflubutamid 
Boscalid 
Clodinafop 
Flumioxazin 
Fluoxastrobin 
Ioxynil 
Isoxaflutole 
MCPA 
Metribuzin 
Prothioconazole 
Tetraconazole 
Thiacloprid 
Thiophanate-methyl 
 
 
As mentioned in the section on delayed development, developmental effects at doses also 
showing maternal toxicity (effects on body weight or food consumption) are often used by 
DARs for setting developmental NOAELs. Therefore, to use the same principles as applied by 
the DAR, it would not be appropriate to exclude compounds having effects at maternal toxic 
doses. 
25.2.3.3. CAG level 3c: Coagulation inhibition as mode of action for developmental effects 
Anticoagulants are considered to be teratogenic due to similarities to warfarin which induces 
prenatal death and malformations in experimental animals as well as in humans. Among the 
listed substances only one (Bentazone) was found to be a coagulation inhibitor acting via 
inhibition of the enzyme vitamin K epoxide reductase. Bentazone had developmental effects 
including prenatal death, delayed prenatal development and decreased prenatal body weight. 
As other active substances (new or old not included in this project) may also be coagulation 
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inhibitors, a CAG for coagulation inhibition as a mode of action for developmental effects is 
recommended. 
 
Table 25.77. CAG level 3c: Coagulation inhibition as mode of action for developmental 
effects 
Bentazone 
 
 
25.2.3.4. CAGs level 4: Mechanism of action 
Based on a search in the open literature, CAGs at level 4 for mechanism of actions could be 
made (Table 25.78). It should be noted, that this information is mainly based on in vitro 
studies, and that such studies have not been made for all active substances. Therefore, these 
CAGs cannot be considered complete. 
 
Table 25.78. CAG level 4: In vitro mechanism of action 
AR antagonism Aromatase 
inhibition 
Aromatase 
induction 
Estrogenicity Anti-
estrogenicity 
Steroid 
synthesis 
inhibition 
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2-phenylphenol 
Bentazone 
Beta-cyfluthrin 
Chlorpropham 
Chlorpyrifos 
Cyfluthrin 
Cypermethrin 
Cyprodinil 
Deltametrin 
Dimethomorph 
Diuron 
Epoxiconazole 
Esfenvalerate 
Fenhexamid 
Fipronil 
Fludioxonil 
Imazalil 
Iprodione 
Isoproturon 
Linuron 
Methiocarb 
Pirimiphos-
methyl 
Propiconazole 
Pyrimethanil 
Quinoxyfen 
Tebuconazole 
Tolyfluanid 
Triadimenol 
(lamda-
Cyhalothrin) 
Difenoconazole 
Diuron 
Epoxiconazole 
Flusilazole 
Glyphosate 
Imazalil 
Linuron 
Penconazole 
Propiconazole 
Tebuconazole 
Triadimenol 
Triflusulfuron 
Clodinafop 
Cypermethrin 
Iprodion 
Oxadiazon 
Pirimicarb 
Propamocarb 
Thiacloprid 
2-phenylphenol 
Bentazone 
Chlorpyrifos 
Cyfluthrin 
Cypermethrin 
Deltamethrin 
Dodemorph 
Methiocarb 
Pendimethalin 
Pirimiphos-
methyl 
Pyriproxyfen 
Thiabendazole 
Tolclofos-
methyl 
Triadimenol 
Tribenuron-
methyl 
Captan 
Chlorsulfuron 
Cyfluthrin 
Diuron 
Epoxiconazole 
Etofenprox 
Isoproturon 
Linuron 
Mecoprop 
Methiocarb 
Pendimethalin 
Propiconazole 
Tebuconazole 
Tolclofos-
methyl 
Triadimenol 
(metabolite) 
Chlorpyrifos 
Cypermethrin 
Dimethoate 
Epoxiconazole 
Esfenvalerate 
Flusilazole 
Glyphosate 
Iprodione 
Isoproturon 
Linuron 
Molinate 
Propiconazole 
Tebuconazole 
 
 
The information on mechanism of action in vitro can be applied for identifying CAGs at level 
4 for compounds with specific reproductive effects (level 2) that may be attributed to the 
listed mechanisms of action. 
 
Table 25.79. CAG level 4a: Substances with effects on male or female fertility or 
reproductive organs in vivo (direct effects or effects in offspring, i.e. presented 
in Table 25.56 or Tables 25.44 to 25.52) and for which AR antagonism is seen 
in vitro 
2-phenylphenol 
Bentazone 
Beta-cyfluthrin 
Chlorpyrifos 
Cyfluthrin 
Cypermethrin 
Deltametrin 
Dimethomorph 
Diuron 
Epoxiconazole 
Esfenvalerate 
Fenhexamid 
Fipronil 
Fludioxonil 
Imazalil 
Isoproturon 
Linuron 
Methiocarb 
Pirimiphos-methyl 
Propiconazole 
Pyrimethanil 
Quinoxyfen 
Tebuconazole 
Tolyfluanid 
Triadimenol 
(lamda-Cyhalothrin) 
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Twenty-seven of the 29 compounds that are AR antagonists in vitro, are also present in CAGs 
for fertility or effects in reproductive organs of males and/or females (exceptions are 
Chlorpropham and Cypronidil). 
 
Table 25.80. CAG level 4b: Compounds with in vivo effects that may be attributed to 
antiandrogenicity (i.e. presented in Table 25.74) and for which AR 
antagonism is seen in vitro 
Bentazone 
Beta-cyfluthrin 
Chlorpyrifos 
Cyfluthrin 
Cypermethrin 
Deltametrin 
Dimethomorph  
Diuron 
Epoxiconazole 
Esfenvalerate 
Fipronil 
Imazalil 
Iprodione 
Isoproturon 
Linuron 
Propiconazole 
Quinoxyfen 
Tebuconazole 
Triadimenol 
Lamda-cyhalothrin 
 
 
It is noted that 20 of 29 compounds listed as AR antagonists in vitro also have effects on the 
male reproductive system in vivo. 
 
Table 25.81. CAG level 4c: Compounds with in vivo effects that may be attributed to 
antiandrogenicity (i.e. presented in Table 25.74) and for which inhibition of 
steroid synthesis is seen in vitro 
Chlorpyrifos 
Cypermethrin 
Dimethoate 
Epoxiconazole 
Esfenvalerate 
Glyphosate 
Iprodione 
Isoproturon 
Molinate 
Linuron 
Propiconazole 
Tebuconazole 
 
 
It is noted that 12 of 13 compounds listed as steroid synthesis inhibitors in vitro also have 
effects on the  male reproductive system in vivo. 
 
Table 25.82. CAG level 4d: Compounds with effects in the female reproductive system in 
vivo (i.e. presented in Table 25.59 or Table 25.50 to 25.52) and for which 
estrogenic activity and/or aromatase induction is seen in vitro 
Clodinafop 
Cyfluthrin 
Cypermethrin 
Iprodion 
Propamocarb 
Pyriproxyfen 
Thiacloprid 
Triadimenol 
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
241 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
Deltamethrin Tribenuron 
 
 
Cyfluthrin 
Cypermethrin 
Deltamethrin 
Dodemorph 
Iprodion 
Methiocarb 
Oxadiazon 
Propamocarb 
Pyriproxyfen 
Thiabendazole 
Tolclofos-methyl 
Triadimenol 
 
 
Ten out of 21 active substances acting as estrogens or aromatase inducers in vitro also affect 
female fertility or female reproductive organs in vivo. 
 
Table 25.83. CAG level 4: Endocrine disruption as mechanism of action for tumours in 
the reproductive system 
Substance Ovary Uterus Testis Mamma Mechanism in vitro 
Benfluralin   x   
Benthiavalicarb  x    
Chlorpropham   x  AR antagonist 
Chlorsulfuron   x  Anti-oestrogenic 
Dimethomorph   x  AR antagonist 
Diuron x    
 x 
AR antagonist, anti-estrogenic 
Epoxiconazole x    AR antagonist,  
aromatase inhibitor,  
anti-estrogenic,  
steroid synthesis inhibitor 
Ethoprophos  x   Anti-estrogenic 
Ethoxysulfuron  x    
Ethoxazole   x   
Flusilazole   x  Aromatase inhibitor 
Fuberidazole  x    
Ioxynil  x    
Iprodione   x  Steroid synthesis inhibitor, 
AR antagonist 
Iprovalicarb  x    
Lenacil    x  
Linuron x x x  AR antagonist, anti-estrogenic,  
steroid synthesis inhibitor 
Pirimicarb  x    
Propaquizafop   x   
Prosulfuron   x   
Quizalofop-P-tefuryl   x   
Thiacloprid x x   Aromatase inducer (in vivo) 
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Tolylfluanid x x    
Tralkoxydim x x x   
Tribenuron (aka 
metometuron) 
   x Oestrogenic 
Triflusulfuron   x  Aromatase inhibitor 
Tritosulfuron    x  
Ziram   x   
 
 
This information can be applied for development of the following CAGs for compounds 
inducing tumours in the reproductive system that can be attributed to AR antagonism: 
 
Table 25.84. CAG level 4e: Compounds inducing tumours that may be attributed to 
endocrine disruption 
Benfluralin 
Benthiavalicarb 
Chlorpropham 
Chlorsulfuron 
Dimethomorph 
Diuron 
Epoxiconazole 
Ethoprophos 
Ethoxysulfuron 
 
Ethoxazole 
Flusilazole 
Fuberidazole 
Ioxynil 
Iprodione 
Iprovalicarb 
Lenacil 
Linuron 
Pirimicarb 
Propaquizafop 
Prosulfuron 
Quizalofop-P-tefuryl 
Thiacloprid 
Tolylfluanid 
Tralkoxydim 
Tribenuron (aka metometuron) 
Triflusulfuron 
Tritosulfuron 
Ziram 
 
 
Table 25.85. CAG level 4f: Compounds inducing tumours that may be attributed to 
endocrine disruption and for which AR antagonistic activity is seen in vitro 
Chlorpropham 
Dimethomorph 
Diuron 
Epoxiconazole 
Ethoprophos 
Iprodione 
Linuron 
 
 
 
Table 25.86. CAG level 4g: Compounds inducing tumours that may be attributed to 
endocrine disruption and for which steroid synthesis inhibition (including 
aromatase inhibition) is seen in vitro 
Epoxiconazole 
Flusilazole 
Iprodione 
Linuron 
Thiacloprid 
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All of the above CAGs at level 3 and level 4 can be recommended for cumulative risk 
assessment (Table 25.74 to 25.86). 
 
25.3. Discussion of CAGs for reproductive and developmental toxicity 
25.3.1. NOAEL/LOAEL selection and inclusion criteria for CAGs 
In the Access database NOAELs and LOAELs can be found for all relevant studies in the 
DARs and other documents as well as studies from the open literature considered appropriate 
for this purpose. This implies that no selection of the ”best” NOAEL/LOAEL has been done. 
The idea is that the lowest NOAEL/LOAEL should be used for cumulative risk assessment (as 
a worst case scenario), and only if the cumulative risk assessment for a specific CAG level 2 
points to a high risk, it may be considered to perform further evaluation of which 
NOAEL/LOAEL is indeed the most correct. The inclusion of all studies in the database will 
make it possible to make this refinement of the cumulative risk assessment. 
Similarly, we have decided to take a precautious approach when distributing specific effects 
into the different CAGs. Certain effects, e.g. reduction of litter size, can have different causes 
and belong to different CAGs, and when the cause cannot be determined the active substance 
is placed in both CAGs. In the example of litter size reduction, this effect may be caused by 
decreased implantation (an effect belonging to the CAG for male or female fertility) or by 
death of fetuses. Therefore, an active substance affecting litter size can be placed in both the 
CAG for fertility and the CAG for prenatal death, if there is no clear indication of the cause of 
the decreased litter size (in generation F1 of a multigeneration study, see text above).  
Thus, there is a risk of “false positives”, i.e. active substances that are placed in a certain CAG 
where they do not belong, if the findings leading to the categorization to a CAG are not real 
but e.g. chance findings. The precautious approach of including also “borderline”-findings is a 
well-reasoned choice in order to keep the risk of “false negatives” as low as possible. With 
“false negatives” is meant active substances that are not placed in a certain CAG where they 
belong. In the cumulative risk assessment a high number of “false negatives” would lead to an 
underestimation of the actual risk, and this should be avoided. However, it is likely that the 
applied approach for making CAGs has not been able to include all relevant active substances 
in all CAGs. This is due to lack of data in DARs for some active substances, and to (inherent 
and unavoidable) variability in the sensitivity of studies to detect effects on some endpoints. 
Additionally, it was decided to look for reproductive/developmental effects only for the 196 
active substances listed as reproductive/developmental toxicants in the preliminary grouping. 
Thus, other compounds than the 196 active substances listed as reproductive/developmental 
toxicants could have effects that were not detected using the current approach (false 
negatives). Overall, we believe that most active substances having major effects according to 
DARs are also presented in the listed CAGs. A complete and accurate database of active 
substance effects is not possible with the available data material, but our approach has been 
able to accommodate the aim of collecting as much information as possible to reach the best 
possible CAGs.  
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25.3.2. Mode and mechanism of action for reproductive/developmental toxicity 
The knowledge on mode or mechanism of action is limited for some effects on reproduction 
and development. For some endocrine disrupting effects, there is mechanistic knowledge, but 
mechanistic studies have not been performed on most of the examined active substances. 
Therefore, the usefulness of CAGs at level 3 and level 4 within reproductive/developmental 
toxicity will probably be improved with time and increased knowledge on mode/mechanism 
of action. Although mechanistic knowledge can make a major contribution to the 
understanding of mixture effects, it is still important to acknowledge that the in vivo effects 
still are important. This was also the conclusion of an expert mixture workshop in Denmark in 
2009 summarizing this as: “A pre-occupation with mechanisms or modes of action as the 
starting point for the grouping of endocrine disrupters into classes to be subjected to mixtures 
risk assessment was seen as not practical and scientifically hard to justify. Instead, grouping 
criteria should focus on common health related effects and the likelihood of co-exposures” 
(Kortenkamp et al., 2009). 
A comparison of in vitro findings with in vivo findings revealed that most of the active 
substances listed in the CAG level 4 as AR antagonists in vitro are also present in the CAGs at 
level 2 for effects on fertility or reproductive organs (direct effects or offspring effects). 
Exceptions were chlorpropham and cyprodinil. Chlorpropham induced Leydig cell tumors 
(related to endocrine disruption), but induced no other effects related to fertility or endocrine 
disruption. Cyprodinil is an AR antagonist but does not reduce reproductive organ weights or 
fertility in vivo in the studies listed in DARs.  
In some cases studies in the open literature revealed fertility effects that were not found in 
studies presented in DARs, indicating that other study designs than those applied in the 
guideline studies may reveal relevant effects related to endocrine disruption. For example, 
reproductive effects of the AR antagonist chlorpyrifos were not found in the DAR but 
reproductive/fertility effects are described in several studies in open literature. 
It is highly interesting that most AR antagonists are recognized by one of various types of 
effects on the female or male reproductive system. The variability in the types of reproductive 
effects described in DARs for active substances identified as endocrine disrupters in vitro may 
have several reasons. It is possible that for some compounds the AR antagonizing effect is 
influenced by competing or synergistic endocrine influences leading do differences in effects. 
Additionally, it is noteworthy that the guidelines applied in most studies described by DARs 
do not cover endocrine-sensitive endpoints such as changes in anogenital distance or nipple 
retention, and that targeted mechanistic analyses of endocrine effects have not been 
performed.  
For other mechanisms of actions than AR antagonism, results showed that some compounds 
that are aromatase inducers or estrogenic in vivo did not affect male or female reproductive 
organs or fertility in vivo (exposed animals and/or offspring of exposed dams) according to 
studies presented in the DAR. This may either indicate that not all estrogenic compounds have 
adverse effects in vivo or that there is a limited sensitivity of guidelines applied in most 
studies described by DARs to endocrine-related (and particularly estrogenic) effects. 
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25.3.3. Mode of action for tumours 
Various modes of action can be related to Leydig cell hyperplasia and Leydig cell tumours 
including anti-androgenic modes of action (androgen receptor antagonism, inhibition of 5a-
reductase, inhibition of testosterone biosynthesis, aromatase inhibition) but also stimulatory 
modes of action (agonism of estrogen, gonadotropin releasing hormone (GnRH), and 
dopamine receptors) (Cook et al., 1999). Most of the active substances in the modified CAG 
level 2f3 for Leydig cell hyperplasia and tumours are also present in the CAG level 3a for 
anti-androgenic mode of action in vivo. The exceptions are benfluralin, chlorpropham, 
chlorsulfuron, flusilazole, prosulfuron and ziram. Five of these compounds (exception is 
chlorpropham) all affect female reproductive organs or female fertility, and benfluralin, 
chlorsulfuron and ziram increase testis weight in rodent studies. This may demonstrate that 
although Leydig cell tumors as such may not be relevant to humans (Cook et al., 1999), the 
ability of compounds to induce Leydig cell tumors appears to be indicative of an endocrine 
disrupting mode of action. 
For e.g. thiacloprid it is noted in DARs that hepatic induction of the enzyme aromatase 
converting testosterone to estradiol may be the cause of uterine and ovarian tumors due to 
excess estrogen levels. For compounds acting as steroid synthesis inhibitors, AR antagonists 
or aromatase inhibitors, a possible mechanism of tumor induction appears to be increased 
levels of gonadotropins LH and FSH leading to growth induction. It should be noted that 
modes of action have not been examined for most compounds. Therefore, it appears 
appropriate to include all compounds with similar effects in CAGs rather than to make 
separate CAGs for compounds with known mode of action (e.g. aromatase inducers or AR 
antagonists). A further elaboration can be suggested where CAGs for tumors in reproductive 
organs may be combined with compounds inducing hyperplasia in reproductive organs, as 
hyperplasia and tumors may be caused by the same mechanism of action and may have 
cumulative effects. 
Overall, the in vitro findings for all listed mechanisms of action appear to be predictive for in 
vivo effects on reproduction and fertility, although exceptions are noted but cannot be 
explained at present.   
25.4. Recommended CAGs for reproductive and developmental toxicity 
The following CAGs at level 2 are recommended for CRA for reproductive and 
developmental toxicity: 
Delayed prenatal development: It is recommended to use the broader CAG level 2a1a 
presented in Table 25.4 for cumulative risk assessment. As a refinement of this CAG, only 
compounds with marked maternal toxicity such as maternal body weight loss during gestation 
or maternal death may be excluded. 
Delayed postnatal development: It is recommended to use the broader CAG level 2a1b which 
includes compounds with effects at doses showing mild maternal toxicity (Table 25.5) for 
cumulative risk assessment. As a refinement of this CAG, only compounds with marked 
maternal toxicity such as maternal body weight loss during gestation or maternal death may be 
excluded. 
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Prenatal body weight decrease: It is recommended to use the broader CAG level 2a2a which 
includes compounds with effects at doses showing mild maternal toxicity (Table 25.13) for 
cumulative risk assessment. As a refinement of this CAG, only compounds with marked 
maternal toxicity such as maternal body weight loss during gestation or maternal death may be 
excluded. 
Postnatal body weight decrease: The broader CAG level 2a2b for postnatal body weight 
decrease presented in Table 25.15 is recommended for cumulative risk assessment. 
Decreased body weight of adult offspring: It is not recommend to use the CAG level 2a2c 
“Decreased body weight in adult offspring” for cumulative risk assessment. 
Increased body weight: It is not recommended to apply CAGs for increased offspring body 
weight for cumulative risk assessment. 
Malformations and variations: The main level 2 CAGs 2b1 Malformations and 2b2 
Variations are recommended, but also the subgroups 2b1a to 2b1g are recommended (Tables 
25.22 to 25.31). 
Pre- and postnatal death: The two CAGs level 2c1 for prenatal death (Table 25.40) and level 
2c2 for postnatal death (Table 25.41) are recommended for cumulative risk assessment. 
Other effects in offspring: The CAGs at level 2d including subgroups presented in Tables 
25.43 to 25.52 are relevant for cumulative risk assessment at level 2, and are all recommended 
for cumulative risk assessment. It is not recommended to use CAGs level 2d4 for changes in 
non-reproductive organs or endpoints in offspring presented in Tables 25.53 and 25.54, for 
cumulative risk assessment. 
The CAGs at level 2d including subgroups presented in Tables 25.43 to 25.52 are relevant for 
cumulative risk assessment at level 2, and are all recommended for cumulative risk 
assessment. It is not recommended to use CAGs level 2d4 for changes in non-reproductive 
organs or endpoints in offspring presented in Tables 25.53 and 25.54, for cumulative risk 
assessment. 
All the CAGs level 2f for tumours including subgroups (Table 25.67 to 25.71) can be 
recommended for cumulative risk assessment. The modified CAG 2f3 for Leydig cell 
hyperplasia and/or Leydig cell tumours (Table 25.72) can also be recommended. 
 
The following CAGs at level 3 and 4 are recommended for CRA for reproductive and 
developmental toxicity: 
All of the listed CAGs at level 3 and level 4 (Tables 25.74 to 25.86) can be recommended for 
CRA. 
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26. Salivary glands 
26.1. Introduction 
The salivary glands produce saliva and the enzyme amylase to aid in digestion. The three main 
types of salivary glands in humans are the parotid, the submandibular and the sublingual 
salivary glands – see Figure 26.1. Acinar cells are responsible for the secretions by the 
salivary glands. Salivary gland secretion is controlled by the autonomic nervous system via 
adrenergic receptors on e.g. the acinar cells. 
 
 
From http://www.suite101.com/view_image.cfm/369068   
Figure 26.1. Anatomy of the salivary glands 
 
 
26.2. Establishment of CAGs for toxicity to the salivary glands 
Only a few active substances were identified to affect the salivary glands. The predominant 
effects reported include hypertrophy and vacuoles. The effects were generally observed only 
in one study for a particular active substance and the findings were often considered in the 
DARs not to be treatment-related. Thus, the salivary glands seem not to be primary target 
organs for the active substances included in this project.  
Overall, CRA for effects on the salivary glands are not considered relevant. Therefore, the 
salivary glands are not considered further for CAGs in this project. 
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26.3. Recommended CAGs for the salivary glands 
No CAGs for toxicity to the salivary glands are recommended. 
 
 
27. Skin 
27.1. Introduction 
The skin is the outer covering of the body. The skin is necessary to protect the body against 
pathogens and excessive water loss. The skin is also important in the regulation of 
temperature and in vitamin D synthesis. The skin contains a variety of nerve endings that 
allows us to sense the world when they react to heat and cold, touch, pressure, vibration, and 
tissue injury. 
The skin is composed of three primary layers (Figure 27.1): 
• The epidermis 
• The dermis  
• The hypodermis 
 
 
From http://www.web-books.com/eLibrary/Medicine/Physiology/Skin/Skin.htm 
Figure 27.1. Anatomy of the skin 
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The epidermis provides waterproofing and serves as a barrier to infection. The epidermis is 
further subdivided. The stratum corneum is the outer layer of the epidermis. The epidermis 
contains no blood vessels. Keratinocytes, which are the predominant cell type in the 
epidermis, are formed at the inner layer of the epidermis and move up the layers changing 
shape and composition as they die due to isolation from their blood source. The cytoplasm is 
released and the protein keratin is inserted. They eventually reach the stratum corneum and 
slough off.  
The dermis is the layer of skin beneath the epidermis that consists of connective tissue, nerve 
endings, blood vessels, lymphatic vessels, hair follicles, and sweat and sebaceous glands.  
The hypodermis lies below the dermis. Its purpose is to attach the skin to underlying bones 
and muscles as well as supplying it with blood vessels and nerves. The hypodermis contains 
50% of body fat which serves as padding and insulation for the body. 
27.2. Establishment of CAGs for toxicity to the skin 
Only a few active substances were identified to affect the skin. The predominant effects 
reported include local dermal effects. The effects were generally observed only in one study 
for a particular active substance. It is plausible that the effects reported are caused by local 
irritant properties of the active substances and due to that the active substances in the diet may 
come in direct contact with the skin rather than caused following systemic uptake of the 
substance.  
Overall, CRA for effects on the skin are not considered relevant. Therefore, the skin is not 
considered further for CAGs in this project. 
27.3. Recommended CAGs for the skin 
No CAGs for toxicity to the skin are recommended. 
 
 
28. Spleen 
28.1. Introduction 
The spleen is a concave, encapsulated organ, which is located in the left upper abdominal 
cavity, curved around a portion of the stomach. Strands of connective tissue (trabeculae) 
extend throughout the spleen from the splenic capsule, dividing the spleen into compartments. 
The compartments contain masses of lymphoid tissue called splenic pulp. The spleen is the 
largest of the secondary lymphoid organs. 
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From http://www.drharper.ca/new_page_12.htm 
Figure 28.1. Location and anatomy of the spleen 
 
 
The portion of arterial blood that enters the spleen first encounters the white splenic pulp, 
which consists of masses of lymphoid tissue containing lymphocytes and macrophages and is 
the chief site of immune and phagocytic function within the spleen. Here blood-borne antigens 
encounter lymphocytes, initiating the immune response, see also Chapter 15. 
Most of the blood oozes through the extremely permeable capillary walls into the principal 
site of splenic filtration, the red pulp. Here the resident macrophages phagocytose old, 
damaged, or dead blood cells of all kinds (but chiefly red blood cells), micro-organisms, and 
particles of debris. Haemoglobin from phagocytosed red blood cells is catabolised, and heme 
(iron) is stored in the cytoplasm of the macrophages or released back into the blood plasma. 
Blood that filters through the red pulp also finds its way into the venous sinuses, highly 
distensible storage areas which serves as a blood reservoir, and hence into the portal 
circulation.  
Other functions of the spleen are less prominent, especially in the healthy adult, and include 
production of red blood cells. While the bone marrow is the primary site of haematopoiesis in 
the adult, the spleen has important haematopoietic functions up until the fifth month of 
gestation. After birth, erythropoietic functions cease, except in some haematological disorders. 
As a major lymphoid organ and a central player in the reticuloendothelial system, the spleen 
retains the ability to produce lymphocytes and, as such, remains an haematopoietic organ. This 
is called extramedullary haematopoiesis. 
 
28.2. Establishment of CAGs for toxicity to the spleen 
28.2.1. CAG level 1: Toxicity to the spleen 
Various types of effects on the spleen were identified including: 
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• Hyperplasia 
• Hypertrophy 
• Hypercellularity 
• Increased extramedullary haematopoiesis 
• Haemosiderosis (increased amounts of a yellow-brown iron containing pigment) 
• (Lymphoid) hypoplasia 
• Lymphoid depletion 
• Reduced cellularity 
• Decreased haematopoiesis 
• Atrophy 
• Necrosis 
• Congestion 
 
Most of the active substances identified to affect the spleen induced hyperplasia, hypertrophy, 
hypercellularity, increased extramedullary haematopoiesis, haemosiderosis, effects that are 
secondary to a direct effect on the cellular elements in the blood stream and are therefore 
covered by the CAGs for the cellular elements in the blood, see Chapter 14. Overall, these 
effects are not considered relevant in terms of CRA for direct effects on the spleen and the 
active substances causing these effects are therefore not considered further for CAGs in 
relation to the spleen.  
Some of the active substances identified to affect the spleen induced reduced hypocellurarity, 
hypoplasia, lymphoid depletion, decreased haematopoiesis, atrophy and/or necrosis, effects 
that are considered as a direct effect on the spleen. The active substances identified as causing 
these effects in the spleen in the toxicological studies included in the DARs are allocated to 
CAG level 1 and are listed in Table 28.1. 
 
Table 28.1. CAG level 1: Toxicity to the spleen 
2,4-D Clodinafop MCPA 
Acibenzolar-S-methyl Clothianidin Metconazole 
Acibenzolar-S-methyl metabolite: 
CGA 210007 
Cymoxanil Oxasulfuron 
Bifenazate Florasulam Thiamethoxam 
Chlorotoluron Fluroxypyr Thiophanate-methyl 
Chlorpropham Flutolanil  
Chlorsulfuron metabolite: IN-A4097 Indoxacarb  
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28.2.2. CAG level 2: Phenomenological / specific effects on the spleen 
Based on the effects on the spleen considered as being direct effects, two distinct CAGs level 
2 are proposed. More information is given in Appendix AN. 
28.2.2.1. CAG level 2a: Hypoplasia 
Hypoplasia is a decrease in the number of cells. 
For the purpose of the CAG project, hypoplasia, reduced cellularity, lymphoid depletion and 
decreased haematopoiesis in the spleen are allocated to a single CAG level 2, termed ‘CAG 
level 2a: Hypoplasia’.  
The active substances identified as inducing one of the abovementioned effects in the spleen 
are allocated to CAG level 2a and listed in Table 28.2. 
 
Table 28.2. CAG level 2a: Hypoplasia 
2,4-D Florasulam Metconazole 
Bifenazate Fluroxypyr Oxasulfuron 
Clothianidin Indoxacarb Thiophanate-methyl 
 
 
28.2.2.2. CAG level 2b: Cell degeneration / cell death 
Atrophy is loss of tissues, totally or partially and necrosis is death of cells and tissues.  
For the purpose of the CAG project, histopathological findings described as atrophy and 
necrosis are allocated to a single CAG level 2, termed ‘CAG level 2b: ‘Cell degeneration / cell 
death’.  
The active substances identified as inducing one or more of the above-mentioned effects in 
the spleen are allocated to CAG level 2b and are listed in Table 28.3. 
 
Table 28.3. CAG level 2b: Cell degeneration / cell death 
2,4-D Chlorsulfuron metabolite: IN-
A4097 
Indoxacarb 
Acibenzolar-S-methyl Clodinafop MCPA 
Acibenzolar-S-methyl metabolite: 
CGA 210007 
Clothianidin Metconazole 
Bifenazate Cymoxanil Thiamethoxam 
Chlorotoluron Flutolanil Thiophanate-methyl 
Chlorpropham   
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28.2.2.3. Effects not considered relevant for CAGs at level 2 
Effects such as discolouration and congestion of the spleen have been reported for some 
substances. These effects are considered as being non-adverse or non-specific effects and 
therefore, not relevant for CAGs at level 2 and consequently, not relevant in terms of CRA for 
effects on the spleen.  
28.2.3. CAG level 3: Mode of action  
No information on mode of action has been found for any of the active substances considered 
as having a direct effect on the spleen. 
28.2.4. CAG level 4: Mechanism of action  
No information on mechanism(s) of action has been found for any of the active substances 
considered as having a direct effect on the spleen. 
28.3. Discussion of CAGs for the spleen 
Nineteen active substances or metabolites were identified to have potential direct effects on 
the spleen and were allocated to CAG level 1. Two distinct CAGs at level 2 have been 
proposed. Information on mode / mechanism(s) of action is not available for any of them. The 
information is summarised in Appendix AO. 
As no information regarding the mode / mechanism(s) of action for the active substances 
allocated to CAG level 2a and 2b, respectively, has been found, these CAGs at level 2 could 
be considered for CRA. 
28.4. Recommended CAGs for the spleen 
The following CAGs at level 2 are recommended for CRA for effects on the spleen: 
• CAG level 2a: Hypoplasia, see Table 28.2. 
• CAG level 2b: Cell degeneration / cell death, see Table 28.3. 
 
 
29. Thymus 
29.1. Introduction 
The thymus is one of the primary lymphoid tissues consisting of two independent lobes 
(cortex and medulla) attached to each other by connective tissue. The two independent lobes 
are comprised by smaller lobules, which basically have the same architecture (a sub-capsular 
and outer cortical area, a cortex, and a medulla). A unique feature of the thymus compared to 
other lymphoid organs is that its microenvironment consists of a reticular epithelium. 
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The basic architecture of the thymus depends on the age and stress hormone status of the 
individual and a ‘normal’ architecture can only be expected between the late gestational 
period and young adulthood. The organ is fully developed around day 17 of gestation in 
rodents and at 16-17th week of gestation in humans. The first contact with exogenous antigens 
after birth directs significant thymus growth in a relatively short time as it has to provide large 
numbers of T cells (lymphocytes produced in the bone marrow before entering the blood and 
passing through the thymus) to secondary lymphoid tissues. When adulthood is reached, the 
organ starts to involute (atrophy) and emigration of T cells decreases dramatically. Acute 
stress or toxic compounds may cause artificial thymus involution leading to a decrease in 
emigrating T cells. 
T cells mature and obtain specificity, from progenitor cells to antigen reactive cells, in their 
passage through the thymus. T cell maturation occurs in different microenvironments; the 
least mature cells enter the lobules from the bloodstream at the cortico-medullary junction and 
then move to the outer sub-capsular cortex (large lymphoblasts) before passing through the 
cortex (small lymphocytes) and migrating to the medulla (mature T cells). Most of the cells 
that enter the thymus die due to a process called ‘negative selection’ which is designed to 
eliminate cells with the potential to react in a damaging way with self antigens. 
29.2. Establishment of CAGs for toxicity to the thymus 
Many active substances were identified to affect the thymus. The predominant effect reported 
is decreased thymus weight. Atrophy (thymic involution) has also been reported for several of 
the substances. In general, the overall study NOAELs and LOAELs are lower than for the 
specific ‘thymus NOAEL’ and ‘thymus LOAEL’ for the majority of the active substances. 
Stress, which in many cases is characterised by increased adrenal weight (and increased levels 
of cortisole) is known to induce decreased thymus weight, which is thus an indirect effect on 
the thymus. Thus, the thymus seems not to be a primary target organ for the active substances 
included in this project. Furthermore, changes in thymus weight or atrophy were reported 
primarily in association with marked effects for other organs, especially in the liver.  
Overall, CRA for effects on the thymus is not considered relevant. Therefore, the thymus is 
not considered further for CAGs in this project. 
29.3. Recommended CAGs for the thymus 
No CAGs for toxicity to the thymus are recommended. 
 
30. Thyroid gland 
30.1. Introduction 
The thyroid gland is shaped like a butterfly and located on the trachea. The gland consists of 
thyroid follicles and small clusters of parafollicular cells in between the follicles. The thyroid 
follicles consist of thyroid follicular cells (cuboidal epithelium on Figure 30.1) surrounding a 
lumen filled with material called colloid. 
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From http://www.drharper.ca/new_page_12.htm 
Figure 30.1. Histological section of a normal thyroid gland 
 
 
The thyroid gland produces hormones that affect the function of almost every organ system in 
the body.  
The parafollicular cells (also called C-cells) produce the hormone calcitonin which 
participates in the regulation of the calcium metabolism. Only few chemicals have been found 
to disturb the structure or function of the parafollicular cells. 
The thyroid follicular cells produce iodine-containing hormones called iodothyronines. 
Thyroxine (T4) and triidothyronine (T3) are the most important iodothyronines. T3 and T4 
play essential roles in the normal development of e.g. brain, testis, lungs, and heart in embryos 
and maturing animals. In adults, T3 and T4 regulate e.g. the energy metabolism and endocrine 
functions. Generally, chemicals that affect the thyroids change the structure or function of the 
follicular cells or change the concentration or peripheral action of T3 and T4. 
30.1.1. Regulation of circulating levels of T3 and T4  
The function of the thyroid gland is primarily regulated via a feedback mechanism in which 
thyrotropin-releasing hormone (TRH) from the hypothalamus and thyroid-stimulating 
hormone (TSH) from the pituitary are released in response to decreased circulating levels of 
T3 and T4. TSH is essential for the thyroid gland to synthesize and secrete T3 and T4.   
30.1.2. Synthesis and secretion of T3 and T4  
The thyroid follicular cells, upon stimulation by TSH, synthesize thyroglobulin, which is 
released into the colloid-filled lumen inside the follicle (Figure 30.2). Iodide is actively 
transported into the thyroid follicular cells, where it is oxidized by thyroid peroxidase (TPO) 
into iodine and released into the colloid. Iodine binds to tyrosine residues within 
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thyroglobulin. T3 and T4 are synthesized within the thyroglobulin molecule via coupling of 
the resulting iodotyrosines. T3 and T4 are stored in the colloid within thyroglobulin.  
Following stimulation by TSH the thyroglobulin with T3 and T4 is reabsorbed into the 
follicular cells. Enzymes cleave the T3 and T4 molecules, and free T3 and T4 are released into 
the blood circulation. 
 
 
From:  Janna Cohen-Lehman, Peter Dahl, Sara Danzi & Irwin Klein (2010). Effects of amiodarone therapy on thyroid 
function. Nature Reviews Endocrinology 6, 34-41 
Figure 30.2. Synthesis of T3 and T4 
 
 
30.1.3. Transport of T3 and T4 
In the blood circulation the major part of T3 and T4 is bound in reversible equilibrium to 
various serum proteins of which thyroxine-binding globulin (TBG) and transthyretin (TTR) 
are the most important. TBG is the major plasma T4-binding protein in humans whereas TTR 
is the major plasma T4-binding protein in rats. The effect of the binding proteins is to 
maintain the serum free T3 and T4 within narrow limits to ensure that the hormones are 
continuously and immediately available to the organs.  In general, T3 is bound less tightly to 
the proteins than T4 resulting in a shorter plasma half-life of T3. T3 is therefore more 
susceptible to alterations in hormone production than T4. 
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The membranes of target cells for T3 and T4 contain transport proteins such as different 
organic anion-transporting polypeptides (OATPs). These transport proteins are responsible for 
moving T3, T4 and metabolites in and out of the cells. 
30.1.4. Biological action of T3 and T4 
The majority of biological actions of iodothyronines seem to be mediated through receptors 
for T3 in the target cells. T3 activates the energy metabolism when it binds to receptors on the 
inner mitochondrial membrane. T3 stimulates the synthesis of membrane proteins, enzymes 
and hormones when it binds to nuclear receptors. 
30.1.5. Metabolism and excretion of T3 and T4 
T4 is only produced in the thyroid gland. T3 is the physiologically active form of the 
iodothyronines.  In humans about 80 % of circulating T3 comes from deiodination of T4. T4 
is converted to T3 predominantly by type I iodothyronine deiodinase (D1).  D1 is found 
largely in the kidney, liver and thyroid, while type II iodothyronine deiodinase (D2) is present 
primarily in skeletal muscle, the central nervous system and the pituitary. Type III 
iodothyronine deiodinase (D3), found in the brain, skin and placenta, inactivates T4 and T3, 
which leads to the formation of reverse T3 (rT3) and T2, respectively. 
T3 and T4 are primarily excreted in bile after conjugation in the liver to glucuronic acid 
(maily T4) or sulphate (mainly T3). T3 and T4 are glucuronidated by different uridine 
diphosphate glucuronyl-tranferases (UDPGT) and sulphated by different sulphotransferases 
(SULT). Sulphate conjugation of T3 also enhances the conversion of T4 to T3 by D1. 
UDPGT and SULT activities can be induced by a number of endogenous and exogenous 
compounds such as drugs and pesticides by various mechanisms i.e.. via nuclear receptors 
such as the pregnane x receptor (PXR), which also encodes for the induction of various 
cytochrome P450 enzymes, such as CYP3A4 in experimental animals and humans. Induction 
of these Phase II enzymes enhances the conjugation of T3 and T4. 
Bacteria in the intestinal lumen hydrolyse biliary excreted conjugated T3 and T4. The 
hydrolysed hormones are partially reabsorbed. 
30.1.6. Studies on effects on the thyroid in experimental animals 
The active substances on the European market typically have been tested in a battery of 
standard toxicological tests.  In the standard guidelines for testing of repeated dose toxicity 
including chronic toxicological studies in rodents, histopathological changes in the thyroid 
such as follicular cell hyperplasia or hypertrophy, different follicular cell tumours, and 
different colloid alterations will be revealed.  However, the standard guidelines do not include 
as a mandatory requirement analysis of hormones such as T3, T4 and TSH as well as thyroid 
weight. However, in a number of the toxicological studies on active substances, thyroid 
hormones and weight have been measured. 
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30.2. Establishment of CAGs for toxicity to the thyroid gland 
30.2.1. CAG level 1: Toxicity to the thyroid gland 
The active substances identified as having an effect on the thyroid gland in the toxicological 
studies included in the DARs are allocated to CAG level 1 and are listed in Table 30.1. 
 
Table 30.1. CAG level 1: Toxicity to the thyroid gland 
2,4-D Flumioxazin Propaquizafop 
2,4-DB (metabolized to 2,4-D) Fluopicolide  Propineb 
Aclonifen Fluoxastrobin Propyzamide  
Amidosulfuron  Flutolanil Prothioconazole 
Amitrole (aminotriazole) Folpet PTU (metabolite of probineb) 
Beflubutamid Formetanate Pymetrozine 
Benalaxyl Fuberidazole Pyrethrins 
Benfluralin Imazosulfuron Pyrimethanil 
Benthiavalicarb Imidacloprid Quizalofop-P-tefuryl 
Boscalid Ioxynil Silthiopham 
Bromoxynil Isoxaflutole Spinosad 
Chlorpropham Lenacil Tepraloxydim 
Clodinafop Lufenuron Tetraconazole 
Clofentezine Maleic hydrazide Thiabendazole 
Cyflufenamid Mancozeb Thiacloprid 
Cyhalofop-butyl Maneb Thiamethoxam 
Cyprodinil MCPA Thiophanate-methyl 
Desmedipham MCPB (metabolized to MCPA) Thiram 
Dinocap Metiram  Tolylfluanid 
EBIS (metabolite of mancozeb, 
maneb and metiram) 
Metribuzin Tribenuron (aka metometuron) 
Etofenprox Oxadiazon Tritosulfuron 
ETU (metabolite of mancozeb, 
maneb and metiram) 
Pendimethalin TTCA (metabolite of tolylfluanid) 
Fenamidone Pethoxamid Ziram 
Fipronil Picloram Zoxamide 
Flufenacet (formerly fluthiamide) Picolinafen   
 
 
30.2.2. CAG level 2: Phenomenological / specific effects on the thyroid gland 
Effects were noted in the follicular cells as well as in the parafollicular cells.  
Various types of effects on the follicular cells and altereations in thyroid hormones have been 
identified as a basis for establishing CAGs at level 2: 
• Changes in serum T3 (and T4) 
• Increased TSH 
• Follicular cell hyperplasia/hypertrophy 
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• Follicular cell tumours. 
 
Thyroid disrupting chemicals may damage the follicular cells and/or interfere with normal 
function generally resulting in decreased serum levels of T3 and/or T4. Hypothalamus and the 
pituitary gland detect the decreased level of thyroid hormones leading to increased secretion 
of TSH. Persistent elevation of TSH leads to thyroid follicular cell hypertrophy and 
hyperplasia and an enlarged thyroid gland. Experiments in rodent have shown that prolonged 
TSH-stimulation may lead to benign or even malignant follicular cell tumours. In some cases, 
chronic stimulation also results in pituitary hyperplasia and tumours (because of increased 
secretion of TRH). 
Experiments in rodents have shown that chemicals that disturb the level of T3 and T4 and/or 
bind to thyroid hormone receptors may also cause developmental effects. 
Epidemiologic studies have shown that adults with subclinical hypothyroidism (elevation in 
TSH with normal T4) have an increased risk of cardiovascular disease because of increased 
blood pressure and poorer blood lipid profiles. Miller et al. (2009) suggest that elevated risk of 
cardiovascular disease should be considered possible from exposure to thyroid disturbing 
chemicals. 
The effects noted on the parafollicular cells were hyperplasia and tumours. 
Based on the effects observed in the follicular and parafollicular cells, six distinct CAGs at 
level 2 are proposed. More information is given in Appendix AP. 
30.2.2.1. CAG level 2a: Decreased T3 and/or T4 
The active substances identified as decreasing T3 and/or T4 levels in serum are allocated to 
CAG level 2a and are listed in Table 30.2. It should be noted that in standard guidelines for 
toxicological studies analysis of hormones such as T3, T4 and TSH are not a mandatory 
requirement. It is therefore possible that more active substances with effects on the follicular 
cells might also have effects of T3/T4 levels. 
 
Table 30.2. CAG level 2a: Decreased serum T3 and/or T4 
2,4-D Flufenacet (formerly fluthiamide) Propyzamide  
Aclonifen Fluoxastrobin Prothioconazole 
Amitrole (aminotriazole) Imidacloprid PTU (metabolite of probineb) 
Benthiavalicarb Ioxynil Pymetrozine 
Boscalid Isoxaflutole Pyrethrins 
Bromoxynil Lenacil Pyrimethanil 
Chlorpropham Lufenuron Tetraconazole 
Clofentezine Mancozeb Thiabendazole 
Cyflufenamid Maneb Thiacloprid 
Desmedipham Metiram  Thiophanate-methyl 
EBIS (metabolite of mancozeb, 
maneb and metiram) 
Metribuzin Tolylfluanid 
Etofenprox Oxadiazon Tritosulfuron 
ETU (metabolite of mancozeb, Pendimethalin Ziram 
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maneb and metiram) 
Fipronil Propineb  
 
 
30.2.2.2. CAG level 2b: Increased TSH 
The active substances identified as increasing TSH levels in serum are allocated to CAG level 
2b and are listed in Table 30.3. It should be noted that in standard guidelines for toxicological 
studies analysis of hormones such as T3, T4 and TSH are not a mandatory requirement. It is 
therefore possible that more active substances with effects on the follicular cells might also 
have effects of TSH levels. 
 
Table 30.3. CAG level 2b: Increased serum TSH 
Aclonifen Mancozeb PTU (metabolite of probineb) 
Amitrole (aminotriazole) Maneb Pymetrozine 
Benthiavalicarb Metiram  Pyrethrins 
Boscalid Metribuzin Pyrimethanil 
Clofentezine Oxadiazon Tetraconazole 
Cyflufenamid Pendimethalin Thiabendazole 
Etofenprox Pethoxamid Thiacloprid 
ETU (metabolite of mancozeb, 
maneb and metiram) 
Propineb Thiophanate-methyl 
Fipronil Propyzamide  Tolylfluanid 
Ioxynil Prothioconazole  
 
 
30.2.2.3. CAG level 2c: Follicular cell hypertrophy / hyperplasia 
Follicular cell hypertrophy is an increase in the size of the cells and hyperplasia is an 
increased number of the cells. These effects are often accompanied by increased organ weight. 
Hypertrophy and hyperplasia frequently occur together and for the purpose of the CAG project 
these findings are allocated to a single CAG level 2, termed ‘CAG level 2a: Follicular cell 
hypertrophy / hyperplasia’.  
The active substances identified as inducing one or more of the above-mentioned effects are 
allocated to CAG level 2c and are listed in Table 30.4. 
 
Table 30.4. CAG level 2c: Follicular cell hypertrophy / hyperplasia 
2,4-D Flufenacet (formerly fluthiamide) Picloram 
2,4-DB (metabolized to 2,4-D) Flumioxazin Picolinafen  
Aclonifen Fluopicolide  Propaquizafop 
Amidosulfuron  Fluoxastrobin Propineb 
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Amitrole (aminotriazole) Flutolanil Propyzamide  
Beflubutamid Folpet PTU (metabolite of probineb) 
Benalaxyl Formetanate Pymetrozine 
Benfluralin Fuberidazole Pyrethrins 
Benthiavalicarb Imazosulfuron Pyrimethanil 
Boscalid Ioxynil Quizalofop-P-tefuryl 
Bromoxynil Isoxaflutole Silthiopham 
Chlorpropham Lenacil Spinosad 
Clodinafop Lufenuron Tepraloxydim 
Clofentezine Maleic hydrazide Tetraconazole 
Cyflufenamid Mancozeb Thiabendazole 
Cyhalofop-butyl Maneb Thiacloprid 
Cyprodinil MCPA Thiamethoxam 
Desmedipham MCPB (metabolized to MCPA) Thiophanate-methyl 
Dinocap Metiram  Thiram 
Etofenprox Metribuzin Tolylfluanid 
ETU (metabolite of mancozeb, 
maneb and metiram) 
Oxadiazon Tritosulfuron 
Fenamidone Pendimethalin Ziram 
Fipronil Pethoxamid Zoxamide 
 
 
30.2.2.4. CAG level 2d: Follicular cell neoplasms 
The active substances identified as inducing follicular cell neoplasms are allocated to CAG 
level 2d and are listed in Table 30.5. 
 
Table 30.5. CAG level 2d: Follicular cell neoplasms 
2,4-D Flufenacet (formerly fluthiamide) Picloram 
2,4-DB (metabolized to 2,4-D) Flumioxazin Picolinafen  
Amitrole (aminotriazole) ETU (metabolite of mancozeb, maneb 
and metiram) 
Pethoxamid 
Beflubutamid Fipronil Propyzamide  
Benfluralin Fuberidazole Pyrethrins 
Benthiavalicarb Ioxynil Silthiopham 
Boscalid Isoxaflutole Thiabendazole 
Cyflufenamid Mancozeb Thiacloprid 
Etofenprox Pendimethalin Thiophanate-methyl 
 
 
30.2.2.5. CAG level 2e: Parafollicular cell hyperplasia 
The active substances identified as inducing parafollicular cell hyperplasia are allocated to 
CAG level 2e and are listed in Table 30.6. 
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Table 30.6. CAG level 2e: Parafollicular cell hyperplasia 
2,4-D Fenamidone Thiram 
2,4-DB (metabolized to 2,4-D) Folpet Ziram 
Amitrole (aminotriazole) Imidacloprid  
Desmedipham Picloram  
 
 
30.2.2.6. CAG level 2f: Parafollicular cell neoplasms 
Only one active substance was identified as inducing tumours in the parafollicular cells. 
Thiram induced an increased incidence of parafollicular cell adenomas in a 2-year rat dietary 
toxicity study. This substance is allocated to CAG level 2f and is listed in Table 30.7. 
 
Table 30.7. CAG level 2f: Parafollicular cell neoplasms 
Thiram   
 
 
30.2.2.7. Effects not considered relevant for CAGs at level 2 
In addition to the above mentioned effects, the DARs have for some active substances also 
reported other hormonal and biochemical changes such as increased/decreased iodide uptake, 
decreased free T4 or T3, increased/decreased free T4 index, increased T3/T4 ratio, 
increased/decreased rT3, decreased T4 volume of distribution, increased/decreased T4 binding 
capacity, increased T4 binding to albumin, decreased T4 binding to TTR, increased/decreased 
plasma bound iodide, and decreased TBG.  
The DARs have also reported other histopathological changes such as increased/decreased 
amount of colloids, small/large follicles, different shapes of the follicular cells, increased 
vascularization, increased vacuolation, follicular cysts, follicular cell pigmentation, follicular 
atrophy, necrosis of follicular cells, and ectopic thyroid tissue surrounding the aortic arch.  
CAGs were not created for the above mentioned effects as many of the histopathological 
changes are a consequence of hyperactivity of the thyroid gland which is already covered by 
the CAG level 2c: Follicular cell hypertrophy / hyperplasia. Anyhow the number of active 
substances causing e.g. follicular cell pigmentation or necrosis of follicular cells is limited.  
The additional hormonal and biochemical changes have only been studied for a limited 
number of active substances. They may help in making hypothesis for the mechanisms behind 
the thyroid disturbing effect but is considered of limited relevance on their own. 
For three active substances, an increased incidence of thyroglossal duct cysts or 
ultimobranchial cysts was reported. These cysts are found in remnants of embryological 
anatomical structures. Thyroglossal duct cysts may form in a thyroglossal duct that fails to 
atrophy. The thyroglossal duct forms an open connection between the initial area of 
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development of the thyroid gland and its final position. Ultimobranchial cysts are remnants of 
the ultimobranchial body, responsible for the distribution of calcitonin secreting C-cells in the 
thyroid. These cysts are not considered to be treatment-related, because the persistence of 
embryonic structures is a congenital lesion and could not have been influenced by the test 
compound.   
30.2.3. CAG level 3: Mode of action  
For some of the phenomenological / specific effects on the thyroid described under CAG level 
2, a mode of action has been proposed. For the remaining substances, no information 
regarding mode of action has been found and consequently, these substances cannot be 
allocated to a CAG level 3. 
A combined mode of action model for the effects of thyroid follicular cell disturbing 
chemicals is outlined in Figure 30.3. The specific mechanisms are described in more detail 
under CAG level 4. 
 
 
Modified from Crofton (2008) and Miller et al. (2009) 
Figure 30.3. A combined mode of action model for the effects of thyroid follicular cell 
disturbing chemicals on cancer and developmental effects 
 
 
As already described under CAG level 2, the different effects on the thyroid follicular cells or 
on the thyroid hormone levels are often not independent effects but rather consequences of 
each other. The combined mode of action model illustrates that many different mechanisms of 
action may lead to serum T3 and T4 changes. Subsequently TSH is increased to compensate 
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for the decreased T3 and/or T4. Persistent elevation of TSH may lead to histopathological 
changes such as thyroid follicular cell hypertrophy and even thyroid follicular cell tumours (at 
least in rodents).  
The combined mode of action model also illustrates that chemicals that disturb the levels of 
T3 and T4 and/or bind to the thyroid hormone receptors may also cause developmental 
effects. 
In order to establish a CAG at level 3 (mode of action) it was decided to group the active 
substances or metabolites that were found to fit into this combined mode of action model 
based on the criteria that at least two of the following effects have been observed for the 
substance: 
• Effect on one or more of the above mentioned mechanisms 
• Serum T3 and/or T4 changes 
• Increased TSH 
• Follicular cell hypertrophy/ hyperplasia and/or increased thyroid weight 
• Follicular cell tumours 
 
30.2.3.1. CAG level 3: Follicular cell toxicity (combined mode of action model) 
The active substances fulfilling the criteria for fitting to the combined mode of action model 
are allocated to CAG level 3 and are listed in Table 30.8. 
 
Table 30.8. CAG level 3: Follicular cell toxicity (combined mode of action model) 
2,4-D Fipronil Propineb 
Aclonifen Flufenacet (formerly fluthiamide) Propyzamide  
Amitrole (aminotriazole) Fluoxastrobin Prothioconazole 
Beflubutamid Fuberidazole PTU (metabolite of probineb) 
Benfluralin Ioxynil Pymetrozine 
Benthiavalicarb Isoxaflutole Pyrethrins 
Boscalid Lenacil Pyrimethanil 
Bromoxynil Lufenuron Silthiopham 
Chlorpropham Mancozeb Tetraconazole 
Clodinafop Maneb Thiabendazole 
Clofentezine Metiram  Thiacloprid 
Cyflufenamid Metribuzin Thiophanate-methyl 
Desmedipham Oxadiazon Tolylfluanid 
Etofenprox Pendimethalin Tritosulfuron 
ETU (metabolite of mancozeb, 
maneb and metiram) 
Pethoxamid Ziram 
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30.2.4. CAG level 4: Mechanism of action 
Thyroid disrupting chemicals may damage the follicular cells and/or interfere with normal 
function at almost all steps of the regulation, synthesis, secretion, transport, biological action, 
metabolism and excretion of T3 and T4, generally resulting in decreased plasma levels of T3 
and/or T4.  
The known mechanisms that may lead to thyroid toxicity are listed in the following. Not all of 
the mentioned mechanisms are relevant for the active substances of this project. 
1. Damage of the follicular cells  
1a) Tumours due to mutagenic properties of the chemical 
1b) Inflammation and/or degeneration of the thyroid gland 
 
2. Interference with regulation 
2a) Induced inability of the hypothalamus and/or pituitary gland to produce TRH and TSH, 
respectively 
2b) Decreased response of TSH-producing cells to TRH 
 
3. Interference with synthesis and secretion 
3a) Inhibition of the active iodide transport into the thyroid follicular cells 
3b) Inhibition of thyroid peroxidise (TPO) 
3c) Inhibition of T3 and T4 secretion 
3d) Disruption of T3 and T4 synthesis because of accumulation of the chemical in the thyroid 
gland 
 
4. Interference with transport of the thyroid hormones 
4a) Competitive displacement of T4 from its binding site on TTR. No similar effect has at 
present been shown with TBG 
4b) Up-regulation of cellular transport proteins such as OATPs 
 
5. Interference with the biological action 
5a) Agonist to the biological actions of T3  
5b) Antagonist to the biological actions of T3 
The underlying mechanisms for interference with the biological action may be binding to the 
thyroid receptor or interference with its expression. A thyroid disrupting chemical may also 
affect one or more of the processes occurring between T3 receptor binding and transcription 
of the target genes 
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6. Interference with metabolism and excretion 
6a) Inhibition of the different iodothyronine deiodinases 
6b) Induction of UDPGT and/or SULT 
6c) Inhibition of SULT 
6d) Reduced re-absorption of T3 and T4 from the intestine 
 
Table 30.9 outlines how the levels of circulating thyroid hormones and TSH in theory may 
change depending on the underlying mechanism of action. 
 
Table 30.9. Circulating thyroid hormone and TSH levels after different mechanisms of 
action  
 Circulating thyroid hormone and 
TSH levels 
Other effects 
Damage of the follicular 
cells  
  
1a) Tumours due to 
mutagenic properties of the 
chemical 
? Positive in mutagenic experiments 
Neoplasi in the thyroid 
1b) Inflammation and/or 
degeneration of the thyroid 
gland 
Decreased T3 and T4 
Increased TSH (and TRH) 
Inflammation/degeneration in the thyroid 
Interference with regulation Decreased T3 and T4 
Decreased TSH 
 
2a) Induced inability of the 
hypothalamus and/or 
pituitary gland to produce 
TRH and TSH, respectively 
(Decreased or increased TRH 
depending on the function of 
hypothalamus) 
 
2b) Decreased response of 
TSH-producing cells to 
TRH 
(Increased TRH)   
Interference with synthesis 
and secretion 
Decreased T3 and T4 
Increased TSH (and TRH) 
 
3a) Inhibition of the active 
iodide transport into the 
thyroid follicular cells 
  
3b) Inhibition of TPO   
3c) Inhibition of T3 and T4 
secretion 
  
3d) Disruption of T3 and T4 
synthesis because of 
accumulation of the 
chemical in the thyroid 
gland 
  
Interference with transport   
4a) Competitive ?  
 
Identification of Cumulative Assessment Groups of Pesticides 
 
 
267 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with 
Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a 
grant agreement between the European Food Safety Authority and the author(s). The present document is published 
complying with the transparency principle to which the European Food Safety Authority is subject. It may not be considered 
as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the 
conclusions reached in the present document, without prejudice to the rights of the authors. 
 
displacement of T4 from its 
binding site on TTR.  
4b) Upregulation of cellular 
transport proteins such as 
OATPs 
Decreased T3 and T4 
Increased TSH (and TRH) 
 
Interference with biological 
action 
Not necessarily affected  
5a) Agonist to the biological 
actions of T3  
  
5b) Antagonist to the 
biological actions of T3 
  
Interference with 
metabolism and excretion 
  
6a) Inhibition of the 
different iodothyronine 
deiodinases 
D1/D2:  
Decreased T3 
Increased T4 
Increased rT3 
Increased TSH 
 
6b) Induction of UDPGT 
and/or SULT 
UDPGTs for both T3 and T4: 
Decreased T3 and T4 
Increased TSH (and TRH) 
Only for T4: 
Lesser effect on T3 and TSH 
SULT: ? 
 
6c) Inhibition of SULT ?  
6d) Reduced reabsorption of 
T3 and T4 from the intestine 
?  
 
 
However, in practice it is not possible to distinguish between the different mechanisms only 
based on the level of thyroid hormones because: 
• Chemicals may affect several mechanisms at the same time. 
• Most of the mechanisms result in a decreased level of T3 and T4 and an increased 
level of TSH.  
• The level of circulating thyroid hormones and TSH may change during experiments 
because of the ability of the body to compensate for the thyroid disturbing effect.   
 
McClain et al. (1988, 1989) e.g. has shown that phenobarbital induces hepatic UDPGT 
resulting in increased elimination of T4. As expected plasma T3 and T4 was markedly 
decreased and TSH was increased at week 1 and 4. However, by week 8 T3 levels returned to 
near normal and the TSH level declined.  
For a specific active substance where many experiments have been performed it is therefore 
common to see changes in especially the level of T3 between experiments. 
Follicular cell hyperplasia or hypertrophy, an enlarged thyroid gland and follicular cell 
tumours are a consequence of persistent elevation of TSH irrespective of the underlying 
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mechanism. Therefore, most of the histopathological changes of the thyroid cannot be used to 
elucidate anything about the underlying mechanism of action.   
Mechanistic studies are necessary to distinguish between most of the mechanisms. Only for 
about half of the active substances with effects on the thyroid, mechanistic studies have been 
performed to try to elucidate the mechanism behind the thyroid effect. Therefore, there is a 
lack of relevant mechanistic data for many of the active substances.  
In the following CAGs at level 4 are established for active substances based on the current 
knowledge about their mechanisms of action. For many of the active substances with effect on 
the thyroid comments are made in the DAR that the effect was likely caused by liver enzyme 
induction. We have however not included such active substances in a CAG unless a 
mechanistic study has shown induction of UDPGT or SULT. 
30.2.4.1. CAG level 4a: Inflammation and/or degeneration 
The active substances allocated to CAG level 4a are listed in Table 30.10. 
 
Table 30.10. CAG level 4a: Thyroid follicular cell toxicity related to inflammation 
and/or degeneration of the thyroid gland 
Pymetrozine Spinosad Tribenuron 
 
 
30.2.4.2. CAG level 4b: Inhibition of active iodide transport 
The active substances allocated to CAG level 4b are listed in Table 30.11. 
 
Table 30.11. CAG level 4b: Thyroid follicular cell toxicity related to inhibition of the 
active iodide transport into the follicular cells 
Amitrole Mancozeb Metiram 
ETU (metabolite of mancozeb, 
maneb, metiram) 
Maneb  
 
 
30.2.4.3. CAG level 4c: Inhibition of TPO  
The active substances allocated to CAG level 4c are listed in Table 30.12. 
 
Table 30.12. CAG level 4c: Thyroid follicular cell toxicity related to inhibition of TPO 
Amitrole Metiram Thiophanate-methyl 
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ETU (metabolite of mancozeb, 
maneb, metiram) 
Propineb TTCA (metabolite of tolylfluanid) 
Mancozeb PTU (metabolite of propineb) Ziram 
Maneb   
 
 
30.2.4.4. CAG level 4d: Competitive displacement of T4 from its binding to TTR 
The active substances allocated to CAG level 4d are listed in Table 30.13. 
 
Table 30.13. CAG level 4d: Follicular cell toxicity related to competitive displacement of 
T4 from its binding to TTR 
Ioxynil   
 
 
30.2.4.5. CAG level 4e: Antagonism to T3 action 
The active substances allocated to CAG level 4e are listed in Table 30.14. 
 
Table 30.14. CAG level 4e: Follicular cell toxicity related to antagonism to T3 action 
Etofenprox PTU (metabolite of propineb)  
 
 
30.2.4.6. CAG level 4f: Inhibition of iodothyronine deiodinases  
The active substances allocated to CAG level 4f are listed in Table 30.15. 
 
Table 30.15. CAG level 4f: Follicular cell toxicity related to inhibition of iodothyronine 
deiodinases 
ETU (metabolite of mancozeb, 
maneb, metiram) 
Propineb TTCA (metabolite of tolylfluanid) 
Flufenacet PTU (metabolite of propineb)  
 
 
30.2.4.7. CAG level 4g: Induction of UDPGT and/or SULT  
The active substances allocated to CAG level 4g are listed in Table 30.16. 
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Table 30.16. CAG level 4g: Follicular cell toxicity related to induction of UDPGT and/or 
SULT 
Benthiavalicarb Flufenacet Prothioconazole 
Boscalid Fluoxastrobin Pymetrozine 
Chlorpropham Isoxaflutole Pyrethrins 
Clodinafob Metribuzin Pyrimethanil 
Clofentezin Pendimethalin Thiabendazole 
Cyflufenamid Pethoxamid Thiacloprid 
Etofenprox Propyzamide Thiophanate-methyl 
Fipronil   
 
 
30.3. Discussion of CAGs for the thyroid gland 
Sixty active substances were identified to have effects on the thyroid and were allocated to 
CAG level 1. Six distinct CAGs at level 2 have been proposed. Information on 
modes/mechanisms of action is available for some of the active substances. The information is 
summarised in Appendices AQ, AR and AS. 
The mechanism of action is known for about half of the active substances with effects on the 
thyroid follicular cells. However, if an active substance is likely to fit into the combined mode 
of action model established, the detailed mechanism of action might not be essential for 
cumulative risk assessment. 
Generally dose addition models are used to predict the response to mixtures of chemicals that 
act through the same mechanism. Response addition models are used to calculate the response 
to mixtures containing chemicals acting through different mechanisms but with a common 
response e.g. decreased circulating T4 concentrations. Integrated addition models are used to 
predict the response to a mixture containing chemicals with similar and dissimilar 
mechanisms that affect a common downstream end point such as serum T4.  
Crofton et al. (2005) investigated a mixture of 18 thyroid disturbing chemicals. All 18 
chemicals tested one by one decreased the level of circulating T4. One mechanism by which 
these chemicals alter the T4 concentration is thought to be via upregulation of the hepatic 
enzyme UDPGT. However, different mechanisms may lie behind this change. Some of the 
chemicals tested were known to bind to the Aryl-hydrocarbon-receptor. Others were known to 
bind to other receptors such as the PXR. Crofton et al. showed that the mixture caused 
decreases in the T4 concentration even though the individual chemical concentrations in the 
mixture were below effective doses. Dose addition predicted the effect (decreased T4) of the 
mixture with a fair degree of accuracy whereas effect addition underestimated the effect.  
Along the same lines, Flippin et al. (2009) investigated a mixture of 21 thyroid disturbing 
chemicals of which 18 stimulate T4 clearance in the liver and 3 inhibit thyroid hormone 
synthesis. The results of dose addition and integrated addition models were similar, and both 
provided better predictions than the effect addition model. 
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These two studies suggest that it may be possible to predict a decreased level of T4 in a 
mixture of chemicals with a fair degree of accuracy using dose addition models without 
knowing the detailed mechanism behind the decreased T4 level.  
It is therefore recommended to consider the CAG level 3: Mode of action for effects on 
follicular cells” for cumulative risk assessment. It should be noted that hormone levels have 
been studied for most but not all of the active substances listed under CAG level 3.  
In toxicological test guideline studies it is not a requirement to measure the level of T3, T4 
and TSH. Therefore, active substances may have influenced the level of the thyroid hormones 
without being listed under CAG level 2a (Decreased T3 and/or T4) and CAG level 2b 
(Increased TSH) simply because the hormone levels were not measured. 
As follicular cell tumours are a consequence of prolonged increased levels of TSH, they are 
often found only at the highest dose levels and only with a slightly increased incidence 
compared to the control group. Therefore, it is not always clear from the DARs or peer review 
reports (if available) whether the experts consider the tumours treatment related.   
Humans, monkeys, guinea pigs, and chickens seem to be less sensitive than rats, mice and 
dogs to thyroid disturbances even though the basic hypothalamic-pituitary-thyroid axis 
functions in a similar way in humans and animals. Rats are more sensitive than mice which 
are more sensitive than dogs. Particularly male rats are considered highly sensitive for thyroid 
disturbances due to higher circulating levels of TSH. The following are some of the species 
differences that may explain sensitivity differences: 
• Differences in the concentration of chemicals needed to inhibit TPO. Monkeys are e.g. 
less sensitive than rats. 
• Differences in the transport of T3 and T4. In humans and monkeys, for instance, T4 is 
mainly bound to TBG whereas in rodents T4 is mainly bound to TTR. TBG has a 
binding affinity for T4 approximately 1000 times higher than TTR. As a result, the 
plasma half-life of T4 is much shorter in rodents than in humans.  The consequence of 
a shorter plasma half life of T4 is a greater susceptibility in rodents for alterations in 
the T4 production or break down. In addition, competitive displacement of T4 from its 
binding site has so far only been shown for TTR and not for TBG. 
• Differences in the activity of deiodinases. The activity of D1 is lower in human than in 
rat liver. 
• Differences in the importance of glucuronidation of T3 and T4 for excretion. 
Glucuronidation is less important in humans than in rats. 
• Differences in the efficiency of the enterohepatic cycle. The efficiency may be greater 
in humans than in rats.  
 
Because of these differences it is generally accepted that non-genotoxic chemicals, which 
cause thyroid tumours in rats and mice because of changes in the thyroid and pituitary 
hormone levels, will not cause thyroid tumours in humans. However, even if the results of 
rodent experiments may not reflect an accurate measure of the degree of thyroid disturbances 
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in humans, they do indicate whether a chemical has the potential to change the level of T3 and 
T4 in humans exposed to high enough doses.  
Therefore, the relevance for humans to a great extent is a question of dose, i.e. whether the 
exposure to a thyroid disturbing chemical is sufficient to cause effects. Even small and 
transient changes in the T3 and T4 levels in humans may affect the developing nervous system 
in the unborn children. To make it even more complicated, the duration and timing of T3 and 
T4 insufficiency are also important and may vary by species. 
30.4. Recommended CAGs for the thyroid gland 
The following CAG at level 3 is recommended for CRA for effects on the thyroid gland: 
• CAG level 3: Follicular cell toxicity (combined mode of action model), see Table 
30.8. 
 
 
31. Urinary bladder 
31.1. Introduction 
The urine formed by the nephrons in the kidney flow from the distal tubules and collecting 
ducts through the renal papilla, and into the calyces, and is collected in the renal pelvis. From 
the renal pelvis, urine is funnelled into the ureters. Peristaltic activity of the ureters propels 
urine into the bladder. Peristalsis is controlled by the nervous system and by the urine volume.  
The bladder is a bag composed of smooth muscle fibres and transitional epithelium. Its 
function is to store urine until elimination. As the bladder fills with urine, it distends and the 
layers of transitional epithelium slide past each other and become thinner as the volume of the 
bladder increases. The urethra extends from the inferior side of the bladder to the outside of 
the body. Two muscles called sphincters control excretion of urine from the bladder through 
the urethra. One of the sphincters is under voluntary control. The other sphincter and the 
bladder are under control of the nervous system via impulses from mechanoreceptors in the 
bladder. (McCance and Huether 1998). 
The urinary passages, the renal pelvis, the ureters, the bladder and the urethra are histological 
similar to each other. They have a mucosal layer lined with transitional epithelium. 
Underlying the mucosal layer are muscle layers covered by a serous membrane or connective 
tissue. (Verlander 1998). Therefore the pathogenesis for effects in the urinary bladder may be 
the same as for effects in the renal pelvis, ureters and urethra (Cohen 1998). Effects on the 
renal pelvis and ureters have been included in the chapter about the kidney 
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From http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Kidney/Aboutkidneycancer/Ureterrenalpelvis.aspx   
Figure 31.1. Anatomy of the urinary passages 
 
 
31.2. Establishment of CAGs for toxicity to the urinary bladder 
31.2.1. CAG level 1: Toxicity to the urinary bladder 
The active substances identified as having an effect on the urinary bladder in the toxicological 
studies included in the DARs are allocated to CAG level 1 and are listed in Table 31.1. 
Table 31.1. CAG level 1: Toxicity to the urinary bladder 
2-Phenylphenol Flusilazole Pyrimethanil 
Aclonifen Fosetyl Quinoclamine 
Azimsulfuron Glyphosate Spiroxamine 
Chloridazon (metabolite) Iprodione Sulfosulfuron 
Chlorothalonil Lufenuron Tepraloxydim 
Clodinafop Maleic hydrazide Thiabendazole 
Cymoxanil Metazachlor Triasulfuron 
Cyromazine (metabolite) Oxasulfuron Tritosulfuron 
Diuron Phenmedipham Ziram 
Fenpropidin Prothioconazole  
Fluoxastrobin Pyraflufen-ethyl  
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31.2.2. CAG level 2: Phenomenological / specific effects on the urinary bladder 
Various types of effects on the urinary bladder were identified as a basis for establishing 
CAGs at level 2. Based on these effects, four distinct CAGs at level 2 are proposed. More 
information is given in Appendix AT. 
31.2.2.1. CAG level 2a: Hypertrophy / hyperplasia 
Hypertrophy is an increased size of cells. Hyperplasia is an increased number of cells. It is 
mainly hyperplasia that has been noted in the urinary bladder. Hyperplasia of the urinary 
bladder may be a response to epithelial irritation, which in turn can be induced by urinary 
crystals, calculi or toxic chemicals (Fukushima and Murai 1999). 
For the purpose of the CAG project, hypertrophy and hyperplasia are interpreted as 
representing the same type of effect in the urinary bladder and therefore, are allocated to a 
single CAG level 2, termed ‘CAG level 2a: Hypertrophy / hyperplasia’. See Annex AT for a 
list of all terms in the DARs interpreted to represent hypertrophy and/or hyperplasia of the 
urinary bladder. 
The active substances identified as inducing hypertrophy and/or hyperplasia in the urinary 
bladder are allocated to CAG level 2a and are listed in Table 31.2. 
 
Table 31.2. CAG level 2a: Hypertrophy / hyperplasia in the urinary bladder 
2-Phenylphenol Fluoxastrobin Pyrimethanil 
Aclonifen Flusilazole Quinoclamine 
Azimsulfuron Fosetyl Spiroxamine 
Chloridazon (metabolite) Glyphosate Sulfosulfuron 
Chlorothalonil Iprodione Tepraloxydim 
Clodinafop Maleic hydrazide Thiabendazole 
Cymoxanil Metazachlor Triasulfuron 
Cyromazine (metabolite) Oxasulfuron Tritosulfuron 
Diuron Prothioconazole Ziram 
Fenpropidin Pyraflufen-ethyl  
 
 
31.2.2.2. CAG level 2b: Cell degeneration / cell death  
Necrosis and ulceration have predominantly been reported in the DARs for the active 
substances allocated to CAG level 2b. See Annex AT for a list of all terms in the DARs 
interpreted to represent cell degeneration / cell death of the urinary bladder. 
The active substance identified as inducing cell degeneration / cell death are allocated to CAG 
level 2b and are listed in Table 31.3. 
 
Table 31.3. CAG level 2b: Cell degeneration / cell death in the urinary bladder 
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2-Phenylphenol Diuron Sulfosulfuron 
Cyromazine (metabolite) Flusilazole Tepraloxydim 
 
 
Calculi may cause erosion and ulceration of the bladder epithelium (Cohen 1998). For four of 
the active substances (2-phenylphenol, cyromazine (metabolite), flusilazole, and 
sulfosulfuron) that induce cell death, calculi have also been noted. However, for 2-
phenylphenol calculi does not seem to be considered part of the mode or mechanism of action 
for urinary bladder toxicity (see section 31.2.4.2). For 2-phenylphenol and diuron oxidative 
stress in the bladder epithelium has been measured and may form part of the mode of action 
for cell death. 
31.2.2.3. CAG level 2c: Inflammation  
Inflammation of the urinary bladder is commonly a response to epithelial irritation, which in 
turn can be induced by urinary crystals, calculi or toxic chemicals. It may be accompanied by 
hyperplasia. (Hard et al. 1999). See Annex AT for a list of all terms in the DARs interpreted 
to represent inflammation of the urinary bladder. 
The active substances identified as inducing inflammation is allocated to CAG level 2c and 
are listed in Table 31.4.. 
Table 31.4. CAG level 2c: Inflammation in the urinary bladder 
Aclonifen Fluoxastrobin Prothioconazole 
Azimsulfuron Flusilazole Pyrimethanil 
Clodinafop Fosetyl Quinoclamine 
Cymoxanil Iprodione Sulfosulfuron 
Cyromazine (metabolite) Lufenuron Tritosulfuron 
Diuron Oxasulfuron  
Fenpropidin Phenmedipham  
 
 
31.2.2.4. CAG level 2d: Neoplasms  
Errors do occur during DNA replication. Therefore with an increasing number of cells 
replications (hyperplasia) an adequate number of mistakes may be generated to lead to an 
increased incidence of neoplasms in life-time studies (Cohen 1998). As all of the active 
substances which cause neoplasms of the urinary bladder are considered non-genotoxic by the 
DARs and cause hyperplasia of the bladder epithelium, it is likely that the hyperplasia is part 
of the mode of action for the neoplasms. See Annex AT for a list of all terms in the DARs 
interpreted to represent neoplasms of the urinary bladder. 
The active substances identified as inducing neoplasms are allocated to CAG level 2d and are 
listed in Table 31.5. 
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Table 31.5. CAG level 2d: Neoplasms in the urinary bladder 
2-Phenylphenol Diuron Metazachlor 
Aclonifen Flusilazole Quinoclamine 
Cyromazine (metabolite) Fosetyl Sulfosulfuron 
 
 
31.2.2.5. Effects not considered relevant for CAGs at level 2 
Dilation:  
Very large calculi can completely fill and distend the bladder lumen (Hard et al. 1999). 
Calculi have been found in the urinary bladder and/or in the kidney for all three active 
substances where dilation was noted. For these substances dilation of the urinary bladder is 
considered secondary to the effect already covered by the CAG level 3a1 for calculi, see 
below. 
 
Oedema: 
Oedema may accompany inflammation (Hard et al. 1999). Oedema in the urinary bladder has 
been found for two active substances together with inflammation. For these substances 
oedema in the urinary bladder is considered secondary to the effects already covered in the 
CAG level 2c for inflammation, see below. 
 
Haemorrhage: 
Haemorrhage in the urinary bladder may occur in conjunction with necrosis and inflammation 
(Hard et al. 1999, Cohen 1998). Haemorrhage in the urinary bladder has been found for three 
active substances together with necrosis and/or inflammation. For these substances 
haemorrhage in the urinary bladder is considered secondary to the effects already covered in 
the CAG level 2b for cell degeneration and/or cell death or in the CAG level 2c for 
inflammation. 
 
Fibrosis: 
Fibrosis is the formation of excess connective tissue in a reaction to toxicity of the urinary 
bladder. Fibrosis in the urinary bladder has been found for two substances together with 
inflammation and hyperplasia. For these substances fibrosis is considered secondary to the 
effects already covered especially in the CAG level 2c for inflammation.  
 
Hyaline droplets: 
Hyaline droplets are lysosomes containing protein. Hyaline droplets in the urinary bladder 
have only been reported for one substance. 
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Arteritis: 
Arteritis is inflammation of the walls of arteries. Arteritis in the urinary bladder has only been 
reported for one substance and is not considered an effect specific for the urinary bladder.  
 
Vacuolation: 
Vacuolation of the transitional epithelium of the urinary bladder is a non-specific lesion as a 
response to cell injury. Eosinophilic inclusions often lie within the vacuoles and may represent 
cytoplasmic degradative products. Vacuolation may also be artefactual resulting from 
autolysis. (Hard et al 1999). Vacuolation has only been reported for two active substances 
where other kinds of cell injury such as necrosis and/or inflammation also have been noted.   
 
Squamous metaplasia: 
The epithelial cells are transformed into squamous epithelial cells typically as a response to 
irritation. Squamous metaplasia of the urinary epithelium has only been noted for two active 
substances where hyperplasia and/or neoplasms were noted in other studies. Although 
squamous metaplasia is not the same as hyperplasia or neoplasms, the squamous metaplasia is 
considered covered by the CAG level 2a for hypertrophy/hyperplasia and/or the CAG level 2d 
for neoplasms. 
 
Dysplasia: 
Dysplasia is delayed cell maturation and differentiation. Dysplasia is often indicative of an 
early neoplastic process. Dysplasia of the urinary epithelium has only been noted for one 
active substance where hyperplasia was noted in other studies. Although hyperplasia and 
dysplasia is not the same, the dysplasia is considered covered by the CAG level 2a for 
hypertrophy/hyperplasia. 
31.2.3. CAG level 3: Mode of action  
For some of the phenomenological / specific effects on the urinary bladder described under 
CAG level 2, a mode of action has been proposed. For the remaining substances, no 
information regarding mode of action has been found and consequently, these substances 
cannot be allocated to a CAG level 3. 
31.2.3.1. CAG level 3a1: Calculi 
Calculi are stones. Calculi may cause erosion and ulceration of the bladder epithelium with 
hemorrhage, inflammation and regeneration. Severe damage to the epithelium may lead to 
hyperplasia and ultimately neoplasms. Formation of calculi requires the concentration of the 
critical substances (e.g. active substance, metabolite, calcium) in the urine to be sufficiently 
high to lead to precipitate formation and ultimately to calculi. This can be influenced by 
specific chemical and physical condition of the urine (e.g. pH, volume). Urinary bladder 
calculi irrespective of composition may cause irritation and cell proliferation also in humans. 
The risk in humans may not be as great as that in rodents because the calculi are usually 
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voided spontaneously or removed by surgical procedures. As rodents are positioned 
horizontally they are less likely to eliminate the calculi spontaneously. (IARC 1999, Cohen 
1998). See Annex AT for a list of all terms in the DARs interpreted to represent calculi. 
The active substances identified as inducing calculi are allocated to CAG level 3a1 and are 
listed in Table 31.6. 
 
Table 31.6. CAG level 3a1: Calculi 
2-Phenylphenol Flusilazole Pyrimethanil 
Chloridazon (metabolite) –  in 
kidney 
Fosetyl Sulfosulfuron 
Cyromazine (metabolite) Maleic hydrazide Thiabendazole 
Fluoxastrobin Oxasulfuron Triasulfuron 
 
 
During the course of an experiment calculi frequently are passed by the animals without being 
detected by the investigators because they are too small for gross visual detection or they have 
dissolved in the urine (Cohen 1998). Therefore, more active substances than those listed may 
cause urinary bladder toxicity by a calculi mode of action.  
Chloridazon (metabolite) has been included in CAG level 3a1 even though calculi have not 
been detected in the bladder but only in the kidney as the substance clearly has the potential to 
produce calculi. 
All of the twelve active substances, which induce calculi, also induce hyperplasia of the 
bladder. However it is only 2-phenylphenol, cyromazine (metabolite), flusilazole, and 
sulfosulfuron, which induce cell death in the bladder. And it is only cyromazine (metabolite), 
fluoxastrobin, flusilazole, fosetyl, oxasulfuron, pyrimethanil, and sulfosulfuron, which induce 
inflammation in the bladder.  
Even though studies with 2-phenylphenol have shown calculi in the bladder, calculi does not 
seem to be considered part of the mode of action for 2-phenylphenol by the DAR. For 
cyromazine (metabolite), fluoxastrobin and fosetyl, calculi have been discussed as part of the 
mode/mechanism of action for these substances (see the section on mechanism of action). For 
the rest of the active substances, which induce calculi, no mode/mechanism of action for the 
bladder toxicity was discussed in the DARs. 
31.2.3.2. CAG level 3a2: Crystals 
Like calculi, crystals in the urine may lead to erosion of the bladder that may result in 
regenerative hyperplasia and ultimately neoplasms usually without inflammation. (Cohen 
1998). See Annex AT for a list of all terms in the DARs interpreted to represent crystals. 
The active substances identified as inducing crystals are allocated to CAG level 3a2 and are 
listed in Table 31.7 
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Table 31.7. CAG level 3a2: Crystals 
Aclonifen Cyromazine (metabolite) Prothioconazole 
Azimsulfuron Fluoxastrobin Sulfosulfuron 
Chloridazon (metabolite) Iprodione  
 
 
All of the eight active substances, which induce crystals, also induce hyperplasia of the 
bladder. Half of the substances also induce calculi (chloridazon (metabolite), cyromazine 
(metabolite), fluoxastrobin, and sulfosulfuron). The other half of the substances induce 
inflammation but not cell death in the bladder (aclonifen, azimsulfuron, iprodione, and 
prothioconazole). 
31.2.3.3. CAG level 3e1: Oxidative stress 
Oxidative stress occurs in cells when the concentration of reactive oxygen species (ROS) 
generated exceeds the antioxidant capability. ROS can be produced in normal cellular 
metabolism or by inflammatory cells. Reactive intermediate metabolites produced in the 
metabolism of xenobiotics may enhance the formation of ROS. Antioxidants such as vitamin 
C, vitamin E, glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GSH-
Px), and catalase normally inactivate ROS. With excessive formation of reactive intermediate 
metabolites and ROS the antioxidant capacity may be overloaded. The result is oxidative 
stress, which may result in damage to DNA, lipids, and proteins in the cell. Unrepaired DNA 
damage may lead to new mutations and potentially tumours. Oxidative injury may also 
produce cell death, which may lead to regenerative hyperplasia and ultimately tumours.  
(Klaunig et al. 1998). 
Active substances, which induce oxidative stress measured as a decreased level of the 
antioxidant GSH are included in this CAG. 
The active substances identified as inducing oxidative stress are allocated to CAG level 3e1 
and are listed in Table 31.8. 
 
Table 31.8. CAG level 3e1: Oxidative stress 
2-Phenylphenol Diuron  
 
 
The standard toxicological guidelines do not include as a mandatory requirement studies on 
oxidative stress. Therefore, more active substances than those listed may cause urinary 
bladder toxicity by an oxidative stress mode of action. 
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31.2.4. CAG level 4: Mechanism of action 
For a few of the active substances affecting the urinary bladder, a mechanism of action has 
been proposed. For the remaining substances, no information regarding mechanisms has been 
found and consequently, these substances cannot be allocated to a CAG level 4. 
31.2.4.1. CAG level 4a1a: Increased calcium in urine 
Both fluoxastrobin and fosetyl induce calculi in the urinary bladder. For both substances 
mechanistic studies have shown an increased level of phosphorous in the faeces, a decreased 
level of phosphorous in the urine and an increased level of calcium in the urine. The two 
substances differed in that the urinary pH was increased for fluoxastrobin but decreased for 
fosetyl. For fluoxastrobin it was stated that fluoxastrobin resulted in reduced phosphate 
absorption in the intestine. A potential phosphate deficiency was counter-regulated by reduced 
renal excretion of phosphate and renal hyper-excretion of calcium. It is proposed by the DAR 
that increased calcium excretion in urine, together with an increase in urinary pH, led to 
calculi formation and following erosive and/or irritative effects of these foreign bodies in the 
urine, moderate to marked diffuse hyperplasia of the transitional epithelium of the urinary 
tract with inflammation developed.  
For four other of the active substances (2-phenylphenol, chloridazon, oxasulfuron, and 
sulfosulfuron), which induced calculi, mineralisation was noted in the urinary bladder. 
Mineralisation in the rat kidney mainly represents calcium salt deposition (Hard et al. 1999). 
Thus for these substances an increased level of calcium in the urine may also be part of the 
cause of bladder calculi. However, no mechanistic studies have been performed to confirm or 
reject that hypothesis.  
The active substances identified in mechanistic studies as inducing increased calcium in urine 
are allocated to CAG level 4a1a and are listed in Table 31.9. 
 
Table 31.9. CAG level 4a1a: Increased calcium in urine 
Fluoxastrobin Fosetyl  
 
 
31.2.4.2. Information not considered relevant for CAGs at level 3 and/or 4 
According to the DAR, the urinary bladder tumours seen in male rats exposed to high doses of 
the cyromazine metabolite, melamine, appear to be produced by a non-DNA-reactive 
mechanism involving epithelial hyperplasia secondary to the presence of melamine-containing 
bladder stones. 
For iprodione the crystals probably consisted of the metabolite 32490 RP.  
For thiabendazole the main component of calculi was protein. 
The information on the content of bladder stones and crystals for melamine and iprodione is 
of no relevance for CAGs at level 4 unless other active substances produce the same 
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metabolites and that is not the case. In order to create a CAG at level 4 for thiabendazole, 
more mechanistic studies are needed to explain whether protein is important for the formation 
of the calculi. 
 
2-Phenylphenol (including the sodium salt of orthophenyl phenol): 
Despite many mechanistic studies with 2-phenylphenol the mechanism(s) of urinary bladder 
toxicity is not clear-cut. Calculi were produced in a couple of lifetime studies. However, 
according to the DAR, the mechanism of tumourigenesis in rats was assumed to be non-
genotoxic, probably based on chronic irritation of the epithelium by a combination of high pH, 
high sodium-ion concentration and/or high concentration of free metabolites at high doses. In 
the studies there was e.g. a positive correlation between urinary pH and the incidence of 
hyperplasia of the urinary bladder. The tumourigenic potential of 2-phenylphenol was 
enhanced by co-administration of sodium bicarbonate as an alkalinising agent while the 
tumourigenesis by its sodium salt  was attenuated by co-administration of ammonium chloride 
as an acidifier.  
The authors of an in vivo micronucleus study from the open literature suggest that both 
chromosomal alterations and cell proliferation occurring in the rat bladder may contribute to 
the carcinogenicity of 2-phenylphenol. The DAR does not contain in vivo micronuclei studies. 
In addition a study in the open literature has shown that 2-phenylphenol induce oxidative 
stress in urinary bladder as described in CAG level 3b.   
 
Diuron: 
EFSA is concluding that the effects on the bladder can be caused by irritation but there is no 
clear indication of this in the available documentation. 
31.3. Discussion of CAGs for the urinary bladder 
Thirty-one active substances were identified to have effects on the urinary bladder and were 
allocated to CAG level 1 (Table 31.1). Four distinct CAGs at level 2 have been proposed. 
Information on mode / mechanism of action is available for about half of the active 
substances. The information is summarised in Appendix AU. 
Four distinct CAGs at level 2 have been proposed. All but two of the active substances 
(lufenuron and phenmedipham) induce hyperplasia of the urinary epithelium and are allocated 
to CAG level 2a. Hyperplasia of the urinary bladder may be a response to epithelial irritation, 
which in turn can be induced by urinary crystals, calculi or toxic chemicals. For about half of 
the active substances the epithelial irritation may be explained by urinary crystals (CAG level 
3a2) and/or calculi (CAG level 3a1). As calculi frequently during the course of an experiment 
are passed by the animals without being detected by the investigators, more active substances 
than those listed may cause urinary bladder toxicity by a calculi mode of action. 
For one of the active substances, 2-phenylphenol, where calculi have been found in a couple 
of studies, calculi does not seem to be considered part of the mode of action for 2-
phenylphenol by the DAR. For most of the active substances, mechanistic studies have not 
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been performed, and the DAR has not elaborated on the mode or mechanism of action. For 
fluoxastrobin and fosetyl mechanistic studies have shown an increased level of calcium in the 
urine (CAG level 4a1a), which may explain the formation of calculi and the subsequent 
urinary bladder toxicity. For the cyromazine metabolite, melamine, the DAR considers the 
melamine-containing bladder stones to be the cause of the urinary bladder toxicity. Thus the 
DARs have no opinion on whether the calculi or crystals may be the cause of urinary bladder 
toxicity for 12 out of the 16 active substances that induce calculi or crystals. For 3 substances 
(fluoxastrobin, fosetyl, and the cyromazine metabolite, melamine) the DAR consider the 
calculi the cause of the urinary bladder toxicity. And for 2-phenylphenol calculi does not seem 
to be considered part of the mode of action by the DAR.  
As cell death (CAG level 2b), inflammation (CAG level 2c) and neoplasms (CAG level 2d) 
for all but 2 substances probably are part of the same irritative mode of action as for 
hyperplasia it is not recommend to consider CAG level 2b, CAG level 2c and CAG level 2d 
for CRA. As oxidative stress (CAG level 3e1) only have been studied for two of the 
substances (2-phenylphenol and diuron) and many other mechanisms also have been 
suggested for 2-phenylphenol, it is not recommended to consider CAG level 3e1 for CRA. 
31.4. Recommended CAGs for the urinary bladder 
The following CAG at level 2 are recommended for CRA for effects on the urinary bladder: 
• CAG level 2a: Hypoplasia, see Table 31.2. 
 
 
32. Database 
The results of the evaluations of the available toxicological studies for the allocation of the 
active pesticide substances into CAGs are presented in the CAPEG database, where the 
information can be searched.  The database is in Microsoft Access version 2003 based on the 
Excel spreadsheet that was developed for the evaluation of the toxicological studies.  
The Excel spreadsheet (and thus the CAPEG database) contains the following entries: 
• Substance number 
• Active substance (trivial name) 
• Category (pesticidal) 
• Chemical class 
• Chemical name (IUPAC) 
• CAS number 
• Pesticidal mode/mechanism of action 
• ADI (mg/kg bw/d) 
• ArfD (mg/kg bw/d) 
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• AOEL (mg/kg bw/d) 
• Target organ/tissue (CAG level 1) 
• Phenomenological specific effect (CAG level 2) 
• Species 
• Strain 
• Sex 
• Duration 
• Route of exposure 
• NOAEL (mg/kg bw/d) 
• LOAEL (mg/kg bw/d) 
• Reference 
• Source (DAR, EFSA peer-review, open literature, etc.) 
• Remarks (to the outcome of the evaluation) 
• Toxicological mode of action (CAG level 3) 
• Toxicological mechanism of action (CAG level 4). 
 
The Excel spreadsheet was directly transformed into Microsoft Access 2003 without any 
further development. The database therefore contains exactly the same entries on the same 
level as the spreadsheet. 
A user manual containing a short introduction to the search functionality of the CAPEG 
system is attached as Appendix AV. 
 
33. Limitations of approaches and resulting uncertainties 
Uncertainty is a consequence of imperfect knowledge and limited data. 
In this project the decision to allocate active substances into a certain CAG is primarily 
dependent on the interpretation of the citations and evaluations of the toxicological studies 
presented in the individual DARs. There are (at least) two areas that give rise to uncertainty: 
• The inherent degree of uncertainties in the measure of effects in the toxicological 
studies: In many cases, specific endpoints were observed in only one or a few studies, 
and/or the findings were not consistent across studies, sex and/or species. In this 
respect, it should be noted that many studies included in the DARs are of an older date 
and not meeting current requirements. 
• The inconsistencies between the various rapporteurs descriptions and interpretations of 
the same toxicological effect: This may result in one active substance being evaluated 
as having a given effect while another substance has not, or vica verca. This may either 
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lead to a substance being wrongly allocated into a given CAG, or on the other hand 
that the substance is wrongly excluded from a CAG. 
 
34. Further needs for data and research in regard to CRA 
Data on mode/mechanism of action are lacking for the vast majority of the different 
toxicological effects produced by the active pesticide substances included in this assessment. 
Obviously, such data is needed in order to improve the establishment of CAGs for CRA 
However, before using many resources to obtain such information a systematic research 
review on pesticide occurrence and exposure data for Europe should be carried out with the 
aim of identifying combinations of active pesticide substances that are either realistic 
candidates for CRA or not. 
 
Conclusions and Recommendations 
CONCLUSIONS  
Cumulative assessment groups (CAG) for phenomenological effects at CAG level 2 were 
recommended to be considered for use in cumulative risk assessment (CRA) for the following 
target organs/tissues: 
• Adrenal gland (chapter 7) 
• Bone marrow (chapter 8) 
• Bones / skeleton (chapter 9) 
• Cardiovascular system (chapter 10) 
• Eye (chapter 11) 
• Gallbladder (chapter 12) 
• Haematological system (chapter 14) 
• Kidney (chapter 16) 
• Liver (chapter 17) 
• Muscles (chapter 20) 
• Nervous system (chapter 21) 
• Parathyroid gland (chapter 23) 
• Reproductive system and developmental toxicity (chapter 25) 
• Spleen (chapter 28) 
• Thyroid gland (chapter 30) 
• Urinary bladder (chapter 31) 
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No CAGs were recommended for CRA the following target organs/tissues: 
• Gastrointestinal tract (chapter 13) 
• Immune system (chapter 15) 
• Lung (chapter 18) 
• Lymph node (chapter 19) 
• Pancreas (chapter 22) 
• Pituitary gland (chapter 24) 
• Salivary gland (chapter 26) 
• Skin (chapter 27) 
• Thymus (chapter 29) 
 
The CAGs at level 2 are established without any knowledge about mode/mechanism of action 
and do therefore not fulfil the criteria for a cumulative mechanism group that can be expected 
to exert dose additivity. However, risk managers may wish to use a CAG at level 2 in order to 
consider whether a realistic cumulative exposure to certain active substances would need to be 
further investigated. 
CAGs at level 3 based on knowledge on the mode of action could only be recommended for 
the bone marrow, bones / skeleton, eye, haematological system, liver, muscles, nervous 
system, reproductive and developmental system, and thyroid gland, whereas CAGs at level 4 
based on the mechanism of action could only be recommended for some toxicological effects 
on the eye, liver, nervous system and reproductive and developmental system. These CAGs 
should provide a reasonable basis for performing CRA. 
A searchable database in Microsoft Access was developed containing information on the 
chemical and pesticidal properties, the acceptable daily intake (ADI) established by the EU for 
the active substances, and the results of the evaluations of the toxicological studies used to 
allocate the active substances into the different CAGs, including the NOAELs and LOAELs 
for these studies (see chapter 32). 
 
RECOMMENDATIONS 
A systematic review, based on pesticide occurrence and exposure data for foods in Europe 
should be carried out with the aim of identifying realistic combinations of active pesticide 
substances that are relevant candidates for cumulative risk assessments. Data on 
mode/mechanism of action will then probably be needed for the majority of the toxicological 
effects produced by the active pesticide substances to be included in such assessments. 
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Although the CAGs at level 2 are established without any knowledge about mode/mechanism 
of action and do therefore not fulfil the criteria for a cumulative mechanism group that can be 
expected to exert dose additivity they can be useful for a preliminary assessment of realistic 
mixtures of active substances. This in particular, because it can be expected that such an 
assessment will be conservative in the absence of dose additivity between the compounds. 
For such an assessment, it is recommended to use the Reference point index (RfPI) (based on 
the NOAELs for the compounds in the CAG) as described by the PPR Panel (EFSA 2008). 
The RfPI is similar to the Point of departure index (PODI) advocated by EFSA (2007) and by 
WHO (2009) to be used in cumulative risk assessment. 
The Reference Point Index (RfPI) represents the sum of the exposures to each pesticide 
expressed as a fraction of their respective RfPs for the relevant effect (e.g., the dose that 
causes a 10% effect, BMD10; or the NOAEL). When the RfPI multiplied by a chosen group 
uncertainty factor (UF) is lower than 1, the combined risk is considered acceptable. An UF of 
100 is recommended. 
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APPENDIX S Haematological system, the cellular elements of the blood – effects 
APPENDIX T CAGs at level 1, 2, 3 and 4 for effects on the haematological system 
APPENDIX U Kidney - effects 
APPENDIX V CAGs at level 1 and 2 for effects on the kidney 
APPENDIX X Liver - effects 
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APPENDIX Y CAGs at level 1, 2, 3 and 4 for effects on the liver 
APPENDIX Z Muscles - effects 
APPENDIX AA CAGs at level 1, 2, and 3 for effects on the muscles 
APPENDIX AB Nervous system - effects 
APPENDIX AC CAGs at level 1, 2, 3 and 4 for effects on the nervous system 
APPENDIX AD Parathyroid gland - effects 
APPENDIX AE CAGs at level 1, 2, and 3 for effects on the parathyroid gland 
APPENDIX AF CAGs at level 2a1 for reproductive and developmental toxicity: Delayed 
development 
APPENDIX AG CAGs at level 2a2 for reproductive and developmental toxicity: Decreased 
body weight 
APPENDIX AH CAGs at level 2b for reproductive and developmental toxicity: 
Malformations and Variations 
APPENDIX AI CAGs at level 2c for reproductive and developmental toxicity: Pre- and 
postnatal death 
APPENDIX AJ CAGs at level 2d for reproductive and developmental toxicity: Other effects 
in offspring 
APPENDIX AK CAGs at level 2e for reproductive and developmental toxicity: Fertility 
APPENDIX AL Subgroups of 2e1 and 2d1:Effects in males 
APPENDIX AM CAGs at level 2f for reproductive and developmental toxicity: Tumours in 
reproductive organs 
APPENDIX AN Spleen - effects  
APPENDIX AO CAGs at level 1, 2 and 3 for effects on the spleen 
APPENDIX AP Thyroid - effects 
APPENDIX AQ CAGs at level 2, 3 and 4 for effects on thyroid follicular cells 
APPENDIX AR CAGs at level 4. Mechanisms of action for effects on thyroid follicular cells 
APPENDIX AS CAGs AT LEVEL 2 FOR EFFECTS ON THYROID PARAFOLLICULAR CELLS 
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APPENDIX AT Urinary bladder - effects  
APPENDIX AU CAGs at level 1 and 2 for effects on the urinary bladder 
APPENDIX AV CAPEG version 1.2 Cumulative Assessment of Pesticide Groups User Guide 
October 2011 
 
 
Remark: Appendices in separate file. 
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Glossary / Abbreviations 
 
GLOSSARY  
 
Active substance 
Any substance, including micro-organisms, 
having general or specific action against harmful 
organisms or on plants, parts of plants or plant 
products (Regulation (EC) No 1107/2009) 
Adaptive effects The effect is observed after relative short time of exposure but vanish after prolonged exposure 
Agonist An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell 
Antagonism 
Two or more agents in combination have an 
overall effect which is less than the sum of their 
individual effects, or: 
A type of receptor ligand or drug that does not 
provoke a biological response itself upon binding 
to a receptor but blocks or dampens agonist-
mediated responses 
Benchmark doses 
The dose of a substance that is expected to result 
in a prespecified level of effect (Setzer & 
Kimmel 2003) 
CAG level 1 
Common assessment group for all compounds 
exerting a toxicological effect on  relevant 
organ/tissue 
CAG level 2 
Common assessment group for all compounds 
showing a common toxic effect on a 
phenomenological/specific effect basis in a target 
organ/tissue 
CAG level 3 Common assessment group for all compounds possessing the same mode of action 
CAG level 4 Common assessment group for all compounds possessing the same mechanism of action. 
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ChemDraw Molecule editor developed by CambridgeSoft 
Cumulative risk 
The combined risks from aggregate exposures to 
multiple agents or stressors 
Cumulative risk assessment 
Analysis, characterization, and possible 
quantification of the combined risks to human 
health from multiple agents or stressors 
Deterministic 
An inevitable consequence of antecedent 
sufficient causes 
Dose addition 
A mixture of compounds in a dilution acts on the 
same biological site by the same 
mechanism/mode of action and differ only in 
their potencies. 
Effect points Toxicological effects on target organs/tissues. 
Hazard Index A summation of the hazard quotients for all chemicals to which an individual is exposed 
Interactions 
The combined actions of compounds resulting in 
a stronger (see synergism) or weaker (see 
antagonism) effect than would be expected based 
on the assumption of additivity (see dose 
additivity) 
LD50 
The median lethal dose of a substance, or the 
amount required to kill 50% of a given test 
population. 
Mechanism of action 
The specific biochemical interaction through 
which a substance produces an effect on a living 
organism or in a biochemical system (IPCS 
2009b). 
Mechanism of pesticidal 
action 
The specific biochemical interaction through 
which a substance produces an effect on a target 
organism 
Microsoft Access 
A relational database management system from 
Microsoft that combines the relational Microsoft 
Jet Database with a graphical user interface and 
software-development tools. 
Mode of action 
A biologically plausible sequence of key events 
leading to an observed effect supported by robust 
experimental observations and mechanistic data. 
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A mode of action describes key cytological and 
biochemical events – that is, those that are both 
measurable and necessary to the observed effect – 
in a logical framework (IPCS 2009b). 
Open literature Peer reviewed literature available through public accessible databases. 
Pesticide  
Substances or mixture of substances intended for 
preventing, destroying, repelling or mitigating 
any pest. 
Point of departure See Benchmark doses (or NOAEL). 
Probabilistic 
A logical relation between statements such that 
evidence confirming one confirms the other to 
some degree  
Reference Point Index 
The sum of the exposures to each pesticide 
expressed as a fraction of their respective 
Reference Points for the relevant effect. 
Response addition 
A mixture of compounds in a dilution where the 
compounds do not interfere with each other but 
they all contribute to a common result. 
Simple dissimilar action See Response addition. 
Simple similar action See Dose-addition 
Synergistic effect  
Effect arising between two or more substances 
that produces an effect greater than the sum of 
their individual effects  
 
 
 
ABBREVIATIONS  
 
4-HHP 
 
4-Hydroxyphenyl Pyruvate 
4-HPLA 4-Hydroxyphenyl Lactic Acid 
4-HPAA 4-Hydroxyphenyl Acetic Acid 
AChE Acetylcholineesterase 
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ACTH Adrenocorticotropic Hormone 
ADI  Acceptable Daily Intake 
AhR Aryl hydrocarbon Receptor 
ALP Alkaline Phosphatase 
ALT Alanine Aminotransferase  
AOEL Acceptable Operator Exposure Level 
APTT Activated Partial Thromboplastin Time 
AR Androgen Receptor 
ARfD  Acute Reference Dose 
AST Aspartate Aminotransferase  
ATP Adenosine Triphosphate 
ATSDR Agency for Toxic Substances and Disease Registry 
BMD Bone Mineral Density 
BSP Bromosulphophtalein 
BW Body Weight 
BWG Body Weight Gain 
CAG Common Assessment Group 
CAPEG Cumulative Assessment of Pesticides Groups 
CAR Constitutive Androstane Receptor 
CAS Chemical Abstracts Service 
CBG Corticosteroid Binding Globulin 
CIRCA Communication & Information Resource Centre 
Administrator 
CMG Common Mode/Mechanism Group  
CNS Central Nervous System 
CoA Coenzyme A 
COT Committee on Toxicity of Chemicals in Food, 
Consumer Products and the Environment 
CRA Cumulative Risk Assessment 
cRfD Chronic Reference Dose 
CRH Corticotropin-Releasing Hormone 
CS2 Carbon disulfide 
CV  Cardiovascular 
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CYP Cytochrome P450 
D1 Type I iodothyronine deiodinase 
D2 Type II iodothyronine deiodinase 
D3 Type III iodothyronine deiodinase 
DAR Draft Assessment Report 
DHT Dihydrotestosterone 
ECCO European Community Co-Ordination 
EC No European Commission Number 
EFSA European Food Safety Authority 
EPA Environmental Protection Agency 
EPCO EFSA Pesticides Peer review Co-Ordination 
ERG Electroretinographic 
EU European Union 
FAO Food and Agriculture Organization 
FC Food Consumption 
FSH Follicle-stimulating hormone 
GABA Gamma-Aminobutyric acid 
GD Gestation Date 
GI Gastrointestinal Tract 
GGT Gamma Glutamyltransferease 
GnRH Gonadotropin Releasing Hormone 
GSH Glutathione 
GSH-Px Glutathione Peroxidase 
Hgb Haemoglobin 
HI  Hazard Index 
HPPD 4-Hydroxyphenyl Pyruvic Acid Dioxygenase 
Ht Haematocrit 
ILSI International Life Sciences Institute 
IPCS International Programme on Chemical Safety 
IUPAC International Union of Pure and Applied Chemistry 
JMPR Joint FAO/WHO Meeting on Pesticide Residues 
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LOAEL Lowest Observed Adverse Effect Level 
LD50 Lethal Dose 50% 
 
LDL Low Density Lipoprotein 
LDH Lactate Dehydrogenase 
LH Luteinizing Hormone 
mAChR Muscarinic Acetylcholine Receptor 
MCH Mean Corpuscular Haemoglobin 
MCHC Mean Corpuscular Haemoglobin Concentration 
MCV Mean Corpuscular Volume 
MOA Mode of Action 
MRL Maximum Residue Level 
mRNA Messenger Ribonucleic Acid 
nAChR Nicotinic Acethylcholine Receptor 
NOAEL No Observed Adverse Effect Level 
OATP Organic Anion-Transporting polypeptide 
OCT Ornithine Carbamyltransferase 
OECD Organisation for Economic Co-operation and 
Development 
OPIDN Organophosphate-Induced Delayed Neuropathy 
PND Postnatal Day  
PNS Peripheral Nervous System 
PODI  Point Of Departure Index 
PPARα Peroxisome Proliferator Activated Receptor alpha 
PPDB Pesticide Properties Database 
PPR Plant Protection Products and their Residues 
PT Prothrombin Time 
PU Propylenurea 
PXR Pregnane X receptor 
RBC Red Blood Cell 
RfP Reference Point 
RfPI  Reference Point Index 
RMS Rapporteur Member States 
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ROS Reactive Oxygen Species 
RPF Relative Potency Factor 
rT3 Reverse T3 
SCLP Straight Chain Lepidoptera Pheromones 
SCP Scientific Committee on Plants 
SDH Sorbitol Dehydrogenase 
SMILES Simplified Molecular Input Line Entry System 
SOD Superoxide dismutase 
StAR protein Steroidogenic Acute Regulatory protein 
SULT Sulphotransferases 
T2 Di-iodothyronine 
T3 Triiodothyronine 
T4 Thyroxine 
TAT Tyrosine Transaminase Enzyme 
TBG Thyroxine-Binding Globulin 
TPO Thyroid Peroxidase 
TRH Thyrotropin-Releasing Hormone 
TSH Thyroid-Stimulating Hormone 
TTR Transthyretin  
UDPGT Uridine Diphosphate Glucuronyl-Transferases 
UF Uncertainty Factor 
U.S. EPA United States Environmental Protection Agency 
WBC White Blood Cells 
WHO World Health Organization 
 
 
 
 
